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Abstract 
Medication non-adherence is common in chronic conditions such as cardiovascular 
diseases (CVD). According to the WHO, over 50% of patients are non-adherent to CVD 
medications, which results in poor health outcomes, hospital readmissions, high mortality 
rates and avoidable costs. The aim of this study was to assess medication non-adherence 
to target CVD medications via the eight-item Morisky Medication Adherence Scale 
(MMAS-8) and quantification of drug concentrations in blood microsamples collected on 
Whatman 903 cards and a volumetric absorptive microsampling device (VAMS) for the 
same patients using liquid chromatography–high resolution mass spectrometry (LC-
HRMS). Iraqi patients who had been taking one or more of nine commonly prescribed 
cardiovascular medications (amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, 
lisinopril, losartan, simvastatin, and valsartan) for at least six months were enrolled in this 
study. MMAS-8 scores for individual patients were determined, and whole blood 
microsamples assessed via LC-HRMS. To estimate overall medication non-adherence, 
MMAS-8 (score < 6) and the results of quantitative LC-HRMS analysis were compared. 
303 patients were recruited for this study (mean age 54) taking an average of four CVD 
medications. Non-adherence assessed via MMAS-8 was 18.2%, as compared to the 
49.2% determined via LC-HRMS analysis of blood microsamples. Both approaches 
showed no significant correlation between non-adherence and age or gender, but was 
significantly associated with the number of medications or tablets being taken daily. 
Quantitative LC-HRMS results obtained via the two microsampling methods (VAMS and 
903 cards) were generally consistent and comparable, confirming good reproducibility. 
MMAS-8 was subject to overestimation and was unable to identify non-adherence to 
multiple medications in the regimens. Conversely, LC-HRMS gave valuable information 
about non-adherence to each medication in each patient’s regimen. In subsequent 
clinician-led patient interviews the main reasons for medication non-adherence were side 
effects, dose frequencies, complicated regimens, medication cost, patient beliefs, patient 
knowledge/understanding, and forgetfulness. The impact of using a combination 
approach of patient MMAS-8 data and objective blood drug concentration data with face-
to-face interviews conducted by the specialist in Iraq has the potential to provide Iraqi 
clinicians with a novel approach to improving patients’ health and reducing the costs of 
treatment by monitoring and optimising CVD medications in routine clinical practice.  
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Healthcare System in Iraq: An Overview 
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This chapter provides background information about the Iraqi healthcare system and 
highlights the global prevalence of, and mortality rates due to cardiovascular diseases. 
Current policies and action plans related to cardiovascular diseases in Iraq are also 
discussed. It provides information about types of healthcare systems, the healthcare 
workforce, and access to, and the prescription of medications in Iraq and the UK. The 
levels of quality control and the price regulations of medications in Iraq are documented. 
In order to assess where the Iraqi healthcare system stands in the global scheme, the Iraqi 
situation is outlined in relation to the healthcare system in the UK, where part of this 
research was conducted. 
1.1. General Background 
Iraq is one of the Middle Eastern countries, whose neighbours are Turkey to the north, 
Iran to the east, with Kuwait and Saudi Arabia to the south, and Syria to the west. Over 
the past 25 years, the population in Iraq has increased by 51.0%, reaching 35.8 million in 
2015 (World Health Organization, 2017b).  
1.2. Mortality and Chronic Disorders  
According to the World Health Organization (WHO), the disease landscape in Iraq has 
undergone a drastic transformation over the years. In 2002, communicable, maternal, 
perinatal and nutritional deficiencies accounted for 44% of all deaths, whilst non-
communicable diseases (NCDs) accounted for 56%. Of the NCDs, cardiovascular 
diseases (CVDs) accounted for 21% of the total deaths, injuries 13%, cancer 6%, diabetes 
1%, and other chronic non-communicable diseases 15% (Figure 1.1) (World Health 
Organization, 2002). In 2014, 19% of all deaths were due to communicable, maternal, 
perinatal and nutritional deficiencies, while NCDs accounted for 81%. CVDs accounted 
for 33% of all deaths, injuries 19%, cancer 10%, diabetes 4%, and other chronic NCDs 
15% (Figure 1.1) (World Health Organization, 2014). In the UK, only 7% of all deaths 
were due to communicable, maternal, perinatal and nutritional deficiencies, while NCDs 
accounted for 93% and CVDs accounted for 31% of all deaths, followed by cancer at 
29%, other NCDs at 20%, chronic respiratory diseases at 8%, injuries at 4%, and diabetes 
at 1% (World Health Organization, 2014). This indicates that CVD represent a major 
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challenge to healthcare systems, whether in low- and middle-income countries such as 
Iraq or in developed nations such as the UK.  
Despite these reports about high mortality rates due to CVDs in Iraq, there are no large-
scale plans or guidelines for their management to reduce the devastating effects of such 
conditions in Iraq (Turk-Adawi et al., 2018). With regards to CVDs in particular, there 
have been operational policies, strategies, or action plans to reduce unhealthy diets and 
tobacco usage and in promoting increased physical activity, but these are not applied at 
the national level in Iraq. There are no insurance health care schemes or drug counselling 
centres for cardiovascular diseases (World Health Organization, 2017d). Thus, patients 
will have to bear the burden of the cost of healthcare services. The absence of drug 
counselling centres would mean extra responsibilities/workload for doctors who already 
have limited time for their patients.  
 
 
Figure 1.1. A comparison of causes of death in Iraq in 2002 and 2014. 
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1.3. Healthcare System in Iraq 
The healthcare system in Iraq is mainly divided into the public, private and intermediate 
sectors. These existing healthcare systems in Iraq are discussed in the following 
subsections. 
1.3.1. Public Healthcare Systems 
In Iraq, the Ministry of Health (MOH) is responsible for the country’s healthcare system. 
The public sector provides preventative and curative services through primary health 
centers (PHC), secondary care (hospital-based) and tertiary care (specialist hospitals) (Al 
Hilfi et al., 2013). The public sector is funded by the MOH. The working hours for 
primary health care centres are between 8.00 a.m. and 3.00 p.m. Secondary and tertiary 
facilities are available for emergencies on a 24/7 basis. Despite the facilities provided by 
the primary, secondary and tertiary health care centres, there are many problems with the 
Iraqi public health system as pertaining to data management and security. The paucity of 
medical doctors and trained medical professionals in Iraq adversely affects health care 
services (Al Mosawi and Al Hasnawi, 2009). These services also suffer from shortages 
of medications and long waiting hours. Those citizens opting for the public health system 
due to their low costs typically live in poverty or, indeed, are unemployed (International 
Organization of Migration, 2018).  
In the past 50 years, there has been a shift away from welfare financing in order to provide 
these healthcare services towards a greater focus on ‘self-sustainability’, increasing the 
financial burden on individuals seeking welfare services (World Health Organization, 
2017a). The role of the MOH is to provide services that are primarily funded by the 
government. In the early 1980s, the MOH was charged with providing services for free, 
or at least for very low fees. In Baghdad, 1997, seven public hospitals began charging 
high fees for medical care and implemented a self-financing policy that quickly cascaded 
to other public hospitals and health centres. By 2003, the MOH had cracked down on 
these self-financing policies by restricting them and enforcing the re-adoption of the 
provision of free or low-fee services (Al Mosawi and Al Hasnawi, 2009). 
Today, austerity measures, resource shortages, and the absence of a more widespread 
adoption of health insurance schemes, are driving up individual patient costs. Patients 
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today must pay for services such as consultations and treatment, although the cost of 
medication is relatively low in comparison to that in the private sector (International 
Organization of Migration, 2016; World Health Organization, 2018a). It is reported that 
23% of Iraqis are under the poverty line with spending of less than $2.2 per person per 
day which is almost equal to £1.8 or 2618 Iraqi Dinars (United Nations Iraq, 2019). This 
could be a significant barrier to adherence to the prescribed medications.  
In the UK, the National Health Service (NHS) is designed to provide medical treatment 
and support to everyone, regardless of their ability to pay, though people can and do 
choose to take out their own private health insurance policies. The public sector in the 
UK consists of primary (e.g., community care, general practitioners, dentists, 
pharmacists, etc.) secondary (hospital-based care accessed through GP referral) and 
tertiary care (specialist hospitals) in a similar way to in Iraq, even though the manner in 
which they operate differs (Grosios et al., 2010). Access to medication in the Iraqi public 
health sector is discussed in Subsection 1.3.1.1. 
1.3.1.1. Medication Supplies and Access to Medications in the Iraqi Public Health 
Sector 
In Iraq, the State Company for Marketing Drugs and Medical Appliances (KIMADIA) 
was the primary service provider of drug and medical appliance import, storage, and 
distribution for both the private- and public-sector hospitals until 2003; thereafter, its 
services were concentrated purely on the public sector. KIMADIA acts as an intermediary 
between drug companies and the public health sector, as shown in Figure 1.2.  
Patients can gain access to medications after visiting the public clinics and, based on their 
diagnoses, the clinician may refer them for laboratory tests or, if further intervention is 
required, they are sent to the hospital on admission. If a patient needs medication, the 
clinician writes a prescription and for patients to get medications from public sector 
pharmacies for the appropriate fee. Although, medicines are available in the public sector 
at a low price in comparison with the private sector, these medicines are frequently subject 
to shortages since demand typically exceeds supply. If medications are not available from 
public sector pharmacies, patients can instead obtain their medications from private sector 
pharmacies.  
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Figure 1.2. KIMADIA medication distribution scheme within the public sector (Al-
Jumaili et al., 2013). 
 
The procedure is slightly different in the UK, where the patient has to book an 
appointment with the clinic and medications are prescribed by appropriate healthcare 
practitioners such as doctors, nurses, dentists and optometrists. These prescriptions are 
only dispensed through pharmacies in community or hospital settings (National Health 
Service, 2017), where direct charges to the patient are made which include prescription 
charges, currently at £9.00 per item (National Health Service, 2019). However, there are 
certain situations that allow individuals to access free prescriptions in England, for 
example those who are under 16 or 60 and over, people with certain medical conditions 
(e.g., cancer, diabetes) and during pregnancy (Black, 2014). 
1.3.2. Private Healthcare Systems in Iraq 
The private sector in Iraq includes private clinics and private hospitals. Private clinics are 
owned and run by specialist physicians and, unlike public clinics, provide services to 
patients after 3.00 p.m. However, the medications prescribed by these physicians are only 
dispensed from community pharmacies of the private sector. Details of access to 
medicines through private healthcare systems are outlined in Subsection 1.3.2.1. A high 
number of private clinics are available in Iraq and are well distributed across the nation 
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in a geographical sense. The physicians who work in private clinics are either retired 
physicians or public sector physicians who finish work at 3 p.m. In the private sector, 
healthcare costs are covered by the individual requesting treatment. 
Specialist private hospitals are mostly located in Baghdad and, to a lesser extent, in the 
outlying provinces. The quality of care provided by private sector services in Iraq is high 
in comparison to that provided by the public sector. Private hospitals and clinics are 
generally owned by individual or group practices and are headed by physicians or 
entrepreneurs (World Health Organization, 2006). This sector mainly provides surgical 
services, obstetrics/gynaecological beds, operative and labour theatres, and support 
services such as medical laboratories and X-ray units.  
In the UK, the private healthcare sector is made up of hospitals and clinics which are run 
independently of the National Health Service (NHS). Private healthcare is directly funded 
by insurance schemes paid for directly by either individuals or major employer schemes 
(Grosios et al., 2010; Chang et al., 2011). Just as with the private sector in Iraq, patients 
using the private sector in the UK are responsible for the any fees that might be payable 
since the NHS itself does not support any of the associated costs.  
1.3.2.1. Medication Supply and Access to Medications in the Iraqi Private Sector 
Private wholesalers obtain medicines from scientific bureaus and national pharmaceutical 
companies. Wholesalers supply medicines to private pharmacies, as shown in Figure 1.3. 
The patient visits a private clinic and pays the consultation fee. The clinician prescribes 
medications which are only administered from private sector pharmacies. In this sector, 
the medications provided by such pharmacies are consistently of high quality and are 
readily available, though the associated costs are themselves quite high and must be 
covered by individuals seeking treatment (International Organization of Migration, 
2016).  
The government does not run an active national medication price monitoring system to 
track the retail prices of drugs in private healthcare facilities (World Health Organization, 
2011). The combined effects of this lack of price regulation and the general lack of health 
insurance schemes has led to individuals incurring high costs when seeking health 
services in this sector (World Health Organization, 2017d). 
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Figure 1.3. Distribution scheme for medicines distributed to the private sector (Al-
Jumaili et al., 2013).  
1.3.3. Intermediate Sector   
The intermediate sector, as the name suggests, refers to the basic healthcare services 
available when primary public services cannot be accessed. The intermediate sector 
provides services via the public clinics. These public clinics embody the interaction 
between the public and private care facilities that operate in PHCs and provide curative 
care to the public beyond the official working hours of public facilities for a period of 
three hours per day (3-6 pm). The clinics recruit staff independently from MOH staff, 
retired professionals, and private practitioners (World Health Organization, 2006).  
1.3.3.1. Medications Supply and Access to Medications in the Intermediate Sector 
The patient pays for the consultation, laboratory analysis, and treatment in the 
intermediate sector; the total cost is higher than in the public sector but considerably less 
than would be charged in the private sector. The price of medications is regulated by the 
MOH. Medication in this sector is subject to shortages, just as with the public sector, 
where again demand exceeds supply.  
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1.3.4. Healthcare Workforce in Iraq 
In Iraq, the average physician to population ratio is 7.5:10,000. The ratios in a sample of 
cities at the high and low end of the range are as follows: Erbil 10.5, Basra 9.0, Kerbala 
9.2; and Thi-Qar 4.4, Diyala 4.3, and Misan 3.5 (World Health Organization, 2018a). A 
particular issue faced by the healthcare system in Iraq is that of a general shortage of 
nurses and support staff in rural areas and health centres (World Health Organization, 
2018a). Staff shortages affect consultations and follow-up waiting periods. The average 
community pharmacist to population ratio is about 1:3; however, there is a limited number 
of clinical pharmacists, usually 1-2 clinical pharmacists for each hospital ward (Al-
Jumaili et al., 2013). Generally, a hospital ward in Iraq will cater for 66 patients, 
suggesting a higher workload for the pharmacists (about 1:30 patients) available.  
In the UK, the doctor to population ratio was 21:10,000 in England and Wales in 2001 
(Yar et al., 2006), and of pharmacist to population ratio was 7.5:10,000 (The Centre for 
Workforce Intelligence, 2013). Consequently, these data obtained from both Iraq and the 
UK indicate that the health workforce to patient ratio may affect the health services 
provided and adds to the burden on both doctors and patients.   
1.3.5. Medication Quality Control 
All pharmaceutical products used in the healthcare sectors in Iraq (Section 1.3) must first 
be registered and licensed according to MOH Public Health Law regulations. This 
registration process falls under the auspices of the Technical Affairs Directorate and 
Registration Department. For prescription medications, full documentation is required, 
including bioavailability and bioequivalence studies. Over-the-counter (OTC) medicines 
require only reduced documentation. Registered products retain their legal status for five 
years, after which they must be re-registered. The National Centre for Drug Control and 
Research (NCDCR) is responsible for safety, quality and efficacy control in Iraq (World 
Health Organization, 2006). In the UK, the Medicines and Healthcare Products 
Regulatory Agency (MHRA) regulates medications, medical devices, and blood 
components for transfusion (Medicines & Healthcare products Regulatory Agency, 
2018). 
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Until recently, KIMADIA was also charged with drug post-marketing surveillance in 
coordination with the MOH anti-poison centre. However, an investigation published in 
2006 indicated that no serious post-marketing surveillance studies had been conducted 
over the preceding 15 years (World Health Organization, 2006). According to the WHO, 
it is estimated that 1 in 10 medical products is substandard/falsified in low and middle-
income countries (World Health Organization, 2018c). The WHO defines substandard 
medicines as “authorized medical products that fail to meet either their quality standards 
or their specifications, or both” and falsified medicines as “medical products that 
deliberately/fraudulently misrepresent their identity, composition or source”  (World 
Health Organization, 2017e). Ultimately, it is difficult to make an informed decision as 
to the availability of substandard and falsified medicines in the Iraqi market; however, a 
number of reports have surfaced about substandard and falsified medicines medications 
circulating in the country. The Iraqi parliament called on the MOH and the Syndicate of 
Iraqi Pharmacists to prevent the distribution of substandard and falsified medicines after 
confiscating 14 containers of such being smuggled into Umm Qasr Port (Alsumaria Iraqi 
Satellite TV Network, 2012). According to the Iraqi Centre of Pharmacovigilance, 
falsified cardiovascular medications such as amlodipine, clopidogrel and valsartan have 
been circulating in the Iraqi market (Syndicate of Iraqi Pharmacist, 2016). It is estimated 
that 30% of medications in the Kurdistan region in Iraq are substandard and falsified 
(Bahram, 2013). Just as quality control is important to ensuring patients are provided with 
the correct medication in the correct dosage, price regulation for medicines is also 
paramount in order to ensure access. 
1.3.6. Medication Price Regulation 
In Iraq, the price of medications prescribed to patients in the public (sections 1.3.1) and 
the intermediate sectors (section 1.3.3) is controlled by MOH; however, there are no legal 
requirements to control medication prices or retail prices for drugs sold in the private 
sector (World Health Organization, 2011), which has led to unstable and high retail prices 
for medications. On the other hand, in the UK, the Pharmaceutical Price Regulation 
Scheme (PPRS), which is a voluntary agreement between the government and 
pharmaceutical industry, has the dual aims of seeking: 
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• To create an environment that ensures safe and effective medications are available 
on reasonable terms to the National Health Services (NHS); and  
• To maintain a strong, efficient, and profitable pharmaceutical industry (The 
Association of the British Pharmaceutical Industry (ABPI), 2018; Paul and 
Morgan, 2018). 
The PPRS puts in place controls on the prices of branded drugs sold to the NHS and 
covers all licensed, branded, prescription medications sold to them. It does not cover 
products without a brand name (generics), nor does it cover those branded products 
available without prescription (OTC) (The Association of the British Pharmaceutical 
Industry (ABPI), 2018; Paul and Morgan, 2018).   
The absence of price regulation, along with the lack of any health insurance scheme, 
facilitates the high prices being charged for health services in Iraq (World Health 
Organization, 2017d). Lack of sufficient documentation and government involvement 
and, indeed, oversight of Iraqi drug prices are a major point of concern. The cost of CVD 
medications in the private sector is significantly higher than those in the public sector. 
Table 1.1 shows the cost of 10 tablets of various forms of medication in the public and 
private sector. The cost is obtained from private sector pharmacies in Misan, Iraq. 
Table 1.1. Estimated cost of 10 tablets of the target medications in the public and private 
sector in Iraq  
Medication Estimated cost (Iraqi Dinar) in the 
public sector 
Estimated cost (Iraqi Dinar) in the 
private sector 
Amlodipine 1000 2000-2500 
Atenolol 500 1500-2000 
Atorvastatin  Not available in this sector 3000-4000 
Bisoprolol 500 1000-1500 
Diltiazem 500 6000-8500 
Lisinopril 500 1500-2000 
Losartan 500 3000-5000 
Valsartan Not available in this sector 3000-5000 
Simvastatin Not available in this sector 2000-4000 
1.3.7. Medical Guidelines for Management of Chronic Diseases 
Medical guidelines provide outlines for clinical decisions and best practices and consist 
of statements and recommendations aimed at improving patient care and communication 
between patients and healthcare professionals. The outlines are informed by systematic 
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reviews of available evidence and assessments of the benefits and potential side effects 
associated with alternative care options (Mazrou, 2013). Such consensus guidelines 
enable greater consistency in the care provided at the local and national levels. Their 
implementation has also had an economic impact, reducing spending on hospitalisation, 
prescriptions, surgeries, and other procedures (Woolf et al., 1999; Kredo et al., 2016).  
In Iraq, there is a guideline for the management of hypertension (Iraqi Ministry of Health, 
2012), but it is not generally applied by physicians. On the other hand, there are no 
applicable national guidelines, protocols, or standards for the management of 
cardiovascular diseases and other major NCDs through primary care. A comparison with 
the UK health system’s guidelines and standards for the management and treatment of 
cardiovascular diseases is given in Table 1.2.  
This may suggest that improving guidelines is vital to the maintenance of good clinical 
care practices. The lack of medical guidelines in Iraq leads to a relatively wide variation 
in decision making as each doctor prescribes medications based on their personal 
experiences. This opens the door to numerous treatment options and overprescribing. 
Moreover, the absence of guidelines will result in undefined priorities.  
Table 1.2. Comparison of health system policies and response to address cardiovascular 
diseases in Iraq and the UK (Grosios et al., 2010; Al Hilfi et al., 2013; World Health 
Organization, 2014). 
 Iraq UK 
Guideline for management and 
treatment of CVD 
Not available Available  
Guideline for management of 
medication non-adherence  
Not available Available  
Operational CVD unit/branch or 
department within the Ministry of 
Health, or equivalent 
Not available Available 
Operational multisectoral national 
policy, strategy or action plan that 
integrates several NCDs and shared 
risk factors 
Not available Available 
Operational policy, strategy, or 
action plan to reduce physical 
inactivity and/or promote physical 
activity 
Available (not applicable) Available 
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Table 1.2 continued  
Operational policy, strategy, or 
action plan to reduce the burden of 
tobacco use 
Available (not applicable) Available 
Operational policy, strategy or action 
plan to reduce the harmful use of 
alcohol 
Available (not applicable) Available 
Operational policy, strategy, or 
action plan to reduce unhealthy diet 
and/ or promote healthy diets 
Available (not applicable) Available 
Evidence-based national guidelines, 
protocols, or standards for the 
management of CVD through 
primary care 
Not Available Available 
1.4. Cardiovascular Diseases and Choice of Medications in Iraq 
Cardiovascular diseases are the leading cause of death in Iraq (Ala'din, 2004). In Iraq, 
Ischemic heart diseases and stroke are the top two causes of death, with 27,500 deaths 
due to ischemic heart disease and 16,800 due to stroke in 2012  (Iraqi Ministry of Health, 
2012; World Health Organization, 2015).  
The increase in the prevalence of CVDs may be due to individual factors such as physical 
inactivity, age, unhealthy diet, alcohol consumption, smoking, economic wellbeing, and 
comorbidities such as diabetes, hypertension, dyslipidaemia, and obesity. Cultural 
changes such as globalisation, urbanisation, and population ageing may also contribute 
(Cooper et al., 2006; Yu et al., 2009; Murakami et al., 2013; National Health Service, 
2016; World Health Organization, 2018b).  
Current clinical therapies for CVDs use certain combinations of medications to treat 
hypertension and lower cholesterol levels (Yusuf et al., 2013). However, doctors do not 
follow any particular medical guidelines in Iraq in this regard, as mentioned earlier in 
section 1.3.7. CVD medications are prescribed based purely on past experience, thus 
leading to some considerable variation in the associated decision making. The most 
commonly prescribed CVD drugs in Iraq are amlodipine, atenolol, atorvastatin, 
bisoprolol, diltiazem, losartan, simvastatin, and valsartan. According to the annual 
medications need list in Iraq for 2016-2017, not all medications were available in 
KIMADIA such as atorvastatin, simvastatin and valsartan (KIMADIA, 2017). As 
KIMADIA provides the public sector in Iraq with its medications, atorvastatin, 
simvastatin and valsartan are not available in the public sector in any of the Iraqi 
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provinces, including Misan. However, these medications are prescribed by cardiologists 
and are only available in the private sector.  
1.5. Thesis Outline 
The following chapter outlines the definition of terms used to express medication-taking 
behaviour and factors associated with non-adherence to medication. Also, Chapter 2 
outlines the prevalence and the consequences of medication non-adherence in addition to 
providing information on the approaches used for the assessment of non-adherence, 
identifying the gap in knowledge and the rationale behind the approach used in the study, 
as well as the specific aims and objectives of this research. 
Chapter 3 describes the simulation and application of a previously validated liquid 
chromatography-high resolution mass spectrometry (LC-HRMS) assay for the 
simultaneous determination of nine commonly prescribed CVD medications in 
microvolume blood samples collected from 303 Iraqi on 903 cards and volumetric 
absorptive microsampling devices (VAMS) for the same volunteers. Volunteers were 
taking one or more of these CVD medications. The correlation between the analyte 
concentration collected on the 903 cards and VAMS was also investigated.  
Chapter 4 detailed the application of the eight-item Morisky Medication Adherence Scale 
(MMAS-8) to assess non-adherence to the most commonly prescribed cardiovascular 
medications in 303 Iraqi volunteers, who were prescribed one or more of these 
medications and who provided blood samples on 903 cards and VAMS. The chapter 
investigates certain factors, such as gender, age, number of medications and number taken 
per day, which are associated with medication-taking behaviour. 
Chapter 5 compares the results of non-adherence to prescribed CVD medications when 
using indirect and indirect methods for 303 Iraqi volunteers. 
Chapter 6 outlines the clinical application of the results obtained from assessment of non-
adherence to cardiovascular medications on the clinical practice in Iraq and suggests the 
proper intervention to improve adherence to medications in Iraqi volunteers based on the 
outcomes obtained from the above direct and indirect methods. 
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Chapter 7 summarises the overall conclusion and gives a number of recommendations for 
any future work.  
1.6. Conclusion  
Based on the information available on the Iraqi health system (as outlined in this chapter), 
the following can be inferred: 
• Mortality due to chronic disorders including CVDs is considerably high and 
represents a challenge for the health system in both Iraq and the UK. 
• In Iraq there are no effective regulatory systems in place with reference to the 
price of medication, prescription of medication, or management of chronic 
diseases such as CVDs in comparsion with the UK. This indicates that the Iraqi 
health system need to be upgraded to implement a multi-sector strategy to control 
cardiovascular diseases such as promoting healthy life style, reduce 
cardiovascular risks and ensuring the optimum use of CVD medications.  
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Chapter 2 
Cardiovascular Diseases and Assessment 
of Medication Non-adherence 
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This chapter outlines cardiovascular diseases and their associated mortality rates, both 
worldwide and in Iraq. It also provides an overview of the problem of non-adherence to 
prescribed medication, the prevalence of non-adherence to medications and concepts and 
terms describing medication-taking behaviour. This chapter also highlights several 
factors that affect medication non-adherence in addition to the associated consequences. 
Furthermore, the current available methods of assessing patient medication non-
adherence and their advantages and disadvantages will also be discussed. The direct 
method for assessment of non-adherence by microsampling analysis, and its advantages, 
challenges and the analytical techniques used in analysis of dried blood spots, namely 
immunoassay and liquid chromatography-mass spectrometry, are also discussed. Finally, 
the gaps in the literature and the aims and the objectives of this research are stated. 
2.1. Introduction 
Cardiovascular diseases (CVDs) refer to disorders of the heart and blood vessels such as 
hypertension, angina, heart attack, stroke, and heart failure (Tanna and Lawson, 2014a). 
This class of diseases accounts for the highest number of deaths worldwide at 17.9 million 
people in 2016 (World Health Organization, 2017a), wherein 7.4 million people are 
estimated to have died from coronary heart disease and 6.7 million from stroke (World 
Health Organization, 2017c).  
CVDs are the leading cause of death in Iraq (Ala'din, 2004). Ischemic heart diseases and 
stroke are the top two causes of death, which resulted in 27,500 deaths due to ischemic 
heart diseases and 16,800 due to stroke in 2012, as mentioned in Chapter 1 Section 1.4 
(Iraqi Ministry of Health, 2012; World Health Organization, 2015).  
In the United Kingdom (UK), CVDs account for nearly 160,000 deaths per a year (British 
Heart Foundation, 2017). Currently, nearly 7 million UK residents endure some form of 
CVD, as equally divided between men and women (British Heart Foundation, 2017).  
Current therapies for CVDs use various combinations of medications including ß-
blockers and angiotensin converting enzyme (ACE) inhibitors to treat hypertension, and 
statins to lower cholesterol levels. Optimum clinical outcomes are not only dependent on 
choosing the proper treatment but also on the dose required to achieve the necessary 
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plasma concentration (Tanna and Lawson, 2016a). The required drug concentration can 
be achieved by adherence to the appropriate regime of medications. It is estimated that 
globally more than half of patients do not adhere to their medications (Sabaté, 2003; 
Kronish and Ye, 2013). This leads to poor clinical outcomes, increases health care 
expenditure and consequently affects labour force productivity and public health in 
general (Sabaté, 2003).  
The World Health Organization (WHO) described non-adherence to prescribed 
medication as a “worldwide problem of striking magnitude” (Sabaté, 2003), which affects 
all disease states including cardiovascular, cancer and diabetes (Cutler et al., 2018). There 
is evidence worldwide that more than 50% of prescribed CVD drugs are not taken by 
patients as recommended (Sabaté, 2003; Tanna and Lawson, 2016a; Ferdinand et al., 
2017). Non-adherence to medications results in increased morbidity, mortality, medicine 
wastage, and raised costs (Tanna and Lawson, 2016a; Giner-Soriano et al., 2018). 
Patient’s physical and psychiatric disabilities are exacerbated by poor adherence to 
medication, affecting family, work and social responsibilities.  
Moreover, poor adherence to medication limits health funding that might otherwise be 
used more effectively elsewhere. The economic cost of medication non-adherence is not 
only due to waste of medications but also due to increased demand for healthcare related 
to rehospitalisation (Stuart et al., 2009; pharmaphorum, 2018; Cutler et al., 2018).  
2.1.1. Definition of Terms Related to Patient Behaviour in Medicine Taking 
Patient behaviour, as associated with taking, or indeed not taking, medication as 
prescribed has been discussed using different terms such as compliance, adherence, 
concordance, and persistence. Whilst these terms are often used interchangeably, they do 
however reflect different views on the relationship between patients and healthcare 
providers (Vrijens et al., 2012).  
2.1.1.1. Compliance 
Compliance can be considered the oldest term to describe patients’ medication-taking 
behaviour. Compliance is defined as “the extent to which the patient’s behaviour matches 
the prescriber’s recommendations” (Haynes, 1979).  
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Using the term compliance exaggerates the role of healthcare providers and imposes a 
paternalistic relationship. It suggests a one-sided interaction where the patient must 
comply with the prescribed medication, regardless of whether it is suitable for them or 
otherwise. The term “compliance” has been criticised since it conveys a negative 
relationship between patients and healthcare providers (Rafii et al., 2014). 
2.1.1.2. Adherence  
The World Health Organization (WHO) defined adherence as “the extent to which a 
person’s behaviour taking medication, following a diet, and/or executing lifestyle 
changes, corresponds with agreed recommendations from a healthcare provider” (Sabaté, 
2003). 
The terms ‘adherence’ and ‘compliance’ are often used interchangeably and, indeed, are 
considered to be synonymous (Cramer et al., 2008). However, they reflect different views 
on the relationship between patients and healthcare providers. Adherence implies a 
certain level of cooperation and the sharing of perspectives and views between patient 
and caregiver in order to improve the patient’s health, since patients are free to agree or 
otherwise with the medical plan proposed by the healthcare provider. The main difference 
between adherence and compliance is the agreement in terms of recommendations and 
sharing decisions (World Health Organization, 2002; Nguyen, 2016). 
Furthermore, adherence focusses on patient autonomy and is patient-centred via the 
collaboration between patient and healthcare provider rather than being a paternalistic 
relationship, and indeed the patient actively participates in the treatment plan (Vermeire 
et al., 2001). For proper medication adherence, six key factors should be involved which 
include taking the correct drug in the correct dose, at the correct time and on the correct 
schedule, under the correrct conditions whilst adopting the correct precautions (Tanna 
and Lawson, 2014b). This further corroborates the WHO definition mentioned earlier. 
2.1.1.3. Concordance 
Concordance is a new approach to the prescription and taking of medicines. It was 
introduced by the Royal Pharmaceutical Society of Great Britain in 1995 (Vrijens et al., 
2012). Concordance is a patient’s medicine-taking behaviour as achieved after equal 
negotiation and agreement between the patient and healthcare professional to determine 
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when and how their medicine is taken (Blenkinsopp et al., 1997). Concordance cannot be 
used as a synonym for adherence because it includes communication, shared decision and 
medical consultation (Cushing and Metcalfe, 2007). 
2.1.1.4. Persistence 
Persistence can be defined as the length of time between the initiation of the first dose of 
medication and the last dose preceding the discontinuation of the therapy (Vrijens et al., 
2012). Persistence is distinct to adherence because the former refers to how long patients 
continue taking medication, whereas adherence refers to how patients respect the medical 
regimen, thus the terms adherence and persistence cannot be used synonymously. It 
describes the medication-taking period, rather than consider the factors that might be 
associated with the decision to stop taking medication. 
2.1.1.5. Medication Non-adherence 
Non-adherence to medication can be defined as a patient’s failure to follow the 
recommendations agreed with their doctor in terms of timing, dosage, and frequency 
(Aldeer et al., 2018). It is a major problem in patients with chronic diseases (Bitton et al., 
2013; Palmer et al., 2018). For instance, medication non-adherence increases the risk of 
heart disease-related hospitalisation and death in cardiovascular patients (Ho et al., 2008; 
Hood et al., 2018).  
The National Institute for Health and Care Excellence (NICE) separates medication non-
adherence into two overlapping categories, namely the intentional and the unintentional 
(Nunes et al., 2009). Medication non-adherence can be intentional, unintentional, or both 
(Usherwood, 2017). In intentional medication non-adherence, the patient actively decides 
not to follow the treatment recommendations given due to associated beliefs and 
perceptions, skipping doses to avoid side effects, the opinions of friends and family or 
due to the cost of the medication (Lehane and McCarthy, 2007b; Usherwood, 2017). 
Considerable research has been carried out to understand the causes of intentional non-
adherence to medication for a wide range of diseases, the results of which indicate similar 
causes (Laba et al., 2015). Furthermore, it is evident that about half of medication non-
adherence cases are intentional (Pound et al., 2005; Mukhtar et al., 2014). 
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Unintentional non-adherence is when the patient wants to follow the treatment 
recommendations but has practical problems in doing so. Unintentional medication non-
adherence is an unplanned, poor medication-taking behaviour due to a condition which 
is out of the patient’s control, and about which the patient can do nothing (Wroe, 2002). 
The following are the common causes of unintentional medication non-adherence: 
forgetfulness, misunderstanding of medical instructions, low level of education, inability 
to access medication, taking substandard/falsified medications, lack of reminders, 
complexity of the regimen (polypharmacy) and dose frequency, and physical problems 
such as poor eyesight (Morisky et al., 1986; Wroe, 2002; Lowry et al., 2005; Atkins and 
Fallowfield, 2006; Lehane and McCarthy, 2007a; Clifford et al., 2008; Unni and Farris, 
2011; Hugtenburg et al., 2013; Tanna and Lawson, 2016a; Usherwood, 2017).  
Studies on cardiovascular medication non-adherence in Iraq are very limited and all 
studies used indirect methods, typically though application of a questionnaire. It is 
estimated that non-adherence to CVD medications in Iraq was between 19.6% and 63% 
(Samer, 2008; Al-Dabbagh and Aswad, 2009; Hasan et al., 2011; Bushra and Kameran, 
2013; Jamal and Saleem, 2014; Safaa and Ali, 2015).  
• A cross-sectional study on 322 diabetic and hypertensive patients in Iraq by the 
application of an eight-item Morisky questionnaire showed that 19.6% of patients 
were non-adherent (Jamal and Saleem, 2014).  
• A cross-sectional study on 323 Iraqi hypertensive patients in using MMAS-8 
combined with a socio-demographic information questionnaire showed that 
42.3% of patients were non-adherent to antihypertensive medications (Safaa and 
Ali, 2015). 
• A cross-sectional study based on a questionnaire designed by the researcher given 
to 100 hypertensive patients showed that 63% of participants were non-adherent 
to medication (Samer, 2008).  
• A cross-sectional study to assess non-adherence to antihypertensive medication 
based on asking patients about their taking behaviour was carried out with 191 
hypertensive patients with acute ischemic stroke and acute myocardial infarction 
(MI). The study reported that 61% of patients were non-adherent to 
antihypertensive medications (Hasan et al., 2011).  
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• A cross-sectional study conducted in Iraq with 400 hypertensive patients using a 
questionnaire designed by the researcher showed that 58.8% of patients were non-
adherent to antihypertensive medications (Bushra and Kameran, 2013).  
The studies mentioned above further support the fact highlighted that there is currently 
more data related to the assessment of hypertension than there is for CVDs. It is therefore 
important that more studies related to CVDs are conducted, and hence the basis for this 
research. With reports (as mentioned in Section 2.2.5) suggesting that between 19.6% and 
63% of prescribed CVD drugs are not taken by patients as recommended, it is important 
to consider factors related to medication adherence. An understanding of the reasons for 
non-adherence associated with each individual patient may allow for the required 
interventions to increase adherence (Monroe et al., 2018) 
2.1.2. Factors Associated with Medication Non-adherence 
Factors affecting non-adherence to medication are different in different parts of the world. 
As highlighted in Chapter 1, Section 1.2, in Iraq, there are no insurance contributions and 
patients have to pay to see a clinician in the public and private sectors, and further pay 
the full cost of the prescription. Hence, the cost of treatment may be a significant 
determinant of non-adherence to medication in Iraq. The situation may be different to 
other countries, such as the UK, as the cost of treatment is subsidised through patients’ 
health insurance. In view of this difference in health systems, interventions designed to 
improve adherence in Iraq may not necessarily be applicable in the UK because due to 
the underlying factors relevant in each case. 
Non-adherence is not only influenced by individuals’ behavioural factors, but also by the 
disease itself, the complexity and duration of the treatment, adverse drug reactions, cost 
of treatment, and social factors. The WHO further classifies factors affecting non-
adherence into five subclasses: socioeconomic, healthcare system, condition-related, 
therapy-related and patient-related (Ferdinand et al., 2017). 
2.1.2.1. Socioeconomic-Related Factors 
A review by Martin et al., (2018), on barriers and strategies to improve adherence showed 
that patients who are supported by their families, friends and healthcare providers in terms 
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of assisting with their medication showed better adherence. However, patients living in 
unstable environments, or who have limited access to healthcare, a lack of financial 
resources, or who are unable to get their medication due to cost showed high levels of 
non-adherence (Kalogianni, 2011).  
2.1.2.2. Healthcare System-Related Factors  
There is a relationship between non-adherence and communication between patients and 
healthcare providers. Martinez and Finken showed that patients who have good 
relationships with their clinicians were generally adherent to their medications, whilst on 
the other hand patients who were not happy with this relationship tended not to be 
adherent (Martinez and Finken, 2017).  
Clinicians’ communication skills are important to the patient’s understanding of their 
conditions, possible complications, and the importance of medication adherence 
(Schoenthaler et al., 2017). Poor communication between healthcare providers and 
patients can sometimes in itself lead to poor adherence, medication errors and 
unnecessary hospital readmissions (Ferdinand et al., 2017).  
Long waiting times at the clinic or pharmacy have been identified as a barrier to patients’ 
medication adherence (Vermeire et al., 2001; Ferdinand et al., 2017; Leslie et al., 2018). 
It has been reported that a lack of support offered from healthcare providers to patients 
and a poor relationship between clinician and patient have been recognised as significant 
determinants of medication non-adherence (Khatib et al., 2014; Leslie et al., 2018). In 
addition, health systems that cannot provide patients with appropriate education on their 
treatment or follow-up on such will promote non-adherence to treatment. For instance, 
patient information leaflets are generally written using a high level of literacy and this 
may make it difficult for patients to understand the required information about the 
prescribed medications (Schoenthaler et al., 2017).  
Healthcare systems should implement the required system changes to ensure that 
assessment of medication non-adherence is properly considered in health practice and 
encourage a blame-free environment between patients and healthcare providers (Abbo et 
al., 2008).  
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2.1.2.3. Condition-Related Factors  
The adherence to medications which are taken as part of long-term treatments is 
associated with a marked decrease over time, especially with conditions that are 
asymptomatic. Absence of symptoms is a barrier to patients taking the appropriate 
medication. It is crucial that patients understand their diseases and the associated 
consequences of not taking medications (Kalogianni, 2011). 
2.1.2.4. Therapy-Related Factors 
Non-adherence to medication is associated with therapy-related factors such as the 
complexity of the medication regimen, duration of the medical course, side effects and 
the medication’s route of administration (Kleeberger et al., 2001; Gellad et al., 2011, Toy 
et al., 2011; Fawzi et al., 2012; Laba et al., 2012; Ruppar et al., 2012; Schneider et al., 
2018). Substandard/falsified medications have also been associated with medication non-
adherence rates (Tanna and Lawson, 2016a). Falsified and substandard medications 
contain raised, reduced or no active pharmaceutical ingredient. Using such medications 
compromises treatment, causing poor clinical outcomes with the possibility of serious 
side effects which consequently leads to or otherwise implies non-adherence to 
medications, since recommended dosages are not adhered to (Buckley and Gostin, 2013). 
Prescription of a complex medication regimen, especially in patients with co-morbid 
conditions, leads to serious consequences and can worsen the condition (Monroe et al., 
2018). A high level of comorbidities is associated with CVD. One in every four patients 
who suffers from CVD has a high probability of the co-occurrence of other chronic 
diseases (Kendir et al., 2018). A combination of drugs in one dosage form is associated 
with a higher rate of adherence in comparison with giving each medication separately 
(Sherrill et al., 2011). Generally, adherence decreases as the number of doses taken per 
day increases (Assawasuwannakit et al., 2015; Xu and Worden, 2016).  
2.1.2.5. Patient-Related Factors  
There are conflicting results regarding the association between gender and medication 
non-adherence. The majority of studies showed that the risk of non-adherence to 
medication regimes is higher in women than in men by 7-10% (Leslie et al., 2018). 
However, other studies have showed that women adhere to medication regimes better 
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than men (Nielsen et al., 2017), whilst others still have showed no association between 
gender and non-adherence (Lewey et al., 2013).  
Cross-sectional studies in Iraq based on a questionnaire designed by the researcher that 
was given to hypertensive patients showed that non-adherence to antihypertensive 
medications in men was higher than in women (Samer, 2008; Bushra and Kameran, 
2013). However, another study showed that females showed greater non-adherence than 
males (Jamal and Saleem, 2014).  
Other studies outside Iraq showed a significant relationship between age and adherence, 
where older patients were likely to be more adherent to antihypertensive medication than 
younger patients (Ramli et al., 2012; Alhewiti, 2014; Meinema et al., 2015; 
Assawasuwannakit et al., 2015; Khayyat et al., 2017). A similar result was obtained from 
a study in Iraq (Al-Dabbagh and Aswad, 2009). On the other hand, a systemic review by 
Yap et al. showed that older patients were more non-adherent to medications (Yap et al., 
2016). This could be because people begin to forget as they get older. A conflicting result 
from a study in Iraq (Bushra and Kameran, 2013) and other studies outside Iraq showed 
no relation between adherence to antihypertensive medications and age (Tomaszewski et 
al., 2014; Krueger et al., 2015; Pandey et al., 2015; Jin et al., 2016). 
Lack of knowledge was frequently associated with medication non-adherence. Patients 
may discontinue treatment when they feel better due to a lack of, or a reduction in their 
symptoms or because they do not understand that their disease is chronic and requires 
long-term treatment (Rashid et al., 2014; Lee et al., 2018). It is estimated that over 80 
million adults in the US have inadequate health literacy and that this leads to suboptimal 
clinical outcomes and consequently increases the risk of hospital readmission (Mayo-
Gamble and Mouton, 2018). 
In addition to patient’s beliefs and attitudes, other factors such as previous treatment 
experiences, religious and cultural beliefs about the condition, mental health problems 
and lack of motivation may affect adherence (Atinga et al., 2018; McQuaid and Landier, 
2018; Kvarnstrom et al., 2018). A systematic review by Rashid et al. showed that the use 
of a self-reporting tool cited fears of dependence on cardiovascular medication as a barrier 
to adherence (Rashid et al., 2014). Patients who believe that medication will control and 
manage their diseases show the highest adherence to medication in comparison with 
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patients with low motivation (Ross et al., 2004; Osterberg and Blaschke, 2005; Joyner-
Grantham et al., 2009; Brunner et al., 2009; Petrie et al., 2012; Alhalaiqa et al., 2012; 
Sjolander et al., 2013; Berglund et al., 2013; Horne et al., 2013; Rajpura and Nayak, 
2014). Physical factors such as visual, hearing and mobility impairment and swallowing 
problems are patient-related factors that have also been associated with medication non-
adherence (Adult Medication, 2006).  
2.1.3. Consequence of Non-adherence to Medication 
2.1.3.1. Clinical Outcomes 
Non-adherence to medication is associated with a significant impact on the efficacy of 
medicines, leading to treatment failure, progression of the disease (which worsens the 
patient’s condition) and consequently increases both morbidity and mortality rates (Tanna 
and Lawson, 2016a). Physicians may incorrectly relate poor clinical outcomes to the 
prescribed medications and therefore look for an unnecessary alternative approach such 
as increasing the dose or prescribing medications that are more potent or more expensive. 
Physicians cannot assess non-adherence for each individual medication based on the 
clinical outcomes especially for patients who take many medication and the physician 
may increase the dose for a medication that patient is already adhering to, which could 
clearly lead to serious consequences such as poor clinical outcomes (Sokol et al., 2005; 
Lam and Fresco, 2015).  
Patients who are non-adherent to cardiovascular medications tend to show multiple poor 
health outcomes such as an increased risk of cardiac events in comparison with adherent 
patients (Gehi et al., 2007; Addison et al., 2011; Wu and Moser, 2018). Patients who 
adhere to antihypertensive medication are able to maintain control over their blood 
pressure (Hyre et al., 2007; Macedo et al., 2010). Non-adherence to antihypertensive 
medication leads to the development of coronary artery diseases and chronic heart failure 
in non-adherent patients (Tanna and Lawson, 2016a). Poor adherence to statins increases 
the risk of cardiovascular diseases by 1.2- to 5.3-fold and an increase in the risk of 
mortality by 2.5-fold in comparison with patients who take their medications as 
prescribed (De Vera et al., 2014). There is a recent debate on the role of statins in 
cardiovascular diseases, in a recent study 50% of patients on long term statin therapy were 
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presented with a sub-optimal level of LDL cholesterol with risks of cardiovascular events 
(Akyea et al., 2019; Mahase, 2019).  
According to a study by Gehi et al, cardiovascular events (coronary heart disease, MI, or 
stroke) in non-adherent patients with stable coronary artery disease increased more than 
two-fold (Gehi et al., 2007). Choudhry et al. found that cardiovascular events in adherent 
patients with a previous history of a heart attack were less likely to happen in comparison 
with a control group (Choudhry et al., 2014). This indicated that a patient who is adherent 
to medication has a lower risk of developing complications or the progression of 
cardiovascular disease in comparison with one who is non-adherent. 
Non-adherence to cardiovascular medication is associated with a high mortality rate. The 
mortality rate in patients who discontinue their medication is higher than in those who 
continue taking their medication as prescribed. For example, in patients taking aspirin 
and statins, the mortality rate increases by almost two-fold in patients who discontinue 
taking aspirin and five-fold in patients who stop taking statins (Ho et al., 2006). 
Rasmussen et al. found that the mortality rate in patients with acute MI who had been 
prescribed statins was 25% in poorly adherent patients and 12% in highly adherent 
patients (Rasmussen et al., 2007). A study by Spertus et al. showed that there was a nine-
fold increase in the mortality rate in patients who discontinued taking anti-platelet 
medications (thienopyridines) (Spertus et al., 2006).  
A study by Rieckmann et al. showed that poor adherence to aspirin increases the risk of 
mortality and cardiovascular events by almost two-fold in patients with acute coronary 
syndrome (Rieckmann et al., 2011). Comparable results were seen in non-adherence to 
clopidogrel for patients receiving drug-eluting medication, where the mortality rate 
similarly increased by two-fold due to MI (Ho et al., 2010).  
2.1.3.2. Increased Healthcare Expenditure 
Non-adherence imposes burden on medical resources (Cutler et al., 2018). Rates of 
hospitalisation are considerably higher in patients with poor adherence to medications for 
chronic diseases such as diabetes, hypercholesterolemia, hypertension and congestive 
heart failure (Miura et al., 2001; Sokol et al., 2005). A total of 33-69% of instances of 
hospitalisation in the US are related to medication non-adherence (Ho et al., 2006). A rise 
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in the trend of hospitalisation was also seen in patients with heart failure who were not 
adherent to digoxin (Miura et al., 2001).  
According to Sokol et al., the consequences of poor adherence to antihypertensive and 
anti-hypercholesterolemia drugs are those of increased hospitalisation and poor clinical 
outcomes (Sokol et al., 2005). A systematic review of the literature by Bitton et al. (2013) 
showed a significant difference in the annual cost of medical care for coronary heart 
disease (CHD) in patients showing adherence and non-adherence. The annual cost of non-
adherent per patient was $4940, as compared to $4040 for adherent patients (Bitton et al., 
2013). A systematic review of the economic impact of cardiovascular diseases as a group, 
showed that the annual CVD medication non-adherence cost per patient per year for 
cardiovascular diseases can be estimated at around $10,000 (Cutler et al., 2018).  
Optimal adherence represents an excellent opportunity for investment in the medical care 
sector. According to the New England Healthcare Institute (NEHI), the estimated 
avoidable medical costs in the US across the range of chronic diseases associated with 
medical-related problems was $290 billion (New England Health Institute (NEHI), 2009). 
The situation in the EU is not particularly different, with non-adherence being associated 
with an annual cost of €125 billion (Pefoyo et al., 2015). According to the National Health 
Service (NHS), 5% of all emergency admissions in the UK were due to inappropriate use 
of medication, costing £500 million a year in England alone (Barnett, 2014). In Australia, 
10% of hospitalisations were due to medication non-adherence, costing an extra $2000 
per patient per year (Sokol et al., 2005; Cutler et al., 2018). In Iraq, there is no available 
data about non-adherence and health expenditure as the study of medication non-
adherence is still effectively in its infancy. 
2.1.3.3. Medicine Wastage 
Suboptimal adherence to medication leads to therapeutic loss and waste of medications, 
which includes unused medication, either disposed of or returned to the pharmacy, or 
medication kept at home without being used. In the UK, it is estimated that £4 billion 
worth of medication prescribed by the NHS is not used as prescribed (Nunes et al., 2009; 
Tanna and Lawson, 2016a) and almost $8 billion worth in the US, where 3-7% of 
medication is wasted (Tchen et al., 2013). In Iraq, the cost of wasted medication is 
unknown because there are no studies that have, to date, focussed on medicine wastage 
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or on non-adherence. In addition to the effects that poor adherence has on health, it also 
has the potential to impact medication development and manufacturing, where the 
estimated losses incurred by US pharmaceutical companies in 2012 were $188 billion 
(Ken, 2015).  
Considering the consequences of non-adherence already mentioned, it is very important 
that different methods, as applicable to different settings, are developed for assessment 
of medication non-adherence. 
2.2. Assessment of Medication Non-adherence 
Although various strategies have been employed to measure medication non-adherence, 
there is no gold standard for routine clinical practice (Kennedy et al., 2008). Each method 
used for the assessment of non-adherence has its own strengths and weaknesses, with 
trade-offs between accuracy and practicality. Moreover, each method provides different 
information on medication (Vitolins et al., 2000; Lehmann et al., 2014). Methods used to 
measure adherence can be categorised into the indirect and the direct, as summarised 
below. 
2.2.1. Indirect Methods 
Indirect methods include patient diaries, patient interviews, pill counts, electronic 
monitoring, adherence questionnaires, and pharmacy refill prescription databases and 
clinical outcomes. These methods are widely used and easily carried out (Mathes et al., 
2014). 
2.2.1.1. Patient Diaries 
Patient diaries are the only self-report tool that documents how the patient follows their 
prescribed regime(s). The use of patients’ diaries as a tool to assess adherence is 
optimistic and subject to overestimation; furthermore, assessment cannot be carried out 
if the patient does not return the diary (Lam and Fresco, 2015; Tanna and Lawson, 2016a). 
This approach cannot be used in Iraq to assess non-adherence because patients’ diaries 
are not updated and are badly documented and stored. 
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2.2.1.2. Patient Interview 
Patient interviews are a non-invasive, straightforward, low-cost subjective method by 
which to assess patient medication non-adherence (Farmer, 1999; Suzanne, 2011). 
Typically, the doctor or the pharmacist asks the patient to report the medication name, 
dose and time of drug intake. The doctor may ask the patient how often per week or per 
month they forget to take their medication; based on the answers, the level of medication 
non-adherence can be determined (Vik et al., 2004; Lam and Fresco, 2015). Nevertheless, 
the assessment of non-adherence through interviewing patients is strongly affected by the 
communications skills of the interviewer (Farmer, 1999). Thus, patient interview is 
subject to overestimation, bias and cannot confirm that medications have been taken as 
prescribed (Osterberg and Blaschke, 2005). 
2.2.1.3. Pill Counts 
Pill counts involve counting the number of dosage units that have been taken between 
two scheduled appointments or clinic visits (Lam and Fresco, 2015). To calculate the 
percentage adherence, the number of pills taken by the patient is divided by the number 
of pills prescribed, the value of which is then multiplied by 100; patients are described as 
adherent when the percentage is 80% or more (Lam and Fresco, 2015). This provides an 
indication of the number of medication units taken by the patient within a given period of 
time (Neiheisel et al., 2014). However, the accuracy of pill counts as a tool for estimating 
medication adherence is uncertain because some patients may not return their unused 
medication (Lawrence et al., 2017). Pill counts is easy applicable and cheap; however, 
there is no confirmation that the patients actually took the medication (Tanna and Lawson, 
2016a).  
2.2.1.4. Electronic Monitoring 
Electronic monitors consist of a microprocessor placed in the medication container. The 
microprocessor is activated and records the date and time at which the patient opens the 
cap of the medication container (Lehmann et al., 2014). Additionally, an electronic 
monitoring device provides accurate information on the time at which the container was 
opened, and thus can provide information about daily adherence variation (Urquhart, 
1997; van Heuckelum et al., 2017). However, such technology is expensive, used more 
in clinical trials, and has limited use for patients taking multiple forms of medication 
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(Lam and Fresco, 2015; Sidorkiewicz et al., 2016). The device is suitable for solid 
pharmaceutical dosage forms and again cannot confirm that the patient has actually taken 
the medication (Choo et al., 1999; Rosen et al., 2004; Lehmann et al., 2014) as patients 
may open the container and then merely discard the medication.  
There are different models of such electronic devices; some can provide information 
about medication adherence patterns to the provider by telephone or modem (Bosworth, 
2014). Some more modern examples are equipped with adherence aids that can remind 
patients to take their medication as prescribed (Haberer et al., 2012). There are various 
limitations to this kind of technology, however; for instance, a patient may take multiple 
doses at a given time when opening the cap just once, or possibility taking more than one 
dose each time they open the cap, especially when leaving home or travelling. 
Furthermore, the recorded data requires the accompanying technology to interpret the 
data collected, and it is a challenge to monitor all the individual forms of medication being 
taken by the patient (Lehmann et al., 2014).  
2.2.1.5. Questionnaires  
A questionnaire can provide both quantitative and qualitative results. Answers that are 
obtained by closed-ended questions with multiple choice provide quantitative results and 
answers that are obtained by open-ended questions provide qualitative results (Research 
Methodology, 2019). Questionnaires can be done by face-to-face and telephone 
interview, on the web or by self-completion (Phillips and Stawarski, 2008).  
Questionnaires are cheap, easily done. However, Questionnaires need that respondents 
must be able to read the questions and respond to them. Therefore, some outcomes by 
questionnaires may not be actual. Moreover, respondents may not able to express their 
other thoughts about a problem because of the absence of a related question (Research 
Methodology, 2019). 
Questionnaires are the most commonly used in the clinical practice for assessing 
medication non-adherence because questionnaire is the cheapest and the simplest method 
in terms of routine care (Osterberg and Blaschke, 2005; Garfield et al., 2011; Stirratt et 
al., 2015). Some questionnaires (Table 2.1) provide information about factors associated 
with medication non-adherence such as forgetfulness and the adverse effects of 
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medications or beliefs (Ogedegbe et al., 2003; Krousel-Wood et al., 2004; Ogedegbe et 
al., 2004). However, questionnaires cannot provide essential information associated with 
clinical outcomes, such as the timing of the doses (Tanna and Lawson, 2016a). Moreover, 
patients tend to overestimate their levels of adherence (Dunbar-Jacob et al., 1991). 
Questionnaires are subject to social desirability and patient recall (Steiner and Prochazka, 
1997; Choo et al., 1999; Althubaiti, 2016).  
A systemic review by Nguyen et al. identified 43 validated questionnaires, which have 
been validated with other approaches such as pharmacy records or electronic monitoring 
across different populations and showed significant correlation. These questionnaires can 
be grouped into five distinct sets:  
• Questionnaires that assess medication-taking behaviour. 
• Questionnaires that assess medication-taking behaviour and barriers to 
adherence. 
• Questionnaires that assess only barriers to adherence. 
• Questionnaires that assess barriers and beliefs. 
• Questionnaires that assess beliefs only.  
Among these validated questionnaires, only 21 valid questionnaires were used to assess 
adherence to medication for cardiovascular diseases (Nguyen et al., 2014). There is no 
agreement as to the best form of questionnaire (Eskås et al., 2016). The eight-item 
Morisky Medication Adherence Scale (MMAS-8) was used in this study because all 
studies in Iraq regarding non-adherence was done by questionnaires and this provide a 
chance to compare the results of the present study with previous studies in Iraq. MMAS-
8 is short, easily scored, can assess non-adherence and identify some reason associated 
with non-adherence such side effects and forgetfulness. MMAS-8 also can define whether 
non-adherence is intentional or unintentional based on the patient response to the 
questions (Detailed information described in detail in Chapter 4).  
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Table 2.1. Validated questionnaires used to assess adherence to cardiovascular diseases 
(Nguyen et al., 2014). 
Cardiovascular diseases Questionnaire Application 
Hypertension/Dyslipidaemia Adherence Self-Report 
Questionnaire 
Medication-taking behaviour 
Medication Adherence 
Rating Scale - 5 
Medication-taking behaviour 
Stages of Change for 
Adherence Measure 
Medication-taking behaviour 
Brief Medication 
Questionnaire 
Medication-taking behaviour 
and barriers 
Hypertension/Dyslipidaemia Choo et al. Questionnaire  Medication-taking behaviour 
and barriers to adherence 
Fodor Adherence 
Questionnaire 
Medication-taking behaviour 
and barriers to adherence 
Hill-bone Compliance Scale 
- 10 
Medication-taking behaviour 
and barriers to adherence 
Hill-Bone Compliance Scale 
- 14 
Medication-taking behaviour 
and barriers to adherence 
Morisky Medication 
Adherence Scale (MMAS-8) 
Medication-taking behaviour 
and barriers to adherence 
Hypertension/Heart failure 
Dyslipidaemia/ 
Coronary heart disease 
Reported Adherence to 
Medication Scale 
Medication-taking behaviour 
and barriers to adherence 
Hypertension/Heart failure 
Dyslipidaemia 
 
 
Medication Adherence 
Questionnaire (4-items) 
Barriers to adherence 
Medication Adherence Self-
Efficacy Scale 
Barriers to adherence 
Medication Adherence Self-
Efficacy Scale-Revised 
Barriers to adherence 
Hypertension/Dyslipidaemia 
Coronary heart disease 
Self-Efficacy for 
Appropriate Medication Use 
Scale 
Barriers to adherence 
Coronary heart disease Gehi et al. Adherence 
Question 
Medication-taking behaviour 
Hypertension/Heart failure 
Coronary heart disease 
Beliefs about Medicines 
Questionnaire 
Beliefs 
Maastricht Utrecht 
Adherence in Hypertension 
Barriers and beliefs 
Heart failure Adherence to Refills and 
Medications Scale 
Medication-taking behaviour 
and barriers to adherence 
Adherence Starts with 
Knowledge - 12 
Medication-taking behaviour 
and barriers to adherence 
Adherence Starts with 
Knowledge - 20 
Medication-taking behaviour 
and barriers to adherence 
Medication Adherence 
Reasons Scale 
Barriers to adherence 
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2.2.1.6. Pharmacy Refills and Claim Data 
Clinicians or pharmacists may assess non-adherence to medication by reviewing 
pharmacy records. Pharmacy databases can be checked when prescriptions are initially 
filled out, repeated or prematurely discontinued. Repeat prescription records provide data 
on the quantity of the medications prescribed (Sidorkiewicz et al., 2016). This approach 
can be used to assess non-adherence, especially in a large population, to multidrug 
regimens (Bosworth, 2014; Lam and Fresco, 2015). However, one of the recognisable 
limitations to this method is that adherence can only be estimated for patients who 
purchase their medication from a certain pharmacy in order to track medication refills 
(Osterberg and Blaschke, 2005).  
The application of this approach depends on the availability of a computerised system, 
which is considered to be a major limitation in countries with limited infrastructure such 
as Iraq, with no confirmation that medications have been taken as prescribed and which 
consequently may result in medication adherence overestimation (Krousel-Wood et al., 
2015; Sidorkiewicz et al., 2016). 
Adherence according to pharmacy refills and claim data is defined as the number of refills 
obtained over time/number of months of follow-up. Patients are considered as adherent 
based on pharmacy repeat prescription data, when the number of repeat prescriptions 
obtained over time/number of months is 80% or greater. This percentage is considered as 
a cut-off point to categorise a patient as adherent or non-adherent (Ho et al., 2009). 
However, there is evidence that blood pressure and LDL cholesterol are decreased with 
an adherence of more than 80%, and this suggested that optimal adherence is achieved 
beyond this point (Bryson et al., 2007). This cut-off point, however, may be too low to 
be effective for other conditions (Ho et al., 2009).  
2.2.1.7. Clinical Outcomes 
Clinical outcomes are a poor indicator of adherence since they may depend on other 
unrelated factors, for instance, patients who are adherent to their antihypertensive 
medications may have uncontrolled blood pressure due to a high dietary intake of salt, or 
increases in body weight, or due to alcohol consumption (Feldman et al., 1998, Murray 
et al., 2009).  
 35 | P a g e 
 
Moreover, clinical outcomes cannot give an idea about non-adherence to each medication 
in the medical regimen for patients taking more than one medication. Healthcare 
providers may increase the number of medicines to add synergic action because they may 
think that the medication(s) are not efficient or may follow new strategies such as 
increasing the doses of medications that the patient already adheres to (Sokol et al., 2005; 
Lam and Fresco, 2015). In addition, they may prescribe expensive medication without 
any real assessment of patient adherence. These factors ultimately may lead to 
uninformed decisions being made by physicians with potentially dangerous and 
expensive consequences.  
2.2.2. Direct Methods 
Direct methods involve the direct observation of the patient taking medicines or analysis 
of biological fluids (such as urine or blood) for the existence of the drugs or their 
metabolites, or the detection of biological markers added to medications (Lam and Fresco, 
2015).  
2.2.2.1. Direct Observation  
Directly observed therapy (DOT) involves inviting patients to the clinic to ingest their 
medications under the direct supervision of a nurse. Hameed et al. (2015) and Gupta et 
al. (2016) reported that the assessment of adherence to antihypertensive medications via 
DOT showed that non-adherent patients were admitted to hospitals due to sudden drops 
in blood pressure because the previously avoided dose of antihypertension medications 
was now being taken (Hameed et al., 2016; Gupta et al., 2016).  
Direct observation is accurate and non-invasive, but its main limitations are that direct 
observation is cost- and labour-intensive. This approach is inconvenient for patients and 
impractical in an outpatient setting, as patients may have to travel long distances to get to 
the hospital and may then have to spend half a day at the clinic. In addition, patient 
supervision has to be undertaken by appropriately trained personnel. Moreover, the 
patient can manipulate medication taking by hiding tablets in their mouths (Hawkshead 
and Krousel-Wood, 2007). 
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Another development in this field is the use of ingestible electronic sensors that are 
attached to pills to track medication ingestion (digital pills) (Abderrahman, 2018). 
However, patient security and privacy may be of concern when sensors are used in this 
manner (Aldeer et al., 2018). 
2.2.2.2. Therapeutic Drug Monitoring in Biofluids 
Therapeutic drug monitoring (TDM) is defined as the management of a patient’s 
medication regime based on the concentration of the target medication in serum, plasma, 
or whole blood (Clarke, 2016). Direct methods measure the concentration of drugs or 
their metabolites in biological fluids such as blood, urine, saliva, sweat or hair. The 
assessment of non-adherence by the direct method of using biological markers is limited 
as biomarkers are only available for a limited number of drugs (Lehmann et al., 2014) 
such as low-density lipoprotein (LDL) levels of statins, platelet function tests for aspirin, 
and other anti-platelet medications. However, they cannot distinguish whether poor 
adherence can be attributed to the pharmacology of the drug or the biology of the patient 
(Kronish and Ye, 2013).  
Measuring the concentration of drugs or metabolites in a biological fluid can be 
performed either at specified intervals or randomly. It provides an indication as to whether 
the patient has taken the medicine (Morrison et al., 2015). Consequently, direct methods 
of assessment are the most accurate approach to measuring adherence (Aonuma et al., 
2017). Conventional direct methods using blood as a biosample require large volumes (1-
10 ml) to obtain a sufficient volume of plasma or serum (Tanna and Lawson, 2016b), and 
can be carried out via liquid chromatography (LC)-tandem mass spectrometry (MS/MS) 
or LC-MS (Gonzalez et al., 2010; Gonzalez et al., 2011; Dias et al., 2013; González et 
al., 2015). In order to get the necessary volume, patients need to visit a phlebotomist. 
Conventional direct methods have special requirements associated with the collection of 
samples (use of a syringe, collection tube, etc.) and their transportation and storage 
(cooling box), thereby increasing the cost and making them unsuitable in routine clinical 
practice for therapeutic drug monitoring (Lawson et al., 2013; Tanna and Lawson, 2016a; 
De Nicolò et al., 2017).  
Urine samples provide a non-invasive means by which to confirm that a particular 
medication has been ingested by detecting the drug either directly or through one of its 
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metabolites as it is eliminated from the body. However, this approach is limited to drugs 
that are predominantly metabolised and excreted in urine (Lehmann et al., 2014). Also, 
in Iraq, using urine as a biosample for assessment of adherence may represent a challenge 
as some individuals might have reservations for cultural and religious reasons. Urine 
samples require sterile containers with boric acid to preserve the sample and prevent 
overgrowth of organisms during transport to the laboratory. Urine samples should be 
stored in a fridge when there is any delay in their transportation (National Health Service, 
2018a). Urine analysis by LC-MS/MS has been used for screening adherence to 
antihypertensive medications for patients exhibiting resistant hypertension (Tomaszewski 
et al., 2014; Hamdidouche et al., 2015; De Nicolò et al., 2017; Hamdidouche et al., 2017).  
Other biological samples such as saliva, sweat and hair have been used to assess 
adherence to antiretroviral therapy and pain management medications because of their 
advantages over blood and urine such as being non-invasive, painless and stress-free 
sampling methods, providing information about the long-term use of medications, their 
low costs and the lack of any need to visit a clinic or hospital to collect samples (Olds et 
al., 2015; Moore, 2015; Ferrari et al., 2017). However, validation and study of the analyte 
stability should be considered before sample collection.  
2.2.2.3. Whole Blood Microsampling Analysis  
Considering the large volumes of blood required for conventional direct methods (as 
mentioned in the preceding section), microsampling might provide a valuable alternative 
for such analysis. Microsampling requires very small volumes of biofluid samples such 
as blood, plasma, urine and milk for determination of the concentration of the target 
analyte or endogenous substance, the most commonly used of which is dried blood spots 
(DBS) (Zane and Emmons, 2013; Ayre et al., 2018). DBS is a dried microsampling matrix 
which involves the collection of liquid whole blood as a dried sample on a paper-type 
substrate. DBS is an alternative matrix of measuring drug concentrations in the blood 
which requires the collection of a micro blood volume (< 30 μl) from a finger or heel 
prick, which has the potential to overcome the barriers associated with conventional 
methods which require blood collection using venepuncture.  
DBS was first introduced in 1960 by Dr Robert Guthrie to screen for phenylalanine in the 
blood samples of newborns in order to diagnose phenylketonuria (Shah et al., 2013). DBS 
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sampling is now used by public health laboratories for the screening of more than 95% of 
all newborns in the USA and 100% of UK newborns for metabolic disorders (Cavanagh 
and Coppinger, 2009; Deep et al., 2012).  
DBS sampling does not require highly skilled staff, and this enables samples to be 
collected by patients themselves or parents/guardians at home and then sent by standard 
mail services to a laboratory (Spooner, 2013). This allows for convenient drug monitoring 
at any time and during a routine check-up. Home sampling does not require patients to 
travel and thus provides them a potential means of money saving, and eliminates the need 
for specialised sample collection. Cost analysis by Martial et al. (2016) showed that DBS 
home sampling reduced the associated costs by 61% for renal transplant patients and 43% 
for haemato-oncology patients in comparison with conventional blood sampling methods 
(Martial et al., 2016). 
The advent of analytical instruments such as liquid chromatography–mass spectrometry 
(LC-MS), liquid chromatography–high resolution mass spectrometry (LC-HRMS) and 
immunoassay, has allowed the DBS technique to be used as an alternative to conventional 
methods. DBS sampling has been used in therapeutic drug monitoring for a wide range 
of medications as detailed in the Table 2.2.  
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Table 2.2. Examples of therapeutic drug monitoring by application of DBS. 
Medications References 
Antiepileptic drugs (Shah et al., 2013; Shah et al., 2013; Linder et 
al., 2016; Das et al., 2017; Linder et al., 2018) 
Immuno-suppressants 
(Koop et al., 2013; Koster et al., 2017; Martial 
et al., 2017; Veenhof et al., 2017) 
Antiretroviral medications 
(Castillo-Mancilla et al., 2013; Hoffman et al., 
2013; Zheng et al., 2014; Alcaide et al., 2017). 
Cardiovascular medications 
(Lawson et al., 2012; Lawson et al., 2013; 
Tanna and Lawson, 2014a; Bernieh et al., 
2017a) 
Antibiotics 
(Al-Ghazawi and AbuRuz, 2010; la Marca et 
al., 2012; Hawwa et al., 2014; Vu et al., 2014; 
Barco et al., 2017; Weber et al., 2017) 
Antidiabetic medications 
(Scherf-Clavel and Högger, 2015) 
Antimalarial drugs 
(Blessborn et al., 2010; Ippolito et al., 2018) 
Pharmacokinetic / toxicokinetic studies 
(Kole et al., 2017) 
Forensic applications of drugs of abuse 
(Chepyala et al., 2017) 
Sports for doping analysis 
(Verplaetse and Henion, 2016) 
Environmental analysis 
(Provatas et al., 2017) 
Food safety 
(Xue et al., 2016) 
Endocrinology and metabolism 
(Heussner et al., 2017) 
2.2.3. Advantages of Blood Microsampling 
Conventional methods of blood sampling require a large volume of blood to obtain the 
required plasma volume. However, from the patients’ perspectives, conventional methods 
are painful, discomforting, frightening, and the blood collection requires a phlebotomist. 
On the other hand:  
• Microsampling requires low blood volumes (< 30 μl) in comparison with 
conventional methods that require an amount of blood (1-10 ml) to obtain the 
required plasma (Tanna and Lawson, 2016a; De Nicolò et al., 2016).  
• Microsampling can be considered “patient friendly” with high patient 
acceptability because blood sampling onto DBS is collected via a minimally 
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invasive approach (Wilhelm et al., 2014; Sharma et al., 2014; Verhaeghe et al., 
2017).  
• Microsampling offers huge savings in terms of cost of shipment. DBS samples are 
easily transported and stored, where DBS samples can be shipped by post without 
special treatment such as a cold box, dry ice or the special equipment at clinical 
sites required for liquid blood or plasma (Sharma et al., 2014).  
• Dried blood spot provides better analyte stability because analytes are held in a 
dried matrix rather than a liquid matrix (Waterman and Adami, 2005; Manicke et 
al., 2016). 
•  Dried microsampling matrix reduced possibility of exposure of biohazards (Zane 
and Emmons, 2013; Sharma et al., 2014; Nys et al., 2017).   
• One of the unique characteristics of microsampling is the possibility of self-
sampling at home by patients (Spielberg et al., 2000) at any desired sampling time 
(Tanna and Lawson, 2014a). Samples can be sent to a laboratory for analysis 
through the regular post (Spooner, 2013). Thus, there is no need for appointments, 
clinical visits and the services of a phlebotomist; consequently, this approach 
should yield significant savings (Martial et al., 2016). The advantages of 
microsampling, including the small volume of blood required for any given 
analysis, have attracted research in the area such as the assessment of medication 
non-adherence, newborn screening (NBS), therapeutic drug monitoring (TDM), 
pharmacokinetic (PK) and toxicokinetic (TK) studies, paediatric studies, 
metabolism and pharmaceutical drug development.  
2.2.4. Current Microsampling Methods 
2.2.4.1. Card Microsampling 
The popularity of dried blood spots has increased due to the small blood volume required, 
low associated costs and good adsorption properties of filter paper, which can be easily 
disposed of because DBS cards are biodegradable or otherwise easily incinerated (Pelton, 
2009). 
Commercially available blood sample collection cards can be grouped into two types, 
namely untreated and chemically treated cards (Wagner et al., 2014). Cards are either 
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cellulose in nature (e.g., Whatman 903, Ahlstrom 226) or non-cellulose-based materials 
(e.g., Tomtec PDMS 7, polyester cards). The loading capacity and blood spreading on the 
filter paper are mainly determined by card thickness, pore size and particle retention 
(Quraishi et al., 2013).  
Three filter paper sampling cards (Perkin-Elmer 226, Ahlstrom 226 and Whatman 903) 
are recommended by the Clinical and Laboratory Standards Institute (CLSI) as the 
conventional devices for blood sample collection. These (cellulose) cards are registered 
by the U.S. Food and Drug Administration (FDA) as in vitro Class II medical devices and 
approved by the Newborn Screening Quality Assurance Program (NSQAP) and the 
Centres for Disease Control and Prevention (CDC) (Wolff, 2017).   
In card microsampling, a few drops of blood are collected on filter paper by a finger prick 
or heel prick, popularly known as DBS cards. Extraction of the target analytes from blood 
samples collected on DBS cards is achieved by punching a fixed size disk from the spot, 
which is then analysed (Figure 2.1). The fixed diameter disk punched from the spot is 
directly proportional to the volumetric measure used in quantitative analysis (Lawson et 
al., 2013). The size of the punched disk acts as volumetric measure of the spotted sample 
as long as the blood has been homogenously absorbed (Mei et al., 2011). It is assumed 
that each punched disk contains the same fixed volume of blood. Haematocrit (HCT) 
level effects the way in which the blood spreads and, consequently, spot size, thickness 
and drying time (Timmerman et al., 2011; Tanna and Lawson, 2016a). HCT represents 
the volume percentage of red blood cell in the blood and it is normally 47% ± 5% for men 
and 42% ± 5% for women (Walker et al., 1990). HCT values may deviate from the normal 
range in certain diseases which affect the percentage volume of red blood cells, such as 
anaemia and polycythaemia, which is a condition in which an excessive number of red 
blood cells are produced by the bone marrow cells.  Blood with high levels of HCT is 
more viscous and produces smaller spots on DBS cards. Thus, the HCT effect is 
significant when a punch is used (O’Mara et al., 2011). 
The problem associated with HCT can be overcome by analysis of the whole spot or pre-
cut disks (Youhnovski et al., 2011; De Kesel et al., 2014; Bernieh, 2017b) or by 
application of volumetric absorptive microsampling (VAMS), which is a novel device 
that utilises a fixed volume of blood regardless of the HCT level. Other developments 
 42 | P a g e 
 
include the HemaSpot–HF blood collection device, Noviplex cards, the Hemaxis-DB 
blood collection device, Ahlstrom 167L cards and Tomtec dry media spot slides (Tanna 
and Lawson, 2016a). 
 
Figure 2.1. A Whatman 903 card containing four spots of dried blood and two spots 
punched from the marked sections. 
 
2.2.4.2. Volumetric Absorptive Microsampling (VAMS) 
Volumetric absorptive microsampling (VAMS) is a novel device for biological fluid 
collection, in particular whole blood. This device has been designed to overcome 
inhomogeneity and blood volume inconsistency, and HCT issues (Denniff and Spooner, 
2014). It consists of a polymeric absorbent tip located on a moulded plastic handle.  
Blood samples are collected by dipping the tip in the blood and waiting until the tip turns 
completely red, which takes 2-3 seconds. The tip of the sampler must not be completely 
submerged into the blood sampler, as this may cause overfilling (Tanna et al., 2018). 
VAMS collects an accurate and precise volume of blood (10 μl or 20 μl) with less than 
±5% volume variation directly from the finger, regardless of HCT level (Denniff and 
Spooner, 2014). The entire sample is used for extraction because a precise volume is 
taken. VAMS come in two or four separated sampling devices in a clamshell which can 
be closed after sample collection, and which are then allowed to dry. On the clamshell, 
there is a label with which to register sample details and information. Figure 2.2 shows 
the VAMS device before application (white tip) and after application of the blood sample 
and use (red tip). 
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Figure 2.2. VAMS consists of a polymeric absorbent tip located on a moulded plastic 
handle. The unused device has a white tip, while the red tip indicates a used device as it 
contains dried blood (Denniff et al., 2015). 
2.2.5. Blood Sample Collection, Spotting and Storage on DBS and VAMS  
Capillary blood collection is the conventional approach to microsampling in which blood 
can be collected from a finger (adults) or heel prick (children) as an alternative to 
venepuncture. The sampling kit consists of either a DBS card or VAMS, a disposable 
tractable sterile lancet, gauze, plaster, desiccant, and zipper storage bags for shipping.  
To encourage blood flow, it is recommended that the fingertip or heel be gently massaged, 
after which the finger is pricked with a retractable lancet. The first drop of blood is wiped 
using sterile gauze and then gentle pressure is applied to deposit a few drops of blood 
onto the marked spotting area on a sampling card or onto the tip of a VAMS device. This 
is then labelled appropriately. DBS samples are left horizontally in a clean place at room 
temperature to dry for at least three hours before storage in the zipper bag with a desiccant.  
2.2.6. Analytical Challenges to Using Dried Matrix Microsampling 
Dried matrix microsampling involves the collection of microvolumes of biosamples such 
as plasma, urine and milk in a dried form onto a dried substrate, the most commonly used 
of which is dried blood spots (DBS) (Ayre et al., 2018). The small sample size and the 
complexity of the matrix and lack of sophisticated detection techniques with sufficiently 
high sensitivity and selectivity resulted in the limited popularity and application of 
microsampling. With the advent of instrumentation such as LC and MS, however, the 
application of this approach has increased (Tanna and Lawson, 2011), and has allowed 
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the quantification of various target analytes in biosamples. Currently, HCT levels have 
been identified as a particularly significant parameter in terms of their influence in 
quantitative analysis in card microsampling methods, as detailed in Section 2.3.4.1. 
Challenges still exist with the collection of microvolumes of blood on DBS cards due to 
problems with analyte recovery from the microsamples, interference from the DBS card 
and blood matrices which sometimes interfere with MS analysis. Sample aging with long-
term storage prevents analyte recovery from paper (Wagner et al., 2014). Moreover, 
issues relating to analyte stability for some compounds such as antiepileptic drugs have 
led to difficulties in recovering the sample from the card (Linder et al., 2016).  
2.2.7. Extraction of Target Analytes from Dried Blood Matrix 
The extraction of DBS can be performed online using flow-through extractions or offline 
by punching DBS spots and placing them in microcentrifuge tubes or well plates before 
using extraction solvents (Heinig et al., 2011).  
Biosamples are complex in nature, and the target analyte is normally present at a lower 
concentration than other constituents (Gjelstad and Pedersen-Bjergaard, 2014). 
Therefore, a clean-up procedure by using of organic solvents such methanol or 
acetonitrile is required to eliminate unwanted materials from the blood and/or card matrix 
before concentration and analysis (Bylda et al., 2014; Tanna and Lawson, 2016a). 
Moreover, the small volume of sample used requires a robust extraction protocol to ensure 
that the analyte is appropriately recovered and detected.  
Dried blood spots are solid samples that must be extracted with an appropriate solvent to 
allow compatible analytical techniques to be used, such as LC-MS. The main extraction 
technique used for analyte extraction from dried blood matrix (DBS and VAMS) is solid-
liquid extraction (SLE) (Cape et al., 2017). 
In solid-liquid extraction, the solid phase is the DBS punched disk or VAMS tip, whilst 
the liquid phase is the extraction solvent. The efficiency of the SLE depends on three 
factors: the target analyte solubility, the matrix effect of the card, and the matrix effect of 
the biosample (Alkhateeb, 2015).  
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Analytes which are tightly bound to proteins and retained on the card, such as amlodipine, 
are extracted by adding 0.5 M sodium hydroxide (NaOH) to the extraction solvent to 
hydrolyse the drug-protein bond to increase the efficiency of the extraction and recovery 
of the target analyte. Following extraction, the resulting supernatant is dried with nitrogen 
gas and reconstituted prior to analysis (Bernieh, 2017b). 
2.2.8. Analytical Techniques Used in Conjunction with Dried Matrix 
Microsampling  
Since the introduction of microsampling, several analytical techniques have been utilised 
for target analyte qualification and identification. For instance, immunoassay methods, 
polymerase chain reaction (PCR)-amplified DNA analysis, high-performance liquid 
chromatography (HPLC), and techniques such as gas chromatography mass spectrometry 
(GC-MS), liquid chromatography-mass spectrometry (LC-MS), liquid chromatography- 
tandem mass spectrometry (LC-MS/MS) and liquid chromatography-high resolution 
mass spectrometry (LC-HRMS) (Tanna and Lawson, 2011).   
2.2.8.1. Immunoassay  
Immunoassay has commonly been used for drug quantification since the 1980s in parallel 
with chromatography methods such as liquid chromatography before the implementation 
of MS detectors in bioanalysis (Cape et al., 2017). Immunoassay depends on the 
selectivity of antibodies in combining with the target medications or metabolites 
(antigens) and in providing signalling or labelling capabilities. The complex which results 
from the antigen-antibody bonding constitutes the selectivity step, and it is necessary for 
the complex to produce a measurable signal that can be directly correlated with level of 
the complex formation (Cox et al., 2014). The availability of this method is restricted to 
kits which may be expensive and specific to a certain target (Tanna and Lawson, 2016a).  
The assays require the handling radioactive materials, prolonged incubation times, and 
choosing the specific antibody for the analyte of interest (Shipkova et al., 2017). 
However, there is possibility of false positives due to cross-reactivity with endogenous 
components that are similar in structure and/or reactivity to the drugs or metabolites 
themselves (Sturgeon and Viljoen, 2011; Cape et al., 2017; Harper et al., 2017). 
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This technique has been used to quantify biomarkers in DBS samples such as 
Apolipoprotein B (ApoB) and C-reactive proteins. ApoB is a biomarker of CVD risk 
(Eick et al., 2017), which is the main protein found in low-density lipoproteins (LDL). 
LDL is amongst the most important causal agents of atherosclerotic cardiovascular 
disease (Shapiro and Fazio, 2017). C-reactive protein is indicative of the inflammatory 
processes related to the pathophysiology of CVD, where slight increases in CRP (> 1–2 
mg/L) indicate a risk of developing cardiovascular problems (McDade et al., 2004).  
2.2.8.2. Liquid Chromatography–Mass Spectrometry (LC-MS)  
Over the past twenty years, the key tool for qualitative and quantitative bioanalysis has 
been LC-MS (Xie et al., 2012). LC-MS provides effective, rapid and specific quantitative 
and qualitative data for the determination of biomarkers in plasma to help in TDM, TK 
and PK studies, metabolism, drug discovery and neonatal screening. LC-MS, operating 
in single ion monitoring mode (SIM) and using a single mass analyser (a quadrupole mass 
filter), is shown in Figure 2.3.  
 
 
Figure 2.3. Schematic structure of a liquid chromatography coupled to a mass 
spectrometer. 
 
The quadrupole mass filter has a relatively low resolution and is only able to measure the 
m/z ratio of an ion to the nearest integer value, and therefore cannot necessarily provide 
or distinguish the elemental composition of an ion (Breidinger and Woolf, 2017). This 
represents a challenge in specificity since there may be several compounds with the same, 
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or nearly the same mass-to-charge ratio (m/z) as the analyte of interest (Lawson et al., 
2012). 
LC-MS also uses a soft ionisation mechanism that primarily yields molecular ions, that 
is, with very little or no fragmentation of the molecule. Therefore, it is unlikely that the 
molecular mass alone will make structural assignment possible. Hence, where there is a 
lack of any data on fragmentation patterns, dependence on retention time will not be 
sufficient to offer the required selectivity. However, the introduction of tandem mass 
spectrometry instruments has solved this problem (Tanna and Lawson, 2011). 
2.2.8.3. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)  
LC coupled with MS/MS has various advantages that include ease of use, specificity, low 
detection limits and high throughput (Li and Lee, 2014; Zakaria et al., 2016). LC-MS/MS 
has gained a considerable reputation in routine laboratories and its application has been 
extended to therapeutic drug monitoring (TDM), newborn screening (NBS), and 
toxicology and drug discovery.  
The increase in the application of LC-MS/MS in DBS analysis is due to developments in 
analytical instrumentation which provide unique specificity, fast method development, 
and simultaneous analysis of various drugs and their metabolites in microsamples within 
a short timeframe (Zakaria et al., 2016). For example, LC-MS/MS has been used for 
quantification of antihypertensive medications (Chernonosov, 2018), oncolytic agent 
(Wickremsinhe et al., 2018), illegal drugs such as cocaine, benzoylecgonine, ecgonine 
methyl ester, norcocaine, meta-hydroxy-benzoylecgonine, cocaethylene (Ambach and 
Stove, 2019). LC-MS/MS also used for analysis of vitamin D (Heath et al., 2014).  
The basic design of an MS/MS includes two mass analysers (MS1) and (MS2) with a 
collision cell between them (Figure 2.4). The ion preselected by MS1 is allowed to enter 
the collision cell where dissociation occurs, the product ions from which are monitored 
by MS2. The target ion (precursor ion) of a specific mass-to-charge ratio (m/z) is selected 
by MS1 and the characteristic fragmentation pattern for that specific compound is 
determined by MS2. This combination of data provides a unique fingerprint through 
which to identify the MS1 precursor ion. Identification is achieved by tuning MS1 to a 
specific mass-to-charge ratio (m/z) and monitoring the characteristic m/z value via MS2. 
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Analysis by LC-MS/MS requires optimisation of MS/MS parameters such as choosing 
the appropriate precursor and product ions and collision energy (CE) optimisation, which 
are different for each compound of interest (Zhang et al., 2009). In LC-MS/MS, only the 
preselected ions that are derived from the sample by MS1 enter the collision cell. Any 
data related to other ions in the sample will be thus be lost, hence there is no possibility 
of rechecking the data collected to look for information on other ions if so required. 
Application of LC-HRMS instruments (Bowen et al., 2016) resolve most of these 
challenges because in HRMS all ions are recorded with the further possibility of revisiting 
data when required, as further detailed in Section 2.3.8.4. 
 
 
Figure 2.4. Schematic structure of liquid chromatography coupled to tandem mass 
spectrometry  
 
2.2.8.4. Liquid Chromatography–High Resolution Mass Spectrometry (LC-
HRMS)  
Although the standard technique for the quantitative bioanalytical assays is LC-MS/MS, 
there has been increased interest over the years within the bioanalytical society in other 
MS approaches with regards to solving certain bioanalytical challenges (Zhang et al., 
2009; Kaufmann et al., 2011). One such alternative to traditional LC-MS/MS has been 
the use of LC coupled with high-resolution MS, that is, LC-HRMS. Thus, HRMS simply 
refers to a mass analyser with high resolving power. Resolving power refers to the ability 
to discriminate species with near-identical m/z values.  
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For years, HRMS was mainly used in a qualitative manner in drug metabolism and 
metabolite identification studies; the reason for this was due to the poor sensitivity of 
older HRMS instruments (Ramanathan and Korfmacher, 2012). However, the suitability 
of HRMS for use in quantitative analysis has recently been improved through 
advancements in instrumentation; for instance, accurate mass determination, where the 
mass of the molecular ion can be measured to better than 1.0 ppm of the relative molecular 
mass (RMM). Hence, this precise value can be used to determine the atomic composition 
based on, for example, C = 12.0000, H = 1.0078, N = 14.0031, O = 15.9949 and therefore 
the likely molecular structure. For example, considering three compounds of mass 266.3, 
where atenolol, a beta-blocker, (C14H22N2O3) = 266.3361, dienestrol (C18H18O2) = 
266.3340 and leptospermone (C15H22O4) = 266.3330, nominal mass measurements would 
be unable to differentiate these species; however, the ability of HRMS to measure to the 
fourth decimal place would allow their differentiation.  
The capability of full-scan acquisition has given HRMS the competitive edge. All mass 
spectral information from a sample is gathered, which offers the possibility to 
reinterrogate the data if such an approach were thought to be clinically important 
(Bernieh, 2017b). Additionally, as data is collected concurrently over a certain mass 
range, it is also likely that interfering ions produced by a sample matrix which interfere 
with the detection and quantification of the target compound will also be directly 
monitored and choosing of narrow extraction window will reduce interference and 
improve quantitative analysis (Meyer and Schilling, 2017). It has been argued that a 
paradigm would make HRMS in MS detectors the method of first choice (Rochat et al., 
2012).  
There is now an increasing use of HRMS in the quantitative analysis in early drug 
discovery (Korfmacher and Ramanathan, 2016), therapeutic drug monitoring (Oliveira et 
al., 2014), adherence to cardiovascular medications (Lawson et al., 2012; Lawson et al., 
2013; Tanna and Lawson, 2014a; Bernieh et al., 2017a), quantification of insulin and 
insulin analogues (Thomas and Thevis, 2018) and environmental studies (Krauss et al., 
2010). Figure 2.5 shows a diagram of the LC-QTOF-HRMS used for the analysis of dried 
blood spots in this study 
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Figure 2.5. A schematic diagram of an LC-QTOF-HRMS (Agilent Technologies, 2014) 
 
There are a number of HRMS platforms available to bioanalysts including the Q-TOF, 
TOF, Fourier transform ion cyclotron resonance and Orbitrap-based mass analysers 
(Sturm et al., 2016). HRMS can provide rich information in a single run and is now 
applied to resolve the majority of bioanalytical challenges across various fields (Zhang et 
al., 2009). For instance, it can provide multiple drug and metabolite profiling in a single 
run (Ma and Chowdhury, 2013; Ramakrishnan et al., 2016). The data acquired can be 
used to improve patient care. The ability of the instrument to perform simultaneous 
analyses of multiple species decreases the sample volume required in comparison to other 
techniques (Shipkova and Svinarov, 2016).  
High selectivity can eliminate interference in samples due to matrix effects, leading to a 
considerable increase in signal-to-noise ratio. LC-MS/MS assays may struggle with 
interference from matrix effects at lower detection limits in comparison with HRMS, and 
may require the use of complex sample preparation and chromatography to isolate the 
species of interest (Li and Tse, 2010). This high selectivity is derived from the fact that 
HRMS can separate mass fragments at m/z ratios that are accurate to the fourth decimal 
place.  
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There are still limitations that have prevented the wider acceptance of this technique 
across the bioanalytical community, whereas there is considerable enthusiasm for the use 
of HRMS to develop bioanalytical assays. However, Rago and Negahban argue that 
additional guidance is required from regulators regarding the acceptance of bioanalytical 
assays developed with HRMS (Rago and Negahban, 2016). 
Another challenge with the extension of HRMS to clinical studies is the informed consent 
process, since full-scan HRMS analysis preserves all the data derived from the sample. 
Therefore, without ensuring proper informed consent on the part of the patient or 
volunteer, the advantages of a full HRMS data scan cannot be realised; furthermore, the 
data generated from full-scan acquisitions requires a much higher storage capacity. The 
advantages and disadvantages of HRMS are summarized in Table 2.3.  
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Table 2.3. Advantages and disadvantages of HRMS. (Hird et al., 2014; Colby et al., 2017; 
Rochat, 2018) 
Advantages of HRMS Disadvantages of HRMS 
1. There is no need for selective molecular 
fragmentation for detection in HRMS except 
when using a Q-TOF instrument in MS/MS 
mode. 
2. HRMS platforms can record various 
acquisitions at high resolution with accurate 
mass determination to better than 1 ppm of 
the RMM, which enables discrimination of 
interferences with highly similar m/z values.  
3. HRMS is capable of full-scan acquisitions.  
4. In HRMS, full-scan acquisition allows a 
better overview of the analysed extract, 
because coeluting compounds, contaminants, 
adducts and charge state can be monitored, 
which are useful during method development 
and troubleshooting.  
1. Slow progress in the implementation of 
HRMS technology may be due to difficulties 
in changing the entire fleet of triple 
quadrupole MSs in clinical laboratories as 
the triple quadrupole can be replaced by an 
engineer.  
2. Cost of HRMS instruments is often twice 
or more that of the triple quadrupole MS. 
3. HRMS maintenance is more complex than 
standard triple quadrupole MS. 
4. Lack of official guidelines for HRMS data 
analysis and acceptability criteria by 
regulatory authorities.  
5. Problems associated with system 
robustness. HRMS requires calibration 
before running samples to maintain the high 
mass accuracy and resolution. 
6. Running HRMS in full-scan mode for 
large samples requires a very large data 
storage capacity.  
 
2.3. Gaps in the Literature  
There is no gold standard method by which to assess medication non-adherence. 
However, the application of multi-approach measures through a combination of feasible 
self-reporting approaches and reasonable objective approaches is recommended by the 
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WHO (Sabaté, 2003) in order to gain results that are likely to be close to reality. The 
selection of two (or more) methods that will allow the strengths of one method to 
compensate for the weaknesses in the other will provide higher reliability, and disclose 
further reasons for non-adherence, are now recommended (Rapoff, 2010, Lam and 
Fresco, 2015, Forbes et al., 2018). However, the complexity of analysis and interpretation 
of results should be considered when multi-measure approaches are applied (Modi et al., 
2006).  
Multiple methods with similar sources of errors, such as using two indirect (subjective) 
methods, will not be helpful to the accurate prediction of the level of adherence (Llabre 
et al., 2006). Also, cost and practicality should be considered (Lam and Fresco, 2015). 
Liu et al. (2001) showed that the application of multi-measures provides for the accurate 
predictive power of adherence measurement in comparison with using individual 
methods, confirms original findings, and minimises discrepancies (Liu et al., 2001; Van 
Onzenoort et al., 2010). 
Studies documenting levels of non-adherence to medication – particularly to CVD 
medications – in Iraq are limited, and those that exist used only indirect methods, with no 
comparisons to true non-adherence as measured by direct methods; no previous study in 
Iraq has assessed non-adherence to CVD medication using a direct method, either by 
conventional means or by application of DBS analysis. 
There is no previous study that assesses and compares non-adherence to the target 
cardiovascular medication using a combination of indirect methods by application of 
MMAS-8 and the application of less invasive direct methods via dried blood 
microsamples analysis onto 903 cards and VAMS via liquid chromatography high-
resolution mass spectrometry (LC-HRMS).  
The approach applied in this study gives information about medication-taking behaviour 
for each medication in the patient’s regimen using the direct approach, and about the 
reasons underlying such behaviour using the indirect approach. This approach will enable 
adherence to be tracked for each individual medication, which is helpful for medication 
dose optimisation and understanding the causes of non-adherence. The outcomes will 
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help healthcare providers and stakeholders to implement appropriate strategies to improve 
adherence.  
2.4. Aims and Objectives  
The aim of this research is to assess non-adherence to selected cardiovascular medications 
prescribed to Iraqi patient volunteers by application of two different approaches, namely 
a practice-based approach (indirect method) and a laboratory-based approach (direct 
method). The indirect approach involves the application of a standardised and validated 
Arabic version of MMAS-8, while the laboratory-based approach (direct method) 
involves the collection of microvolumes of blood on a special substrate (Whatman 903 
cards and a VAMS device).  
Analysis of the collected whole blood samples via a validated liquid chromatography 
high-resolution mass spectrometry (LC-HRMS) method will be used to answer the 
following questions: 
1. What is the level of non-adherence to cardiovascular medications among Iraqi 
cardiovascular patients as determined by application of an indirect method, namely the 
MMAS-8 questionnaire? 
2. What is the level of non-adherence to cardiovascular medications among Iraqi 
cardiovascular patients as determined by application of a direct method of determination 
of the target drugs’ concentrations in dried blood spots on 903 cards and using VAMS? 
3. What is the agreement between the indirect and direct methods of assessment of non-
adherence for the same volunteers? 
4. Is there concordance between cardiovascular drug concentrations measured via DBS 
cards and in via the VAMS device? 
5. What are the factors associated with non-adherence among Iraqi cardiovascular 
patients and what are the possible, successful and effective interventions which may 
tackle and improve adherence to cardiovascular medications in the target population? 
6. How can this research be adopted in the clinical practice in Iraq?  
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2.5. Conclusion  
Optimum clinical outcomes can be achieved by adherence to cardiovascular medication 
which will consequently reduce the morbidity, mortality and increased health expenditure 
due to waste of medications and increased demand on the health service. Different 
methods can be used to assess non-adherence to medications. Each method has its own 
strengths and weakness and there is no real agreement on the method of choice. The use 
of a questionnaire is popular in the clinical setting because of its low cost and ease of 
application. The eight-item Morisky Medication Adherence Scale (MMAS-8) is a 
standardised questionnaire which is widely used to assess non-adherence and some of the 
associated causes. Direct methods can assess non-adherence to each medication taken by 
the patient, but of course would be unable to determine the reasons associated with non-
adherence. Direct methods are well documented in the literature and require large 
volumes of blood, as collected by venepuncture. Whole blood microsampling approach 
requires few drops of blood collected by finger prick on a substrate such as 903 cards or 
VAMS in dried form is a successful alternative to conventional methods. These collected 
samples are easily transported by post with minimum requirements and low biohazard 
risk in comparison with conventional methods.  
A mixed approach between the direct method by analysis of blood microsamples using 
LC-HRMS and the indirect method through the use of MMAS-8 and integration of the 
outcomes from two approaches (MMAS-8 and LC-HRMS analysis) with face-to-face 
interview to assess non-adherence to CVD medications is considered a novel research 
through which to fill this gap in the literature. The rational to using this mixed approach 
is to provide more information about medication non-adherence based on individual 
medication and the associated reasons. The overall outcome of this research will help to 
improve the health care system in Iraq in terms of the patient’s health and quality of life, 
reducing the number of hospital admissions and eventually mortality rate 
Application of liquid chromatography coupled to high resolution mass spectrometry can 
achieve a full scan with high specificity using a precise mass to charge ratio for the target 
medication. The full scan method is useful for retrospective studies or can be used by the 
clinician if further information is required.   
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Chapter 3 
Determination of Cardiovascular 
Medication Levels in Microsamples and 
Assessment of Non-adherence 
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This chapter details the application of a previously validated liquid chromatography-high 
resolution mass spectrometry (LC-HRMS) assay for the simultaneous determination of 
nine commonly prescribed CVD medications (amlodipine, atenolol, atorvastatin, 
bisoprolol, diltiazem, lisinopril, losartan, simvastatin and valsartan) in finger prick 
microvolume blood samples collected from 303 Iraqi volunteers who had been prescribed 
one or more of these CVD medications. This chapter also investigates the correlation 
between the analyte concentration determined on 903 cards and VAMS for extraction of 
the target medications for the same volunteers.  
3.1. Introduction 
Measurements of CVD medication concentrations in plasma and serum using liquid 
chromatography mass spectrometry (LC-MS) or liquid chromatography-tandem mass 
spectrometry tandem (LC-MS/MS) is well documented in the literature (Gonzalez et al., 
2010; Gonzalez et al., 2011; Dias et al., 2013; González et al., 2015). However, as 
detailed in Chapter 2 Section 2.3.2.2, a relatively large volume of blood is needed when 
compared to microsampling. Microsampling involves the collection of only a very small 
volume (<30 μl) of blood to determine the concentration of the target analyte or 
endogenous substance (Zane and Emmons, 2013). Dried blood spot (DBS) is a type of 
microsample and is an alternative approach to conventional liquid blood sampling for 
drug quantification (Tanna and Lawson, 2014b).  
Studies have demonstrated a link between poor clinical outcomes in patients with 
cardiovascular diseases and medication non-adherence (Zullig et al., 2017). The 
prescribed medication should produce therapeutic drug levels in the blood. Medication 
adherence ensures that the prescribed drug concentration is within the therapeutic window 
so as to obtain the maximum benefits from medication and improve patient clinical 
outcomes (Tanna and Lawson, 2016a). Researchers and healthcare providers are therefore 
interested in medication adherence assessment to optimise treatment of patients and 
maximise drug efficacy.  
The value of maximum drug concentration (C max,), the time required for a drug to reach 
the maximum plasma concentration (tmax) and time required for a drug concentration to 
decrease to one-half of the initial concentration (t1/2) each play a key role in the 
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concentrations of medications in the blood (Flanagan et al., 2008). Figure 3.1(a) simulates 
the pharmacokinetic profile of a single oral drug administration. Following the 
administration of the drug, the drug concentration in plasma increases as the drug is 
absorbed into the blood until it reaches a maximum concentration (Cmax) after time (tmax), 
after which it starts to decline due to metabolism or excretion. The rate of concentration 
decrease is calculated according to its half-life (t1/2) in the body, as follows (Shinya, 
2011): 
• The peak level decreases to 50% in the first t 1/2 
• Further decrease to 25% by 2(t 1/2) 
• Further decrease to 12.5% by 3(t 1/2) 
• Further decrease to 6.25% by 4(t 1/2) 
• Further decrease to 3.125% by 5(t 1/2) 
In the instance of regular medication intake, the drug concentration fluctuates about the 
steady-state concentration as shown in Figure 3.1(b). The pharmacological action is 
proportional to the blood concentration of medication within a given range of 
concentrations, above which toxicity may occur and below which the drug is only present 
in sub-therapeutic concentrations. Patients who take medication as prescribed have blood 
concentrations that remain within the effective therapeutic window and thus the patient 
will gain the full benefits of the medications, leading to a better clinical response (Tanna 
and Lawson, 2016a; Keenan, 2017). On the other hand, if a patient misses a drug dose, 
the drug concentration may drop to sub-therapeutic concentrations, as indicated in Figure 
3.1(a). In this case, the patient may experience serious consequences, leading to poor 
clinical outcomes (Tanna and Lawson, 2016a; Otto, 2017). The WHO stated that 
medications have no pharmacological effect after about 4.5 half-lives, which is equivalent 
to < 5% of the Cmax (Moffat et al., 2011), as the amount of drug present has reduced by 
almost 94% to 97% of the peak level (Shinya, 2011). In the present study, CVD patients 
will be classified as non-adherent by microsample analysis when one or more of their 
prescribed medication concentrations is < 5% of Cmax or > Cmax. The PK parameters and 
dose information for these target CVD medications are derived from plasma samples for 
the selected target drugs (Table 3.1).  
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Figure 3.1. Pharmacokinetic profile of a drug concentration versus time profile in the 
instances of (a) non-adherence and (b) adherence. (Bernieh, 2017b).  
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Table 3.1. Pharmacokinetic information for the selected cardiovascular medications. 
Medication Cmax ng/ml tmax hr. t1/2 hr. References 
Amlodipine 5 mg 5-7.5 5-8 35-50 (Meredith and Elliott, 1992; 
Vincent et al., 2000; Shah et 
al., 2012) 
Atenolol 50 mg 159-377 1.5-6 2.5-11 (Lewis et al., 1988; de 
Abreu et al., 2003; Chang 
and Shin, 2012) 
Atenolol 100 mg 240-1370 2-4 5-9.1 (WU et al., 2003; Najib et 
al., 2005; Lawson et al., 
2012) 
Atorvastatin 40 mg 5.53-28.57
  
0.38-1.37 7.18-17.15 (Koytchev et al., 2004; 
Mendoza et al., 2006) 
Bisoprolol 5 mg 20.71-26.9 1.2-3 7.1-10.82 (Ding et al., 2007; 
Tjandrawinata et al., 2012) 
Bisoprolol 10 mg 37-87 1.5-4 5-16 (Lewis et al., 1988) 
Diltiazem 60 mg 74.72-82.38 2.23-2.49 3.18-14.8 (Loffreda et al., 1999; Yan et 
al.,2013) Diltiazem 90 mg 105.65-
150.87 
10.05-12.25 
Lisinopril 10 mg 41.75-80.47 5.79-6.91 8.13-13.4 (Shin et al., 2008; Zhou et 
al.,2008) Lisinopril 20 mg 86.4-139 
 
5.6-6.6 
Losartan 25 mg 43.6-125.4 0.5-1.1 0.94-4.02 (Ohtawa et al., 1993; Zhou 
et al., 2008; Salvadori et 
al.,2009) 
Losartan 50 mg 89.1-306.1 0.5-2.2 
Losartan 100 mg 263.67-
783.41 
0.54-1.88 
Simvastatin 20 mg 4.88-5.86 1.98-2.52 1.3-3.06 (Selvan and Pal, 2009; Lilja 
et al., 2004) Simvastatin 40 mg 5-40 2-3 
Valsartan 80 mg 1010-2270 2 4.1-8.63 (Flesch et al., 1997; 
Bindschedler et al., 1997) Valsartan 160 mg 1930-4000 1.5-3 
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3.2. Materials and Methods 
3.2.1. Ethical Statement 
Ethical approval for the collection of blood microsamples from Iraqi volunteers with 
cardiovascular diseases was obtained from the Ethical Committee in Misan Health 
Directorate (Reference 244 in 11/4/2016) (Appendix 1). Ethical approval for the 
collection of blood samples had already been obtained from De Montfort University’s 
Faculty of Health and Life Science Research Ethics Committee and updated to include 
the name of the PhD student Ahmed Alalaqi (Reference 1212 in 01/10/2013) (Appendix 
2). All participants were required to read a study participant information leaflet and 
provide written consent before being able to participate in this research. 
3.2.2. Recruitment, Inclusion and Exclusion Criteria 
The sample size was calculated based on the Daniel equation (Daniel, 1999; 
Pourhoseingholi et al., 2013).  
 
Where n is the sample size 
Z = Z statistic, corresponding to level of confidence, taken as 1.96 for a 95% confidence 
interval. 
P = expected prevalence or proportion 
d = precision (as a proportion of one; if 5%, d = 0.05).  
Since there is no literature available showing the prevalence of cardiovascular disease in 
Iraq, sample size calculation in this study was determined based on the assumption that 
the prevalence of cardiovascular diseases was 27%, which is close to the prevalence of 
hypertension at 26.5% (Al-Ghuzi and Al-Asadi, 2014). Accordingly, 303 patients were 
recruited in this study to assess non-adherence to selected cardiovascular medications. 
Cardiovascular patients were recruited from Alsader Teaching Hospital and Misan 
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Cardiac Centre in Iraq during a routine clinical visit between July 2016 and March 2018 
according to the following inclusion criteria  
(i) Had been prescribed at least one medication to treat cardiovascular disease including 
amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, lisinopril, losartan, simvastatin 
and valsartan.  
(ii) Had been taking one or more cardiovascular medications for more than six months. 
(iii) Were aged 18 years and above. 
(iv) Were able to understand and communicate in Arabic.  
(v) Had completed a written consent form. 
 
Potential volunteers were provided with Arabic translations of: 
• Participant information leaflets 
• Consent form 
• CVD drug prescription ‘mini’ questionnaire. 
These are detailed in Appendices 3-5 overleaf. The translation of documents into Arabic 
was crucial to helping participants understand the aims of the study (Appendices 6-8). 
The CVD drug prescription ‘mini-questionnaire’, asked for information concerning the 
prescribed drug, the dose and time at which the last dose had been taken. Information 
regarding all medication taken by the patients is included in Appendix 9.  
3.2.3. Sample Collection Kits 
Prior to visits to the Alsader Teaching Hospital and Misan Cardiac Centre in Iraq, sample 
collection kits were prepared based on either the dried blood spot (DBS) or the volumetric 
adsorptive microsampling (VAMS) methodologies. 
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Kit 1 prepared for DBS sample collection comprised:  
• DBS 903 Sample collection card } (Sigma–Aldrich, UK) 
• 2 mm lancet    } (Owen Mumford, UK) 
• Gauze pad    } (Shemond, UK) 
• Plaster     } (Reliance Medical, UK) 
• Plastic resealable bag  } (Fischer Scientific Loughborough, UK) 
• Desiccant    } (CelloExpress, UK) 
• Alcohol Pad                                 } (BSN Medical GmbH, Germany)  
Kit 2 prepared for VAMS sample collection comprised: 
• 1 clamshell pack (x4 Mitra TM) devices } (Neoteryx, Torrance, CA, USA) 
• Plastic resealable bag    } (Fischer Scientific, 
Loughborough, UK) 
• Dessicant     } (CelloExpress, UK) 
 
It was anticipated that, where possible, both sampling methods would be used to test the 
same patient and therefore duplicate plasters, gauzes and lancets would not be required 
in the second kit. 
3.2.4. Reference CVD Drug Samples 
The most prescribed CVD medications in Iraq were amlodipine, atenolol, atorvastatin, 
bisoprolol, diltiazem, lisinopril, losartan, simvastatin and valsartan.  Reference samples 
of all of these drugs (> 98% purity), amlodipine, atenolol (R-(+), (99%)), atenolol-d7, 
atorvastatin calcium salt, bisoprolol hemifumarate salt, diltiazem hydrochloride, 
lisinopril, losartan potassium salt, simvastatin and valsartan were obtained from Sigma 
Aldrich, Poole, Dorset, UK. 
3.2.5. Solvents and Other Equipment for Sample Extraction and Analysis 
For work of this nature, solvents of the highest purity are required. The necessary liquid 
chromatography mass spectrometry (LC-MS) grade solvents were: 
• Methanol  (Fisher Scientific Loughborough, UK) 
• Water   (Fisher Scientific Loughborough, UK) 
• Acetonitrile  (Fisher Scientific Loughborough, UK) 
• Formic acid  (Sigma Aldrich, Poole, Dorset, UK) 
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Microcentrifuge tubes (1.5 ml), volumetric pipettes, and pipette tips were purchased from 
Fisher Scientific, Loughborough, UK. Autosampler vials with 250 µl inserts and vial caps 
were obtained from Agilent Technologies (Cheshire, UK). 
Drug calibration standards were prepared in freshly donated whole blood using lithium 
heparin-coated blood collection tubes. These tubes were obtained from International 
Scientific Supplies Ltd. (Bradford, UK). 
3.2.6. Sample Collection Methods  
Volunteers were recruited as part of their routine visits to the Alsader Teaching Hospital 
and Misan Cardiac Centre in Iraq. Blood samples were collected from volunteers taking 
one or more of the target CVD medications. A series of blank control samples were also 
obtained from healthy Iraqi volunteers who were not taking any of the target drugs. These 
control samples were collected using the same protocols as the trial samples. The protocol 
developed for the collection of 903 card and VAMS samples was as reported in Appendix 
10. 
3.2.7. Sample Transport and Storage 
After collection, the DBS cards were left on the storage racks for at least 2 hours to dry. 
Once dry, they were sealed into labelled bags containing a desiccant pouch. VAMS 
samplers do not require a drying period and can be shipped once the clamshell package 
is closed and sealed in a bag containing a desiccant. The DBS card samples and the 
VAMS devices were transported to De Montfort University, Faculty of Health and Life 
Sciences under ambient conditions and delivered to the secure laboratory (00.15 
Hawthorn Building). 
3.2.8. Sample Extraction, Analysis and Quantification  
Initial work by Bernieh (2017) provided information on both blood microsamples 
calibration/QC sample preparation, extraction and analysis (Bernieh, 2017b). Prior to the 
analysis of the volunteer samples, both the extraction and the analytical methodology 
were assessed under the same conditions as the previous validated method. This required 
the preparation of stock solutions of all the drugs, both individually and with one 
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containing all the drugs at known concentrations. These were used to test the separation 
capabilities of the LC-HRMS instrumentation and the extraction capabilities using dosed 
calibration/QC whole blood to provide known samples on both the 903 DBS card and the 
VAMS samplers.  
3.2.8.1 Preparation of Stock Solutions to Test the Separation Capability of the LC-
HRMS System 
Standard stock solutions of amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, 
lisinopril, losartan, simvastatin and valsartan with concentrations of 1 mg/ml in methanol 
were prepared for each target medication after which an intermediate solution of 10,000 
ng/ml was prepared from the standard stock for each medication. 100 ng/ml of a 
multicomponent working solution was prepared from the intermediate stock solutions 
using methanol: water (70:30, v/v) as a diluent, which was used for LC-HRMS analysis. 
3.2.8.2 Preparation of Spiked Blood Calibration Samples for DBS 
Standard stock and intermediate solutions of amlodipine, atenolol, atorvastatin, 
bisoprolol, diltiazem, lisinopril, losartan, simvastatin and valsartan were prepared for 
each target medication as prescribed in Section 3.2.8.1. Multicomponent working 
solutions for the nine CVD medications were prepared from individual stock solutions to 
cover the calibration range for each medication as detailed in Table 3.6. The standard 
operation procedure (SOP) for the preparation of blood calibration standards for the nine 
target medications is detailed in Appendix 11. The spiked blood standards were prepared 
by spiking 100 µl of one of each multicomponent working solution with 900 µl of blank 
blood and vortexed for 1 min to produce the final concentration. Volumetric pipettes were 
used to apply 30 µl of multicomponent blood standards onto the 903 sampling paper. 
Blank DBS standards were prepared by spiking 100 µl from a 70:30 MeOH: H2O, v/v 
with 900 µl of blood that was then mixed thoroughly by vortexing for 1 min. Volumetric 
pipettes were used to apply 30 µl of blank bloods standards onto the 903-sampling paper. 
Spot sizes were ~9.5 mm after applying 30 µl of calibration standards and blanks on the 
sampling paper. Sampling cards were left to dry at room temperature for at least 3 hours 
and then stored individually in labelled plastic resealable bags containing desiccant. 
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3.2.8.3. Preparation of Quality Control Standards (QC) for DBS  
Three concentrations were chosen independently at low, medium and high concentration 
levels for each target medication, as detailed in Table 3.6, as quality control standards. 
The spiked blood QC standards were prepared by spiking 100 µl of one of each 
multicomponent working solution with 900 µl of blood and vortexing for 1 min to 
produce the final concentration. Volumetric pipettes were used to apply 30 µl of QC 
standards directly onto the 903 sampling cards. Sampling cards were left to dry at room 
temperature for at least 3 hours prior to processing.  
3.2.8.4. Preparation of Spiked Blood Samples for VAMS 
The spiked blood standards for VAMS were prepared using the 10 μl tip size devices by 
dipping the upper part of VAMS device into a volume of spiked whole blood and blank 
and waiting for about 2 seconds till the tip had turned completely red. Care needed to be 
taken to avoid completely dipping the tip into the blood to avoid overfilling (Tanna et al., 
2018).  
3.2.8.5. Preparation of Quality Control Standards (QC) for VAMS  
QC samples at the low, medium and high concentration levels of the target analytes, as 
detailed in Table 3.2, were independently prepared by spiking 100 µl of one of each 
multicomponent working solution with 900 µl of blood and vortexing for 1 min to 
produce the final concentration. The spiked blood QC standards on VAMS were prepared 
by dipping the upper part of the VAMS into a volume of spiked whole blood and waiting 
for about two seconds until the tip turned completely red. 
Table 3.2. Calibration range of the target medications in whole blood. 
Drug 
  
Calibration 
range ng/ml 
 Calibration standards (ng/ml) 
     LOW     MED   HIGH 
Amlodipine 0.5-100   0.5 1 5 10 25 50 100 
Atenolol 10-1500  10 20 50 100 200 500 1000 1500 
Atorvastatin 0.5-100   0.5 1 5 10 25 50 100 
Bisoprolol 0.1-100  0.1 0.5 1 5 10 25 50 100 
Diltiazem   0.5-600  0.5 1 5 10 50 100 300 600 
Lisinopril 0.1-100  0.1 0.5 1 5 10 25 50 100 
Losartan 5-1000  5 10 25 50 100 250 500 1000 
Simvastatin 0.1-100  0.1 0.5 1 5 10 25 50 100 
Valsartan 50-4000  50 100 250 500 1000 2000 3000 4000 
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3.3 Results and Discussion  
3.3.1. Operation of the LCMS System 
The LC-HRMS system consisted of an Agilent 1290 LC which was coupled to an Agilent 
G6530A QTOF mass spectrometer using the TOF mode. Target drugs were analysed on 
a Zorbax Eclipse C18 rapid resolution HD column (Agilent Technologies, Cheshire, UK, 
100 mm x 2.1 mm i.d., 1.8 µm particle pore size) which was preceded by a Security Guard 
Ultra guard column (Phenomenex, Macclesfield, UK).  
100 ng/ml of a multicomponent working solution of the target cardiovascular medication 
was prepared from the intermediate stock and the injected volume of 2 µl. The mobile 
phase consisted of water containing 0.1% (v/v) formic acid (eluent A) and acetonitrile 
containing 0.1% (v/v) formic acid (eluent B), and was delivered at 0.6 ml/min with 
gradient elution. The mobile phase was initiated at 4% B and maintained for 0.5 min 
before increasing to 65% and then to 95% B for 1.5 min., and was then maintained for 
2.5 min. before returning to 4% B. The gradient elution program was then held for 1.5 
min. to re-equilibrate the column prior to the next injection. The overall run time was 4 
min.  
The operation of the mass spectrometer was in electrospray positive ion mode. The MS 
source and chamber conditions were as follows: fragmentor voltage: 165V; skimmer: 65 
V; drying gas temperature: 350◦C; dry gas flow: 10 L/min; nebuliser: 45.0 psig; sheath 
gas temperature: 400◦C; sheath gas flow: 12 L/min. mass range: 100–1000 m/z; recording 
rate: 1 Hz. HRMS lock reference masses: 121.0508 m/z and 922.0097 m/z. MassHunter 
Workstation Acquisition Software for TOF/Q-TOF version B. 06.00 (Agilent 
Technologies, UK) was used to operate the system and acquire all data, which was 
processed using Qualitative Analysis B. 06.00 and Quantitative Analysis B. 06.00 
software (Agilent Technologies). External calibration of the TOF mass spectrometer was 
performed daily before starting the analysis. 
The mass to charge (m/z) ratios of the ionised species for the target medications were 
calculated based on their molecular formulae using the mass calculator in the qualitative 
analysis software version 6.00 and compared to the m/z ratios used in the previously 
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validated method. These m/z ratios were used because the ionised species for the target 
medications produced the highest signal intensities (Bernieh, 2017b). 
The initial data obtained represents the total ion chromatogram (TIC), where all ions were 
recorded via TOF during the sample run (Figure 3.2). A mass window within 5 ppm was 
used to extract each drug in the multicomponent solution to produce an extracted ion 
chromatogram (EIC) using [M+Na]+ for amlodipine m/z 431.1344 and simvastatin m/z 
441.2611 and the protonated molecule  [M+H]+ for atenolol at m/z 267.1703, atorvastatin 
at m/z 559.2610, bisoprolol at m/z 326.2326, diltiazem at m/z 415.1686, lisinopril at m/z 
406.2336, losartan at m/z 423.1695, and valsartan at m/z 436.2343, as shown in Figure 
3.3.   
 
 
 
 
    Acquisition time (min) 
Figure 3.2. Representative LC-HRMS total ion chromatogram (TIC) of a 100 ng/ml 
multicomponent solution standard containing the selected target drugs. 
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The detector response was high for atenolol, atorvastatin and diltiazem (≥ 1,800,000 
counts) (Figure 3.3). The detector responses for bisoprolol and lisinopril were about 
700,000 and 900,000 counts, respectively. For amlodipine, losartan, valsartan and 
simvastatin, the detector responses were all almost 400,000. All the target medications 
were detected with good peak shapes.  
3.3.2 Extraction of Target Analytes from Dried Blood Matrix  
3.3.2.1. Preparation of Internal Standard and Extraction Solution 
The internal standard (IS) stock solution of (atenolol-d7) was prepared at 1 µg/µl by 
dissolving 0.4 mg in 400 µl methanol. The standard operation procedure (SOP) for the 
preparation of IS is detailed in Appendix 11. The stock solution was further diluted with 
methanol/water (70:30, v/v) to produce an extraction solvent consisting of methanol 
containing 20 ng/ml of the internal standard (IS).  
3.3.2.2. Extraction and Analysis of Target Medications from DBS 
An 8-mm disc (approximately 20 µl of blood) was punched from each DBS spot into a 
1.5 ml microcentrifuge tube. A 300 µl volume of extraction solvent consisting of 
methanol and 20 ng/ml atenolol-d7 as an internal standard (IS) was used for the extraction 
of the CVD medications from the DBS spot. Microcentrifuge tubes were vortexed for a 
minute then sonicated for 30 minutes at 40◦C in a temperature-controlled ultrasonic bath. 
Afterwards, sonication tubes were centrifuged at 13,200 rpm for 10 minutes. 270 µl of 
Acquisition time (min) 
Figure 3.3. Representative LC-HRMS overlaid extracted ion chromatograms (EIC) of 
a 100 ng/ml multicomponent solution standard containing the selected target drugs. 
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the liquid supernatants were transferred into new 1.5 ml labelled microcentrifuge tubes 
and dried using a gentle stream of nitrogen gas. The dried samples were reconstituted 
with 150 μl of methanol/water (40:60, v/v) containing 0.1% formic acid and vortexed for 
1 minute. Finally, the liquid samples were transferred into autosampler LC vials with a 
250 µl insert for analysis via LC–HRMS (Figure 3.4). 
 
 
Figure 3.3. Extraction and analysis of dried blood samples on 903 cards. 
 
Analysis of the spiked DBS standard showed that all the target analytes were detectable 
except amlodipine whereas amlodipine was detected in solution (Bernieh, 2017b).  The 
application of the same extraction procedure of the previous validated study by Bernieh 
in the present study showed that amlodipine was not detected in the DBS extract, Figure 
3.5 shows overlaid EICs from a spiked DBS standard containing the eight target analytes 
and the internal standard. Amlodipine was not detected in the DBS extract, which may be 
the result of poor extraction of amlodipine from the DBS. Card material and the complex 
matrix of blood may interfere with the extraction of amlodipine from filter paper, and this 
is considered to be a challenge during extraction. It has been reported that amlodipine has 
high degree of protein binding (98%) (Nirogi et al., 2007). Thus, there is a possibility of 
amlodipine being retained on the DBS card and this may explain the reason behind its 
poor detection in the DBS extract.  
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Bernieh (2017) extracted amlodipine in DBS using 300 μl of acetonitrile containing 20 
ng/ml atenolol-d7. 10 μl 0.5 M sodium hydroxide (NaOH) were added to the extraction 
solvent. The dried residue was reconstituted with 150 μl of acetonitrile/water (40:60, v/v) 
containing 0.1% formic acid, and was vortexed again for 1 minute, then transferred to an 
autosampler vial for analysis. Methanol containing 10 μl of 0.5 M sodium hydroxide 
(NaOH) could not be used to extract amlodipine from DBS because the addition of NaOH 
produced a dark supernatant that could not be used for extraction (Bernieh, 2017b). 
Amlodipine was identified and the EIC at m/z 431.1344 showed a good peak shape when 
acetonitrile was used as the extraction solvent (Figure 3.6).   
 
 
 
 
 
 
 
 
 
Analyte Identification  
1- Atenolol d7 
2- Amlodipine  
2 
1 
   
 
 
    Acquisition time (min) 
Figure 3.4. Representative LC-HRMS overlaid with an extracted ion chromatogram of 
the highest concentration DBS standard of the target drugs and 20 ng/ml of the IS. 
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Acquisition time (min) 
Figure 3.5. Representative LC-HRMS overlaid with an extracted ion chromatogram of 
the highest concentration DBS standard of amlodipine extracted using acetonitrile 
containing 20 ng/ml of the IS. 
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3.3.2.3. Extraction and Analysis of Target Medications from VAMS 
Each VAMS whole tip was transferred to individual 1.5 ml labelled microcentrifuge 
tubes. 300 µl of extraction solvent consisting of methanol and 20 ng/ml atenolol-d7 was 
used for the extraction of the CVD medication VAMS samples. These tubes were 
vortexed for 1 minute then sonicated for 30 minutes at 40◦C in a temperature-controlled 
ultrasonic bath. After sonication, tubes were centrifuged at 13,200 rpm for 10 minutes. 
270 µl of the liquid supernatants were transferred into new 1.5 ml labelled 
microcentrifuge tubes and dried by a gentle stream of nitrogen gas. The dried samples 
were reconstituted using 150 μl of methanol/water (40:60, v/v) containing 0.1% formic 
acid, and the tubes were vortexed again for 1 minute (Figure 3.7). Then, the liquid samples 
were transferred into autosampler LC vials with 250 µl inserts for analysis via LC–HRMS 
(Figure 3.8).  
 
Figure 3.6. Extraction and analysis of dried blood samples on VAMS. 
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Acquisition time (min) 
Figure 3.7. Representative LC-HRMS overlaid with the extracted ion chromatogram of 
the highest concentration VAMS standard of the target drugs and 20 ng/ml of the IS. 
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Amlodipine in VAMS was also extracted using 300 μl of acetonitrile containing 20 ng/ml 
atenolol-d7. 10 μl of 0.5 M sodium hydroxide (NaOH) was added to the extraction solvent 
and the dried residue was reconstituted with 150 μl of acetonitrile/water (40:60, v/v) 
containing 0.1% formic acid, which was then vortexed again for 1 minute and transferred 
to an autosampler vial for analysis. Amlodipine was identified and an EIC at m/z 431.1344 
showed a good peak shape when acetonitrile was used as the extraction solvent (Figure 
3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
Different ratios of methanol and acetonitrile (50:50, 75:25, 75:25 v/v) were tested to 
optimise the extraction procedure of the previous validated method by Bernieh (2017) to 
get a standard procedure for all CVD medications in a single run. However, the 
amlodipine peak didn’t fulfil the validation criteria and further research to optimise the 
extraction for all CVD medications in the present study is recommended.  
 
3.3.2.4. Collection of Calibration Data 
To demonstrate that the previously validated method by Bernieh (2017) for the 
determination of the target cardiovascular medications in microsamples collected onto 
903 cards and VAMS was capable of replicating and producing an acceptable level of 
performance, parameters such as LLOQ, selectivity precision and accuracy were checked 
1 
2 
Analyte Identification 
1- Atenolol-d7 
2- Amlodipine  
  
 
Acquisition time (min) 
Figure 3.8. Representative LC-HRMS overlaid with the extracted ion chromatogram of 
the highest concentration VAMS standard of amlodipine extracted using acetonitrile 
containing 20 ng/ml of the IS. 
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based on FDA guidelines for the method verification procedure (Food and Drug 
Administration, 2014). 
3.3.2.4.1. Limit of Quantification  
A minimum 7-point calibration curve that was prepared for the target medication as 
detailed in Section 3.2.8.2 was generated in replicate (n = 6) using the ratio of the target 
analyte/IS peak area against the nominal concentration for each analyte. The limit of 
quantification for the target analyte was determined as the lowest concentration that 
produced a signal-to-noise (S/N) ratio ≥ 10. The obtained limit of quantification (LOQ) 
for the present study using 903 paper and VAMS as a sampling substrate showed that 
results were in agreement with those obtained from the previous validated method in this 
laboratory. 
3.3.2.4.2. Selectivity  
Investigation of the possibility of interference from the matrix was undertaken by 
extracting and analysing blank blood obtained from three individuals with blood spiked 
with the target analyte onto 903 card and VAMS. EICs were obtained using the accurate 
masses for each target cardiovascular medication and internal standard using 5 ppm as 
the mass window at the limit of quantification.  Qualitative analysis software version B. 
06.00 (Agilent Technologies, UK) was used to extract EICs for the protonated molecule 
[M+H]+ for atenolol at m/z 267.1703, atorvastatin at m/z 559.2610, bisoprolol at m/z 
326.2326, diltiazem at m/z 415.1686, lisinopril at m/z 406.2336, losartan at m/z 423.1695, 
valsartan at m/z 436.2343, atenolol-d7 (internal standard) at m/z 274.2143, and the sodium 
adduct with amlodipine at m/z 431.1344 and simvastatin at m/z 441.2611. The applied 
method, which used a DBS- and VAMS-based LC-HRMS approach, showed good 
selectivity and no interfering peaks were seen at the retention times for any of the target 
drugs or IS. Appendix 12 shows the representative EICs for each analyte and internal 
standard.  
3.3.2.4.3. Accuracy and Precision  
The accuracy and precision were determined by analyses of replicates (n = 6) of blood 
spots spiked with the target analyte of the target CVD medications prepared on 903 cards 
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and VAMS separately, using the same conditions and extraction protocol used by 
(Bernieh 2017). Back calculation using the same equations as the previous validated 
method for DBS and VAMS – see Tables 3.3 and 3.4 (Bernieh, 2017b) – produced 
relative errors (RE %) ≤ 15% (between 2-6% for DBS and 3-5% for VAMS), which is 
considered acceptable with reference to international guidelines (Committee for 
Medicinal Products for Human Use, 2011; Food and Drug Administration, 2013). A 
summary of the results is shown in Table 3.5 and Table 3.6.  
Table 3.3. Equations used for quantification of the target medications on 903 sampling 
paper for Iraqi volunteers (Bernieh, 2017b). 
Drug Range (ng/ml) y = ax + b R2 LOQ (ng/ml) 
Amlodipine  0.5 – 100  y = 0.004x + 0.043  0.993 ± 0.004  0.5 
Atenolol  10 – 1500  y = 0.0044x – 0.047  0.997 ± 0.001  10 
Atorvastatin  0.5 – 100  y = 0.0014x + 0.0244  0.986 ± 0.013  0.5 
Bisoprolol  0.1 – 100  y = 0.019x + 0.034  0.994 ± 0.003  0.1 
Diltiazem  0.5 – 600  y = 0.016x + 0.053  0.997 ± 0.002  0.5 
Lisinopril  0.1 – 100  y = 0.002x + 0.031  0.978 ± 0.007  0.1 
Losartan  5 – 1000  y = 0.004x + 0.0713  0.995 ± 0.002  5 
Simvastatin  0.1 – 100  y = 0.013x + 0.081  0.996 ± 0.003  0.1 
Valsartan  50 – 4000  y = 0.002x – 0.139  0.994 ± 0.003  50 
Table 3.4. Equations used for quantification of the target medications in VAMS for Iraqi 
volunteers (Bernieh, 2017b).  
Drug Range (ng/ml) y = ax + b R2 LOQ (ng/ml) 
Amlodipine 0.5 – 100 y = 0.007x + 0.086 0.990 ± 0.002 1 
Atenolol 10 – 1500 y = 0.0074x – 0.136 0.992 ± 0.001 10 
Atorvastatin 0.5 – 100 y = 0.0033x + 0.023 0.997 ± 0.001 0.5 
Bisoprolol 0.1 – 100 y = 0.0097x + 0.096 0.996 ± 0.002 0.1 
Diltiazem 0.5 – 600 y = 0.008x + 0.224 0.995 ± 0.003 0.5 
Lisinopril 0.1 – 100 y = 0.0013x + 0.021 0.985 ± 0.004 0.1 
Losartan 5 – 1000 y = 0.0024x + 0.110  0.993 ± 0.007 5 
Simvastatin 0.1 – 100 y = 0.016x + 0.215 0.988 ± 0.003 0.1 
Valsartan 50 – 4000 y = 0.0006x + 0.125 0.992 ± 0.001 50 
The following equation was used; 𝑦 = 𝑎𝑥 + 𝑏, where y is the ratio of analyte to IS response, 
a is the gradient, x represents the concentration and b is the y-intercept 
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Table 3.5. Accuracy and precision data for the nine target cardiovascular drugs in 903 
sampling paper extracts (n = 6). 
Drug Nominal conc. 
(ng/ml) 
Mean conc. 
(ng/ml) 
SD Accuracy 
(RE) % 
Precision 
(CV) % 
Amlodipine 0.5 0.53 0.01 -5.33 1.18  
1 1.01 0.05 -0.67 5.28 
 5 4.93 0.16 1.40 3.30 
 10 10.07 0.03 -0.67 0.34  
25 24.54 0.76 1.85 3.09 
 50 50.32 0.46 -0.64 0.91  
100 101.14 0.92 -1.14 0.91 
Atenolol 10 9.91 0.06 0.93 0.63 
 20 19.65 0.09 1.75 0.45  
50 51.13 1.02 -2.26 1.99 
 100 101.84 1.57 -1.84 1.54 
 200 200.64 0.45 -0.32 0.23  
500 498.98 5.75 0.20 1.15 
 1000 1000.31 3.28 -0.03 0.33  
1500 1495.94 6.19 0.27 0.41 
Atorvastatin 0.5 0.51 0.02 -1.52 3.56  
1 1.00 0.03 -0.33 3.39 
 5 4.98 0.12 0.33 2.50 
 10 9.96 0.05 0.43 0.50  
25 24.52 0.06 1.91 0.25 
 50 50.65 0.69 -1.30 1.35  
100 101.13 1.50 -1.13 1.48 
Bisoprolol 0.1 0.11 0.01 -6.33 9.10 
 0.5 0.49 0.01 1.79 2.77  
1 1.06 0.01 -6.33 0.89 
 5 5.11 0.16 -2.27 3.09 
 10 9.79 0.11 2.05 1.17  
25 24.88 0.49 0.48 1.96 
 50 49.81 0.44 0.37 0.88  
100 100.03 0.06 -0.03 0.06 
Diltiazem 0.5 0.50 0.01 0.46 1.84 
 1 1.06 0.01 -5.66 1.33  
5 5.25 0.02 -4.93 0.39 
 10 10.05 0.03 -0.50 0.29 
 50 49.57 0.48 0.86 0.97 
 100 99.88 0.46 0.12 0.46 
 300 
600 
300.04 
599.67 
0.78 
0.55 
-0.01 
0.05 
0.26 
0.09 
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Table 3.5 continued 
Drug Nominal conc. 
(ng/ml) 
Mean conc. 
(ng/ml) 
SD Accuracy 
(RE) % 
Precision 
(CV) % 
Lisinopril 0.1 0.10 0.01 -2.67 5.11 
 0.5 0.50 0.01 -0.34 1.10  
1 0.98 0.01 1.67 0.96 
 5 5.02 0.01 -4.00 0.16 
 10 9.95 0.03 0.47 0.33  
25 24.70 0.44 1.19 1.78 
 50 49.90 0.09 0.19 0.17  
100 100.58 0.92 -0.58 0.91 
Losartan 5 4.9 0.1 1.1 2.1 
 10 9.9 0.1 1.3 1.1  
25 25.23 0.01 -1.00 0.05 
 50 49.9 0.86 0.19 1.73 
 100 100.25 0.45 -0.25 0.45  
250 250.21 0.48 -0.09 0.19 
 500 500.65 0.84 -0.13 0.17  
1000 999.25 0.54 0.75 0.05 
Simvastatin 0.1 0.10 0.01 -2.67 5.11 
 0.5 0.51 0.01 -1.68 1.53  
1 1.00 0.01 0.33 0.95 
 5 5.02 0.01 -0.40 0.16 
 10 9.97 0.03 0.32 0.26  
25 25.23 0.02 -0.91 0.08 
 50 50.24 0.55 -0.47 1.09  
100 99.96 0.05 0.04 0.05 
Valsartan 50 49.87 0.13 0.26 0.26 
 100 99.97 0.05 0.03 0.05  
250 249.10 0.25 0.36 0.10 
 500 500.28 0.55 -0.06 0.11 
 1000 999.78 1.52 0.02 0.15  
2000 2009.97 0.87 -0.50 0.04 
 3000 3001.59 1.24 -0.05 0.04 
  4000 4005.59 3.98 -0.14 0.10 
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Table 3.6. Accuracy and precision data for the nine target cardiovascular drugs in VAMS 
extracts (n = 6). 
Drug Nominal conc. 
(ng/ml) 
Mean conc. 
(ng/ml) 
SD Accuracy 
(RE) % 
Precision 
(CV) % 
Amlodipine 0.5 0.50 0.01 0.67 1.26  
1 1.00 0.01 -1.00 0.82 
 5 5.04 0.01 -0.07 0.25 
 10 9.72 0.46 2.80 4.68  
25 24.87 0.31 0.52 1.23 
 50 50.61 0.12 -1.22 0.23  
100 100.21 0.23 -0.21 0.23 
Atenolol 10 9.96 0.02 0.42 0.20 
 20 19.89 0.05 0.53 0.26  
50 50.38 0.40 -0.76 0.80 
 100 101.37 1.04 -1.37 1.03 
 200 200.14 0.04 -0.07 0.02  
500 500.48 0.78 -0.10 0.16 
 1000 999.94 1.46 0.01 0.15  
1500 1499.19 1.63 0.05 0.11 
Atorvastatin 0.5 0.50 0.01 -0.19 1.75  
1 0.99 0.01 0.67 1.26 
 5 5.01 0.07 -0.13 1.33 
 10 9.98 0.03 0.17 0.29  
25 25.52 0.06 -2.09 0.24 
 50 50.32 0.21 -0.63 0.43  
100 99.47 0.27 0.53 0.27 
Bisoprolol 0.1 0.11 0.01 -5.00 6.73 
 0.5 0.49 0.01 1.79 2.77  
1 0.99 0.01 0.67 1.26 
 5 5.10 0.15 -2 2.96 
 10 9.86 0.10 1.39 1.04  
25 25.48 0.50 -1.92 1.97 
 50 49.61 0.39 0.77 0.78  
100 99.03 0.76 0.97 0.77 
Diltiazem 0.5 0.50 0.01 -0.88 2.12 
 1 1.04 0.02 -3.67 1.82  
5 5.23 0.02 -4.53 0.39 
 10 10.05 0.01 -0.47 0.12 
 50 49.91 0.05 0.19 0.10 
 100 99.83 0.42 0.17 0.43 
 300 299.91 0.15 0.03 0.05 
 600 600.31 0.50 -0.05 0.08 
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Table 3.6 continued 
Drug Nominal conc. 
(ng/ml) 
Mean conc. 
(ng/ml) 
SD Accuracy 
(RE) % 
Precision (CV) 
% 
Lisinopril 0.1 0.10 0.01 -2.33 5.31 
 0.5 0.51 0.01 -2.34 2.33  
1 1.01 0.03 -1.33 3.26 
 5 5.02 0.01 -0.40 0.16 
 10 9.99 0.02 0.13 0.21  
25 25.03 0.01 -0.12 0.06 
 50 49.61 0.49 0.78 0.99  
100 100.11 0.10 -0.11 0.10 
Losartan 5 4.93 0.05 1.13 1.10 
 10 9.94 0.23 0.62 2.33  
25 24.59 0.50 1.65 2.02 
 50 50.24 0.55 -0.47 1.09 
 100 99.92 0.04 0.08 0.04  
250 249.95 0.18 0.02 0.07 
 500 500.42 0.69 -0.08 0.14  
1000 999.59 0.52 0.04 0.05 
Simvastatin 0.1 0.10 0.01 -2.67 5.11 
 0.5 0.50 0.01 -0.34 1.89  
1 1.00 0.02 0.33 1.71 
 5 5.02 0.01 -0.47 0.25 
 10 9.98 0.04 0.15 0.38  
25 25.23 0.80 -0.91 3.16 
 50 49.90 0.09 0.19 0.17  
100 99.63 0.44 0.37 0.44 
Valsartan 50 49.91 0.15 0.19 0.29 
 100 99.64 0.43 0.36 0.43  
250 249.77 0.72 0.09 0.29 
 500 499.86 0.47 0.03 0.09 
 1000 999.44 1.05 0.06 0.10  
2000 2005.97 4.22 -0.30 0.21 
 3000 3000.25 0.37 -0.01 0.01 
  4000 4006.59 4.92 -0.16 0.12 
 
3.3.2.4.4. Accuracy and Precision of QC  
The accuracy and precision of the quality control standards (QC) were determined by 
running replicate (n = 6) analyses of the QC standards for the target CVD medications 
(amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, lisinopril, losartan, simvastatin 
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and valsartan). Accuracy was expressed in terms of relative error (RE %) and precision 
as the coefficient of variation (CV %). Back calculations produced accuracies and 
precisions within ≤ 15% with reference to international guidelines (Committee for 
Medicinal Products for Human Use, 2011; Food and Drug Administration, 2013). QC 
standards were run alongside the patients’ samples in each batch for the Iraqi volunteers 
in order to determine the performance of the instrument.  
3.3.3. Application of Method for Assessment of Non-adherence   
3.3.3.1. Statistical Analysis 
Descriptive statistical frequency distributions were obtained using the SPSS software 
(version 22. Armonk, NY: IBM Corp). Qualitative variables such as gender and 
medications were expressed in terms of frequencies and percentages. Spearman’s 
correlation coefficient was used to determine the relationship between non-adherence 
assessed by blood microssamples analysis and age, number of CVD medications in 
patients’ regimens and number of tablets taken by patients. A Chi-squared test was used 
to examine the relationship between medication adherence and gender. Mean and 
standard deviation were used to express the concentration of medications in the biological 
samples. A Bland-Altman plot was used to compare the results obtained from the two 
microsampling methods (DBS and VAMS). 
3.3.3.2. Qualitative Analysis 
After extraction of patient microsamples collected on DBS cards and VAMS, qualitative 
analysis was conducted using qualitative analysis software version B. 06.00 (Agilent 
Technologies, UK) by extracting EICs using the accurate mass values (m/z) of the target 
cardiovascular medications. An extraction window of 5 ppm was used for EIC extraction. 
Qualitative analysis was used to confirm the existence of the target medication in the 
(DBS and VAMS) blood microsamples, as per Appendix 13. Qualitative analysis for the 
target medications in DBS and VAMS showed good agreement between these two 
sampling methods.  
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3.3.3.3. Quantitative Analysis 
Medications which were qualitatively identified in the blood microsamples (DBS AND 
VAMS) from 303 Iraq volunteers in Section 3.3.3.3 were quantified by quantitative 
analysis B. 06.00 software (Agilent Technologies). Quantitative analysis was undertaken 
by extracting EICs using the accurate masses for each target cardiovascular medication 
within a 5 ppm mass window. The ratio of the target analyte/IS peak area was used in the 
equation used for the previous validated method (Bernieh, 2017b). Patients were 
categorised as non-adherent when one or more of their prescribed medications 
concentration was < 5% of Cmax or > Cmax. The results of this analysis are summarised in 
Appendix 14. 
The non-adherence to the target cardiovascular medications in the present study was not 
uniform. The average non-adherence to medications in the target sample was almost 41%; 
however, patients adhere in different ways to medications, as shown in Table 3.7.  
Table 3.7. Percentage of adherence and non-adherence to the target cardiovascular 
medication in the Iraqi volunteer sample. 
 Medications Adherence (%) Non-adherence (%) Total 
Amlodipine 66.7 33.3 15 
Atenolol 78.0 22.0 59 
Atorvastatin 44.4 55.6 18 
Bisoprolol 74.0 26.0 77 
Diltiazem 58.8 41.2 34 
Lisinopril 65.8 34.2 73 
Losartan 46.8 53.2 47 
Simvastatin 48.0 52.0 50 
Valsartan 50.8 49.2 65 
 
Amlodipine was taken by 15 Iraqi volunteers, to which 10 patients (66.7%) were adherent 
(Patient reference numbers …125, 126, 127, 128, 160,161, 162, 163, 197 and 222) and 
five patients (33.3%) were non-adherent (Patient reference numbers …195, 196, 198, 240 
and 252). Figure 3.10 shows the representative LC-HRMS overlaid with the EIC of 
patients who were adherent and non-adherent to amlodipine. Patients who were suspected 
to be non-adherent to amlodipine reported the time since their last dose was less than 24 
hrs (5-8 hrs). However, amlodipine was detected in the other 10 volunteers where the 
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ingestion time was similar to non-adherent patients, which was 5-8 hrs. A possible 
explanation is that those patients who did not take their medication was either due to 
forgetfulness or because they thought the medication has been taken but was not, which 
may have been due to them being on complex medical regimens. Another possible 
explanation is that volunteers did not tell the truth about their medication-taking 
behaviour. The t1/2 of amlodipine is quite long at 35-50 hrs, and this may suggest that 
patients who were non-adherent to amlodipine and had not taken it for more than 5 days. 
 
 
 
 
 
For other calcium channel blockers, diltiazem was taken by 34 volunteers. Twenty 
patients (85.8%) were adherent to diltiazem (Patient reference numbers …61, 65, 72, 76, 
86, 117, 118, 119, 120, 152,153, 154, 155, 186, 187, 188, 189, 213, 218, 219). On the 
other hand, 14 volunteers (41.2%) were non-adherent (Patient reference numbers …21, 
60, 220, 236, 237, 238, 247, 248, 267, 269, 277, 282, 285 and 289). Figure 3.11 shows 
representative LC-HRMS overlaid with the EIC of patients who were adherent and non-
adherent to diltiazem.  
 
Acquisition time (min) 
Figure 3.9. Comparison between LC-HRMS extracted ion chromatograms for 
amlodipine (m/z 431.1344) in DBS samples for patient reference number …125 who was 
adherent to amlodipine (black line) and patient reference number …195 who was non-
adherent (blue line), with the red line showing the blank control.  
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Fifty-nine volunteers were taking atenolol and it was detected in 50 volunteers (Patient 
reference numbers …14, 23, 34, 37, 40, 42, 45, 51, 52, 53, 58, 67, 100, 101, 102, 103, 
104, 105, 106, 107, 138, 139, 140, 141, 142, 143, 144, 169, 170, 171, 172, 173, 174, 175, 
176, 206, 207, 208, 209, 210, 211, 226, 227, 228, 229, 244, 245, 256, 257, 258) and not 
detected in nine volunteers ( Patient reference numbers …08, 264, 270, 274, 283, 287, 
296, 307 and 310). Four of the patients taking atenolol were considered non-adherent 
even though atenolol was detected in their blood (Patient reference numbers …23, 45, 53, 
58) because the measured concentration exceeded the corresponding Cmax for the reported 
dose of atenolol (50 mg or 100 mg). Therefore, 46 patients (78%) were considered 
adherent and 13 patients (22%) were considered non-adherent in total. Figure 3.12 shows 
a representative LC-HRMS overlaid with the EIC of an adherent and non-adherent patient 
to atenolol.  
 
Acquisition time (min) 
Figure 3.10. Comparison between LC-HRMS extracted ion chromatograms for 
diltiazem (m/z 415.1686) in DBS samples for patient reference number …61 who was 
adherent to diltiazem (black line) and patient reference number …21 who was non-
adherent (blue line), with the red line showing a blank control. 
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Patient reference numbers …23 and 45 reported that atenolol 50 mg had been prescribed 
to them; however, the concentrations measured exceeded the Cmax for the reported dose 
of atenolol. This may indicate that patients took double the dose by mistake or there was 
a prescribing error (prescribing 100 mg atenolol instead of 50 mg) or possibly the patients 
incorrectly reported the dose of atenolol they had taken in the mini-DBS questionnaire. 
Since the information provided by patients was assumed to be correct, these patients were 
labelled as non-adherent.  
For patient reference number …53, the concentration of atenolol measured in their DBS 
sample was higher than the Cmax for a dose of 100 mg of atenolol even though the reported 
time since the last dose was 13 hrs, which may indicate that the patient took two 100 mg 
tablets of atenolol. The high concentration of atenolol in this patient may have been due 
to dosage errors. Further investigation by the doctor is required in this case to determine 
the cause of this high concentration. Atenolol is water soluble and it is highly dependent 
on renal elimination, and there is a possibility of drug accumulation in patients with 
chronic kidney diseases (CKD) (Faull and Lee, 2007), thus this patient needs further 
investigation with regards to adjusting the dose and overcoming possible drug side effects 
and toxicity.  
The volunteer with reference number …58 was taking atenolol 50 mg and atorvastatin 40 
mg and reported an ingestion time for both medications of 15 hrs. However, the atenolol 
Acquisition time (min) 
Figure 3.11. Comparison between LC-HRMS extracted ion chromatograms for atenolol 
(m/z 267.1703) in DBS samples for patient reference number …14 who was adherent to 
atenolol (black line) and patient reference number…08 who was non-adherent to atenolol 
(blue line), with the red line showing a blank control.  
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concentration exceeded the Cmax  for atenolol and atorvastatin was not detected. In the 
Iraqi market, there is increasing prevalence of generic medications which have similar 
shapes and colours, and patients may depend on the shape and/or colour of the pill to take 
their medication doses without knowing other characteristics of the medication, such as 
name and dosage, and consequently this might account for taking more than required dose 
(Lenahan et al., 2013). This patient may have taken double the dose of atenolol and 
missed the dose of atorvastatin, for instance, which may explain why the concentration 
of atenolol was so high. 
The results of the current study showed that statins group such as atorvastatin and 
simvastatin showed high level of non-adherence at 55.6% and 52% respectively. 18 
volunteers were taking atorvastatin, to which eight patients (44.4%) were adherent 
(Patient reference numbers…70, 82, 291, 301, 311, 320, 330 and 331). On the other hand, 
10 volunteers (55.6%) were not adherent to atorvastatin (Patient reference numbers …17, 
55, 56, 58, 59, 62, 64, 72, 75, and 88). Figure 3.13 shows representative LC-HRMS 
overlaid with EIC of a patient adherent to atorvastatin and a patient who was non-
adherent. 
 
 
 
 
 
Acquisition time (min) 
Figure 3.12. Comparison between LC-HRMS extracted ion chromatograms for 
atorvastatin (m/z 559.2610) in DBS samples for patient reference number…70 who was 
adherent to atorvastatin (black line) and patient reference number…17 who was non-
adherent (blue line), with the red line showing a blank control. 
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Simvastatin was taken by 50 volunteers, 24 patients (48%) were adherent to simvastatin 
(Patient reference number…100, 101, 102, 103, 123, 132, 138, 139, 140, 141, 156, 167, 
169, 170, 171, 172, 191, 192, 194, 206, 207, 208, 226, and 227). 26 volunteers (52%) 
were non-adherent (Patient reference numbers …07, 20, 121, 122, 124, 133, 157, 158, 
159, 168, 190, 193, 202, 221, 239, 249, 250, 251, 314, 323, 324, 325, 326, 328, 334, and 
336). Figure 3.14 shows representative LC-HRMS overlaid with EIC of a patient adherent 
to simvastatin and one who was non-adherent. Simvastatin has a relatively short t1/2 (1.3-
2.7 hrs) and there was a need to check the presence of one of its metabolites, simvastatin 
acid at m/z 436.5815, for adherent and non-adherent to confirm that volunteers were 
adherent or non-adherent. Since the LC-HRMS system operates in the full-scan mode, 
the data was revisited to look for the simvastatin metabolite without having to run a new 
sample. Simvastatin acid was detected in blood microsamples in adherent patients, 
however, it was not detected in non-adherent patients, and this confirmed that these 
patients were non-adherent to their prescription.  Simvastatin is recommended to be taken 
in the evening. There is evidence showed that considerable increase in the level of total 
and low-density lipoprotein cholesterol occurred due to switching taking of simvastatin 
from the evening to the morning (Wallace et al., 2003). 
Side effects associated with statins such as muscle pain may account for high rates of 
non-adherence to these CVD medications. Patients with cardiovascular disease normally 
take medications from different therapeutic classes (complex regimen) (Anderson and 
Nawarskas, 2001) and this combined therapy consequently increases the risk of adverse 
drug effects and drug interactions (Abolbashari et al., 2017).  
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Both atorvastatin and simvastatin were not available in the public sector in Iraq according 
to annual need for medication in 2016 (Chapter 1 Section 1.4). Patients need to pay from 
their own pockets to get these medications from private sector, and this extra cost may 
lead to high rates of non-adherence to these medications. Participants may decrease the 
number of doses in order to decrease their out of pocket expenses, and this will 
consequently lead to the poor clinical outcomes associated with poor adherence. 
Bisoprolol was a very popular cardiovascular medication in the Iraqi samples collected, 
where it was taken by 77 volunteers. This regularity in the prescription of bisoprolol may 
be due to availability of the medication in both the public and private sectors, or possibly 
due to the relatively low cost of this medication compared to the other medications, as 
shown in Chapter 1 Section 1.3.6. Bisoprolol was detected in 57 patients (74%) (Patient 
reference numbers …15, 27, 30, 36, 38, 48, 57, 70, 87, 90, 91, 96, 99, 108, 109, 110, 111, 
112, 113, 114, 115, 116, 145, 146, 147, 148, 149, 150, 177, 178, 180, 181, 182, 183, 184, 
185, 212, 214, 215, 216, 217, 329, 230, 231, 232, 233, 234, 235, 246, 259, 260, 261, 262, 
293, 297, 298, and 303). On the other hand, bisoprolol was not detected in 20 volunteers 
(Patient reference numbers …10, 19, 59, 95, 268, 272, 278, 281, 284, 290, 300, 304, 306, 
315, 316, 319, 322, 327, 333, and 335). Figure 3.15 shows representative LC-HRMS 
overlaid with the EIC of a patient adherent to bisoprolol and a patient who was non-
Acquisition time (min) 
Figure 3.13. Comparison between LC-HRMS extracted ion chromatograms for 
simvastatin (m/z 441.2611) in DBS samples for patient reference number…100 who was 
adherent to simvastatin (black line) and patient reference number…07 who was non-
adherent (blue line), with the red line showing a blank control. 
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adherent. Volunteers taking bisoprolol showed high rates of adherence to this medication 
in comparison to the non-adherent at 74% and 26%, respectively.  
 
 
 
 
 
Lisinopril was the second-most popular medication used by patients in the samples 
collected where 73 volunteers were found to be taking it and it was actually detected in 
47 patients (64.4%) (Patient reference numbers …6, 32, 57, 66, 77, 91, 93, 104, 105, 106, 
110, 111, 117, 118, 119, 142, 143, 144, 147, 152, 153, 154, 155, 173, 174, 175, 176, 178, 
182, 187, 188, 209, 210, 213, 214, 219, 228, 229, 232, 244, 245, 246, 256, 257, 258, 259, 
and 260), whereas 26 volunteers (35.6%) (Patient reference numbers …56,107, 108, 109, 
120, 145, 146, 177, 180, 181, 184, 186, 189, 211, 212, 220, 230, 231, 236, 237, 238, 247, 
248, 294, 313, and 332) were non-adherent. Figure 3.16 shows representative LC-HRMS 
overlaid with the EIC of a patient adherent to lisinopril and a patient who was non-
adherent. 
 
Acquisition time (min) 
Figure 3.14. Comparison between LC-HRMS extracted ion chromatograms for 
bisoprolol (m/z 326.2326) in DBS samples for patient reference number…15 who was 
adherent to bisoprolol (black line) and patient reference number…10 who was non-
adherent (blue line), with the red line showing a blank control. 
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Losartan was prescribed for 47 patients. 22 patients (46.8%) were adherent (Patient 
reference numbers …25, 27, 50, 55, 69, 121, 122, 123, 129, 130, 131, 156, 164, 165, 166, 
191, 192, 194, 199, 200, 201, and 223). Patients showed high levels of non-adherence, 
where 25 volunteers (53.2%) were non-adherent (Patient reference numbers ...33, 38, 41, 
61, 124, 157, 158, 159, 190, 193, 221, 239, 249, 250, 251, 265, 271, 275, 279, 288, 295, 
299, 305, 308, and 317). Figure 3.17 shows a representative LC-HRMS overlaid with EIC 
for the DBS microsample of a patient adherent to losartan and a patient who was non-
adherent. Various factors may be the cause of the non-adherence, in this instance such as 
side effects. It was reported that vertigo is one of the more common side effects associated 
with the use of losartan (National Health Service, 2018c). However, other factors may 
have contributed to poor adherence, such as patients’ attitudes and beliefs, and medication 
cost and availability. Losartan has a short t1/2 (0.94-4.02 hrs) and to confirm that a given 
volunteer was non-adherent, data was revisited in order to look for losartan metabolites 
(losartan acid), as was checked at m/z 436.8941. Losartan acid was not detected in non-
adherent patients but was detected in adherent patients, and this confirmed that non-
adherent patients were indeed not adhering to their prescribed medication regimen.  
 
 
Acquisition time (min) 
Figure 3.15. Comparison between LC-HRMS extracted ion chromatograms for lisinopril 
(m/z 406.2336) in DBS samples for the patient with reference number …6 who was 
adherent to lisinopril (black line) and the patient with the reference number …56 who 
was non-adherent (blue line) with the red line showing a blank control. 
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Valsartan was taken by 65 volunteers, where adherence and non-adherence were almost 
equal. 33 volunteers (50.8%) were adherent  (Patient reference numbers ...12, 16, 17, 24, 
30, 68, 78, 84, 89, 113, 114, 115, 136, 137, 148, 149, 150, 183, 184, 185, 205, 215, 216, 
225, 233, 234, 243, 254, 255, 292, 302, 312, and 321); conversely, 32 volunteers (49.2%) 
were non-adherent (Patient reference numbers …11, 31, 36, 48, 61, 72, 73, 74, 80, 82, 
99, 112, 116, 134, 135, 204, 217, 224, 235, 241, 242, 253, 261, 262, 263, 266, 273, 276, 
280, 286, 309, and 318). Figure 3.18 shows a representative LC-HRMS overlaid with the 
EIC in DBS for a patient adherent to valsartan and a patient who was non-adherent. To 
confirm adherence and non-adherence to valsartan, data was revisited to look for valsartan 
metabolites (4-hydroxy valsartan at m/z 535.2790). 4-hydroxy valsartan was seen in 
adherent volunteers but not seen in non-adherent group of volunteers. Valsartan is not 
available in the public sector in Iraq, and this may be the cause of the high prevalence of 
valsartan non-adherence.  
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Acquisition time (min) 
Figure 3.16. Comparison between LC-HRMS extracted ion chromatograms for losartan 
(m/z 423.1695) in DBS samples for patient reference number …25 who was adherent to 
losartan (black line) and patient reference number…33 who was non-adherent (blue line), 
with the red line showing a blank control. 
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Assessment of non-adherence by the direct, objective method of microsamples analysis 
in the present study showed that 154 patients (50.8%) were adherent to medications (82 
males and 72 females) and 149 patients (49.2%) were non-adherent (68 males and 81 
females). This level of non-adherence is almost close to 50%, which was essentially the 
figure reported for non-adherence in the case of chronic illnesses in developed countries 
by the WHO (Sabaté, 2003). These results are based on cumulative data from analyses 
using DBS and VAMS since results using either sampling method were in good 
agreement (as highlighted in 3.4.4). All previous adherence studies in Iraq used indirect 
methods only, and hence this is the first research to use a direct method to assess non-
adherence to medications and, in particular, cardiovascular medication in Iraq. Thus, 
there is no previous data about the level of non-adherence found by direct methods to 
compare with in Iraq. This study is considered novel in this regard, and an original 
contribution to knowledge regarding assessment of levels of non-adherence to 
medications in Iraq. As mentioned in Chapter 1 Section 1.3.5, the quality of medicines is 
also an important issue to consider, with reports of high incidences of 
substandard/falsified medicines in the markets of developing countries such as Iraq. 
Assessment of non-adherence to the target medication in this study was based on the 
associated concentrations measured in the microsamples. On the other hand, there is a 
possibility of patients being identified as non-adherent as a result of taking substandard 
and falsified medicines which contain little or no active pharmaceutical ingredients. In 
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Acquisition time (min) 
Figure 3.17. Comparison between LC-HRMS extracted ion chromatograms for valsartan 
(m/z 436.2343) in DBS samples for patient reference number …12 who was adherent to 
valsartan (black line) and patient reference number …11 who was non-adherent (blue 
line), with the red line showing a blank control. 
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these cases, non-adherence would not be due to the patient’s failure to take the medication 
as prescribed but rather as a result of treatment-related factors where the drugs actually 
being administered are not as they should be. 
The current results indicated a huge difference in levels of non-adherence in comparison 
with a previous study conducted in the UK, which showed that 10% of volunteers were 
suspected to be non-adherent to CVD medications (Bernieh, 2017b). A possible 
explanation for this difference in results may be due to the relatively poor approach 
adopted by the Iraqi health system in comparison with that in the UK, as highlighted in 
Chapter 1 Section 1.3.7. In Iraq, there is no fully applicable operational multisectoral 
national policy, strategy or action plan to deal with cardiovascular diseases, there are no 
evidence-based national guidelines, protocols, or standards for the management of CVD 
disease or non-adherence of CVD medications through primary care in Iraq (World 
Health Organization, 2014; Turk-Adawi et al., 2018).  
Moreover, there is no insurance-based healthcare, free CVD medications schemes or 
medication counselling centres for cardiovascular patients in Iraq (World Health 
Organization, 2017d). The availability of suitable insurance or some other programme 
that might provide a degree of protection factor non-adherence is essentially non-existent 
(Schneider et al., 2018). However, medication non-adherence is affected by various 
factors such as patients’ attitudes towards medication, differential regimen complexity, 
patient knowledge and education, social biases hindering amicable patient-doctor 
relationships and access to medications. All these are considered challenges to healthcare 
systems worldwide. The differences in these factors might accounted for difference in 
non-adherence levels observed specifically between Iraq and the UK. 
The differences in design between studies may be responsible for the considerable 
difference in non-adherence levels since for volunteers in the study conducted in the UK, 
patients had prior knowledge that blood microsamples would be collected in the clinic to 
assess adherence to the target medication, so the ‘white coat’ effect could be anticipated 
(Bernieh, 2017b). However, the Iraqi samples were collected from patients during routine 
visits to the clinic, that is, without prior knowledge. Moreover, the assessment of non-
adherence to medication is not applicable in routine clinical practice in Iraq.  
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The cost of the medications prescribed may account for the high levels of non-adherence 
in Iraq. Patients in Iraq have to pay for medication, some of which are not available in the 
public sector such as atorvastatin, simvastatin and valsartan (KIMADIA, 2017) and which 
instead must be procured from the private sector. Paying out of pocket increases the 
burden on patients and consequently impacts on their adherence to medications. 
Shortage of staff in the Iraqi hospitals and clinics could affect the level of non-adherence. 
In Iraq, the average health care worker to population ratio is 7.5:10,000 (World Health 
Organization, 2018a) in comparison with 21:10,000 in the UK (Yar et al., 2006). Staff 
shortages lead to long waiting times and shorter consultation times/discussion between 
doctor and patient. Long waiting periods in hospital are associated with a high prevalence 
of medication non-adherence (Ibrahim and Deleu, 2018). Time spent with the doctor has 
a significant impact on the degree to which the patient engages in discussion about 
prescribed medications (Albaz, 1997; Brown and Bussell, 2011).  
The research showed no significant correlation between non-adherence determined via 
blood microsamples analysis and patient gender in the current sample (Chi-squared value 
= 1.707, df = 1, p value = 0.185); a similar result was obtained from another study (Jones 
et al., 2017). However, a further study indicated contradictory results, showing that non-
adherence to medications was correlated with gender (Pandey et al., 2015). The outcomes 
showed no significant correlation between level of non-adherence to the prescribed CVD 
medications and age (ρ = 0.025, p value > 0.05). Non-adherence to CVD medications in 
this study affects all age groups, and this is possibly due to the absence of any form of 
action plan to treat cardiovascular diseases, or guidelines to manage poor adherence to 
CVD medications. In addition, there is the absence of a free health scheme to obtain free 
CVD drugs, and indeed of social support programmes for CVD patients, as detailed in 
Chapter 1 Section 1.3.6. 
There was a significant positive correlation between the level of non-adherence measured 
by the direct method and the number of medications in the regimen (ρ = 0.636, p value ˂ 
0.05) and the number of tablets taken by patients (ρ = 0.674, p value ˂ 0.05). The mean 
(± SD) of medications in the non-adherent group was 5.46 ± 2.15, compared to 2.5 ± 1.40 
in the adherent group. Polypharmacy is a common problem for patients with multiple 
comorbidities, where the risk of adverse drug reactions is exacerbated by an increase in 
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the number of the medications used (Dagli and Sharma, 2014). A similar result was seen 
in other studies (Ryan et al., 2017; Schneider et al., 2018). In contrast, other studies 
showed no correlation between the level of adherence and number of medications 
(Tomaszewski et al., 2014; Pandey et al., 2015; Lee et al., 2018; Ulley et al., 2019).  
The disagreement, and thus conflicting results regarding the correlation between non-
adherence and gender and number of medications show that adherence is a complex issue 
associated with different medication-taking behaviours such as attitudes towards 
medication, differential regimen complexities, patient education and knowledge, social 
biases that hinder amicable patient-doctor relationships, and access to medications.  
Microsample-based LC-HRMS analyses were successfully used to quantify the target 
cardiovascular medications in blood microsamples from 303 Iraqi volunteers. Thus, this 
method is able to track non-adherence to each medication in the regimen, which is helpful 
to clinicians in terms of monitoring patient adherence to prescribed drug therapy and in 
guiding clinicians towards the personalisation and optimisation of patients’ medications. 
For example, patient reference number …99 was taking bisoprolol 5 mg and valsartan 80 
mg once daily, but with poor clinical outcomes. The physician referred this patient for 
assessment of medication non-adherence by microsampling blood analysis via the 
validated LC-HRMS method, the results of which indicated that this patient was only 
adherent to bisoprolol and non-adherent to valsartan. Figure 3.19(a) shows the LC-HRMS 
extracted ion chromatograms for patient reference number …99, whilst Figure 3.19(b) 
shows the LC-HRMS extracted ion chromatograms for patient reference number…114 
who, by contrast, was adherent to both bisoprolol and valsartan. The objective blood drug 
concentration data provided an evidence-base to the clinician to initiate a friendly 
discussion with the patient ….99 to establish the causes of non-adherence and to plan the 
next steps in the treatment to improve the patient outcomes.  
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Patient reference number…122 was taking losartan 50 mg and simvastatin 40 mg, for 
whom assessment of non-adherence showed adherence to losartan and non-adherence to 
simvastatin. Figure 3.20 shows the EIC of this patient in comparison with patient 
reference number…156, who was adherent to both medications. 
 
 
 
 
 
 
Bisoprolol m/z 326.2326 (a) 
Bisoprolol m/z 326.2326 
Valsartan m/z 436.2343 (b) 
   
Acquisition time (min) 
Figure 3.18. LC-HRMS extracted ion chromatograms (a) in patient reference number 
…99, who was adherent to bisoprolol but non-adherent to valsartan, and (b) patient 
reference number …114, who was adherent to both medications (green line – bisoprolol; 
blue line – valsartan; red line - blank). 
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Patient reference number …38 was taking bisoprolol 5 mg and losartan 50 mg. 
Assessment of non-adherence showed that this patient was adherent to bisoprolol and 
non-adherent to losartan. Figure 3.21 shows the EIC of this patient in comparison with 
patient reference number …27, who was adherent to both medications.  
 
 
 
 
 
Losartan m/z 423.1695 
(a) 
Losartan m/z 423.1695 
Simvastatin m/z 441.2611 
(b) 
  
 
Acquisition time (min) 
Figure 3.19. Comparison between LC-HRMS extracted ion chromatograms (a) in patient 
reference number …122, who was adherent to losartan but non-adherent to simvastatin, 
and (b) patient reference number …156, who was adherent to both medications (purple 
line – losartan; brown line – simvastatin; red line – blank). 
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The information obtained by LC-HRMS approach can individualise information for each 
medication for each patient and this will help to optimise medication and improve patient 
safety. For example, for patient reference number…99, who had poor clinical outcomes, 
the clinician may unknowingly increase the dose for both bisoprolol and valsartan; this 
in turn would increase the concentration of valsartan, which the patient was already 
adherent to, increasing the possibility of associated side effects.  
The outcomes of this research have confirmed the possibility of the application of 
microsampling-based LC-HRMS in the monitoring of the CVD drugs used in routine 
clinical practice in Iraq. Application of such a convenient analysis method will improve 
adherence among CVD patients and allow self-sampling at home without need to visit a 
clinic.  
Bisoprolol m/z 326.2326 (a) 
Bisoprolol m/z 326.2326 Losartan m/z 423.1695 (b) 
  
Acquisition time (min) 
Figure 3.20. LC-HRMS extracted ion chromatograms (a) in patient reference number 
…38, who was adherent to bisoprolol but non-adherent to losartan, and (b) patient 
reference number …27, who was adherent to both medications (green line – bisoprolol; 
purple line – losartan; red line – blank). 
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Previous work in the literature used urine analysis as a qualitative tool for assessment of 
medication adherence, which provide yes/no-type answers for the existence/absence of a 
drug or its metabolites in the urine (Hamdidouche et al., 2015, Hamdidouche et al., 2017, 
Tomaszewski et al., 2014). Microsample analysis via LC-HRMS provided quantitative 
data based on the concentration of the target medication measured in the blood 
microsamples. Moreover, HRMS provides full-scan mass spectrometry for the sample, 
which can provide more information if required without re-running the sample. This 
information should provide an evidence base for clinicians in the instance of poor patient 
progress, as the effectiveness of the treatment is related to blood drug concentration. 
Hence it will help the clinician to tailor each individual treatment to each patient.  
Moreover, when urine samples are used to assess adherence, the relationship between 
ingestion time, ingested dose, and the amount of drug in blood cannot be established. 
Secondly, quantitative blood concentration data provides information on concentrations 
for each medication and each patient; this can help to monitor and personalise treatment, 
which is not otherwise possible with urine samples.  
White coat syndrome is a major limitation to assessing medication adherence via direct 
methods, where patients take the dose before visiting the clinic. White coat syndrome is 
reported to be very common when urine samples are used for analysis (MacLaughlin et 
al., 2005). However, the method used in this research can identify such a situation when 
it is anticipated by analyses of DBS samples collected from the same volunteers several 
hours apart. When the drug concentration in the second sample is significantly less than 
in the first sample, this would indicate that the dose was taken because the test has been 
anticipated, whereas in adherent patients the drug concentration would be at a comparable 
level, that is, indicative of the steady state.  
The main limitation of the microsampling-based LC-HRMS assay developed in the 
current study is that the extraction of amlodipine from DBS or VAMS samples requires 
a separate extraction procedure to that used for the other eight CVD drugs (atenolol, 
atorvastatin, bisoprolol, diltiazem, lisinopril, losartan, simvastatin and valsartan). That 
means four DBS or VAMS samples are required from each patient on amlodipine and 
any medication from the other eight CVD medications for the analysis of volunteers’ 
dried blood samples. 
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For medications which were not detected in patients with reference numbers between 263 
and 290, and between 304 and 336, to ensure that LC-QTOF was working properly and 
that these results were not due to some malfunction or problem with extraction, data were 
rechecked where the internal standard and target medications in the QC samples were 
detected. For example, in volunteer reference number… 268, bisoprolol was not detected 
in their sample but both the IS and bisoprolol were in the QC samples (Figure 3.22). In 
another example, volunteer reference number 30, losartan was not detected in the blood 
microsamples, but both the IS and losartan were detected in the QC samples (Figure 3.23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bisoprolol in the QC 
Atenolol d7 
Losartan in the QC 
Atenolol d7 
  
 
  
 
Acquisition time (min) 
Figure 3.21. LC-HRMS extracted ion chromatograms showing the performance of the 
instrument in patient reference number…263 who was taking bisoprolol even though it 
was not detected in DBS sample, despite this medication and the internal standard 
(atenolol-d7) being detected in the QC. 
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Figure 3.22. LC-HRMS extracted ion chromatograms showing the performance of the 
instrument in patient reference number… 265, who was taking losartan even though it 
was not detected in DBS sample, despite this medication and the internal standard 
(atenolol-d7) being detected in the QC. 
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3.3.3.4. Comparison between DBS and VAMS  
Assessing the agreement between two methods is often one of the requirements made of 
medical laboratories to confirm method integrity. Correlation studies using linear 
relationship is not recommended, and instead a Bland-Altman plot can be used to assess 
the agreement between two quantitative methods by studying the mean difference, a 
method which now is recommended for assessment of agreement (Giavarina, 2015).   
Bland-Altman plot was used to compare the results obtained from 903 sampling cards 
and VAMS for 75 volunteers. The x-axis represents the average concentration found by 
DBS and VAMS, whilst the y-axis represents the difference in concentration between 
DBS and VAMS. The upper limit of agreement was defined as the mean difference + two 
standard deviations, whilst the lower limit was defined as the mean difference - two 
standard deviations. The value of two is an approximation to 1.96, which is the z-value 
for a 95% confidence interval (Giavarina, 2015).  
Bland-Altman plot showed that the measured concentration of the target medication on 
903 cards and VAMS were scattered around the mean with good concordance in the 
concentrations found using VAMS and DBS (Figure 3.24), where the associated 
differences were less than 2 SD from the mean. The results confirmed acceptable 
reproducibility and agreement between the two microsampling methods and 
demonstrated that microsampling methodologies can produce comparable quantitative 
results and may thus be used interchangeably. A bridging study to determine the drug 
concentrations in 903 cards and VAMS also confirmed the integrity and accuracy of the 
original method.  
However, there was one outlier point for patient reference number …17. The valsartan 
concentration measured for this patient on 903 cards was 147.34 ng/ml, but was 160.21 
ng/ml on VAMS with a mean difference of -12.87 ng/ml. This difference in concentration 
may be due to sampling error resulting from overfilling the VAMS tip (Tanna et al., 
2018).  
The results showed significant agreement between 903 cards and VAMS in the 
determination of the concentrations of selected cardiovascular medications in the blood 
of Iraqi volunteers. However, taking blood samples on 903 cards is more difficult than 
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VAMS for some volunteers as a sufficient volume of blood has to be deposited on the 
predetermined circles located on the card. Sometimes, blood drops fall outside the 
sampling area when the finger is directed towards the spotting area. 903 cards require 
more time to complete sampling and additional assistance is sometimes required. Care is 
required to avoid touching the blood spot on the card as this leads to sample 
contamination.  
In contrast, VAMS is designed to absorb a fixed volume of blood until the substrate is 
full, making VAMS easier and quicker, and for which assistance is not required; in 
comparison with DBS, this method facilitates patient self-sampling. Moreover, there is 
no need for drying racks or the use of a puncher with VAMS as the entire tip is extracted 
and analysed, saving time and effort. Sometimes clamshell may cause inconvenience. 
DBS cards are easier to label as VAMS have no suitable labelling surface on the clamshell 
or plastic holder. Although VAMS has many advantages over 903 cards, the cost of 
VAMS must also be considered.  
VAMS appears to be more promising than DBS due to ease of use and, most importantly, 
the fact that it overcomes HCT bias issues and sample inhomogeneity. Cost, it seems, is 
the only disadvantage of the VAMS microsampler in comparison to 903 cads; one VAMS 
sampler is almost five times more expensive than a 903 card. Therefore, the cost of a 
VAMS microsampler is, unfortunately, a significant consideration, especially in areas 
with limited resources (Kip et al., 2017). 
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Figure 3.23. Bland-Altman plot comparing DBS and VAMS concentrations for the target 
medications in volunteer samples. 
 
3.4. Conclusion 
The application of microsampling-based LC-HRMS analyses is a potential alternative to 
conventional methods of monitoring CVD drugs in routine clinical practice, providing 
objective and specific information for each individual medication in any given patient’s 
regimen. All the mass spectral data from the sample is collected in one run with no need 
to run the sample again, as data can be revisited at some later point if there is need for 
more clinical assessment to help manage the patient’s condition. For example, the patient 
may be taking medications in addition to the prescribed medications without having 
informed their doctor of such, where such medications may be responsible for poor 
clinical outcomes. In the case of poor patient progression to medications, this will provide 
an evidence base for clinicians that could help determine whether this is due to medication 
non-adherence, incorrect diagnosis, or poor selection of medication.    
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Therapeutic drug monitoring (TDM) in routine clinical practice is currently limited 
because obtaining blood samples is highly invasive (venepuncture) and requires s 
phlebotomist and prior booking of clinical appointments. Therapeutic drug monitoring 
using microvolume blood samples collected by a less invasive approach can help 
clinicians to optimise and personalise a patient’s medication. This approach is more 
convenient to patients because it is less invasive and allows self-sampling at home, and 
so without the need to visit a clinic. Medication individualisation and optimisation of the 
use of medication allows for huge savings due to better patient outcomes, reducing 
avoidable hospital readmissions, and lowering associated mortality rates.  
The application of the microsampling approach may be more feasible and economic to 
both patient and healthcare providers in comparison with the conventional approach. The 
former approach has its advantages for patients in term of saving patient time and costs 
as it eliminates the need to book an appointment with a phlebotomist or to travel to a 
clinic to provide the blood sample. The ease of transportation and reduced storage 
requirements of DBS samples – without the need for cooling, ice boxes, or dry ice – will 
reduce the cost in comparison with conventional methods, making it is easy to collect 
DBS samples in remote areas where there is limited infrastructure. They can then be sent 
via standard postal services to a hospital laboratory for analysis in less affluent regions. 
In addition, the DBS and VAMS sample collection methods do not require the use of 
syringes or collection tubes. Thus, disposal of DBS and VAMS is easy in comparison 
with the disposal of liquid samples such as plasma or indeed the disposal of containers or 
syringes.  
The level of non-adherence to the target cardiovascular medication by measurement of 
drug concentration in the DBS samples was 49.2%. However, non-adherence to CVD 
medication was not uniform, and patients may adhere differently to each medication in 
their prescribed regimens. This high rate of non-adherence could explain the high 
mortality rate in Iraq from cardiovascular diseases especially in the absence of strategies 
to manage and control the risk factors associated with cardiovascular diseases. The 
outcomes of the study showed no significant relationship between non-adherence to 
cardiovascular medications and gender or age. However, there was significant positive 
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correlation between non-adherence and number of medications and number of tablets 
taken per day. 
Measuring the concentration of the target cardiovascular medications in dried blood 
samples from Iraqi volunteers on 903 cards and VAMS showed both reliable and 
comparable data with no significant bias, which confirmed the integrity of the outcomes 
and showed the acceptability of the validated microsampling-based LC-HRMS method 
for the quantitative determination of CVD drugs when using DBS or VAMS. 
Nevertheless, of the two VAMS is considerably more patient friendly and convenient, 
enabling self-sampling at home rather than requiring a visit to the clinic and the services 
of the appropriate medical professional(s).  
The main limitation of the microsampling-based LC-HRMS assay developed in the 
current study is that the extraction of amlodipine from DBS or VAMS samples requires 
a separate extraction procedure.  
As the direct method cannot provide information about factors associated with non-
adherence, Chapter 4 assesses the non-adherence amongst the same patient sample as in 
the current chapter by application of the Morisky Medication Adherence Scale (MMAS-
8) to understand the causes associated with non-adherence and to allow comparison with 
the objective data gathered in this chapter. 
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Chapter 4 
Assessment of Non-adherence to 
Cardiovascular Medications by the 
Eight-item Morisky Medication 
Adherence Scale (MMAS-8). 
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This chapter focusses on the application of the eight-item Morisky Medication Adherence 
Scale (MMAS-8) to assess non-adherence to the cardiovascular medications (Chapter 1 
Section 1.4) most frequently prescribed to Iraqi volunteers who were prescribed one or 
more such medications. In addition, a number of factors associated with medication-
taking behaviour such as gender, age, number of different medications and number of 
tablets taken daily is discussed.   
4.1. Introduction  
Indirect methods for the assessment of medication non-adherence such as the use of a 
validated questionnaire have been found to be more popular used in clinical practice 
(Garfield et al., 2011p Moon et al., 2018). However, there is no agreement regarding the 
questionnaire of choice (Eskås et al., 2016).  
Morisky et al.(2008) developed a self-reported scale with four items with respect to 
common medication-taking behaviour that could lead to drugs not being taken, and 
indeed this scale has been used widely (Morisky et al., 2008). However, in order to 
overcome some of its limitations, four additional items addressing the circumstances 
surrounding such behaviour were used to supplement the original four items (Morisky et 
al., 1986; Shalansky et al., 2004; Thorpe et al., 2009). This updated scale was named the 
eight-items Morisky Medication Adherence Scale (MMAS-8) which is probably the most 
well-known and recognized self-report questionnaire to be used as a non-adherence 
screening tool across a range of circumstances (Lam and Fresco, 2015) including 
cardiovascular diseases (Kassab et al., 2013; Park et al., 2014; Vinluan et al., 2015; 
Granger et al., 2015; Kharameh et al., 2018; Kosobucka et al., 2018), diabetes mellitus 
(Bramlage et al., 2014; Chan and Hassali, 2014; Arora et al., 2014; Cummings et al., 
2014; Guo et al., 2014; Tabasi et al., 2014; Katalenich et al., 2015; Almadhoun and Hala, 
2018), neoplasm (Berry et al., 2015) and chronic kidney diseases (Kefale et al., 2018).   
The MMAS-8, as mentioned, consists of eight items, the first seven of which require 
yes/no answers, while question 8 is rated according to a five-point Likert scale rating 
(strongly disagree to strongly agree) (Table 4.1). The total score that can be awarded in 
the MMAS-8 ranges from 0 to 8. Scores of less than 6 indicate low adherence, scores of 
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6 to 8 indicate moderate adherence, and a score of 8 indicate high adherence (Morisky et 
al., 2008).  
Table 4.1. Questions constituting the eight-item Morisky Medication Adherence Scale 
(MMAS-8). 
 
 Use of the MMAS is protected by US copyright laws. Permission for use is required. A license agreement is 
available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, department of Community. Health 
Sciences, UCLA Fielding School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 
90095±1772, dmorisky@ucla.edu. 
 
MMAS-8 has been translated into more than 50 languages because of the simplicity of its 
application and scoring (Morisky et al., 1986; Oliveira-Filho et al., 2012). An Arabic 
version of MMAS-8 is used in Arabic countries for the assessment of adherence to 
Questions   No=1 Yes=0 
1. Do you sometimes forget to take your cardiovascular     
medication(s)? 
 
  
2. People sometimes miss taking their medications for 
reasons other than forgetting. Thinking over the past two 
weeks, were there any days when you did not take your 
cardiovascular medication(s)? 
 
 
 
 
 
 
 
3. Have you ever cut back or stopped taking your 
medication(s) without telling your doctor, because you felt 
worse when you took it? 
 
 
 
 
 
4. When you travel or leave home, do you sometimes forget 
to bring along your cardiovascular medication(s)? 
 
 
 
 
 
5. Did you take your cardiovascular medication(s) yesterday? 
 
  
6. When you feel like your cardiovascular disease is under 
control, do you sometimes stop taking your medication(s)? 
 
 
 
 
 
7. Taking medication(s) every day is a real inconvenience for 
some people. Do you ever feel hassled about sticking to 
your cardiovascular treatment plan? 
 
 
 
 
 
 
 
8.  How often do you have difficulty remembering to take all your medication(s)?                                               
                                                                          (Please circle your answer below) 
Never/Rarely 4 
Once in a while 3 
Sometimes 2 
Usually 1 
All the time 0 
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medications for a range of diseases (Sa’ed et al., 2013; Aljumah et al., 2014; Alkatheri et 
al., 2014; Ashur et al., 2015; Alhalaiqa et al., 2016). As Arabic is the official language in 
Iraq, MMAS-8 can be used there without further adaptation. MMAS-8 is protected by 
copyright and prior permission to use it is required from its owner, Professor Donald 
Morisky (Appendix 15).  
Little attention has been paid to non-adherence to medications in Iraq. There are very 
limited studies that have used MMAS-8 to assess medication non-adherence in Iraq; 
Jamal and Saleem (2014) used it for assessment of adherence amongst diabetic and 
hypertensive patients (Jamal and Saleem, 2014), for instance, and Al-Tukmagi and AL-
Auqbi (2015) used MMAS-8 to assess non-adherence to oral hypoglycaemic agents in a 
sample of Iraqi patients with type 2 diabetes mellitus (Al-Tukmagi and Al-Auqbi, 2015). 
There have been other studies in Iraq which used non-standardised questionnaires 
prepared by the researchers involved in these studies as indirect methods of assessing 
non-adherence to cardiovascular medications (Samer, 2008; Hasan et al., 2011; Bushra 
and Kameran, 2013). Therefore, the outcomes of this study can be compared to at least 
few previous studies since MMAS-8 is employed. There has been no known use of direct 
methods to assess medication non-adherence in Iraq. Thus, the application of the direct 
method used in this research to assess medication non-adherence is novel research in Iraq.  
The MMAS-8 scale can be used to assess both medication-taking behaviour and some of 
the reasons for such non-adherence, such as gaining an understanding of the medication 
regimen, reasons for non-adherence, patient’s attitudes and beliefs toward medicines, and 
other factors (Nguyen et al., 2014; Menditto et al., 2015). Each of the eight questions in 
MMAS-8 assesses a specific medication-taking behaviour (Morisky et al., 2008; Bae et 
al., 2015; Bae et al., 2016). The questions associated with intentional non-adherence 
include: 
• Have you ever cut back or stopped taking your medication(s) without telling your 
doctor, because you felt worse when you took it? 
• When you feel like your cardiovascular disease is under control, do you 
sometimes stop taking your medication(s)? 
• Taking medication(s) every day is a real inconvenience for some people. Do you 
ever feel hassled about sticking to your cardiovascular treatment plan? 
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The questions associated with unintentional non-adherence include: 
• Do you sometimes forget to take your cardiovascular medication(s)? 
• People sometimes miss taking their cardiovascular medications for reasons other 
than forgetting. Thinking over the past two weeks, were there any days when you 
did not take your cardiovascular medication(s)? 
• When you travel or leave home, do you sometimes forget to bring along your 
cardiovascular medication(s)?  
• How often do you have difficulty remembering to take all your medication(s)? 
A patient is labelled as an intentional non-adherent patient when the majority of their 
answers infer intentional non-adherence. On the other hand, the patient is labelled as 
unintentionally non-adherent when the majority of their answers infer unintentional non-
adherence (Menditto et al., 2015). 
One of the objectives of this study was to assess non-adherence to cardiovascular 
medications in adult Iraqi patients who had been prescribed one or more of CVD 
medication. This was achieved through the application of a standardized Arabic version 
of the eight-item Morisky Medication Adherence Scale (MMAS-8) to help understand 
some of the reasons associated with poor adherence. The results of this section of the 
study will be compared with the findings from previous Iraqi studies and literature.  
4.2. Material and Methods 
4.2.1. Ethics Statement  
Ethical approval for the application of an MMAS-8 questionnaire was obtained from the 
Ethical Committee in Misan Health Directorate (Appendix 1) and from De Montfort 
University’s Faculty of Health and Life Science Research Ethics Committee (Appendix 
16). Written informed consent was obtained from each participant.   
Recruited patients, as detailed in Chapter 3 Section 3.2.2, who provided blood samples as 
detailed in Chapter 3 Section 3.2.6, were provided with Arabic translations of: 
• Participant information leaflets 
• Consent form 
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• Eight-item Morisky Medication Adherence Scale (MMAS-8). 
The participant information leaflet (PIL) and the consent form are detailed in Appendices 
17 and 18, with the MMAS-8 as previously detailed in Table 4.1. The Arabic version of 
PIL, the consent form and the Arabic version of the MMAS-8 are detailed in Appendices 
(19-21). Consent forms and questionnaire papers were transported to the UK and stored 
in a secure place at De Montfort University, Faculty of Health and Life Sciences, Room 
00.15. 
4.2.2. Evaluation of Medication Non-adherence Using MMAS-8 
Medication non-adherence to CVD medications was assessed using a validated Arabic 
version of MMAS-8 (Morisky et al., 2008; Krousel-Wood et al., 2009; Morisky and 
DiMatteo, 2011). The scale consists of eight standardized questions; questions 1 to 7 
require an answer of YES (assigned a score of 0) or No (assigned a score of 1) while 
question 8 is a Likert scale-type question which has a five-item rating scale (scores of 0-
4). Regarding item 5, the response is reversed in a positive direction where Yes = 1 and 
No = 0.  
Item 8 uses a five-point Likert scale and can take one of five values (0-4) which has to be 
divided by 4 to get the summated score. The level of adherence is determined by 
summating the scores for items 1–7, and then adding the result of the summation of item 
8 (De las Cuevas and Peñate, 2015). 
4.2.3. Statistical Analysis 
Statistical analyses were conducted using the SPSS software (version 22. Armonk, NY: 
IBM Corp). Qualitative variables such as gender and medications were expressed in terms 
of frequencies and percentages. The Spearman’s correlation coefficient was used to 
determine the relationship between levels of non-adherence as measured by the MMAS-
8 and patients’ ages, number of CVD medications in patients’ regimens and numbers of 
tablets taken. A Chi-squared test was used to examine the relationship between levels of 
non-adherence and gender. A P-value less than 0.5% was considered significant.  
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4.3. Results and Discussion  
4.3.1. Patient Characteristics 
303 Iraqi patients were recruited in this study: 150 males (49.5%) and 153 females 
(50.5%) with a mean age of 53.93 (SD = ±8.97). Patients were prescribed one or more 
CVD medications, where the mini-DBS questionnaire enabled the identification of which 
CVD medication(s) each volunteer had been prescribed. The prescribed CVD 
medications, the number of CVD medications per regimen, and the number of tablets 
taken per day, as detailed in Tables 4.2 and 4.3, were extracted from the mini-DBS 
questionnaire, as detailed in chapter 3 section 3.2.2. Patients’ ages were obtained from 
their clinical records, where patient characteristics and medication(s) prescribed to 
patients are summarized in Table 4.2 and Table 4.3. 
 Table 4.2. Patient population sample characteristics (n = 303). 
Variables Total number of participants = 303 
 N % 
Gender   
Male 150 49.5 
Female 153 50.5 
Age Mean (SD) 53.93 (8.97)  
30-39 25 8.3 
40-49 87 28.7 
50-59 100 33 
60-69 91 30 
Number of medications Mean (SD) 3.95 (2.33)  
1-2 130 42.9 
3-4 57 18.8 
5-6 53 17.5 
˃6 63 20.8 
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 Table 4.3. Medications Prescribed for the treatment of CVD in the Iraqi sample. 
Medication type  N (%) of patients prescribed 
medication 
β blockers   
Atenolol 59 (13.5) 
Bisoprolol 77 (17.5) 
  
ACE inhibitor  
Lisinopril 73 (16.7) 
  
Angiotensin II Receptor Blockers  
Valsartan 65 (14.8) 
Losartan 47 (10.7) 
  
Statins  
Atorvastatin  18 (4.1) 
Simvastatin  50 (11.4) 
  
Calcium Channel Blockers  
Amlodipine 15 (3.4) 
Diltiazem 34 (7.8) 
Total 438 (100) 
 
4.3.2. Medication Non-adherence  
Patients were categorized into three groups based on their responses to the MMAS-8 
questions: low adherence (MMAS-8 score < 6), medium adherence (MMAS-8 score 6 to 
< 8) or high adherence (MMAS-8 score of 8). The current study found that 54.1% (164 
participants) showed high adherence, 27.7% (84 participants) showed medium adherence 
and 18.2% (55 participants) showed low adherence (Table 4.4). Responses to MMAS-8 
for all 303 participants are summarized in Table 4.5. For the purposes of this analysis, 
patients were classified as adherent or non-adherent rather than low, medium and high 
using a score of 6 as the cut-off point (Morisky et al., 2008; Khayyat et al., 2017). Thus, 
248 participants (81.8%) were adherent of which 125 were male (50.4%) and 123 were 
female (49.6%). By contrast, 55 participants (18.2%) were non-adherent (25 males, 
45.5%, and 30 females, 54.5%).  
The proportion of non-adherent patients, as determined by MMAS-8 in the current study, 
was 18.2%. This result almost matches that observed in an earlier study in Iraq, where the 
reported level of non-adherence was 19.6% (Jamal and Saleem, 2014). However, the level 
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of non-adherence to CVD medication in this research was significantly lower than that 
reported in other studies in Iraq (Al-Dabbagh and Aswad, 2009; Hasan et al., 2011; 
Bushra and Kameran, 2013) and less than the non-adherence reported for other 
developing countries such as Lebanon (22.4%) (Yassine et al., 2015) Saudi Arabia 
(33.7%) (Altuwairqi, 2016) and Iran (54%) (Moharamzad et al., 2015). 
Table 4.4. Adherence amongst Iraqi cardiovascular disease patients based on MMAS-8   
Adherence level (score) Total study population (N = 303) 
N % 
Low adherence 55 18.2 
Medium adherence 84 27.7 
High adherence 164 54.1 
Total 303 100 
 
The difference in the level of non-adherence found in the current study and the literature 
may suggest that adherence is a complex and dynamic psychological behaviour issue. 
Non-adherence can be affected by many variables such as differences in the study 
populations, or other factors such as patient knowledge, the complexity of the medical 
regimen, and patients’ health conditions. It is possible that patients overestimated their 
adherence in the current study to a greater degree than in previous studies. The possibility 
of such overestimation can be confirmed through a comparison with direct methods of 
assessment of medication adherence by determining drug levels in dried blood spots 
obtained from the same study participants (Chapter 3). 
The results of the present study revealed no significant relationship between the level of 
non-adherence assessed by MMAS-8 and gender (Chi squared value = 0.441, df = 1, p 
value = 0.507). In the literature, there are conflicting results about the correlation between 
adherence and gender. Results from the USA, Saudi Arabia, Hong Kong and the UK 
showed greater levels of non-adherence in females than males (Irvin et al., 2012; Pandey 
et al., 2015; Kang et al., 2015; Safaa and Ali, 2015; Khayyat et al., 2017; Gohar et al., 
2008). However, other studies showed higher levels of non-adherence in males than 
females (Al-Dabbagh and Aswad, 2009: Jamal and Saleem, 2014; Sandoval et al., 2018). 
Discrepancies between the level of non-adherence to cardiovascular medications and 
gender in such studies may indicate complex psychological behavioural factors and 
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sociological gender-based dynamics are at play. Such factors may include social biases 
that hinder amicable patient-doctor relationships due to social, cultural or religious issues.  
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Table 4.5. Responses for each question in the MMAS-8 scale. 
Questions Study population (N = 303) 
Yes (%) No (%) 
1. Do you sometimes forget to take your cardiovascular medication(s)? 59 (19.5) 244 (80.5) 
2. People sometimes miss taking their medications for reasons other than 
forgetting. Thinking over the past-two weeks, were there any days when 
you did not take your cardiovascular medication(s)? 
45 (14.9) 258 (85.1) 
3. Have you ever cut back or stopped taking your medication(s) without 
telling your doctor, because you felt worse when you took it? 
75 (24.8) 228 (75.2) 
4. When you travel or leave home, do you sometimes forget to bring along 
your cardiovascular medication(s)? 
17 (5.6) 286 (94.4) 
5. Did you take your medication(s) yesterday? 260 (85.8) 43 (14.2) 
6. When you feel like your cardiovascular disease is under control, do you 
sometimes stop taking your medication (s)? 
73 (24.1) 230 (75.9) 
7. Taking medication(s) every day is a real inconvenience for some people. 
Do you ever feel hassled about sticking to your cardiovascular treatment 
plan? 
43(14.2) 260 (85.8) 
8. How often do you have difficulty remembering to take 
all your medication(s)? 
All the time Never/Rarely Sometimes Once in a while Usually 
0 (0%) 286 (94.4) 8 (2.6) 5 (1.7) 4 (1.3) 
 
Use of the MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, ScD, 
ScM, MSPH, Professor, department of Community. Health Sciences, UCLA Fielding School of Public Health, 650 Charles E. Young Drive South, Los 
Angeles, CA 90095±1772, dmorisky@ucla.edu.
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Bivariate correlation using Spearman’s correlation coefficient (ρ) showed no significant 
correlation between age and non-adherence to CVD medications (ρ = 0.092, p value ˃ 
0.05). This result was in line with the findings reports in several different studies (Bushra 
and Kameran, 2013; Krueger et al., 2015; Pandey et al., 2015; Jin et al., 2016). However, 
this was contrary to other studies which suggested a significant correlation between age 
and non-adherence to antihypertensive medication (Ramli et al., 2012; Alhewiti, 2014; 
Meinema et al., 2015; Yap et al., 2016; Khayyat et al., 2017). Results indicating a lack 
of correlation between age and levels of non-adherence are agreeable due to certain 
factors highlighted in Chapter 1(Table 1.2). 
Bivariate correlation using Spearman’s correlation coefficient (ρ) indicated a significant 
positive correlation between non-adherence and number of medications taken (ρ = 0.966, 
p value ˂ 0.05) and the number of tablets of different medications taken (ρ = 0.976, p 
value ˂ 0.05). As the number of medications taken by a patient increased, the possibility 
of non-adherence correspondingly increased. In the non-adherent group, the mean 
number of cardiovascular medications taken by patients was 6.53 ± 1.63 in comparison 
with 3.38 ± 2.07 in the adherent group. The need to take a larger number of medications 
can lead to non-adherence because this can lead to errors in dosing and administration. 
Furthermore, medications may be missed on a daily basis and, thus, increase the 
possibility of adverse drug events and impose a treatment-related burden on patients. All 
the above can lead to medication non-adherence (Marcum and Gellad, 2012; Kvarnstrom 
et al., 2018). There are also conflicting results between this study and others regarding 
the correlation between number of medications in a regimen and subsequent adherence. 
Some of these studies indicate that low adherence to CVD medications is associated with 
the number of medications taken (Shalansky and Levy, 2002; Choudhry et al., 2011; 
Bazargan et al., 2017). By contrast, other studies have showed that regimen complexity 
and number of medications may not influence the level of non-adherence (Stange et al., 
2013; Jamal and Saleem, 2014). The responses to the MMAS-8 in the non-adherent group 
(n = 55 patients) are summarized in Table 4.6 where the responses of non-adherent 
patients to MMAS-8 are: 
• 85.5% of non-adherent participants, according to MMAS-8, answered YES to the 
question “When you feel like your cardiovascular disease is under control, do you 
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sometimes stop taking your medication (s)?”. This response may indicate that 
patients do not understand their disease well enough to realise that it is a chronic 
condition (Oliveira-Filho et al., 2014; Alhalaiqa et al., 2016) which thus requires 
continuous treatment, and that medications should not be stopped even when the 
patient feels better.  
• 81.8% of non-adherent participants, according to MMAS-8, answered YES to the 
question “Do you sometimes forget to take your cardiovascular medication(s)?” 
where this response indicates that the major cause of non-adherence was 
forgetfulness (Al-Ramahi, 2015; Alhalaiqa et al., 2016; Miyazaki et al., 2018).  
• 81.8% of non-adherent participants, according to MMAS-8, answered YES to the 
question “Have you ever cut back or stopped taking your medication(s) without 
telling your doctor, because you felt worse when you took it?” which indicates 
that medication-based side effects accounted for considerable non-adherence 
among CVD patients (Al-Ramahi, 2015; Alhalaiqa et al., 2016).  
• 70.9% of non-adherent participants, according to MMAS-8, answered YES to the 
question “People sometimes miss taking their medications for reasons other than 
forgetting. Thinking over the past-two weeks, were there any days when you did 
not take your cardiovascular medication (s)?”.  Patients gave no reasons for not 
taking medications. This indicates that the questionnaire itself may need 
improvement in order to better assess the reasons for non-adherence. For instance, 
other reasons for non-adherence which are not addressed in the questionnaire may 
be the financial cost of the medications, or patients’ beliefs about their use. 
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Table 4.6. The responses to the eight-item Morisky Medication Adherence Scale (MMAS-8) in the non-adherent group of patients. 
Questions 
Study population (N = 55 patients) 
Yes (%) No (%) 
1. Do you sometimes forget to take your cardiovascular medication(s)? 
45 (81.8) 10 (18.2) 
2. People sometimes miss taking their medications for reasons other than 
forgetting. Thinking over the past-two weeks, were there any days when 
you did not take your cardiovascular medication(s)? 
39 (70.9) 16 (29.1) 
3. Have you ever cut back or stopped taking your medication(s) without 
telling your doctor, because you felt worse when you took it? 45 (81.8) 10 (18.2) 
4. When you travel or leave home, do you sometimes forget to bring along 
your cardiovascular medication(s)? 14 (25.5) 41 (74.5) 
5. Did you take your medication(s) yesterday? 
17 (30.9) 38 (69.1) 
6. When you feel like your cardiovascular disease is under control, do you 
sometimes stop taking your medication (s)? 47 (85.5) 8 (14.5) 
7. Taking medication(s) every day is a real inconvenience for some people. 
Do you ever feel hassled about sticking to your cardiovascular treatment 
plan? 
34 (61.8) 21 (38.2) 
8. How often do you have difficulty remembering to take 
all your medication(s)? 
All the time Never/Rarely Sometimes Once in a while Usually 
0 (0%) 50 (90.9) 2 (3.6) 0 (0%) 3(5.5) 
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• 61.8% of non-adherent participants, according to MMAS-8, answered YES to the 
question “Taking medication(s) every day is a real inconvenience for some people. 
Do you ever feel hassled about sticking to your cardiovascular treatment plan?”. 
This shows that non-adherent patients felt sticking to their medications to be an 
imposition (Al-Ramahi, 2015; Alhalaiqa et al., 2016). The tools applied could not 
provide information about the sources of this inconvenience. However, reasons 
for such feelings of inconvenience could be the dose frequencies, prescription 
refills, the need to take with or without food, etc.  
• 25.5% of non-adherent participants, according to MMAS-8, answered YES to the 
question “When you travel or leave home, do you sometimes forget to bring along 
your cardiovascular medication(s)?” According to the answers received, patients 
forgetting to bring their medications while traveling or leaving home accounted 
for their non-adherence (Alhalaiqa et al., 2016). The majority of non-adherent 
participants (90.9%) have no problem with remembering to take their 
medications.  
This research is one of the few studies in Iraq to have assessed non-adherence to 
cardiovascular medications. This study identified five risk factors associated with CVD 
medication non-adherence. These are: poor understanding of the diseases, forgetfulness, 
side effects, medication inconvenience and travelling and leaving home. 
Several limitations to the present study in using MMAS-8 to assess medication non-
adherence need to be acknowledged: 
• The sample size in this study was determined based on the prevalence of 
hypertension because there was no documentation about the prevalence of 
cardiovascular diseases in Iraq. Thus, the results may not have precisely 
determined the level of non-adherence to CVD medications amongst all CVD 
patients. 
• The samples were taken at two hospitals in Misan, where patient characteristics 
may vary from other regions in Iraq. Moreover, the study excluded patients who 
were unable to read and write and those with cognitive impairment, which may 
limit the generalisability of this study.  
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• The assessment of medication adherence by application of MMAS-8 may be 
subject to a degree of overestimation. Patients may not answer questions truthfully 
in an attempt to please their doctors, instead claiming what they believe their 
doctors want to hear from them.  
• There is a possibility of bias in the responses known as the “Acquiescence 
response”, where the participants give affirmative answers regardless of the 
content of the question, and this possibility for bias might be expressed within the 
self-reported questionnaire (Watson, 1992).  
• MMAS-8 provides a single qualitative adherence assessment depending on the 
total score of a patient’s responses to the questions and it thus unable to 
differentiate non-adherence to multiple medications in the prescribed 
pharmacotherapy regimens. For example, a patient subject to polypharmacy may 
unintentionally take a double dose of one medication and miss the other. In such 
scenarios, the medication was taken but the patient took the wrong dose and 
therefore this patient was nevertheless non-adherent. 
• MMAS-8 categorizes patients as adherent or non-adherent based on their 
medication-taking behaviour as defined by the answers to the eight questions. 
However, there are differences between females and males in terms of their body 
compositions, physiologies (e.g., influence of hormones during the menstrual 
cycle, menopause, pregnancy), pharmacokinetics (e.g., reduction in renal and 
liver functions due to aging) and pharmacodynamic parameters (Jochmann et al., 
2005; Sera and McPherson, 2012; Rosano et al., 2015; Tamargo et al., 2017). 
Thus, the efficacy and safety of medications can differ depending on the sex of 
the patient (Rosano et al., 2015; EUGenMed et al., 2016).  
• The application of MMAS-8 is not helpful in personalizing CVD treatments. For 
example, a patient may have a genetic difference in the production of enzymes 
responsible for drug metabolism, leading to either unusually slow metabolism of 
medications (e.g., clopidogrel) or unusually rapid metabolism (e.g., Warfarin) 
(Vermeire et al. 2001). Consequently, patients may have different therapeutic 
outcomes despite taking the same dose. Clopidogrel is a prodrug that is absorbed 
through the intestines and then metabolized in the liver to form its active 
metabolites (Savi et al., 1992; Lins et al., 1999). Slow metabolism of clopidogrel 
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will lead to the reduced biotransformation of clopidogrel to its active metabolite. 
On the other hand, warfarin is metabolized into inactive metabolites (Cavallari 
and Limdi, 2009) which will lead to variation in clinical outcomes among patients 
taking the same dose and thus increase the possibility of cardiovascular events.  
• The MMAS-8 can only capture a few of the reasons associated with non-
adherence such as forgetfulness, patient knowledge and medication-based side 
effects. Thus, it is difficult to develop interventions to improve adherence based 
purely on the results of the MMAS-8 scale (Unni and Farris, 2015).  
4.4. Conclusion  
The application of MMAS-8 as a tool to assess adherence indicated that 81.8% of patients 
were adherent to the target cardiovascular medications and accordingly that 18.2% of 
patients were non-adherent. The main causes of non-adherence were a limited 
understanding of the medication regimen, medication-based side effects and 
forgetfulness. However, some patients gave no reasons for their poor adherence which 
may indicate that the MMAS-8 needs further development to gain a better assessment of 
the reasons behind non-adherence.  
The use of MMAS-8 as the sole method of assessment of medication non-adherence has 
certain drawbacks, such as overestimation and inability to track non-adherence for each 
medication in multiple drug regimens. MMAS-8 can assess medication-taking behaviour 
but cannot identify pharmacokinetic differences between individual patients, which can 
lead to variations in clinical outcomes for a given dose in different patients. MMAS-8 can 
simply generate yes or no results, and it is well-known that self-report questionnaires can 
produce a certain bias in results in terms of assessment of non-adherence. This indicates 
the need for a reliable and practical approach to assess medication non-adherence. The 
desired clinical outcomes for Iraqi patients can be achieved by optimising the use of 
medicines through application of a feasible, time efficient and objective therapeutic drug 
monitoring method that can allow the adherence to each medication in the regimen to be 
assessed with due consideration for patient-to-patient pharmacokinetic and 
pharmacodynamic variations. The results based on MMAS-8 also showed that there was 
no correlation between the level of non-adherence to CVD medication and gender or age. 
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On the other hand, MMAS-8 showed a significant positive correlation between non-
adherence and number of medications in the patient’s regimen and the number of tablets 
taken by the patient.  
The next chapter compares the assessment of medication non-adherence by MMAS-8 and 
by analysis of DBS samples via LC-HRMS to study the agreement and disagreement 
between the two approaches.   
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This chapter compares the results of non-adherence in 303 Iraqi volunteers using two 
different approaches, namely the indirect method of using a standardized Arabic version 
of the eight-item Morisky Medication Adherence Scale (MMAS-8) and the direct method 
of analysis of blood microsamples via liquid chromatography-high resolution mass 
spectrometry (LC-HRMS). The combination of these two methods was expected to help 
to confirm whether volunteers were adherent or otherwise to the prescribed CVD 
medications. Additionally, some of the causes of non-adherence were expected to be 
obtained by the application of MMAS-8.  
5.1. Introduction 
Although various strategies have been employed to measure prescription adherence, to 
date no consensus has been reached as to an appropriate ‘gold standard’ for such for 
application in routine clinical practice (Kennedy et al., 2008). As detailed in chapter 2 
Section 2.6, the various methods used for assessment of non-adherence each have their 
particular strengths and weaknesses, with trade-offs between accuracy and practicality, 
which makes their acceptability subjective. Moreover, each method (direct or indirect) 
provides different information on medication-taking behaviour (Vitolins et al., 2000; 
Lehmann et al., 2014).  
According to a report by the World Health Organization (WHO) entitled “Adherence to 
Long-Term Therapies”, a multi-measure approach, as applied by combining feasible self-
reporting and reasonable objective approaches, is recommended (Sabaté, 2003). Selecting 
two or more methods allows one method’s strengths to compensate for the weaknesses in 
another, improving the quality of information used to determine adherence levels.  
In the current research, a combination of the indirect and direct methods should provide 
more comprehensive information about non-adherence and its causes, facilitating more 
effective efforts towards improving adherence by the clinician. 
There are different statistics to measure the agreement between the two methods, such as 
Cohen’s kappa (for two raters) and Fleiss kappa (for three or more raters).  Poor 
agreement is considered to have occurred when kappa is less than 0.40, fair to good 
agreement in the range 0.40 to 0.75, whilst higher than 0.75 represents excellent 
agreement (Landis and Koch, 1977). For clinical studies, it is recommended that a kappa 
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of 0.8 should be taken as the minimum acceptable value for agreement (McHugh, 2012), 
as will be used in the present study.  
5.2. Participants 
The agreement between the MMAS-8 and the determination of drugs concentration in 
DBS was assessed for the same sample of Iraqi volunteers who consented to provide 
blood samples as described in section 3.2.2 in chapter 3 and completed the MMAS-8 as 
described in chapter 4 Section 4.2.1.  
5.3. Statistical Analysis 
Descriptive statistical frequency distributions were obtained using the SPSS software 
(version 22. Armonk, NY: IBM Corp). Qualitative variables, such as gender and 
medications, were expressed using frequencies and percentages. Spearman’s correlation 
coefficient was used to determine the relationship between non-adherence level measured 
by the MMAS-8 questionnaire or via blood microsamples analysis and number of CVD 
medications and number of tablets taken daily. A Chi-squared test was used to examine 
the relationship between level of non-adherence and gender. Means and standard 
deviations were used to express the concentration of medications in the biological 
samples. The kappa concordance test was used to measure the degree of agreement 
between the non-adherence classified by the Morisky questionnaire and the blood 
microsample analyses, where a P-value of less than 0.5% was considered significant. 
5.4. Results and Discussion  
5.4.1. Assessment of Adherence to Target CVD Medications Using MMAS-8 
and Blood Microsample Analyses for 303 Iraqi Volunteers 
The blood microsampling analysis using LC-HRMS and its integration with MMAS-8 is 
the first study to attempt to assess non-adherence to cardiovascular medications in Iraq. 
The assessment of non-adherence to CVD medications by MMAS-8 was based on the 
cut-off point of a score of 6. On the other hand, patients were classified as non-adherent 
through blood microsample analysis when one or more of their prescribed medications 
concentration was < 5% of Cmax or was > Cmax for that prescribed medication. The 
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concentration of the target CVD medications determined in the blood microsamples, as 
collected onto 903 cards and VAMS from the 303 Iraqi volunteers in the present study, 
showed significant agreement, as detailed in Chapter 3 Section 3.4.4. Thus, the 
assessment of non-adherence in the blood microsamples represents the results obtained 
from both 903 cards and VAMS.    
MMAS-8 showed that 248 (81.8%) participants were adherent, namely 125 males 
(50.4%) and 123 females (49.6%), whilst 55 (18.2%) participants were non-adherent, 
namely 25 male (45.5%) and 30 females (54.5%); by comparison the assessment of non-
adherence by determination of the target drugs’ concentrations in blood microsamples 
from the same volunteers indicated that 154 patients (50.8%) were adherent to 
medications (82 males and 72 females) and 149 patients (49.2%) were non-adherent (68 
males and 81 females). The detailed agreement, or indeed disagreement, between these 
two methods of assessment for this sample of 303 volunteers is summarized in Table 5.1. 
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Table 5.1. The results of assessment of adherence to target CVD medications using 
MMAS-8 and blood microsample analyses for 303 Iraqi volunteers. 
Patient reference 
number  
Sex Adherence assessment 
by MMAS-8 
Adherence assessment by 
microsampling analysis 
903-280716-AA-06 Female YES YES 
903-310716-MT-07 Male YES NO 
903-310716-AA-08 Female NO NO 
903-310716-AA-10 Male NO NO 
903-310716-AA-11 Female NO NO 
903-310716-AA-12 Female YES YES 
903-310716-AA-14 Male YES YES 
903-310716-AA-15 Female YES YES 
903-010816-AA-16 Female YES YES 
903-010816-AA-17 Male YES NO 
903-030816-AA-19 Female NO NO 
903-030816-AA-20 Male NO NO 
903-030816-AA-21 Female YES NO 
903-030816-AA-23 Male YES NO 
903-030816-AA-24 Female YES YES 
903-030816-AA-25 Female YES YES 
903-030816-AA-27 Female YES YES 
903-040816-AA-30 Male YES YES 
903-040816-AA-31 Male NO NO 
903-040816-AA-32 Female YES YES 
903-040816-AA-33 Male NO NO 
903-050816-AA-34 Male YES YES 
903-050716-AA-36 Female YES NO 
903-050816-AA-37 Male YES YES 
903-050816-AA-38 Male YES NO 
903-050816-AA-40 Female YES YES 
903-050816-AA-41 Female YES NO 
903-050816-AA-42 Male YES YES 
903-060816-AA-45 Male YES NO 
903-060816-AA-48 Male NO NO 
903-060816-AA-50 Male YES YES 
903-060816-AA-51 Male YES YES 
903-060816-AA-52 Male YES YES 
903-060816-AA-53 Male YES NO 
903-070816-AA-55 Female YES NO 
903-070816-AA-56 Female YES NO 
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Table 5.1 continued  
Patient reference 
number  
Sex Adherence assessment 
by MMAS-8 
Adherence assessment by 
microsampling analysis 
903-070816-AA-57 Female YES YES 
903-070816-AA-58 Male YES NO 
903-070816-AA-59 Female YES NO 
903-070816-AA-60 Female YES NO 
903-070816-AA-61 Male NO NO 
903-070816-AA-62 Male NO NO 
903-070816-AA-64 Male YES NO 
903-070816-AA-65 Male YES YES 
903-080816-AA-66 Female YES YES 
903-080816-AA-67 Male YES YES 
903-080816-AA-68 Male YES YES 
903-080816-AA-69 Male YES YES 
903-080816-AA-70 Male YES YES 
903-080816-AA-72 Female YES NO 
903-090816-AA-73 Female YES NO 
903-090816-AA-74 Male NO NO 
903-090816-AA-75 Female YES NO 
903-090816-AA-76 Male YES YES 
903-090816-AA-77 Male NO YES 
903-090816-AA-78 Male YES YES 
903-100816-AA-80 Male NO NO 
903-100816-AA-82 Male YES NO 
903-100816-AA-84 Male NO YES 
903-100816-AA-86 Female YES YES 
903-100816-AA-87 Female YES YES 
903-100816-AA-88 Male YES NO 
903-100816-AA-89 Female NO YES 
903-110816-AA-90 Male YES YES 
903-120816-AA-91 Male YES YES 
903-120816-AA-93 Male YES YES 
903-150816-AA-95 Male YES NO 
903-150816-AA-96 Male YES YES 
903-150816-AA-99 Female YES NO 
903-200717-AA-100 Male YES YES 
903-200717-AA-101 Male YES YES 
903-200717-AA-102 Male YES YES 
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Table 5.1 continued  
Patient reference 
number  
Sex Adherence assessment 
by MMAS-8 
Adherence assessment by 
microsampling analysis 
903-200717-AA-103 Male YES YES 
903-200717-AA-104 Male YES YES 
903-200717-AA-105 Male YES YES 
903-200717-AA-106 Male YES YES 
903-200717-AA-107 Male YES NO 
903-200717-AA-108 Male YES NO 
903-200717-AA-109 Male YES NO 
903-200717-AA-110 Male YES YES 
903-200717-AA-111 Male YES YES 
903-200717-AA-112 Male YES NO 
903-200717-AA-113 Male YES YES 
903-200717-AA-114 Male YES YES 
903-200717-AA-115 Female YES YES 
903-200717-AA-116 Female YES NO 
903-200717-AA-117 Female YES YES 
903-200717-AA-118 Male YES YES 
903-200717-AA-119 Male YES YES 
903-200717-AA-120 Male YES NO 
903-210717-AA-121 Male YES NO 
903-210717-AA-122 Female YES NO 
903-210717-AA-123 Male YES YES 
903-210717-AA-124 Female YES NO 
903-210717-AA-125 Female YES YES 
903-210717-AA-126 Male YES YES 
903-210717-AA-127 Female YES YES 
903-210717-AA-128 Male YES YES 
903-210717-AA-129 Female NO YES 
903-210717-AA-130 Male NO YES 
903-220717-AA-131 Male YES YES 
903-220717-AA-132 Male NO YES 
903-220717-AA-133 Male YES NO 
903-220717-AA-134 Male YES NO 
903-220717-AA-135 Male YES NO 
903-220717-AA-136 Male YES YES 
903-220717-AA-137 Female YES YES 
903-220717-AA-138 Female YES YES 
903-220717-AA-139 Male YES YES 
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Table 5.1 continued  
Patient reference 
number  
Sex Adherence assessment 
by MMAS-8 
Adherence assessment by 
microsampling analysis 
903-220717-AA-140 Female YES YES 
903-230717-AA-141 Male YES YES 
903-230717-AA-142 Female YES YES 
903-230717-AA-143 Male YES YES 
903-230717-AA-144 Male YES YES 
903-230717-AA-145 Male YES NO 
903-230717-AA-146 Male YES NO 
903-230717-AA-147 Female YES YES 
903-230717-AA-148 Male YES YES 
903-230717-AA-149 Female YES YES 
903-230717-AA-150 Female YES YES 
903-240717-AA-152 Male YES YES 
903-240717-AA-153 Male YES YES 
903-240717-AA-154 Female YES YES 
903-240717-AA-155 Female YES YES 
903-240717-AA-156 Male YES YES 
903-240717-AA-157 Female YES NO 
903-240717-AA-158 Female YES NO 
903-240717-AA-159 Female YES NO 
903-240717-AA-160 Male YES YES 
903-250717-AA-161 Female YES YES 
903-250717-AA-162 Female YES YES 
903-250717-AA-163 Male YES YES 
903-250717-AA-164 Male NO YES 
903-250717-AA-165 Male YES YES 
903-250717-AA-166 Female YES YES 
903-250717-AA-167 Male NO YES 
903-250717-AA-168 Male YES NO 
903-250717-AA-169 Female YES YES 
903-250717-AA-170 Male YES YES 
903-270717-AA-171 Female YES YES 
903-270717-AA-172 Male YES YES 
903-270717-AA-173 Female YES YES 
903-270717-AA-174 Female YES YES 
903-270717-AA-175 Female YES YES 
903-270717-AA-176 Male YES YES 
903-270717-AA-177 Female YES NO 
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Table 5.1 continued  
Patient reference 
number  
Sex Adherence assessment 
by MMAS-8 
Adherence assessment by 
microsampling analysis 
903-270717-AA-178 Male YES YES 
903-270717-AA-180 Female YES NO 
903-280717-AA-181 Male YES NO 
903-280717-AA-182 Female YES YES 
903-280717-AA-183 Female YES YES 
903-280717-AA-184 Male YES YES 
903-280717-AA-185 Male YES YES 
903-280717-AA-186 Female YES NO 
903-280717-AA-187 Male YES YES 
903-280717-AA-188 Male YES YES 
903-280717-AA-189 Female YES NO 
903-280717-AA-190 Female YES NO 
903-290717-AA-191 Female YES YES 
903-290717-AA-192 Female YES YES 
903-290717-AA-193 Female YES NO 
903-290717-AA-194 Male YES YES 
903-290717-AA-195 Male YES NO 
903-290717-AA-196 Male YES NO 
903-290717-AA-197 Male YES YES 
903-290717-AA-198 Male YES NO 
903-290717-AA-199 Female YES YES 
903-290717-AA-200 Male YES YES 
903-300717-AA-201 Male YES YES 
903-300717-AA-202 Male YES NO 
903-300717-AA-204 Male YES NO 
903-300717-AA-205 Male YES YES 
903-300717-AA-206 Female YES YES 
903-300717-AA-207 Male YES YES 
903-300717-AA-208 Female YES YES 
903-300717-AA-209 Female YES YES 
903-300717-AA-210 Female YES YES 
903-300717-AA-211 Female YES NO 
903-300717-AA-212 Female YES NO 
903-300717-AA-213 Male YES YES 
903-300717-AA-214 Male YES YES 
903-300717-AA-215 Male YES YES 
903-300717-AA-216 Female YES YES 
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Table 5.1 continued  
Patient reference 
number  
Sex Adherence assessment 
by MMAS-8 
Adherence assessment by 
microsampling analysis 
903-300717-AA-217 Male YES NO 
903-300717-AA-218 Female YES NO 
903-300717-AA-219 Female YES YES 
903-300717-AA-220 Female YES NO 
903-310717-AA-221 Female YES NO 
903-310717-AA-222 Male YES YES 
903-310717-AA-223 Female YES YES 
903-310717-AA-224 Female YES NO 
903-310717-AA-225 Male YES YES 
903-310717-AA-226 Female YES YES 
903-310717-AA-227 Female YES YES 
903-310717-AA-228 Female YES YES 
903-310717-AA-229 Female YES YES 
903-310717-AA-230 Male YES NO 
903-100817-AA-231 Male YES NO 
903-100817-AA-232 Male YES YES 
903-100817-AA-233 Female YES YES 
903-100817-AA-234 Female YES YES 
903-100817-AA-235 Female YES NO 
903-100817-AA-236 Female YES NO 
903-100817-AA-237 Female YES NO 
903-100817-AA-238 Female YES NO 
903-100817-AA-239 Male YES NO 
903-100817-AA-240 Male YES NO 
903-020817-AA-241 Male NO NO 
903-020817-AA-242 Male YES NO 
903-020817-AA-243 Male YES YES 
903-020817-AA-244 Female YES YES 
903-020817-AA-245 Female YES YES 
903-020817-AA-246 Male YES YES 
903-020817-AA-247 Female YES NO 
903-020817-AA-248 Female YES NO 
903-020817-AA-249 Female YES NO 
903-020817-AA-250 Female YES NO 
903-030817-AA-251 Female YES NO 
903-030817-AA-252 Female YES NO 
903-030817-AA-253 Male YES NO 
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Table 5.1 continued  
Patient reference 
number  
Sex Adherence assessment 
by MMAS-8 
Adherence assessment by 
microsampling analysis 
903-030817-AA-254 Female YES YES 
903-030817-AA-255 Female YES YES 
903-030817-AA-256 Female YES YES 
903-030817-AA-257 Female YES YES 
903-030817-AA-258 Male YES YES 
903-030817-AA-259 Female YES YES 
903-030817-AA-260 Female YES YES 
903-040817-AA-261 Male YES NO 
903-040817-AA-262 Male YES NO 
903-040817-AA-263 Male NO NO 
903-040817-AA-264 Male NO NO 
903-040817-AA-265 Male NO NO 
903-040817-AA-266 Male NO NO 
903-040817-AA-267 Female NO NO 
903-040817-AA-268 Female NO NO 
903-040817-AA-269 Female NO NO 
903-040817-AA-270 Female NO NO 
903-050817-AA-271 Female NO NO 
903-050817-AA-272 Male NO NO 
903-050817-AA-273 Female NO NO 
903-050817-AA-274 Male NO NO 
903-050817-AA-275 Female NO NO 
903-050817-AA-276 Female NO NO 
903-050817-AA-277 Female NO NO 
903-050817-AA-278 Female NO NO 
903-050817-AA-279 Female NO NO 
903-050817-AA-280 Female NO NO 
903-100817-AA-281 Female NO NO 
903-100817-AA-282 Female NO NO 
903-100817-AA-283 Male NO NO 
903-100817-AA-284 Female NO NO 
903-100817-AA-285 Female NO NO 
903-100817-AA-286 Female NO NO 
903-100817-AA-287 Female NO NO 
903-100817-AA-288 Female NO NO 
903-100817-AA-289 Female NO NO 
903-100817-AA-290 Female NO NO 
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Table 5.1 continued  
Patient reference 
number  
Sex Adherence assessment 
by MMAS-8 
Adherence assessment by 
microsampling analysis 
903-210318-AA-291 Male YES YES 
903-210318-AA-292 Male YES YES 
903-210318-AA-293 Female YES YES 
903-210318-AA-294 Male NO NO 
903-210318-AA-295 Female YES NO 
903-210318-AA-296 Male YES NO 
903-210318-AA-297 Male YES YES 
903-210318-AA-298 Female YES YES 
903-210318-AA-299 Male YES NO 
903-210318-AA-300 Female YES NO 
903-240318-AA-301 Female YES YES 
903-240318-AA-302 Female YES YES 
903-240318-AA-303 Female YES YES 
903-240318-AA-304 Male NO NO 
903-240318-AA-305 Female YES NO 
903-250318-AA-306 Male YES NO 
903-250318-AA-307 Female YES NO 
903-250318-AA-308 Female YES NO 
903-250318-AA-309 Male YES NO 
903-250318-AA-310 Female YES NO 
903-260318-AA-311 Female YES YES 
903-260318-AA-312 Female YES YES 
903-260318-AA-313 Female NO NO 
903-260318-AA-314 Male YES NO 
903-260318-AA-315 Female NO NO 
903-260318-AA-316 Male YES NO 
903-260318-AA-317 Male YES NO 
903-260318-AA-318 Female YES NO 
903-260318-AA-319 Female YES NO 
903-260318-AA-320 Female YES YES 
903-260318-AA-321 Male YES YES 
903-260318-AA-322 Female NO NO 
903-260318-AA-323 Female YES NO 
903-260318-AA-324 Male YES NO 
903-260318-AA-325 Female YES NO 
903-260318-AA-326 Female YES NO 
903-260318-AA-327 Male YES NO 
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Table 5.1 continued  
Patient reference 
number  
Sex Adherence assessment 
by MMAS-8 
Adherence assessment by 
microsampling analysis 
903-260318-AA-328 Female YES NO 
903-270318-AA-329 Female YES YES 
903-270318-AA-330 Female YES YES 
903-270318-AA-331 Male YES YES 
903-270318-AA-332 Female NO NO 
903-270318-AA-333 Male YES NO 
903-270318-AA-334 Female YES NO 
903-270318-AA-335 Female YES NO 
903-270318-AA-336 Male YES NO 
 
To assess the agreement and disagreement between MMAS-8 and blood microsample 
analysis approaches, the measurement of drug concentration in the blood microsamples 
was considered to represent the ‘true’ classification of non-adherence. Thus, 248 
participants were classified as adherent by MMAS-8 (Score > 6). However, blood 
microsample analyses showed that only 146 (58.9%) of these 248 patients were actually 
adherent because the CVD concentrations measured were between 5% of Cmax and Cmax; 
the other 102 patients (41.9%) were non-adherent. This suggests the likely overestimation 
of adherence to medication by the 102 patients identified as being non-adherent via DBS 
analysis or possibly this result was related to the quality of medicines used.  
On the other hand, 55 patients were categorized as non-adherent by MMAS-8, with 47 
(85.5%) of these 55 patients confirmed as being non-adherent by subsequent blood 
microsample analysis. The other eight patients (14.5%) patients were defined as being 
adherent by blood microsample analysis. This discrepancy may be explained by the 
acquiescence bias response where the participants give affirmative answers regardless of 
the content of the question, and where the chances of this form of bias becoming apparent 
in self-reported questionnaires is quite high (Watson, 1992). Affirmative answers in 
MMAS-8 take a value of zero. Thus, the total score will classify patients as being non-
adherent.  
The agreement between the two approaches to assessing CVD medication adherence was 
tested via the kappa test, which showed significantly poor agreement (kappa = 0.28, P-
value ˂  0.05). This result is different to those reported in other, studies which showed that 
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questionnaires are generally highly concordant with drug level measurements (Garber et 
al., 2004; Warren et al., 2013; Fabbiani et al., 2016). Other studies have showed limited 
concordance between questionnaires and drug concentrations (Pandey et al., 2015; 
Dawood et al., 2018). However, these studies either used statistical analysis, such as the 
Pearson coefficient, which is not recommended for assessment of agreement between two 
approaches, or using an arbitrary cut-off point in the kappa test. For example, some 
considered 0.3 to represent good concordance (Hidalgo et al., 2014) while other studies 
considered this value to represent only weak concordance (Warren et al., 2013). As noted 
previously, for clinical studies it is recommended that a kappa of 0.8 should be used as 
the minimum acceptable value for agreement (McHugh, 2012).  
As shown in Table 5.2, agreement and disagreement between MMAS-8 and blood 
microsample analyses for each medication showed high agreement for atenolol and 
bisoprolol at 88.1 and 87%, respectively, and high disagreement for atorvastatin and 
simvastatin, at 50 and 52%, respectively. The average agreement was 67% in comparison 
with 33% disagreement. However, as mentioned earlier, the overall agreement for patient 
non-adherence as assessed by the kappa test showed significant weak agreement between 
the two approaches (kappa = 0.28, P-value ˂ 0.05).  
Table 5.2. Agreement and disagreement of non-adherence assessment between MMAS-
8 and blood microsamples analysis. 
Medication (n) Agreement between MMAS-8 
and blood microsamples analysis 
(%)  
Disagreement between MMAS-8 
and blood microsamples analysis 
(%) 
Amlodipine (15) 10(66.7) 5(33.3) 
Atenolol (59) 52(88.1) 7(11.9) 
Atorvastatin (18) 9(50) 9(50) 
Bisoprolol (77) 67(87) 10(13) 
Diltiazem (34) 25(73.5) 9(26.5) 
Lisinopril (73) 49(67.1) 24(32.9) 
Losartan (47) 26(55.3) 21(4.7) 
Simvastatin (50) 24(48) 26(52) 
Valsartan (65) 44(67.7) 21(32.3) 
Average 67.0 33.0 
Where (n) = number of patients taking medication) 
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5.4.2. Face-to-Face Interview with Non-adherent Volunteers by the Clinician   
Despite the discrepancy between MMAS-8 and blood microsample analysis in the 
assessment of non-adherence, the insights generated by the responses to the MMAS-8, 
when validated by the blood microsample analysis, showed that 93.6% of validated non-
adherent patients answered YES to the question “Have you ever cut back or stopped 
taking your medication(s) without telling your doctor because you felt worse when you 
took it?”  
It has been reported that medication side effects mainly affect patients with cardiovascular 
diseases that require polypharmacy (Abolbashari et al., 2017). Face-to-face interviews 
between the clinician and patients showed that patients taking statins reported that the 
associated side effects, such as muscle pain and weakness, was the cause of non-
adherence (Appendix 22 Section 1). 
[… Muscle pain…] [Patient reference number…17, 323,334] 
[...Feel tired…weakness in muscle….] [Patient reference number…59] 
[…Feel worse… and complicated regimen…] [Patient reference number…88] 
[…I sometimes do not take medication because I feel not good…] [Patient reference 
number…314] 
Other non-adherent patients stated that the side effects associated with taking losartan, 
such as vertigo, was the cause of their non-adherence (Appendix 22 Section 1).  
[…Losartan makes me ill…………] [Patient reference number…190] 
[…Feeling bad taking losartan …dizziness…] [Patient reference number…305] 
This may indicate that frequent follow-ups by clinics are important to monitor the side 
effects patients are experiencing and to adjust prescriptions as needed to alleviate them. 
Patients’ fears and concerns about adverse drug reactions should be considered by the 
health care professionals to prevent them if possible.  
 
91.5% of validated non-adherent patients answered YES to the question “When you feel 
like your cardiovascular disease is under control, do you sometimes stop taking your 
medication(s)?”  
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Face-to-face interviews between the clinician and patients indicated that some patients 
had little or no knowledge about or understanding of their particular cardiovascular 
diseases (Appendix 22 Section 3). 
[I think some medications are used as needed….] [Patient reference number…157] 
[I feel OK…. I did not take medications….] [Patient reference number…168] 
[…feel that this condition is under control, no need for medications] [Patient reference 
number…220]                                                                                                          
This may indicate that patients do not understand their diseases well enough to realize 
when they represent chronic conditions that require continuous treatment. Inadequate 
knowledge about medications and their usage can leave the patient unconvinced as to the 
need for treatment, and consequently affect their adherence.  
 
85.1% of validated non-adherent patients answered YES to the question “Taking 
medication(s) every day is a real inconvenience for some people. Do you ever feel hassled 
about sticking to your cardiovascular treatment plan?”  
This question is difficult to address because the source of this inconvenience is not 
directly assessed by MMAS-8. Reasons for feelings of inconvenience could be related to 
patient-physician discordance which will lead to patient dissatisfaction; it has been 
reported that 40%-60% of patients misunderstand the directions for use of any medicine 
prescribed immediately after visiting their doctors (Jimmy and Jose, 2011). Face-to-face 
interviews between the clinician and patients showed that some non-adherent patients 
were too embarrassed to ask their clinician how to take their medications (Appendix 22 
Section 6).  
[…. I was shy to ask….] [Patient reference number…285,296] 
[…. I did not understand …. I was shy…] [Patient reference number…300] 
Inconvenience may also be the result of the required dose frequencies, complicated 
regimens, or improper time of administration. A significant number of non-adherent 
patients reported that taking many tables a day is distracting and disturbs their daily 
routines and was ultimately the reason they stopped taking their medications (Appendix 
22 Section 1).  
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[It is inconvenient to me to take many medications...] [Patient reference number…8] 
[Taking many medications disturbs my life…work] [Patient reference number…10] 
[Daily life disturbed by taking many medications…] [Patient reference number…11] 
85.1% of validated non-adherent patients also answered YES to the question “Do you 
sometimes forget to take your cardiovascular medication(s)?” This indicates the major 
role of forgetfulness in non-adherence. Face-to-face interviews between the clinician and 
patients provided more information about the source of this forgetfulness, where some 
non-adherent patients reported that this was due to having a busy life and long working 
hours (Appendix 22 Section 4).  
[We are old…forgetfulness is common in our age group…] [Patient reference 
number…198]                              
[Busy life…. forget medications….] [Patient reference number…240] 
[…Missed medications….] [Patient reference number…274] 
[…Forget medications….] [Patient reference number…283] 
[...Work made me forget my medications….] [Patient reference number…310] 
70.9% of validated non-adherent patients gave no reasons for not taking their 
medications. This indicates that the MMAS-8 provides only limited information about 
the reasons associated with levels of non-adherence and may need to be improved or 
further developed to allow for better assessment of the associated reasons. Triangulation 
with other methods such as face-to-face interviews between the clinician and patients was 
helpful in gaining additional information in this regard. For instance, other reasons for 
non-adherence that were not addressed in the MMAS-8 were the financial cost of 
medications or patient’s belief. Some patients who were non-adherent to atorvastatin, 
simvastatin and valsartan reported that the cost of these medications was their primary 
reason for non-adherence. These patients could not afford the price as these medications 
are not always available in the public sector, requiring instead that they be purchased from 
the private sector (Appendix 22 Section 2).  
[I cannot find these medications in the hospital] [Patient reference number…17, 55, 62, 134, 
204]                                                                                                                   
[Medications are expensive…I am jobless...] [Patient reference number…64] 
[I cannot afford the price…….] [Patient reference number…75] 
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[I did not take medicines…I could not find medicines in the hospital...] [Patient             
reference number…121, 24,133,159]                                                                        
Other non-adherent patients did not believe in medications, whilst some believed that 
taking medications would harm them. On the other hand, some patients believed that 
taking high doses of medication would lead to improved health outcomes (Appendix 22 
Section 5).  
[We think if we continue using medications, we you cannot stop; your body will get used to it] 
[Patient reference number…242]                                                                        
[…. will addict on these medications…….] [Patient reference number…252] 
[In my opinion, these tablets cannot improve my diseases, so I decided to stop it] [Patient 
reference number…263]                                                                                            
[This dose may not be enough …….] [Patient reference number…23] 
[Taking high dose is better….] [Patient reference number…45] 
[Taking two tables will not harm…. better….] [Patient reference number…53] 
12.7% of non-adherent patients indicated that forgetting to bring their medications while 
traveling or when leaving home accounted for their non-adherence (Appendix 22 Section 
4). 
[Forget my medications when I travelled ….] [Patient reference number…224] 
[Forget taking medicine when travelling….] [Patient reference number…238] 
This research proposes a convenient, rapid, cost-effective, specific, and sensitive method 
for directly detecting drug concentrations for use alongside such questionnaires as 
MMAS-8. It should be possible to apply this method to assess non-adherence to a wide 
range of CVD medications.  
Intentional non-adherence was noticed in almost 75% of patients and may indicate that 
the problem may arise from the beliefs, attitudes and expectations that influence them and 
a lack of motivation to continue their treatment regimen (Horne et al., 2005). The required 
interventions for addressing both intentional and unintentional non-adherence are detailed 
in chapter 6.  
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Assessment of non-adherence to a medication regimen is crucial to optimising the clinical 
use of medications and to preventing unnecessary increases in dose or adding more 
medications to the medical regimen. In cases of poor clinical outcomes, the clinician may 
incorrectly consider these to be due to the previous treatment being ineffective, and thus 
may add more medications, or intensify the dose(s) of those already being taken. This 
increases the possibility of introducing or exacerbating side effects, thus increasing the 
associated number of hospital visits. Clinicians should, therefore, take the prevalence of 
non-adherence seriously and seek to develop relationships of mutual trust with patients 
in order to limit false reports of high adherence. Simultaneously, standardised direct 
measurement methods of adherence using the convenience of DBS samples should be 
incorporated into routine clinical practices to gain an accurate understanding of 
adherence. Clinicians must be adequately informed when making the decision to alter a 
prescription. 
Blood microsample analysis by LC-HRMS, can provide information about levels of non-
adherence for each medication taken and would be helpful to clinicians in terms of 
optimizing and individualising each medication in the regimen for each patient. For 
example, patient reference number …121 was taking losartan and simvastatin and was 
categorized as adherent according to MMAS-8. However, blood microsample analysis of 
this patient showed that he was only adherent to losartan but not simvastatin. 
MMAS-8 alone cannot determine whether patients took the correct dose at the correct 
time. For example, patient reference numbers …23, 45, and 53 were taking atenolol and 
were categorised as adherent based on MMAS-8; however, they were considered non-
adherent based on blood microsample analysis as the measured concentrations exceeded 
the corresponding Cmax for the reported dose of atenolol (50 mg or 100 mg). Face-to-face 
interviews between the clinician and these patients, however, revealed very important 
information which both blood micosample analysis and MMAS-8 were unable to obtain 
(Appendix 22). When the clinician asked them about their non-adherence to their 
medications, the patients believed that taking more than the prescribed dose would lead 
to an improved clinical outcome than the recommended dose. Another example was 
patient reference number… 58 who was prescribed atenolol 50 mg and atorvastatin 40 
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mg; this patient was categorised as adherent by MMAS-8, but the concentration of 
atenolol in their blood sample was high for their prescription and atorvastatin did not 
appear to be present. After reporting this result, the clinician interviewed this patient and 
found that patient had mistakenly inserted the atenolol blister pack in the atorvastatin 
packaging, and so had been taking a double dose of atenolol whilst missing their dose of 
atorvastatin (Appendix 22). This explained the high concentration of atenolol and lack of 
atorvastatin in the blood sample taken from this patient. 
Nonadherence to cardiovascular medications was not uniform (Figure 5.1). Non-
adherence can be influenced by the medication group prescribed (Lane et al., 2019). A 
study by Gupta et al. showed that non-adherence to statins was higher than other 
cardiovascular medications such as β-blockers, ACE inhibitors and calcium channel 
blockers (Gupta et al., 2018). Medication side effects may be associated with these 
differences in levels of non-adherence (Lane et al., 2019). However, other factors could 
have accounted for these differences, such patient-related factors or the health system, as 
detailed in Chapter 2 Section 2.2.5.1.  
 
Figure 5.1. Comparison of the levels of non-adherence based on individual medication 
between MMAS-8 and blood microsample analyses 
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5.5. Conclusion    
The integrated approach adopted to assess non-adherence to CVD medications by 
determination of the concentration of the target medications in blood microsample via 
LC-HRMS and by MMAS-8 is a novel research that can provide information on the levels 
of each medication in the patients’ blood and provide at least some of the reasons behind 
poor patient progress. This information can help clinicians to track adherence for each 
medication and determine the reasons for poor adherence, such as incorrect dose or poor 
choice of medication, and can also help the clinician to apply an appropriate strategy to 
improve adherence. Since MMAS-8 provides limited information about the causes of 
non-adherence, integration of results obtained from blood microsample analysis and 
MMAS-8 with face-to-face interviews between the clinician and patients providing 
additional crucial information related to medication non-adherence such as 
polypharmacy, cost, patient’s beliefs and patient-clinician relationships.   
Both approaches showed no significant correlation between the level of non-adherence 
and either age or gender. Moreover, the levels of non-adherence could be significantly 
associated with the number of medications in the regimen and the number of tablets taken 
per day. The agreement between the two approaches for assessment of non-adherence 
was found to be relatively poor. Despite the discrepancy in outcomes found for the two 
methods, the insights generated by the responses to MMAS-8, when validated by the 
blood microsample analyses, demonstrated that 72.3% of patients were intentionally non-
adherent to their medications, the main causes of which were the associated side effects, 
complicated regimens, dose frequency, patient-physician discordance, cost of medication 
and patients’ beliefs. By contrast, 27.3% of patients were unintentionally non-adherent, 
the most common reasons for which were a lack of understanding of the disease, 
forgetfulness, and travelling and leaving home. 
MMAS-8 is unable to assess non-adherence to multiple medications in the prescribed 
pharmacotherapy regimens. The assessment of non-adherence by MMAS-8 is subject to 
overestimation because this is dependent on the total score obtained from a given patient’s 
responses to the questions. By contrast, blood microsamples analysis can accurately 
assess non-adherence for each form of medication. However, blood microsample analysis 
clearly cannot provide any information about the causes of non-adherence. The main 
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limitation to face-to-face interviews in the present study was that the clinician was unable 
to meet all the volunteers due to time constraints and contact details, such as email or 
phone numbers, not being available to the clinician. 
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Chapter 6 
Implications of This Research for the 
Assessment of Non-adherence to 
Cardiovascular Medications on Clinical 
Practice in Iraq 
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6.1. Introduction   
Each country has its own perspectives on the construction of their healthcare systems and 
delivery policies (Lloyd et al., 1999). The proficiency of the healthcare system of any 
given country is representative of the future of that same country. A highly efficient 
healthcare system can help people to improve their health and quality of life. Healthcare 
regulations and policies must seek to improve both the health environment of the 
associated populace and promote awareness of health problems.   
Two extreme examples of healthcare systems are the US’s provisions and the National 
Health Service (NHS) in the UK. Healthcare in the US is almost totally in the hands of 
private companies who have the leverage to control healthcare system delivery within the 
country (Ridic et al., 2012). In other words, to gain access to healthcare, patients need to 
pay out of their own pockets. Thus, the quality of the US healthcare service will always 
depend on how much the patient pays. The US drug formulary represents the focal point 
for the prescription of medications to promote cost-effective prescription and includes 
lists of developed, and approved generic and brand medications and pharmaceutical 
products to ensure efficient dispensing of prescription drugs without sacrificing quality. 
The inclusion of these medications is based on recommendations from a committee of 
doctors, pharmacists, and other medical experts on the basis of drug efficacy, safety, and 
cost-effectiveness. The prescription of these medication is usually covered by health 
insurance plans (Fox, 2003). 
As detailed in chapter 1 Section 1.3.1.1, the UK’s NHS can be considered a social 
healthcare system that is ‘free at the point of delivery’ in the majority of circumstances 
(National Health Service, 2019). Examples in the UK where direct charges are made as a 
matter of course include prescription charges, currently set at £9.00 per item (National 
Health Service, 2019). Medications are prescribed by appropriate healthcare practitioners 
such as doctors, dentists in the UK. These prescriptions are only dispensed through 
pharmacies in either community or hospital settings (National Health Service, 2017). A 
range of exemptions by which people can obtain free prescriptions is available in 
England, for example those under 16, those who are 60 or over, people with certain 
medical conditions (e.g., cancer, diabetes) and during pregnancy (Black, 2014). 
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The British National Formulary (BNF) contains a wide spectrum of information and 
advice about prescribing and pharmacology, along with specific facts and details about 
the medicines available from the UK National Health Service (Barbour, 2001). Private 
healthcare is available in the UK and is directly funded by insurance schemes that are 
paid for directly by either individuals or by major employer schemes. 
As described in chapter 1 Section 1.3, the healthcare system in Iraq is a combination of 
public and private supply. In Iraq, the Ministry of Health (MOH) is responsible for the 
country’s healthcare system and funds the public health sector (Al Hilfi et al., 2013). 
Private healthcare is delivered by entrepreneurs. In Iraq, if patients are checked by doctors 
in the public sector, the doctors can prescribe medications which patients can get from 
hospital pharmacies after paying the appropriate fee. This is comparable to the NHS, 
where the price for such is low in comparison with their real-term costs or indeed their 
cost in the private sector. If their medications are not available in public sector 
pharmacies, patients have to pay extra in order to get them from private sector pharmacies 
instead. The cost of medications is high, especially for brand medications. In Iraq, there 
are no applicable guidelines, such as those given by the BNF, which can lead to arbitrary 
decisions at the time of prescription and which is considered one of the major weaknesses 
of the Iraqi healthcare system.  
Today, the growth of the internet has allowed people to get their medications from other 
sources, such as buying them online. There has been an increased use of the internet to 
gain access to medicines in Iraq since 2003. However, many online pharmacies 
worldwide are unregistered, and this increases the possibility of buying potentially 
unsafe, substandard or falsified medications (Jackson et al., 2012; National Health 
Service, 2018b; Food and Drug Administration, 2018). Substandard or falsified 
medicines are now a significant problem worldwide. The WHO estimates that around 
10% of all medicines currently reaching developing countries fall into this category 
(World Health Organization, 2017f). In the UK, MHRA reported that the number of 
substandard medicines within the country had increased ten-fold between 2001 and 2011 
(Almuzaini et al., 2013). Similar concerns are prevalent in the US, but more frequently 
for ‘lifestyle drugs.’ Buying prescription-only medicines from unauthorized sources 
significantly increases the risk of getting substandard medicines (Almuzaini et al., 2013). 
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The potential negative effects of using substandard or falsified medications is that of using 
such without actually getting the desired clinical benefit, increasing the risk of disease 
progression, side effects, or the need to change the treatment plan. This accounts for poor 
patient outcomes and increased costs (Johnston and Holt, 2014).  
In Iraq, there is no current information about the distribution of substandard or falsified 
medicines from online sources. However, reports have recently surfaced about 
substandard or falsified medications circulating in the country. The Iraqi parliament 
called on the Ministry of Health and the Syndicate of Iraqi Pharmacists to prevent the 
distribution of substandard or falsified medications (Alsumaria Iraqi Satellite TV 
Network, 2012).  
6.2. Assessment of Medication Non-adherence 
Perhaps somewhat surprisingly, the NHS considers questioning a patient’s adherence to 
medication to be unethical and this is therefore not generally undertaken. Exceptions 
include immunosuppressant therapy in organ transplant patients, lithium determinations 
and therapeutic drug monitoring in patients with persistent hypertension (Tanna and 
Lawson, 2016a). The reverse is true in the US, with drug monitoring in patients being a 
prerequisite to the continued supply of certain forms of pain medication (Tanna and 
Lawson, 2016a). As discussed previously in chapter 2 Section 2.1.1, the WHO defines 
adherence as “the extent to which a person’s behaviour taking medication, following a 
diet, and/or executing lifestyle changes, corresponds with agreed recommendations from 
a healthcare provider” (Sabaté, 2003). The methods used to assess adherence can be 
categorized as either direct or indirect. Indirect methods include patient interviews, 
patient diaries, pill counts, questionnaires, electronic monitoring, patient self-reports, 
prescription-refill databases and clinical outcomes. Direct assessment methods are based 
either on measuring the concentration of drugs or metabolites in a biological sample (such 
as urine, blood or saliva), the presence of a biological marker, or by direct observation of 
the patient taking their medicines (Lam and Fresco, 2015).  
Although indirect methods are cheap and easily applied in clinical settings, the 
application of approaches such as prescription refills depend on the availability of 
computerised systems, but this is considered a major limitation in Iraq because of the 
country’s limited infrastructure. Prescription refill cannot confirm whether patients have 
 149 | P a g e 
 
taken or thrown away their medications and consequently this may result in the 
overestimation of medication adherence. Furthermore, it is rather challenging for the 
researcher to obtain information regarding barriers to medication adherence in terms of 
individual patients (Krousel-Wood et al., 2015). Patient interviews to assess non-
adherence are also highly dependent on the communication skills of the interviewers 
(Lam and Fresco, 2015, Farmer, 1999).   
The accuracy of pill counts as a tool for estimating medication adherence is uncertain 
because some patients may not return their unused medications (Lawrence et al., 2017). 
Electronic monitoring is of only limited use in patients taking multiple medications 
(Sidorkiewicz et al., 2016). The pill count method is optimistic as it cannot confirm 
whether the patient has taken their medication as, for instance, the patient may open the 
container and merely discard the medication (Aldeer et al., 2018).  
Questionnaires can assess general medication-taking behaviour but cannot provide 
essential information about specific medications or the concentrations of drugs in the 
blood (Mathes et al., 2014; Tanna and Lawson, 2016a). Also, this approach may be 
subject to bias because it depends on patient recall and perceptions (Choo et al., 1999; 
Althubaiti, 2016). Patients may unintentionally overestimate their adherence to 
medications.  
Direct methods involve either the observation of the patient taking their medicines or the 
collection and analysis of a biosample (such as urine or blood) to measure the 
concentration of drugs or metabolites eliminated (Lam, Fresco 2015). Assessment of 
adherence as based on the detection of biomarkers is limited, as biomarkers are only 
available for a limited number of drugs (Lehmann et al., 2014). Furthermore, direct 
methods clearly cannot identify the reasons for non-adherence to medications (Lam, 
Fresco 2015), although concentration data may suggest confusion when taking multiple 
medications.  
The observation of the patient taking their medicines is inconvenient for patients and 
impractical in an out-patient setting as the patients involved may have to travel a 
considerable distance to get to a hospital and/or may have to spend half their day at the 
clinic, which will clearly be costly to them (Alipanah et al., 2018). In addition, 
supervision of patients may have to be undertaken by trained personnel. Moreover, 
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patients can manipulate medication-taking observations by hiding the medication in their 
mouths (Hawkshead and Krousel-Wood, 2007). 
Direct methods of measuring the concentration of drugs or metabolites in biosamples 
requires complex and costly instrumentation based either on immunoassay or LC-MS 
techniques. Analyses can be undertaken at specified intervals or randomly when 
appropriate. Direct methods of assessment are the most informative approach to 
measuring adherence (Aonuma et al., 2017). They provide direct confirmation that the 
patient has taken the medicine (Morrison et al., 2015). The application of either LC-MS 
or immunoassay for the determination of drug concentration is well documented in the 
literature (González et al., 2015, Gonzalez et al., 2011, Gonzalez et al., 2010, Dias et al., 
2013). However, some assays require large volumes (1-10 ml) of blood (Tanna and 
Lawson, 2016a), and are time consuming and costly as they require special tubes for the 
collection of blood samples and centrifugation to obtain the required volume of plasma 
or serum, plus refrigeration to maintain sample stability. This complexity is clearly 
unsuitable for routine drug monitoring (Lawson et al., 2013, De Nicolò et al., 2017). All 
these steps for the collection and preparation of samples and their subsequent analysis 
will delay the time between collection and results being made available.  
Dried blood spots represent an alternative matrix for measuring blood drug concentrations 
and require the collection of only a few drops (< 30 μl) of blood. This approach is helpful 
to overcoming the barriers associated with blood collection using venepuncture. Blood 
samples are easily collected and transported with no associated special requirements, such 
as refrigeration. There is no need for facilities to store DBS samples. Sample collection 
requires less time in comparison with conventional approaches and even offers the 
possibility of self-collection at home. 
6.3. Benefits and Implications of this Research.  
6.3.1. Starting Collaboration with Health Directorate in Misan-Iraq 
Arrangements were made with Dr Yaseen Obaid to provide access to the CVD Clinic at 
the Alsader Teaching Hospital and Misan Cardiac Centre after getting the required ethical 
approval and permission. Assessment of adherence to CVD medications by comparing of 
MMAS-8 and blood microsampling analysis and the response of the clinician to the 
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outcomes of this research can be considered the first such study of clinical practice in 
Iraq. Moreover, this collaboration represents the first of its type between De Monfort 
University and Misan Health Directorate in Iraq.  
6.3.2. Transfer of Experiences in Sample Collection and Analysis  
All aspects of volunteer recruitment were arranged by Mr Alalaqi, as detailed earlier in 
chapter 3. Samples were collected by Mr Alalaqi, which was helpful in improving skills 
in sample collection. The researcher will be transferring the experience regarding the 
application of LC-HRMS in the clinical analysis and will be training lab staff and other 
professionals on collection of microsamples using DBS cards and VAMS using the same 
protocol applied in this study.   
6.3.3. Individualisation of Medication and Clinician Responses 
The applied approach can determine the concentration of nine cardiovascular medications 
in one run, which represents cost-effectiveness for patients by helping to decrease patient 
spending on health and facilitating drug optimisation within clinical practice. Patients 
differ in their responses to medication, and thus the resultant clinical benefits differ 
accordingly. Integration the outcomes of DBS analysis with the outcomes from MMAS-
8 will be helpful to the clinician in terms of finding the required interventions and 
response to improve adherence.  
Assessment of medication non-adherence can help in the selection of a more effective 
drug or in suggesting the use of a combination of medications. DBS analysis via LC-
HRMS can measure the concentration for each individual drug in a patient’s blood. 
Physicians can identify more appropriate drugs or doses for individual patients, and 
indeed personalize patients’ treatments. For example, patient reference number …114 
was taking bisoprolol 5 mg and valsartan 80 mg once daily. This patient had poor clinical 
outcomes, despite the assessment of non-adherence by MMAS-8 showing they were 
adherent. DBS analysis also showed that the patient was adherent to both medications. 
The clinician may choose to increase the patient’s dose or add other medications to 
improve their progression, or indeed consider whether the patient may need other 
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interventions. The applied approach can help the clinician to determine the required steps 
as based on the data available.  
Assessment of medication non-adherence can help in the personalization of patients’ data 
for each medication. Take, for example, patient reference number …99, who was taking 
bisoprolol 5 mg and valsartan 80 mg once daily. This patient was categorized as adherent 
based on his response to the MMAS-8 questions. However, their clinical outcomes were 
not optimum. LC-HRMS extracted ion chromatograms that showed the patient was only 
adherent to bisoprolol. Without detailed data about each medication in the regimen, the 
clinician may have chosen to increase the dose of bisoprolol and valsartan, which would 
of course mean increasing the concentration of bisoprolol to which the patient was already 
adherent – which would likely have increased the possibility of bisoprolol-related adverse 
effects.  
In this study, 72.3% of non-adherent patients were found to be intentionally non-adherent, 
where the most common reasons for such were due to side effects at 93.6%, for example, 
patients taking statins reported that the associated side effects such as muscle pain 
ultimately led to non-adherence. Other patients stated that the side effects associated with 
taking losartan, such as vertigo, led to non-adherence. The collaborating clinician in Iraq 
started friendly discussions with non-adherent patients who reported side effects as a 
barrier to medication adherence and explained to them the possible and significant side 
effects associated with medications such as statins on muscles, and of losartan such as 
vertigo, and patients were engaged in their treatment plan, such as being made aware of 
the possibility of switching to another medicine that offered a reduced risk or severity of 
side effects. Moreover, patient concerns about medicines were considered. A systematic 
review by Kuntz et al. showed that patient education would improve patient knowledge 
and thus improve adherence (Kuntz et al., 2014). However, shortage of staff and time 
pressures can limit the application of such in routine clinical practice. (Foster et al., 2016). 
The clinician may prescribe medication with fewer or less severe side effects such as 
prescribing angiotensin receptor blockers (ARB) as an alternative to ACE inhibitors in 
patients experiencing the associated dry cough. Side effects associated with statins can be 
managed by prescribing non-statin-based medications such as ezetimibe, which works by 
limiting the absorption of cholesterol (Vavlukis and Vavlukis, 2018), or evolocumab, 
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which inhibits proprotein convertase subtilisin–kexin type 9 inhibitor (PCSK9i) and 
reduces levels of low-density lipoprotein (LDL) (Sabatine et al., 2017). A study that 
compared the non-adherence to statins and PCSK9i showed figures of 79.4% and 30.9%, 
respectively (Gragnano et al., 2017). 
85.1% of non-adherent patients reported that medication-related inconvenience was 
associated with non-adherence, where the reasons for such feelings of inconvenience 
could be associated with the complexity of the regimen and the dose frequencies, as 
reported by non-adherent patients. Iraqi volunteers in the present study reported that 
taking a large number of medications each day interrupted the patient’s normal routine, 
and therefore that prescribers should simplify the medical regimen as much as possible. 
Adherence may be improved by reducing the frequency of administration or through the 
introduction of combination medicines (Usherwood, 2017). Patients may prefer 
medications that must be administered once daily, prescribing the maximum number of 
doses possible at one time and thus limiting the frequency at which treatment is required. 
Physicians should prescribe a fixed-dose combination (FDC) of pills if possible. FDC 
combinations can be helpful for patients on multiple medicines and may improve 
adherence in some settings (Webster et al., 2016). The clinician simplified the medication 
regimen if possible. 
Swapping medications may cause confusion and is certainly inconvenient, and may 
consequently impair adherence (Usherwood, 2017). Swapping medications is very 
common in clinical practice in Iraq because there are no guidelines for the prescription of 
cardiovascular medications. Pharmacists are responsible for patients’ and carers’ 
education if they swap their medication (Usherwood, 2017). Inconvenience may be 
associated with the inability to swallow tablets (Cooper et al., 2015). Discussion between 
patients and their pharmacist may be helpful in tailoring appropriate preparations or 
formulations.   
Another reason for feelings of inconvenience could be the result of patient-physician 
discord. Some non-adherent patients stated that they were too embarrassed to ask their 
clinician how to take their medication correctly. Improving communication between the 
physician and patient with due consideration for patient’s beliefs is a key and effective 
strategy for improving adherence (Palacio et al., 2016). In this study, the clinician 
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initiated friendly discussions with patients to improve communication and encourage 
them to ask about their diseases and medications.  
70.9% of non-adherent patients gave no reason for their refusal to take their medications. 
This indicates that the questionnaire itself may need improvement in order to better assess 
such reasons. Subsequent face-to-face discussion, as detailed in chapter 5 Section 5.4.2, 
provided additional information which was not captured by the MMAS-8. For instance, 
other reasons for non-adherence which are not addressed in the questionnaire may be the 
cost of medications or patients’ beliefs. The most easily recognised barrier to accessing 
medicines is their out-of-pocket cost (Sinnott et al., 2013). Doctors should consider the 
cost of a medication prior to its prescription to Iraqi patients. The pharmacist can help in 
this regard by prescribing generic or lower-cost brand medicines when appropriate 
(Usherwood, 2017). Iraqi health providers should improve patient access to 
cardiovascular medications in the public sector. Some cardiovascular medications are not 
available in the public sector in Iraq, and this will increase the burden on patients by 
forcing them to obtain them from the private sector. The clinician in Iraq responded to 
this outcome in patients who reported that non-adherence was related to medication cost 
by prescribing them less expensive medications, as available in the public sector, to 
reduce the associated costs. 
Patient attitude and beliefs are important factors associated with medication adherence, 
where the clinician explained the rationale behind prescribing particular medicines and 
the possibility of adverse drug reactions and toxicity if the patient takes a higher dose 
than prescribed. The clinician should discuss patient beliefs without imposing his/her 
beliefs or values on them, as the definition of adherence is agreement regarding the 
proposed medical plan between the clinician and the patient. Patient beliefs about their 
diseases and medications can be improved through the use of patient-centred counselling 
techniques such as motivational interviews to inspire behavioural change by supporting 
positive intentions and challenging negative ideas. It has been shown that interviews by 
pharmacy staff, by both face-to-face and/or by telephone, can improve adherence 
(Usherwood, 2017, van Buskirk and Wetherell, 2014, Hill and Kavookjian, 2012). 
27.7 % of non-adherent patients in the present study were non-intentional, where the most 
common reasons for non-adherence were due to a poor understanding of the disease 
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(91.5%), forgetfulness (85.1%) and travelling and leaving home (12.7%). The clinician 
in Iraq started discussions with patients to improve patient knowledge about 
cardiovascular diseases, particularly as being chronic in nature and which thus require 
continuous treatment; ultimately, patients should not stop taking their medications even 
if they begin to feel well and explained the correct use of each medication using everyday 
language. Jargon should not be used, making information more accessible and 
understandable. 
The clinician prepared cards for non-adherent patients, including information about the 
prescribed medication, its benefits, its expected side effects, how to use the medicine, and 
what to do if a dose is missed. The clinician advised these patients to use available 
technology, such as mobile phones, to alert them to take their next dose. Friendly 
discussions about life balance and the importance of being healthy were initiated with 
patients who forgot medications due to being busy or who worked long hours, or because 
of travelling or leaving home. 
6.4. Discussion  
Assessment of non-adherence to cardiovascular medications has a potential impact on 
clinical practice in Iraq. This assessment is helpful to patients, clinicians and the 
healthcare system in general. Assessment of medication non-adherence has a potential 
impact on patients through the optimisation and personalisation of required doses, 
maximising the benefit of the prescribed medication, preventing unnecessary 
interventions such as being prescribed an increased dose or adding further medications to 
the regimen, thus improving patients’ clinical outcomes and their quality of life. 
Medication non-adherence may lead to increased mortality and morbidity and increase 
costs due to rehospilisation and medication wastage.  
The data obtained from the MMAS-8 and blood microsampling analysis and integration 
of the outcome with face-to-face interviews can help the clinician to individualise patient 
care and understand why patients are not adherent to a particular medication, which will 
consequently help the clinician in terms of finding the interventions required to improve 
adherence. For instance, the clinician may respond to non-adherence related to 
medication side effects by educating such patients about the possible and the significant 
 156 | P a g e 
 
side effects associated with medications prior to prescription or by prescribing 
medications with a low risk of, or less severe side effects. Moreover, the clinician can 
simplify the medication regimen to reduce the possibility of medication side effects. 
Non-adherence to medication due to cost can by managed by prescribing less expensive 
brand medicines when appropriate or prescribing generic medications which are 
accessible and available in the public sector to reduce out of pocket expenses to the 
patient. The pharmacist can advise the clinician about the availability of low-price 
medications or by prescribing generic, rather than brand, medications. 
Unintentional non-adherence due to patients’ lack of knowledge about the nature of 
chronic diseases, such as cardiovascular diseases, can be managed by the clinician 
improving patient education about the diseases and the rational use of medication using 
everyday language, and making such information more accessible and understandable. 
Non-adherence due to forgetfulness also can be managed by preparation of cards that 
includes information about the prescribed medication, its benefits, its expected side 
effects, how to use it, and what to do if a dose is missed. Patients can be advised to use 
available technology, such as mobile phones, to alert them that it is time to take their 
medication. The patient–provider relationship is crucial to improving adherence, where 
the key related point is ensuring a blame-free and friendly environment for discussions 
with patients in which they are encouraged to ask about their conditions and the associated 
medications.  
Some patients intentionally do not adhere to their medications due to their beliefs. The 
clinician should explain to such patients the rationale behind prescribing particular 
medicines and the possibility of adverse drug reactions if a higher dose than prescribed is 
taken. Patients’ beliefs about their diseases and medications can be improved through the 
use of patient-centred counselling techniques, such as motivational interviews, to 
challenge negative ideas. The assessment of non-adherence represents an excellent 
investment in clinical practice that may improve quality of patients’ lives and reduce the 
cost of treatment.  
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6.5. Conclusion  
Assessment of non-adherence can help the clinician to apply the required interventions to 
improve medication adherence, individualise patient medication, and to facilitate drug 
optimisation within clinical practice. Different factors are associated with non-adherence, 
so understanding the underlying causes is crucial to the adoption of the required 
interventions. Adherence can be improved by educating patients about their diseases, 
expected side effects and the medication regimen; it can also be improved by prescribing 
less expensive medications which are available from the public sector. Patient beliefs and 
attitudes can be improved through the use of patient-centred counselling techniques, such 
as motivational interviews, to inspire behavioural change and challenge negative ideas. 
Patients who forget to take medication can be advised to use various forms of technology 
to remind them to take their dose. 
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Chapter 7 
Overall Conclusion and Future Work 
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This chapter summarises the general findings of this study and also highlights future 
prospects for related research. 
7.1 Introduction 
Globally, there has been a definite increase in patients requiring polypharmacy for chronic 
diseases (Mangin et al., 2018). For instance, in the UK, it is estimated than 24% of adults 
taking more than three medications (Moody and Mindell, 2017). Associated non-
adherence to medication is accordingly common and could result in poor clinical 
outcomes or increased mortality and morbidity. Thus, reduced medication adherence 
could imply adverse events, and increased costs to healthcare systems due to the increased 
need for rehospitalisation. Measures to improve medication adherence are urgently 
needed worldwide in order to increase general life expectancy. Optimising adherence to 
medications may represent a powerful means of reducing morbidity and mortality. 
Medication adherence has a positive effect on the healthcare sector and indeed most 
healthcare providers.   
Research into medication adherence and investigating the reasons for non-adherence to 
prescribed pharmacotherapy in Iraq is still in its infancy. To date, there has been no 
previous application of direct methods for the assessment of non-adherence, and indeed 
only limited studies using indirect methods through the use of questionnaires. The 
majority of such studies have used non-standard questionnaires.  
The current research assessed non-adherence to certain target cardiovascular medications 
and further attempted to identify some of the causes of non-adherence to these same 
medications; it further proposed a number of interventions since CVD is one of the top 
killers in Iraq. Two different methods (direct and indirect) were used to assess non-
adherence to selected CVD medications in 303 Iraqi patients who took one or more of 
these medications: the indirect method, by application of the eight-item Morisky 
Medication Adherence Scale (MMAS-8), and the direct method, through determination 
of the concentrations of these medications in dried blood spots by application of 
microsampling-based LC-HRMS assay. This study is, to the best of our knowledge, the 
first to use the direct method of analysis of dried blood spots (DBS) analysis by LC-
HRMS in Iraq and further, again to the best of our knowledge, there has been no previous 
study that integrates DBS analysis by the previously validated LC-HRMS method and 
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MMAS-8 to assess non-adherence to cardiovascular diseases. This demonstrates a novel 
research approach. The outcomes determined for the present study suggested 
interventions to improve adherence to CVD medication after commencing friendly 
discussions between the clinician and patient, which would also represent novel clinical 
practice in Iraq. 
The outcomes from the integrated approaches in the present study produced the 
following conclusions:  
Significant weaknesses in the Iraqi health system with regard to dealing with chronic 
diseases and, particularly, cardiovascular diseases, have been noticed. Despite the fact 
that cardiovascular diseases are the top killer in Iraq, there is no documentation about 
their prevalence in the general population. Moreover, there are no guidelines for the 
treatment or management of cardiovascular medications, which has led to arbitrary 
decision making regarding their prescription. 
The mortality rate associated with cardiovascular diseases in Iraq is very high, and there 
are no applicable action plans or strategies enacted at the national level to control CVD. 
This mortality rate may in part be due non-adherence to CVD medications. The study 
showed that 49.2% of Iraqi volunteers were non-adherent to one or more of their 
prescribed CVD medications, thus the assessment of medication non-adherence should 
be considered a priority and should be enforced in routine follow-up visits in clinical 
practice in Iraq. 
Not all medications used for the treatment of cardiovascular diseases are available and 
accessible to patients in the public sector, which may be due to poor assessments of 
patients’ annual needs for CVD medications. The lack of availability of CVD medications 
within the public sector will place additional economic burdens on patients and 
consequently result in poor adherence to medication. This may suggest that the 
assessment of the annual need of CVD medications should be improved and provide a 
free medication scheme to patients with cardiovascular diseases.  
Different methods of assessment of non-adherence can produce different outcomes. Huge 
differences and discrepancies in the assessment of non-adherence to the selected 
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cardiovascular medications in the Iraqi volunteers was apparent through the application 
of the indirect method, using the eight-item Morisky Medication adherence scale 
(MMAS-8), and the direct method of measurement of drug concentrations in DBS 
samples for the same volunteers. MMAS-8 indicated that 18.2% of volunteers were non-
adherent. However, the level of non-adherence to the target cardiovascular medications 
as determined by DBS analysis was 49.2%. The results showed that 72.3% of patients 
were intentionally non-adherent to their medication, the main causes of which were side 
effects and the inconvenience associated with taking the medication. However, 70.9% of 
non-adherent patients did not specify a reason for their non-adherence. MMAS-8 was not 
able to provide information about the source of inconvenience or non-specified reasons, 
which suggests that MMAS-8 needs further development or can be combined with face-
to-face interviews to provide accurate information about the sources of inconvenience or 
other reasons.  
Only 27.3% of patients were unintentionally non-adherent, the main causes of which were 
a poor understanding that cardiovascular diseases are chronic and require that medication 
be taken for the rest of their lives, forgetfulness, and travelling and leaving home. 
Otherwise, this may also possibly indicate that the problems arise from patients’ beliefs, 
attitudes and expectations and a lack of motivation to continue their treatment regimen; 
all this requires additional study. 
The application of indirect methods such as MMAS-8 is unable to track non-adherence 
to each medication in the regimen. Moreover, tracking both dosing error and prescription 
error is not possible. Patients may take the wrong medication or the wrong dose at the 
wrong time, and in this case whilst the medication-taking behaviour is present the patient 
will lose the benefits of their medications or may experience adverse side effects. 
Moreover, MMAS-8 cannot determine patient-to-patient variation in pharmacokinetics, 
pharmacodynamics and pharmacogenetics, which affect bioavailability and drug 
concentrations in the blood. On the other hand, the direct method using DBS analysis can 
track non-adherence to each medication taking into consideration all variables and 
individual patient’s data.  
Microsampling analysis can individualise patient data by providing information on the 
levels of each medication in the patient’s blood. Thus, in case of a poor patient response 
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to treatment, this information can help clinicians to assess adherence to each medication 
and the determination of which medication(s) in the regimen the patient is non-adherent 
to. The results of this DBS assay can provide objective data on blood drug levels to enable 
the clinician to make an informed decision about future treatment, i.e., this method 
provides a valuable evidence base. The results could represent a useful approach to 
improving patients’ health through dose optimisation and individualisation and reduce 
costs by reducing hospital readmission and medications wastage. The application of the 
MMAS-8 and microsampling analysis in conjunction with clinician led face-to-face 
interview where questionable results are obtained can help healthcare providers to 
accurately assess non-adherence and identify barriers associated with non-adherence, and 
thus improve individual patient outcomes.  
The outcomes of this study demonstrated no significant relation between non-adherence 
to the target medication and either gender or age. Also, the results showed a significant 
positive relationship between non-adherence to cardiovascular medication and the 
number of such medications being taken by individual patients.  
The validated and developed method, through the application of microsampling-based 
LC-HRMS, was able to simultaneously determine a number of cardiovascular 
medications in a given volunteer’s blood sample in a single run. This offers a reliable, 
cost-effective method for assessment of different cardiovascular medications. The applied 
method could represent a feasible alternative to traditional blood sampling (venepuncture) 
for the TDM of cardiovascular drugs, which is less invasive. The sample can be collected 
by patients at home and sent to the laboratory by post, which may enable the 
implementation of routine TDM for CVD medications in everyday clinical practice. This 
is considered to represent a novel approach in Iraq.  
The developed microsampling-based LC-HRMS assay can be adapted and extended to 
assess adherence to other medications used for cardiovascular diseases or, indeed, other 
chronic diseases such as diabetes, depression and cancer. The full mass scan offered by 
LC-HRMS is useful in TDM. In cases of poor patient progression, it is still possible to 
revisit data at a later time to provide additional clinical data if required with need for 
further testing. 
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The results showed that 903 cards and VAMS provide comparable quantitative results for 
assessing non-adherence to target medications. However, VAMS overcomes some of the 
limitations to the use of conventional DBS cards since there is no need to use a puncher 
with VAMS. Eliminating card punching from the process would save considerable time 
and effort. Sampling using VAMS is quick and does not require assistance. Sometimes, 
however, the VAMS clamshell may cause some inconvenience. Labelling a DBS card is 
more convenient in comparison with VAMS since spaces are provided to record 
information on the DBS cards while this is not the case with VAMS. VAMS is also 
significantly more expensive than DBS cards.  
It was observed in this study, as highlighted in chapter 6 Section 6.3.3.7, that the clinician 
reported improved adherence to medications after appropriate discussions were initiated 
with the patients.   
7.2 Future Work 
7.2.1. Analytical Aspects 
The extraction procedure used for atenolol, atorvastatin, bisoprolol, diltiazem, lisinopril, 
losartan, simvastatin and valsartan in microvolume blood samples collected on VAMS 
and DBS cards was not suitable for amlodipine. Thus, a different extraction procedure 
needs to be developed to enable analysis of all compounds, including amlodipine, in a 
single LC-HRMS analytical run. 
Furthermore, since plasma is considered to represent the gold standard matrix for TDM, 
a study to determine the ratio between drug concentrations in DBS and plasma for the 
selected cardiovascular drugs should be undertaken in future research. 
Currently, the extraction procedure requires a considerable amount of time, especially 
when running hundreds of patient samples. The extraction procedure involves the manual 
punching of 903 cards, followed by the addition of solvents to the punched disk, 
vortexing, centrifuging, and the evaporation of the supernatant and reconstitution of the 
dried residue in solvent for analysis. In addition, although efforts towards the 
miniaturisation of mass spectrometers have been explored over the last three decades, 
these instruments, as are currently available, require a considerable amount of space and 
hence would not be ideal for a hospital ward. However, this instrument could be placed 
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in one regional central laboratory where all samples could be sent for analysis. Funds will 
therefore be needed to procure such instruments as well as to provide the necessary 
training for the technicians required to operate the equipment. Thus, automation is a 
particular requirement to reducing processing time and increasing analytical throughput. 
Automation of the instrument is further required in everyday practice, such as in sample 
preparation, performing analyses and producing reports. Automation of the equipment 
will, of course, enhance its applicability to clinical practice.  
Considering the potential of this research, it is important to explore the application and 
development of microsampling-based LC-HRMS assay for screening other 
cardiovascular medications which were not included in this research. This will help to 
provide more efficient clinical practice and, consequently, decrease mortality and 
morbidity of cardiovascular diseases in Iraq and decrease medication waste.  
7.2.2. Technology Transfer and Implementation of Microsample Analysis in 
Iraq 
The microsampling-based LC-HRMS assay developed in this study has drawn 
considerable interest from the Iraqi government and, dependent on its final outcomes, is 
being considered for implementation in clinical practice. There is a serious desire on the 
part of the Misan health directorate to transfer this technology for application in its 
laboratories (Appendix 23). Analysis of large patient samples requires extensive memory 
space/storage, and this could possibly slow down data processing; software upgrades will 
also be required. Long waiting times for the results may delay the proper response to 
patients’ cases in the worst case leading to patient death.  
Medicine optimisation is critical to ensuring the effectiveness of medications in the 
management and treatment of chronic diseases such as cardiovascular diseases and 
diabetes. The Iraqi Ministry of Health should set appropriate guidelines to manage the 
treatment of cardiovascular diseases and regulate the costs of treatment. Quality of 
medicines should also be assessed since if the medicine is falsified/substandard and a 
patient takes it, this could lead to unintentional non-adherence (amongst other poor 
patient outcomes). The MOH should apply such a policy by facilitating the availability 
of cardiovascular medications from the public sector, prevention or control of tobacco 
use through stringent policy making, increased taxes for foods high in fat, salt, and sugar, 
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the construction of walking and cycling paths, running awareness campaigns regarding 
the importance of physical activity, and should implement strategies to reduce the harmful 
effects of alcohol consumption.  
Other socioeconomic factors, such as the cost of medication, level of education, and route 
to accessing medications, could be considered to develop further ideas related to factors 
associated with poor adherence. Qualitative methods can also be explored to gain 
patients’ insights to understand more of the causes associated with non-adherence. 
Triangulation of quantitative and qualitative methods in future research to assess non-
adherence could reveal additional associated causes.     
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Appendix 1. Ethical Approval for the Application of the MMAS-8 and Collection 
of Biosamples from Misan Health Directorate  
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Appendix 2. Ethical Approval for the Collection of Blood Samples Obtained from 
De Montfort University’s Faculty of Health and Life Science Research  
Ethics Application - Novel methods for drug monitoring using microanalysis (dried blood 
spot analysis) 
 
Ethics Application Ref: 1212 
 
Sangeeta Tanna, Graham Lawson, Dennis Bernieh 
 
Leicester School of Pharmacy, Faculty of Health and Life Sciences 
 
Addition of new PhD student: Ahmed Alalaqi 
 
Start Date: 1st October 2013 
 
End Date: 31st December 2019 
 
 
This project is on the development of a simple non-invasive test to assess adherence to 
cardiovascular therapy in primary and secondary care. 
 
Cardiovascular disease is one of the biggest killers worldwide affecting 1 in 3 people in 
the UK. Current care of such patients and increasingly for patients over 50 years old is 
the prescription of a combination of a beta blocker (BB), an ace inhibitor (AI) and a statin 
(ST). Good patient recovery depends on the combination of clinical skills and adherence 
with drug therapy. Non-adherence to cardiovascular medication is a growing concern to 
clinicians and other healthcare professionals because of mounting evidence that it is 
prevalent. There is evidence that up to 60% of patients prescribed cardiovascular drugs 
do not adhere to their prescribed regimen leading to increases in le morbidity, mortality 
and higher costs of care. In cases of poor clinical outcomes, it is essential to the clinical 
decision-making process that adherence is assessed. A simple test to monitor adherence 
would therefore be highly valued. 
 
In this non-patient project, we present a compliance assay test for beta blockers, ace 
inhibitors and statins, to help the clinical decision-making process. Sample collection for 
such a test would be via dried blood spots (DBS) in which a drop of blood is collected on 
a card non-invasively by a simple finger prick procedure. Sampling can be carried out by 
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the volunteer and the card then posted to the laboratory for analysis. The assay of the 
target drugs or metabolites would be carried out using mass spectrometry techniques. 
 
The Project would be divided into the following stages: 
 
1. Identifying the use of the principal cardiovascular drugs (BB, AI, ST) drugs based on 
current pharmacy practice. 
2. Developing a DBS based simultaneous analytical method for the cardiovascular drugs 
identified. 
3. Fully validating the developed DBS based simultaneous method for cardiovascular 
drugs. 
4. Applying the validated analytical method to DBS samples from volunteers in order to 
inform medication taking behaviour (or adherence). Volunteers on the target 
cardiovascular drugs would be recruited from the University, the Square Mile, and from 
clinics in Iraq. All samples will be anonymous and there will be no means of identifying 
the sampled volunteer. The only information requested from the volunteer will be: 
a. Cardiovascular drug prescribed 
b. Date/time the last dose of the prescribed CVD drug(s) was taken 
c. Dose prescribed 
5. Initial assessment of results on a YES/NO basis and comparison with data supplied 
above. 
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Appendix 3. Patient Information Leaflet (English Version). 
PARTICIPANT INFORMATION LEAFLET 
Dried blood spot analysis to assess adherence to cardiovascular medications  
 
Faculty of Health and Life Sciences   
 
What is the study?                                                                                        
This project is on the development of a simple minimally invasive test to assess adherence to 
cardiovascular therapy in primary and secondary care. Cardiovascular disease is one of the biggest 
killers worldwide affecting 1 in 3 people in the UK. Current care of such patients and increasingly 
for patients over 50 years old is the prescription of a combination of cardiovascular therapy drugs 
including beta blockers (BB), ACE inhibitors (AI) and statins (ST). There is evidence that up to 
60% of patients prescribed cardiovascular drugs do not adhere to their prescribed regimen leading 
to increases in morbidity, mortality and higher costs of care. The estimated cost of unused 
prescription medicines in the UK is ~£4 billion annually. A simple test to monitor prescription 
drug levels would therefore be highly valued. 
What will happen? 
The programme for this study will involve testing the developed and validated of a dried blood 
spot (DBS) based analytical method for the principal cardiovascular drugs identified. This 
analytical method will be used to test DBS samples obtained from participants who are currently 
taking cardiovascular medication(s) to confirm the successful detection of these drugs in their 
blood. 
How will you be involved? 
After reading this Participant Information Leaflet you will be asked to sign a consent form prior 
to giving a blood spot sample and you will also be asked to complete a small questionnaire. 
Information requested in this questionnaire will be: 
1. Cardiovascular drug(s) prescribed 
2. Time since the last dose of the prescribed CVD drug(s) was taken 
3. Dose prescribed 
The blood spot collection card or device and the questionnaire will remain anonymous. 
How is a blood spot sample collected? 
The general approach for the collection and uses of DBS is as follows: One or two drop(s) of 
blood are obtained minimally invasively by a simple finger prick or thumb prick procedure. This 
small volume of blood (~25 µl) is applied to a sample collection card or other blood sampling 
device and dried at room temperature for at least 2-3 hours. The sampling can be done almost 
anywhere. For example, in a laboratory or at home by the participant; in a clinic by a nurse; or in 
a pharmacy by the community pharmacist. The dried blood spot sample will then be sent to our 
laboratory for analysis. 
How is the blood spot analysed? 
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In the laboratory, a fixed area of the DBS is extracted, either directly or as a disk punched from 
the DBS, and the presence of the drug in question is identified by mass spectrometry. 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept on a 
password protected database and is strictly confidential. Your sample will be given a reference 
code which will be used instead of your name. Any identifiable information you may give will be 
removed and anonymised. 
What will happen to the results of the research study? 
The results will be an essential part of PhD thesis in clinical pharmacy practice at De Montfort 
University, Leicester 
Who is organising and funding the research? 
The research is for a PhD studentship at De Montfort University Leicester and is funded by the 
Iraqi Ministry of Health, Misan Health Directorate. 
Who has reviewed the study? 
This study has been reviewed and approved by De Montfort University, Faculty of Health and 
Life Sciences Research Ethics Committee. 
Directions for collection of dried blood sample (DBS) on a sample collection card 
Kit contents: 
- DBS sample collection card (1) 
- Alcohol Prep Pad (1) 
- Lancet (1) 
- Gauze Pad (1) 
- Plaster (1) 
- Plastic re-sealable bag (1) 
1. Fill out the participant reference number on the DBS sample collection card. 
2. Warm the skin on a finger or thumb by gentle rubbing. 
3. Clean sample site with the alcohol pad provided and allow site to AIR DRY. 
4. Lance the sample site and wipe away the first blood drop with sterile gauze. 
5. Gently apply intermittent pressure near the puncture site to obtain the blood sample on the 
finger. 
6. Allow blood to accumulate on the finger or thumb tip and drop onto the sampling card in the 
circled area. The blood drop(s) should fall freely to the sampling card. 
7. AVOID TOUCHING the sampling card and DO NOT spread/smear/smudge blood to cover the 
circled area as this will render the DBS sample invalid. 
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8. Allow multiple drops to fall on the same circled area until this area is COMPLETELY covered 
and soaked. 
9. Once a circled area is covered, start on the next one. At least 2 circles on the DBS card must 
be filled for each sample – this would be from the same finger prick. Over spotting or layering 
can give rise to erroneous results and the sample will be rejected. 
10. The participant will be supplied with a gauze pad and plaster. 
11. Sample cards must then be dried for 2-3 hours at room temperature. Sample cards should be 
kept apart (i.e., not stacked with each other if there is more than one card) and away from heat. 
12. After drying the sample cards must be stored in individual a plastic resealable bag and are 
ready for collection or postage to the laboratory with the accompanying completed consent form 
and adherence questionnaire. 
Directions for collection of dried blood sample (DBS) on a Mitra™ blood sampling device 
Kit contents: 
- Mitra™ (1 clamshell pack containing 4 samplers) 
- Alcohol Prep Pad (1) 
- Lancet (1) 
- Gauze Pad (1) 
- Plaster (1) 
- Plastic resealable bag (1) 
- Desiccant 
 
1. Open sealed packaging and remove clamshell package. 
2. Label samplers with participant reference number (see Quick Start Guide provided). 
3. Uncover the samplers by pulling apart the clamshell and pressing the sides together to create 
a handle (Quick Start Guide step 2). 
4. Clean sample site (side or tip of finger) with the alcohol pad provided and allow site to AIR 
DRY. 
5. Lance the sample site and wipe away the first blood drop with sterile gauze. 
6. Gently apply intermittent pressure near the puncture site to obtain the blood sample on the 
finger. 
7. Apply sampler tip to surface of blood sample at an angle as shown in Steps 3 and 4 on the 
Quick Start Guide. 
8. Wait for the tip to go fully red and then count 2 additional seconds. Slowly remove the 
sampler tip from the blood. 
9. Repeat 7 and 8 above with the remaining three samplers in the four–pack. 
10. Unfold clamshell to cover sampler tips and press closed. 
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11. The participant will be supplied with a gauze pad and plaster. 
12. The covered sampler tips can be immediately placed in the bag with the desiccant. 
13. The sampler is now ready for collection or postage to the laboratory with the accompanying 
completed consent form and adherence questionnaire. 
 
Dr Sangeeta Tanna               Dr Graham Lawson                     Ahmed Alalaqi 
Leicester School of Pharmacy           Leicester School of Pharmacy    Leicester School of Pharmacy 
De Montfort University               De Montfort University         De Montfort University 
The Gateway                              The Gateway                        The Gateway 
Leicester LE1 9BH               Leicester LE1 9BH                      Leicester LE1 9BH 
T: 0116 2078274                              T: 0116 2577129                           T: 00447714714552 
E: stanna@dmu.ac.uk               E: glawson@dmu.ac.uk        E: 14018429@my365.dmu.ac.uk 
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Appendix 4. English Version of Patient Consent Form for DBS Collection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dried blood spot analysis to assess adherence to cardiovascular medications 
Participant Reference Number: 
(To be completed by research team) 
Name of Researchers: Dr Sangeeta Tanna, Dr Graham Lawson & Ahmed Alalaqi 
                                                                                                                       Please initial box 
                                                                                                                                   
 
 
 
 
 
 
 
 
 
 
__________________           ____________________          __________________ 
Name of Participant                Signature                                  Date 
____________________            ____________________       __________________ 
Name of person                               Signature                                            Date 
taking consent                                            
 
1 copy to participant; 1 copy for research file 
 
I agree to take part in this study 
I confirm that I have read and understand the information sheet for 
the above study. I have had the opportunity to consider the 
information and ask questions and have had these answered 
satisfactorily. 
I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my legal 
rights being affected. 
I understand that the data collected during the study, may be looked 
at by responsible individuals from the research team or from 
individuals from regulatory authorities. 
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Appendix 5. English Version of Mini-DBS Questionnaire 
ADHERENCE QUESTIONNAIRE 
 
Dried blood spot analysis to assess adherence to cardiovascular medications 
 
Participant Reference Number: 
 
 
Q1. Have you read the participation information sheet and signed the consent form? 
 
 
Q2 Gender: M or F 
 
Q3.       Are you prescribed any cardiovascular (heart disease) medications?  Y/N 
 
If Yes to Q3, please complete Table 1. 
 
Table 1: Names of prescribed medicines 
 
Approved name Prescribed Dose Frequency Approximate time 
since last 
 (√ ) (mg) (x daily) 
dose (hours) 
     
Amlodipine     
     
Atenolol     
     
Atorvastatin     
     
Bisoprolol     
     
Diltiazem     
     
Doxazosin     
     
Lisinopril     
     
Losartan     
     
Ramipril     
     
Simvastatin     
     
Valsartan     
     
(Not listed) *     
     
 
* Other cardiovascular medicines? Please give name 
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 secneicS efiL dna htlaeH fo ytlucaF
 
 تحليل بقعة الدم لتقييم الالتزام أدوية القلب والأوعية الدموية
 ما هي الدراسة؟
مراكز تقديم هذا المشروع يعتمد على اليه قليله الايذاء للمريض لتقييم التزام المريض بادويه القلب والاوعيه الدمويه في 
 الخدمه الاوليه والثانويه
أشخاص في  3من   1أمراض القلب والأوعية الدموية هي واحدة من أكبر أسباب الوفاة التي تؤثر في جميع أنحاء العالم في  
ويتضمن عاما  05المملكة المتحدة. لرعاية الحالية لهؤلاء المرضى وعلى نحو متزايد للمرضى  الذين اعمارهم أكثر من 
والادويه الخافظه للدهنيات في الدم. وهناك ادله  ECA)، مثبطات BBالعلاج  مزيج من الأدوية بما في ذلك حاصرات بيتا (
٪ من المرضى لا يلتزمون باخذ عقاقير القلب والاوعيه الدمويه كما منصوص عليه مما يودي 06على ان هناك ما يصل إلى 
وارتفاع تكاليف الرعايه الطبيه . التكاليف المتوقعه لعدم استخدام الادويه  في المملكه  الى زياده نسبه الاعتلال والوفيات
 بليون باوند سنويا . اختبار بسيط لمراقبه تركيز الادويه في الدم سيكون ذو قيمه عاليه. 4المتحده هي تقريبا 
 
 ماذا سيحدث؟
مبدا التحليل لبقعه الدم الجافه للكشف ومعرفه تراكيز الادويه  برنامج الدراسه يتضمن اختبار متقدم ومصادق عليه معتمدا على
المستخدمه في علاج امراض القلب والاوعيه الدمويه. وسوف تستخدم هذه الطريق التحليليه لاختبار عينات الدم والتي يتم 
 الناجح لهذه الادويه في الدم.الحصول عليها من المشاركين الذين يتناولون ادويه القلب والاوعيه الدمويه لتاكيد الاكتشاف 
 
 كيف لك أن تشارك؟
بعد قراءه المعلومات عن البحث سيطلب منك التوقيع على استماره المشاركه قبل اعطاء وكما يطلب منك مليء استبيان صغير 
 وستكون المعلومات في هذا الاستبيان مايلي 
 .الادويه المستخدمه من قبلك1
 ادويه القلب والاوعيه الدمويه. اخر وقت تم اخذ اخر جرعه من 2
 . الجرعه الموصوفه3
 جميع المعلومات عن فيما يتعلق بالعينه والاستبيان ستكون محفوظه وتمتع بالخصوصيه 
 
 كيف يتم جمع عينة بقعة الدم؟
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الاصبع وتوخذ النهج العام في هذا الاختبار يتضمن الحصول على قطره او قطرتين من الدم  بواسطه اجراء بسيط يتضمن وخز 
مايكرومل وسيتم وضع هذه العينه على ورقه خاصه او عن طريق تقنيات اخرى وتترك العينات لتجف  52كميه صغيره تعادل 
ساعات على الاقل .اخذ العينات يمكن ان يكون في اي مكان على سبيل المثال في المنزل او  3-2في درجه حراره الغرفه لمده 
 يض او في الصيدليه وبعدها يتم ارسال العينات الى المختبر.المختبر او في عياده التمر
 
 كيف يتم تحليل بقعه الدم؟
في المختبر يتم اخراج منطقه معينه من العينه بشكل مباشر او عن طريق قص منطقه من العينه الموجوده على الورقه 
 الخاصه .
 
 سريه؟ البحث في مشاركتي ستبقى هل
 إزالة سيتم .تامة وسرية مرور بكلمة محمية بيانات قاعدة في البحث أثناء عنك جمعها يتم التي المعلومات جميع وستبقى
 .تعطي قد تعريفية معلومات وأية اسمك من بدلا استخدامها سيتم التي إشارة رمز
 
 الدراسة؟ لنتائج سيحدث ماذا
 ليستر مونتفورت، دي جامعة في السريرية الصيدلة في الدكتوراه رسالة من أساسيا جزءا الدراسه نتائج تكون وسوف
 
  من يمول هذا البحث
هذا البحث هو لدراسه لدرجة الدكتوراة في جامعة دي مونتفورت , ليستر وتموله وزارة الصحة 
 العراقية، دائره صحة ميسان.
    
 من يتابع ويشرف على الدراسه؟
والموافقة عليها من قبل جامعة دي مونتفورت، كلية الصحة وعلوم وقد استعرضت هذه الدراسة 
 الحياة ولجنة أخلاقيات البحث في دائره صحة ميسان.
 
 ارشادات جمع العينه 
 المحتويات :
 .بطاقات جمع العينات1
 . وساده كحول للتعقيم2
 . لانسيت3
 . شاش 4
 .بلاستر5
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 . كيس من البلاستك لحفظ العينات6
 الرقم المرجعي للمشارك على بطاقه جمع العينات. تعبئه 1
 . تدفئه جلد الاصبع بالدلك الخفيف2
 . تعقيم موقع اخذ النموذج بالكحول وتركه ليجف 3
 . وخز الاصبع ومسح اول قطره بالشاش المعقم4
 . اضغط ضغطا خفيفا بالقرب من موقع الوخز من اجل الحصول على العينه5
 صبع للسقوط الحر على الورقه الخاصه في المنطقه المخصصه للعينهالا .السماح لقطره الدم6
 . تجنب لمس بطاقه اخذ العينات او نشر العينه حيث ان ذلك يودي الى جعل العينه غير صالحه7
 .السماح لقطرات متعدده من السقوط على منطقه العينه حتى يتم تغطيتها بالكامل 8
الى العينه الاخرى وعلى الاقل يتم مليء دائرتين من الورقه  وهذا يكون من نفس مكان .عند اكمال عينه معينه يتم الانتقال 9
 الوخز.يتم رفض العينه في حاله تكون طبقات في العينه
 . يتم تزويد المشارك بالشاش والبلاستر01
 بعيدا عن الحرارهساعات ولا يتم حفظ العينات الا بعد التاكد من جفافها وان تحفظ  3-2.تترك العينات لتجف من 11
.بعد جفاف العينات يتم حفظ العينات في الاكياس البلاستيكيه وتكون مهياه للنقل عن طريق البريد العادي مع استماره 21
 الموافقه على المشاركه والاستبيان 
 
 ™artiMارشادات جمع العينه  بواسطه 
 .وساده كحول1
 . لانسيت2
 . شاش3
 . بلاستر4
 .كيس من البلاستك لحفظ العينات5
 .مجففات الرطوبه6
 . افتح مختومة التعبئة والتغليف1
 . عينات تسمية مع الرقم المرجعي للمشارك2
 . سحب العينات3
 .تنظيف موقع العينه وتركه ليجف4
 . وخز الاصبع ومسح اول قطره بالشاش 5
 . الضغط الخفيف قرب موضع اخذ العينه للحصول على الدم6
  4و  3كما موضح في الخطوات . تطبيق راس اخذ العينه بزاويه  و7
 . انتظر حتى يصبح راس اخذ العينه اخر ثم انتظر ثانيتين اخريتين  وبسرعه ارفع الراس من من الدم8
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 مع العينات المتبقيه  8و7. كرر الخطوات 9
 .حفظ العينات المسحوبه01
 . يجهز المريض بالشاش والبلاستر11
 مانع الرطوبه  . راس اخذ العينات يتم وضعه في الكيس مع21
 . العينات الان جاهزه للتجميع والنقل عن طريق البريد مع استماره الموافقه والاستبيان 31
 
 بمن يمكن الاتصال للمزيد من المعلومات؟
  د. سانكيتا تانا
 مدرسه ليستر للصيدله 
 جامعه دي مونت فورت 
 كيت وي
 HB9 1ELليستر 
 4728702 6110هاتف 
البريد الالكتروني  
 ku.ca.umd@annats
 د.كراهام لاوسن
 مدرسه ليستر للصيدله 
 جامعه دي مونت فورت 
 كيت وي                                                                                                
 HB9 1ELليستر 
 9217752 6110هاتف 
         البريد الالكتوني
 ku.ca.umd@noswalg
 
 
 احمد العلاق 
 مدرسه ليستر للصيدله 
 جامعه دي مونت فورت 
كيت وي
 ليستر HB9 1EL
 25541741774400هاتف 
 البريد الالكتوني         
 ku.ca.umd.liame@92481041P
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 MROF TNESNOC 
 استماره الموافقه
 بقعه الدم الجافه لتقييم الالتزام بادويه القلب والاوعيه الدمويه
 الرقم المرجعي للمشارك:
 يملىء من قبل فريق البحث 
 اسماء الباحثين    احمد العلاق            د.سانكيتا تانا    د.كراهام لاوسن            
 
 أؤكد أنني قد قرأت وفهمت ورقة المعلومات للدراسة المذكورة أعلاه. وقد أتيحت لي الفرصة للنظر
                 في المعلومات، وطرح الأسئلة، وكان هذه الإجابة مرضية.                                                                           
 
 وأنا أفهم أن مشاركتي طوعية وأنا حر في الانسحاب في أي وقت دون إبداء أي سبب، دون  تاثر
      حقوقي القانونية        
 
 وأنا أفهم أن البيانات التي تم جمعها خلال هذه الدراسة، يمكن النظر فيها من قبل الأفراد المسؤولين 
 عن فريق البحث أو من الأفراد من السلطات التنظيمية.
 
 أنا أوافق على المشاركة في هذه الدراسة  
                                                                                         
 التاريخ     التوقيع                                                 اسم المشارك                                                   
 التاريخ التوقيع                                                                        اسم الشخص الذي اخذ الموافقه         
 نسخه الى المشارك ونسخه الى الملف 
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  .)noisreV cibarA( eriannoitseuQ ecnerehdA iniM .8 xidneppA
 ERIANNOITSEUQ ECNEREHDA   
 استبيان الالتزام 
 بقعه الدم الجافه لتقييم الالتزام بادويه القلب والاوعيه الدمويه 
 الرقم المرجعي للمشارك:
 .  هل قراءت معلومات المشاركه بالبحث ووقعت استماره الموافقه               نعم                      لا1س 
 .الجنس   ذكر او انثى2س 
 ويه                                       نعم                       لا. هل تصرف لك ادويه القلب والاوعيه الدم3س 
 1في حاله الاجابه بنعم  يرجى مليء الجدول  رقم 
 اسماء الادويه الموصوفه 1جدول رقم 
عدد الجرعات اليوميه  الجرعه ملغم موصوف  اسم الدواء 
 (يوميا)
الوقت التقريبي 
 بالساعات لاخر جرعه 
       enipidolmA
  lolonetA  
 
    
  nitatsavrotA
 
    
  lolorposiB
 
    
  mezaitliD
 
    
  nisozaxoD
 
    
  lirponisiL
 
    
  natrasoL
 
    
  lirpimaR
 
    
  nitatsavmiS
 
    
  natraslaV
 
    
     اخرى *
 اخرى يرجى ذكر اسم الدواء 
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Appendix 9. All Medications Prescribed to the Iraqi Volunteers.  
Patient Ref. Target CVD 
Medication 
Other medications  Total 
number of 
medications 
No. of tablet 
taken per a 
day 
903-280716-AA-01 Control - - - 
903-280716-AA-02 Control - - - 
903-280716-AA-03 Control - - - 
903-280716-AA-04 Control - - - 
903-280716-AA-05 Control - - - 
903-280716-AA-06 Lisinopril 10mg  1 1 
903-310716-AA-07 Simvastatin 20mg Aspirin 100mg  3 3 
  Enalapril 20mg   
903-310716-AA-08 Atenolol 50 mg Aspirin 100mg 8 13 
  Clopidogrel 75mg   
  Metformin 500mg   
  Chlordiazepoxide 5mg   
  Multivitamin nd   
  Ranitidine 150mg   
  Diclofenac 50mg   
903-310716-AA-09 Control - - - 
903-310716-AA-10 Bisoprolol 10mg Clopidogrel 75mg 8 11 
  Lorazepam 2mg   
  Ranitidine 150mg   
  Indomethacin 20mg   
  Multivitamin nd   
  Aspirin 100mg   
  Chlordiazepoxide 5mg   
903-310716-AA-11 Valsartan 80mg Clopidogrel 75mg 8 11 
  Aspirin 100mg   
  Naproxen 500mg   
  Ranitidine 150mg   
  Chlordiazepoxide 5mg   
  Gemfibrozil 600mg   
  Multivitamin nd   
903-310716-AA-12 Valsartan 160mg  1 1 
903-310716-AA-13 Control - - - 
903-310716-AA-14 Atenolol 100mg Enalapril 20mg 2 2 
903-310716-AA-15 Bisoprolol 5mg Rosuvastatin 40mg 2 2 
03-010816-AA-16 Valsartan 80mg  1 1 
903-010816-AA-17 Atorvastatin 40mg Carbamazepine 200mg 6 6 
 Valsartan 80mg Amiodaron 200mg   
  Aspirin 100mg   
  Lorazepam 2mg   
903-010816-AA-18 Control - - - 
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Patient Ref. Target CVD 
Medication 
Other medications  Total 
number of 
medications 
No. of tablet 
taken per a 
day 
903-030816-AA-19 Bisoprolol 5mg Clopidogrel 75mg 8 11 
  Warfarin 2mg   
  Ibrufen 200mg   
  Carbamazepine 
200mg 
  
  Lorazepam 2mg   
  Furosemide 40mg   
  Gemfibrozil 600mg   
903-030816-AA-20 Simvastatin 20mg Candesartan 8mg 5 6 
  Furosemide 40mg   
  Aspirin 100mg   
  Clopidogrel 75mg   
903-030816-AA-21 Diltiazem 90mg Rosuvastatin 20mg 7 11 
  Aspirin 100mg   
  Clopidogrel 75mg   
  Metformin 500mg   
  Lorazepam 2mg   
  Famotidine 20mg   
903-030816-AA-22 Control - - - 
903-030816-AA-23 Atenolol 50mg Aspirin 100mg 8 11 
  Clopidogrel 75mg   
  Metformin 500mg   
 
 Carbamazepine 
200mg 
  
  Bplex   
  Lorazepam 2mg   
  Furosemide 40mg   
903-030816-AA-24 Valsartan 80mg - 1 1 
     
903-030816-AA-25 Losartan 25mg  Clopidogrel 75mg 2 3 
903-030816-AA-26 Control    
903-030816-AA-27 Bisoprolol 5mg - 2 2 
 Losartan 100mg    
903-030816-AA-28 Control    
903-030816-AA-29 Control    
903-040816-AA-30 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
903-040816-AA-31 Valsartan 80mg Amiodarone 200mg 5 8 
  Clopidogrel 75mg   
  Metformin 500mg   
 
 Carbamazepine 
200mg 
  
903-040816-AA-32 Lisinopril 10mg Rosuvastatin 20mg 2 2 
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Patient Ref. Target CVD 
Medication 
Other medications  Total 
number of 
medications 
No. of tablet 
taken per a 
day 
903-040816-AA-33 Losartan 25mg Metoprolol 50mg 8 9 
  Telmisartan 80mg   
  Spironolactone 50mg   
  Rosuvastatin 40mg   
  Chlordiazepoxide 5mg   
  Aspirin 100mg   
  Lorazepam 2mg   
903-050816-AA-34 Atenolol 50mg Gemfibrozil 600mg 2 2 
903-050816-AA-35 Control - - - 
903-050816-AA-36 Bisoprolol 5mg Lorazepam 2mg 5 7 
 Valsartan 160mg Metformin 500mg   
  Chlordiazepoxide 5mg   
903-050816-AA-37 Atenolol 50mg Aspirin 100mg 3 3 
  Isosorbide 10mg   
903-050816-AA-38 Bisoprolol 5mg Lorazepam 2mg 5 7 
 Losartan 50mg Metformin 500mg   
  Chlordiazepoxide 5mg   
903-050816-AA-39 Control - - - 
903-050816-AA-40 Atenolol 50mg - 1 1 
903-050816-AA-41 Losartan 25mg - 1 1 
     
903-050816-AA-42 Atenolol 50mg Aspirin 100mg 2 2 
903-060816-AA-45 Atenolol 50mg Gemfibrozil 300mg 4 6 
  Lorazepam 2mg   
  Metformin 500mg   
903-060816-AA-46 Control - - - 
903-060816-AA-47 Control - - - 
903-060816-AA-48 Bisoprolol 5mg Clopidogrel 75mg 8 12 
 Valsartan 89mg Aspirin 100mg   
  Famotidine 20mg   
  Lorazepam 2mg   
  Metformin 500mg   
  Chlordiazepoxide 5mg   
903-060816-AA-49 Control - - - 
903-060816-AA-50 Losartan 50mg Aspirin 100mg 2 2 
903-060816-AA-51 Atenolol 100mg Candesartan 16mg 4 5 
  Aspirin 100mg   
  Famotidine 20mg   
903-060816-AA-52 Atenolol 50mg Aspirin 100mg 4 6 
  Clopidogrel 75mg   
  Famotidine 20mg   
903-060816-AA-53 Atenolol 100mg Enalapril 10mg 5 8 
  Diclofenac 50mg   
  Gabapentin 300mg   
  Metformin 500mg   
903-060816-AA-54 Control - - - 
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Patient Ref. Target CVD 
Medication 
Other medications  Total 
number of 
medications 
No. of tablet 
taken per a 
day 
903-070816-AA-55 Losartan 100mg Aspirin 100mg 5 7 
 Atorvastatin 40mg Famotidine 20mg   
  Clopidogrel 75mg   
903-070816-AA-56 Atorvastatin 40mg Clopidogrel 75mg 3 4 
 Lisinopril 20mg    
903-070816-AA-57 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-070816-AA-58 Atenolol 50mg Isosorbide 10mg 8 12 
 Atorvastatin 40mg Famotidine 20mg   
  Diclofenac 50mg   
  Gabapentin 300mg   
  Metformin 500mg   
  Aspirin 100mg   
903-070816-AA-59 Atorvastatin 40mg Aspirin 100mg 7 9 
 Bisoprolol 5mg Ranitidine 150mg   
  Diclofenac 50mg   
  Folic acid 1mg   
  Lorazepam 2mg   
903-070816-AA-60 Diltiazem 90mg Rosuvastatin 20mg 8 11 
  Candesartan 20mg   
  Aspirin 100mg   
  Metformin 500mg   
  Aspirin 100mg   
  Ranitidine 150mg   
  Lorazepam 2mg   
903-070816-AA-61 Diltiazem 60mg Aspirin 100mg 8 10 
  Losartan 50mg Ranitidine 150mg   
 Valsartan 160mg Lorazepam 2mg   
  Folic acid 1mg   
  Diclofenac 50mg   
903-070816-AA-62 Atorvastatin 40mg Candesartan 16mg 5 6 
  Metoprolol 100mg   
  Furosemide 40mg   
  Aspirin 100mg   
903-070816-AA-64 Atorvastatin 40mg Aspirin 100mg 8 12 
  Isosorbide 10mg   
  Enalapril 10mg   
  Ranitidine 150mg   
  Lorazepam 2mg   
  Diclofenac 50mg   
  Metformin 500mg   
903-070816-AA-65 Diltiazem 60mg Rosuvastatin 20mg 2 2 
903-070816-AA-66 Lisinopril 10mg - 1 1 
903-080816-AA-67 Atenolol 100mg - 1 1 
903-080816-AA-68 Valsartan 80mg Metoprolol 50mg 4 5 
  Fluvastatin 20mg   
  Aspirin 100mg   
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Patient Ref. Target CVD 
Medication 
Other medications  Total 
number of 
medications 
No. of tablet 
taken per a 
day 
903-080816-AA-69 Losartan 50mg Metoprolol 50mg 2 3 
903-080816-AA-70 Atorvastatin 40mg - 1 1 
903-080816-AA-71 Control - - - 
903-090816-AA-72 Atorvastatin 40mg - 3 3 
 Diltiazem 60mg    
 Valsartan 160mg    
903-090816-AA-73  Valsartan 80mg Metoprolol 50mg 3 4 
  Gemfibrozil 600mg   
903-090816-AA-74 Valsartan 80mg Aspirin 100mg 7 12 
  Clopidogrel 75mg   
  Famotidine 20mg   
  Diclofenac 50mg   
  Gabapentin 300mg   
  Metformin 500mg   
903-090816-AA-75 Atorvastatin 40mg Chlortalidone 25mg 3 4 
  Metoprolol 50mg   
903-090816-AA-76 Diltiazem 90mg - 1 1 
903-090816-AA-77 Lisinopril 10mg Aspirin 100mg 3 4 
  Clopidogrel 75mg   
903-090816-AA-78 Valsartan 160mg  Trimetazidine 35mg 2 2 
903-090816-AA-79 Control - - - 
903-100816-AA-80 Valsartan 80mg Rosuvastatin 20mg 7 9 
  Aspirin 100mg   
  Ranitidine 150mg   
  Diclofenac 50mg   
  Folic acid 1mg   
  Lorazepam 2mg   
903-100816-AA-81  Control - - - 
903-100816-AA-82 Atorvastatin 40mg Metoprolol 50mg 4 5 
 Valsartan Aspirin 100mg   
903-100816-AA-83 Control    
903-100816-AA-84 Valsartan 160mg Aspirin 100mg 4 6 
  Ranitidine 150mg   
  Clopidogrel 75mg   
903-100816-AA-85  Control - - - 
903-100816-AA-86 Diltiazem 60mg Hydrochlorothiazide 
50mg 
2 2 
903-100816-AA-87 Bisoprolol 5mg - 1 1 
903-100816-AA-88 Aspirin 100mg  Atorvastatin 40mg 3 4 
  Metoprolol 50mg    
903-100816-AA-89 Valsartan 160mg Metoprolol 50mg  4 6 
  Aspirin 100mg   
  Ranitidine 150mg   
903-110816-AA-90 Bisoprolol 5mg Candesartan 8mg 2 2 
903-120816-AA-91 Bisoprolol 5mg  2 2 
 Lisinopril 10mg    
903-120816-AA-92 Control - - - 
903-120816-AA-93 Lisinopril 10mg Metoprolol 50mg 2 3 
 228 | P a g e 
 
Patient Ref. Target CVD 
Medication 
Other medications  Total 
number of 
medications 
No. of tablet 
taken per a 
day 
  903-120816-AA-94 Control - - - 
903-150816-AA-95 Bisoprolol 5mg Verapamil 40mg 3 3 
  Aspirin 100mg   
903-150816-AA-96 Bisoprolol 5mg Aspirin 100mg 2 2 
  903-150816-AA-97  Control - - - 
903-150816-AA-98 Control - - - 
903-150816-AA-99 Bisoprolol 5mg - 2 2 
 Valsartan 160mg    
903-200717-AA-100 Atenolol 50mg - 2 2 
 Simvastatin 40mg    
903-200717-AA-101 Atenolol 50mg - 2 2 
 Simvastatin 40mg    
903-200717-AA-102 Atenolol 100mg - 2 2 
 Simvastatin 40mg    
903-200717-AA-103 Atenolol 50mg Aspirin 100mg 3 3 
 Simvastatin 40mg    
903-200717-AA-104 Atenolol 50mg - 2 2 
 Lisinopril 10mg    
903-200717-AA-105 Atenolol 50mg - 2 2 
 Lisinopril 10mg    
903-200717-AA-106 Atenolol 100mg - 2 2 
 Lisinopril 10mg     
903-200717-AA-107 Atenolol 100mg Amiodarone 200mg 3 3 
 Lisinopril 10mg    
903-200717-AA-108 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-200717-AA-109 Bisoprolol 5mg Aspirin 100mg 3 3 
 Lisinopril 10mg    
903-200717-AA-110 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-200717-AA-111 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-200717-AA-112 Bisoprolol 5mg Famotidine 20mg 3 4 
 Valsartan 80mg    
903-200717-AA-113 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
903-200717-AA-114 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
903-200717-AA-115 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
903-200717-AA-116 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
903-200717-AA-117 Diltiazem 60mg - 2 2 
 Lisinopril 10mg    
903-200717-AA-118 Diltiazem 90mg - 2 2 
 Lisinopril 10mg    
903-200717-AA-119 Diltiazem 90mg Lorazepam 2mg 4 5 
 Lisinopril 10mg Ranitidine 150mg   
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Patient Ref. Target CVD 
Medication 
Other medications  Total 
number of 
medications 
No. of tablet 
taken per a 
day 
903-200717-AA-120 Diltiazem 90mg Aspirin 100mg 4 4 
 Lisinopril 10mg Warfarin 2mg   
903-210717-AA-121 Losartan 50mg Aspirin 100mg 4 4 
 Simvastatin 40mg Furosemide 40mg   
903-210717-AA-122 Losartan 50mg Aspirin 100mg 4 5 
 Simvastatin 40mg  Ranitidine 150mg   
903-210717-AA-123 Losartan 50mg - 2 2 
 Simvastatin 40mg    
903-210717-AA-124 Losartan 50mg - 2 2 
 Simvastatin 40mg    
903-210717-AA-125 Amlodipine 5mg Clopidogrel 75mg 2 3 
903-210717-AA-126 Amlodipine 5mg Aspirin 100mg 2 2 
903-210717-AA-127 Amlodipine 5mg Aspirin 100mg 2 2 
903-210717-AA-128 Amlodipine 5mg Aspirin 100mg 2 2 
903-210717-AA-129 Losartan 50mg Aspirin 100mg 3 3 
  Furosemide 40mg   
903-210717-AA-130 Losartan 50g Clopidogrel 75mg 2 3 
903-220717-AA-131 Losartan 50mg Aspirin 100mg 2 2 
903-220717-AA-132 Simvastatin 40mg Clopidogrel 75mg 2 3 
903-220717-AA-133 Simvastatin 40mg Aspirin 100mg  4 5 
  Furosemide 40mg   
  Clopidogrel 75mg   
903-220717-AA-134 Valsartan 80mg Aspirin 100mg 2 2 
903-220717-AA-135 Valsartan 80mg Aspirin 100mg 2 2 
903-220717-AA-136 Valsartan 80mg Clopidogrel 75mg 2 3 
903-220717-AA-137 Valsartan 80mg - 1 1 
903-220717-AA-138 Atenolol 50mg Aspirin 100mg 4 4 
 Simvastatin 40mg Gemfibrozil 600mg   
903-220717-AA-139 Atenolol 100mg - 2 2 
 Simvastatin 40mg    
903-220717-AA-140 Atenolol 50mg - 2 2 
 Simvastatin 40mg    
903-230717-AA-141 Atenolol 100mg - 2 2 
 Simvastatin 40mg     
903-230717-AA-142 Atenolol 50mg  2 2 
 Lisinopril 10mg    
903-230717-AA-143 Atenolol 50mg  2 2 
 Lisinopril 10mg    
903-230717-AA-144 Atenolol 50mg Aspirin 100mg 3 3 
 Lisinopril 10mg    
903-230717-AA-145 Bisoprolol 5mg Aspirin 100mg 4 5 
 Lisinopril 10mg Ranitidine 150mg   
903-230717-AA-146 Bisoprolol 15mg - 2 2 
 Lisinopril 10mg    
903-230717-AA-147 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-230717-AA-148 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
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903-230717-AA-149 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
903-230717-AA-150 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
903-240717-AA-152 Diltiazem 60mg - 2 2 
 Lisinopril 10g    
903-240717-AA-153 Diltiazem 60mg Isosorbide 10mg 5 7 
 Lisinopril 10mg Paracetamol 500mg   
  Chlordiazepoxide 
5mg 
  
903-240717-AA-154 Diltiazem 60mg Amiodaron 200mg 3 3 
 Lisinopril 10mg    
903-240717-AA-155 Diltiazem 90mg - 2 2 
 Lisinopril 10mg    
903-240717-AA-156 Losartan 100mg - 2 2 
 Simvastatin 40mg    
903-240717-AA-157 Losartan 50mg  - 2 2 
 Simvastatin 40mg    
903-240717-AA-158 Losartan 50mg - 2 2 
 Simvastatin 40mg    
903-240717-AA-159 Losartan 100mg - 2 2 
 Simvastatinn 40mg    
903-240717-AA-160 Amlodipine 5mg Clopidogrel 75mg 3 4 
  Aspirin 100mg   
903-250717-AA-161 Amlodipine 5mg - 2 2 
 Aspirin 100mg    
903-250717-AA-162 Amlodipine 5mg - 2 2 
 Aspirin 100mg    
903-250717-AA-163 Amlodipine 5mg Aspirin 100mg 5 7 
  Isosorbide 10mg   
  Paracetamol 500mg   
  Chlordiazepoxide 
5mg 
  
903-250717-AA-164 Losartan 50mg  Aspirin 100mg  7 11 
  Clopidogrel 75mg    
  Famotidine 20mg    
  Lorazepam 2mg   
  Paracetamol 500mg   
  Chlordiazepoxide 
5mg 
  
903-250717-AA-165 Losartan 50mg Aspirin 100mg 2 2 
903-250717-AA-166 Losartan 50mg Aspirin 100mg 2 2 
903-250717-AA-167 Simvastatin 40mg Isosorbide 10mg 7 11 
  Aspirin 100mg   
  Metformin 500mg   
  Diclofenac 50mg   
  Lorazepam 2mg   
  Naproxen 500mg   
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903-250717-AA-168 Simvastatin 40mg Aspirin 100mg 2 2 
903-250717-AA-169 Atenolol 50mg - 2 2 
 Simvastatin 40mg     
903-250717-AA-170 Atenolol 100mg  2 2 
 Simvastatin 40mg    
903-270717-AA-171 Atenolol 50mg  2 2 
 Simvastatin 40mg     
903-270717-AA-172 Atenolol 100mg Aspirin 100mg 4 4 
 Simvastatin 40mg  Isosorbide 10mg   
903-270717-AA-173 Atenolol 50mg Famotidine 20mg 4 5 
 Lisinopril 10mg Aspirin 100mg   
903-270717-AA-174 Atenolol 50mg Aspirin 100mg 4 4 
 Lisinopril 10mg Clopidogrel 75mg   
903-270717-AA-175 Atenolol 100mg  2 2 
 Lisinopril 10mg    
903-270717-AA-176 Atenolol 100mg Carbamazepine 
200mg 
6 8 
 Lisinopril 10mg Warfarin 2mg   
  Ranitidine 150mg   
  Naproxen 500mg   
903-270717-AA-177 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-270717-AA-178 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-270717-AA-180 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-280717-AA-181 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-280717-AA-182 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-280717-AA-183 Bisoprolol 5mg Aspirin 100mg 6 6 
 Valsartan 80mg Gemfibrozil 300mg   
  Diazepam 5mg   
  Amiodarone 200mg   
903-280717-AA-184 Bisoprolol 5mg Aspirin 100mg 3 3 
 Valsartan 80mg    
903-280717-AA-185 Bisoprolol 5mg Aspirin 100mg 4 4 
 Valsartan 80mg Lansoprazole 30mg    
903-280717-AA-186 Diltiazem 60mg Clopidogrel 75mg 5 7 
 Lisinopril 10mg Ranitidine 150mg   
  Mefenamic acid 
250mg 
  
903-280717-AA-187 Diltiazem 90mg - 2 2 
 Lisinopril 10mg    
903-280717-AA-188 Diltiazem 90mg Ibrufen 200mg 5 6 
 Lisinopril 10mg Carbamazepine 
200mg 
  
  Lorazepam 2mg   
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903-280717-AA-189 Diltiazem 90mg - 2 2 
 Lisinopril 10mg    
903-280717-AA-190 Losartan 50mg Aspirin 100mg 5 5 
 Simvastatin 40mg Furosemide 40mg   
  Lansoprazole 30mg   
903-290717-AA-191 Losartan 100mg  2 2 
 Simvastatin 40mg    
903-290717-AA-192 Losartan 100mg Aspirin 100mg 6 8 
 Simvastatin 40mg Warfarin 2mg   
  Ranitidine 150mg   
  Naproxen 500mg   
903-290717-AA-193 Losartan 100mg Clopidogrel 75mg 5 6 
 Simvastatin 40mg Warfarin 2mg   
  Amiloride 5mg   
903-290717-AA-194 Losartan 100mg  2 2 
 Simvastatin 40mg    
903-290717-AA-195 Amlodipine 5mg  2 2 
 Aspirin 100mg    
903-290717-AA-196 Amlodipine 5mg  2 2 
 Aspirin 100mg    
903-290717-AA-197 Amlodipine 5mg  2 3 
 Clopidogrel 75mg    
903-290717-AA-198 Amlodipine 5mg Aspirin 100mg 8 10 
  Metformin 500mg   
  Warfarin 2mg   
  Ranitidine 150mg   
  Naproxen 500mg   
903-290717-AA-199 Losartan 50mg - 2 3 
 Clopidogrel 75mg    
903-290717-AA-200 Losartan 50mg - 2 2 
 Aspirin 100mg    
903-300717-AA-201 Losartan 50mg Warfarin 2mg 5 7 
  Ranitidine 150mg   
  Naproxen 500mg   
  Aspirin 100mg   
903-300717-AA-202 Simvastatin 40mg Aspirin 100mg 5 8 
  Ranitidine 150mg   
  Naproxen 500mg   
  Clopidogrel 75mg   
903-300717-AA-203 Control - - - 
903-300717-AA-204 Valsartan 80mg Clopidogrel 75mg 7 10 
  Diclofenac 50mg   
  Ranitidine 150mg   
  Mefenamic acid 
250mg 
  
  Aspirin 100mg   
  Amiloride 5mg   
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903-300717-AA-205 Valsartan 80mg  2 2 
 Aspirin 100mg    
903-300717-AA-206 Atenolol 50mg Aspirin 100mg 4 5 
 Simvastatin 40mg Clopidogrel 75mg   
903-300717-AA-207 Atenolol 100mg Aspirin 100mg 5 8 
 Simvastatin 40mg Metformin 500mg   
  Diclofenac 50mg   
903-300717-AA-208 Atenolol 50mg Aspirin 100mg 7 8 
 Simvastatin 40mg  Furosemide 40mg   
  Naproxen 500mg   
  Omeprazole 40mg   
  Lorazepam 2mg   
903-300717-AA-209 Atenolol 100mg Aspirin 100mg 5 6 
 Lisinopril 10mg Ranitidine 150mg   
  Naproxen 500mg   
903-300717-AA-210 Atenolol 1oomg  2 2 
 Lisinopril 10mg    
903-300717-AA-211 Atenolol 100mg Clopidogrel 75mg 6 9 
 Lisinopril 10mg Alprazolam 0.5mg   
  Ibrufen 200mg   
  Isosorbide 10mg   
903-300717-AA-212 Bisoprolol 5mg Famotidine 20mg 6 10 
 Lisinopril 10mg Metformin 500mg   
  Clopidogrel 75mg   
  Lansoprazole 30mg   
903-300717-AA-213 Diltiazem 90mg - 2 2 
 Lisinopril 10mg    
903-300717-AA-214 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
     
903-300717-AA-215 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
     
903-300717-AA-216 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
     
903-300717-AA-217 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
     
903-300717-AA-218 Diltiazem 60mg Aspirin 100mg 6 8 
 Lisinopril 10mg Omeprazole 20mg   
  Lorazepam 2mg   
  Metformin 500mg   
903-300717-AA-219 Diltiazem 90mg - 2 2 
 Lisinopril 10mg    
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903-300717-AA-220 Diltiazem 90mg Aspirin 100mg 7 8 
 Lisinopril 10mg Ranitidine 150mg   
  Gabapentin 300mg   
  Folic acid 1mg   
  Chlordiazepoxide 
5mg 
  
903-310717-AA-221 Losartan 100mg Aspirin 100mg 4 5 
 Simvastatin 40mg Diclofenac 50mg   
903-310717-AA-222 Amlodipine 5mg - 2 2 
 Aspirin 100mg    
903-310717-AA-223 Losartan 50mg - 2 2 
 Aspirin 100mg    
903-310717-AA-224 Valsartan 80mg - 2 2 
 Aspirin 100mg    
903-310717-AA-225 Valsartan 80mg Aspirin 100mg 3 4 
  Ranitidine 150mg   
903-310717-AA-226 Atenolol 100mg  2 2 
 Simvastatin 40mg    
     
903-310717-AA-227 Atenolol 50mg Clopidogrel 75mg 5 7 
 Simvastatin 40mg Ibrufen 200mg   
  Lansoprazole 30mg   
903-310717-AA-228 Atenolol 100mg - 2 2 
 Lisinopril 10mg    
903-310717-AA-229 Atenolol 100mg Omeprazole 20mg 4 6 
 Lisinopril 10mg Naproxen 500mg   
903-310717-AA-230 Bisoprolol 5mg Carbamazepine 
200mg 
5 6 
 Lisinopril 10mg Diazepam 2mg   
  Naproxen 200mg   
903-010817-AA-231 Bisoprolol 5mg Aspirin 100mg 5 5 
 Lisinopril 10mg Amiodarone 200mg   
  Isosorbide 10mg   
903-010817-AA-232 Bisoprolol 5mg - 2 2 
 Lisinopril 10mg    
903-010817-AA-233 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
903-010817-AA-234 Bisoprolol 5mg - 2 2 
 Valsartan 80mg    
903-010817-AA-235 Bisoprolol 5mg Aspirin 100mg 5 6 
 Valsartan 80mg Furosemide 40mg    
  Diclofenac 50mg   
903-010817-AA-236 Diltiazem 60mg Aspirin 100mg 5 6 
 Lisinopril 10mg Clopidogrel 75mg   
  Lorazepam 2mg   
     
903-010817-AA-237 Diltiazem 90mg  2 2 
 Lisinopril 10mg    
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903-010817-AA-238 Diltiazem 90mg Aspirin 100mg 3 3 
 Lisinopril 10mg    
903-010817-AA-239 Losartan 100mg Aspirin 100mg 4 4 
 Simvastatin 40mg Chlordiazepoxide 
5mg 
  
903-010817-AA-240 Amlodipine 5mg Aspirin 100mg 5 7 
  Clopidogrel 75mg   
  Furosemide 40mg   
  Diclofenac 50mg   
903-020817-AA-241 Valsartan 80mg Aspirin 100mg 7 8 
  Furosemide 40mg   
  Chlordiazepoxide 
5mg 
  
  Omeprazole 40mg   
  Alprazolam 0.5mg   
  Meloxicam 7.5mg   
903-020817-AA-242 Valsartan 80mg  2 2 
 Aspirin 100mg    
     
903-020817-AA-243 Valsartan 80mg  2 2 
 Aspirin 100mg    
903-020817-AA-244 Atenolol 100mg Amiloride 5mg 4 4 
 Lisinopril 10mg Omeprazole 40mg   
     
903-020817-AA-245 Atenolol 100mg Nifedipine 20mg 3 4 
 Lisinopril 10mg    
903-020817-AA-246 Bisoprolol 5mg  2 2 
 Lisinopril 10mg    
903-020817-AA-247 Diltiazem 90mg Omeprazole 20mg 4 5 
 Lisinopril 10mg Mefenamic acid 
250mg 
  
903-020817-AA-248 Diltiazem 90mg Clopidogrel 75mg 3 4 
 Lisinopril 10mg    
903-020817-AA-249 Losartan 100mg Aspirin 100mg 5 5 
 Simvastatin 40mg Warfarin 2mg   
  Furosemide 40mg   
903-020817-AA-250 Losartan 100mg Aspirin 100mg 7 10 
 Simvastatin 40mg Warfarin 2mg   
  Furosemide 40mg   
  Ranitidine 150mg   
  Paracetamol 500mg   
903-030817-AA-251 Losartan 100mg Aspirin 100mg 3 3 
 Simvastatin 40mg    
903-030817-AA-252 Amlodipine 5mg Clopidogrel 75mg 5 8 
  Lorazepam 2mg   
  Ranitidine 150mg   
  Diclofenac 50mg   
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903-030817-AA-253 Valsartan 80mg Clopidogrel 75mg 5 7 
  Furosemide 40mg    
  Amiodarone 200mg   
  Famotidine 20mg   
903-030817-AA-254 Valsartan 80mg Clopidogrel 75mg 2 3 
903-030817-AA-255 Valsartan 80mg Furosemide 40mg 3 3 
  Aspirin 100mg   
903-030817-AA-256 Atenolol 100mg Amiodarone 200mg 4 5 
 Lisinopril 10mg Famotidine 20mg   
     
903-030817-AA-257 Atenolol 100mg Aspirin 100mg 4 5 
 Lisinopril 10mg Famotidine 20mg   
903-030817-AA-258 Atenolol 100mg  2 2 
 Lisinopril 10mg    
903-030817-AA-259 Bisoprolol 5mg  2 2 
 Lisinopril 10mg    
903-030817-AA-260 Bisoprolol 5mg  2 2 
 Lisinopril 10mg    
903-040817-AA-261 Bisoprolol 5mg Aspirin 100mg 3 3 
 Valsartan 80mg    
903-040817-AA-262 Bisoprolol 5mg Warfarin 2mg 3 3 
 Valsartan 80mg    
903-040817-AA-263 Valsartan 80mg Aspirin 100mg 5 7 
  Clopidogrel 75mg   
  Famotidine 20mg   
  Diazepam 2mg   
903-040817-AA-264 Atenolol 100mg Aspirin 100mg 7 11 
  Ranitidine 150mg   
  Diclofenac 50mg   
  Metformin 500mg   
  Furosemide 40mg   
  Lansoprazole 30mg    
903-040817-AA-265 Losartan 100mg Aspirin 100mg 6 7 
  Isosorbide 10mg   
  Paracetamol 500mg   
  Furosemide 40mg   
  Lansoprazole 30mg    
903-040817-AA-266 Valsartan 80mg Aspirin 100mg 8 13 
  Metformin 500mg   
  Lorazepam 2mg   
  Diclofenac 50mg   
  Folic acid 1mg   
  Isosorbide 10mg   
  Paracetamol 500mg   
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903-040817-AA-267 Diltiazem 90mg Aspirin 100mg 8 11 
  Metformin 800mg   
  Paracetamol 500mg   
  Lorazepam 2mg   
  Folic acid 1mg   
  Clopidogrel 75mg   
  Lorazepam 2mg   
903-040817-AA-268 Bisoprolol 5mg Clopidogrel 75mg 7 11 
  Lorazepam 2mg   
  Omeprazole 40mg   
  Aspirin 100mg   
  Famotidine 20mg   
  Ibrufen 200mg   
903-040817-AA-269 Diltiazem 90mg Aspirin 100mg 6 8 
  Famotidine 20mg   
  Ibrufen 200mg   
  Lorazepam 2mg   
  Amiodarone 200mg   
903-040817-AA-270 Atenolol 100mg Aspirin 100mg 8 8 
  Hydrochlorothiazide 
50mg 
  
  Lorazepam 2mg   
  Mefenamic acid 
500mg 
  
  Metoclopramide 5mg   
  Lorazepam 2mg   
  Amiodarone 200mg   
903-050817-AA-271 Losartan 50mg Aspirin 100mg 6 6 
  Famotidine 40mg   
  Carbamazepine 200mg   
  Lorazepam 2mg   
  B-complex   
903-050817-AA-272 Bisoprolol 5mg Paracetamol 500mg 6 9 
  Furosemide 40mg   
  Ibrufen 200mg   
  Lansoprazole 30mg   
  Diazepam 2mg   
903-050817-AA-273 Valsartan 80mg Aspirin 100mg 6 7 
  Ibrufen 200mg   
  Isosorbide 10mg   
  Amiodarone 200mg   
  Folic acid 1mg   
903-050817-AA-274 Atenolol 50mg Furosemide 40mg 7 8 
  Isosorbide 10mg   
  Lansoprazole 30mg   
  Aspirin 100mg   
  Ibrufen 200mg   
  Folic acid 1mg   
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903-050817-AA-275 Losartan 50mg Aspirin 100mg 6 7 
  Furosemide 40mg    
  Isosorbide 10mg   
  Ibrufen 200mg   
  Folic acid 1mg   
903-050817-AA-276 Valsartan 80mg Clopidogrel 75mg 6 10 
  Aspirin 100mg   
  Ibrufen 200mg   
  Gabapentin 300mg   
  Famotidine 20mg   
903-050817-AA-277 Diltiazem 90mg Aspirin 100mg 8 10 
  Clopidogrel 75mg   
  Amiodarone 200mg   
  Lansoprazole 30mg   
  Metoclopramide 5mg   
  Ibrufen 200mg   
  Gabapentin 300mg   
903-050817-AA-278 Bisoprolol 5mg Clopidogrel 75mg 5 7 
  Ranitidine 150mg   
  Carbamazepine 
200mg 
  
  Furosemide 40mg   
903-050817-AA-279 Losartan 50mg Aspirin 100mg 8 12 
  Omeprazole 20mg   
  Gabapentin 300mg   
  Indomethacin 20mg   
  Clopidogrel 75mg   
  Ranitidine 150mg   
  Lorazepam 2mg   
903-050817-AA-280 Valsartan 80mg Aspirin 100mg 6 7 
  Gemfibrozil 600mg   
  Furosemide 40mg   
  Ibrufen 200mg   
  Lorazepam 2mg   
903-100817-AA-281 Bisoprolol 5mg Aspirin 100mg 5 6 
  Clopidogrel 75mg   
  Lorazepam 2mg   
  Furosemide 40mg   
903-100817-AA-282 Diltiazem 60mg Aspirin 100mg 7 9 
  Amiodarone 200mg   
  Metformin 500mg   
  Meloxicam 7.5mg   
  Lorazepam 2mg   
  Furosemide 4mg   
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903-100817-AA-283 Atenolol 100mg Gabapentin 300mg 7 10 
  Naproxen 500mg   
  Omeprazole 40mg   
  Metformin 500mg   
  Domperidone 10mg   
  Ibrufen 200mg   
903-100817-AA-284 Bisoprolol 5mg Aspirin 100mg 4 4 
  Gabapentin 300mg   
  Chlordiazepoxide 
5mg 
  
903-100817-AA-285 Diltiazem 90mg Lorazepam 2mg 8 10 
  Omeprazole 40mg    
  Domperidone 10mg   
  Ibrufen 200mg   
  Metformin 500mg   
  Aspirin 100mg   
  Omeprazole 40mg   
903-100817-AA-286 Valsartan 80mg Aspirin 100mg 6 10 
  Clopidogrel 75mg   
  Metformin 500mg   
  Diclofenac 50mg   
  Lorazepam 5mg   
903-100817-AA-287 Atenolol 50mg Aspirin 100mg 5 7 
  Metformin 500mg   
  Furosemide 40mg   
  Gabapentin 300mg   
903-100817-AA-288 Losartan 50mg Aspirin 100mg 5 5 
  Isosorbide 10mg   
  Lorazepam 5mg   
  Furosemide 40mg   
903-100817-AA-289 Diltiazem 60mg Aspirin 100mg 5 5 
  Mefenamic acid 
500mg 
  
  Carbamazepine 
200mg 
  
  Omeprazole 40mg   
903-100817-AA-290 Bisoprolol 5mg Aspirin 100mg 6 9 
  Metformin 500mg   
  Diclofenac 50mg   
  Lorazepam 5mg   
  B-complex   
903-210318-AA-291 Atorvastatin 40mg Aspirin 100mg 3 4 
  Clopidogrel 75mg   
903-210318-AA-292 Valsartan 80mg Aspirin 100mg 2 2 
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903-210318-AA-293 Bisoprolol 5mg Aspirin 100mg 3 3 
  Lorazepam 2mg   
903-210318-AA-294 Lisinopril 10mg Clopidogrel 75mg 7 11 
  Aspirin 100mg   
  Famotidine 20mg   
  Lorazepam 2mg   
  Metformin 500mg    
  Chlordiazepoxide 
5mg 
  
903-210318-AA-295 Losartan 25mg Lorazepam 2mg 6 8 
  Clopidogrel 75mg   
  Aspirin 100mg   
  Famotidine 20mg   
  Gemfibrozil 600mg   
903-210318-AA-296 Atenolol 50mg Aspirin 100mg 8 11 
  Clopidogrel 75mg   
  Lorazepam 2mg   
  Omeprazole 20mg   
  Folic acid 1mg   
  Ibrufen   200mg   
  Chlordiazepoxide 
5mg 
  
903-210318-AA-297 Bisoprolol 5mg Aspirin 100mg 6 10 
  Metformin 500mg   
  Isosorbide 10mg   
  Diclofenac 50mg   
  Famotidine 20mg   
903-210318-AA-298 Bisoprolol 5mg Aspirin 100mg 8 13 
  Clopidogrel 75mg   
  Lorazepam 2mg   
  Famotidine 20mg   
  Chlordiazepoxide 
5mg 
  
  Metformin 500mg   
  Diclofenac 25mg   
903-210318-AA-299 Losartan 50mg Aspirin 100mg 6 12 
  Ibrufen 200mg   
  Famotidine 20mg   
  Lorazepam 2mg   
  Metformin 500mg   
903-240318-AA-300 Bisoprolol 5mg Aspirin 100mg 7 12 
  Clopidogrel 75mg   
  Famotidine 20mg   
  Diclofenac 50ng   
  Gabapentin 300mg   
  Metformin 500mg   
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903-240318-AA-301 Atorvastatin 40mg Aspirin 100mg 2 2 
903-240318-AA-302 Valsartan 80mg Aspirin 100mg 3 4 
  Famotidine 20mg   
903-240318-AA-303 Bisoprolol 5mg Naproxen 500mg 3 5 
  Famotidine   
903-240318-AA-304 Bisoprolol 5mg Aspirin 100mg 6 8 
  Ranitidine 150mg   
  Diclofenac 50mg   
  Folic acid 1mg   
  Lorazepam 2mg   
903-240318-AA-305 Losartan 50mg Aspirin 100mg 6 8 
  Ranitidine 150mg   
  Diclofenac 50mg    
  Folic acid 1mg   
  Lorazepam 2mg   
903-250318-AA-306 Bisoprolol 5mg Aspirin 100mg 6 8 
  Clopidogrel 75mg   
  Famotidine 20mg   
  Lorazepam 2mg   
  Folic acid 1mg   
903-250318-AA-307 Atenolol 50mg Clopidogrel 75mg 6 9 
  Famotidine 20mg   
  Lorazepam 2mg   
  Ibrufen 200mg   
  Folic acid 1mg   
903-250318-AA-308 Losartan 25mg Aspirin 8 12 
  Clopidogrel   
  Famotidine   
  Lorazepam    
  Ranitidine   
  Indomethacin    
  Multivitamin    
903-250318-AA-309 Valsartan Aspirin 100mg 8 12 
  Clopidogrel 75mg   
  Metformin 500mg   
  Chlordiazepoxide 
5mg 
  
  Multivitamin    
  Ranitidine 150mg   
  Diclofenac 50mg   
903-250318-AA-310 Atenolol 50mg Clopidogrel 75mg 7 9 
  Lorazepam 2mg   
  Ranitidine 150mg   
  Indomethacin 20mg   
  Multivitamin    
  Aspirin 100mg   
903-260318-AA-311 Atorvastatin 40mg Aspirin 100mg 2 2 
  
 242 | P a g e 
 
Patient Ref. Target CVD 
Medication 
Other medications  Total number 
of 
medications 
No. of 
tablet taken 
per a day 
903-260318-AA-312 Valsartan 80mg Aspirin 100mg 3 3 
  Furosemide 40mg   
903-260318-AA-313 Lisinopril 20mg Clopidogrel 75mg 6 8 
  Aspirin 100mg   
  Ranitidine 150mg   
  Lorazepam 2mg   
  Furosemide 40mg   
903-260318-AA-314 Simvastatin 40mg Aspirin 100mg 7 9 
  Naproxen 500mg   
  Ranitidine 150mg   
  Lorazepam 2mg   
  Furosemide 40mg   
  Folic acid 1mg   
903-260318-AA-315 Bisoprolol 5mg Clopidogrel 75mg 7 10 
  Aspirin 100mg   
  Naproxen 500mg   
  Ranitidine 150mg   
  Chlordiazepoxide 
5mg 
  
  Gemfibrozil 600mg   
903-260318-AA-316 Bisoprolol 5mg Clopidogrel 75mg 8 10 
  Warfarin 2mg   
  Ibrufen 200mg   
  Carbamazepine 
200mg 
  
  Lorazepam 2mg   
  Furosemide 40mg   
  Gemfibrozil 600mg   
903-260318-AA-317 Losartan 50mg Aspirin 100mg 5 5 
  Warfarin 2mg   
  Carbamazepine 5mg   
  Bplex   
903-260318-AA-318 Valsartan 80mg  Aspirin 100mg 8 11 
  Clopidogrel 75mg   
  Metformin 500mg   
  Carbamazepine 
200mg 
  
  Bplex   
  Lorazepam 2mg   
  Furosemide 40mg   
903-260318-AA-319 Bisoprolol 5mg Clopidogrel 75mg 7 12 
  Aspirin 100mg   
  Ibrufen   200mg   
  Carbamazepine 
200mg 
  
  Metformin 500mg   
  Omeprazole 20mg   
903-260318-AA-320 Atorvastatin 40mg Clopidogrel 75mg 2 3 
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Patient Ref. Target CVD 
Medication 
Other medications  Total number 
of 
medications 
No. of 
tablet taken 
per a day 
903-260318-AA-321 Valsartan 80mg Aspirin 100mg 3 4 
  Clopidogrel 75mg   
903-260318-AA-322 Bisoprolol 5mg Aspirin 100mg 6 9 
  Lorazepam 2mg   
  Diclofenac 50mg   
  Ranitidine 150mg   
  Clopidogrel 75mg   
903-260318-AA-323 Simvastatin 20mg Clopidogrel 75mg 6 9 
  Diclofenac 25mg   
  Lorazepam 2mg   
  Aspirin 100mg   
  Ranitidine 150mg   
903-260318-AA-324 Simvastatin 20mg Warfarin 2mg 7 8 
  Aspirin 100mg   
  Gemfibrozil 600mg   
  Famotidine 20mg   
  Lorazepam 2mg   
  Carbamazepine 
200mg 
  
903-260318-AA-325 Simvastatin 40mg Aspirin 100mg 8 12 
  Lansoprazole 30mg   
  Mefenamic acid 
500mg 
  
  Chlordiazepoxide 
5mg 
  
  Clopidogrel 75mg   
  Furosemide 40mg   
  Ibrufen 200mg   
903-260318-AA-326 Simvastatin 20mg Aspirin 100mg 7 12 
  Diazepam 2mg   
  Famotidine 20mg   
  Furosemide 40mg   
  Metformin 500mg   
  Alprazolam 0.5mg   
903-260318-AA-327 Bisoprolol 5mg Aspirin 100mg 8 12 
  Clopidogrel 75mg   
  Furosemide 40mg   
  Metformin 500mg   
  Alprazolam 0.5mg   
  Famotidine 20mg   
  Folic acid 1mg   
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Patient Ref. Target CVD 
Medication 
Other medications  Total 
number of 
medications 
No. of tablet 
taken per a 
day 
903-260318-AA-328 Simvastatin 20mg Aspirin 100mg 7 10 
  Clopidogrel 75mg   
  Furosemide 40mg   
  Gemfibrozil 600mg   
  Ibrufen 200mg   
  Famotidine    
903-260318-AA-329 Bisoprolol 5mg Aspirin 100mg 2 2 
903-260318-AA-330 Atorvastatin 40mg Aspirin 100mg 3 3 
  Omeprazole 20mg   
903-260318-AA-331 Atorvastatin 40mg Aspirin 100mg 2 2 
903-260318-AA-332 Lisinopril 20mg Aspirin 100mg 8 11 
  Clopidogrel 75mg   
  Furosemide 40mg   
  Gabapentin 300mg   
  Isosorbide 10mg   
  Paracetamol 500mg   
  Chlordiazepoxide  
5mg 
  
903-270318-AA-333 Bisoprolol 5mg Carbamazepine 
200mg 
7 9 
  Amiodaron 200mg   
  Aspirin 100mg   
  Lorazepam 2mg   
  Isosorbide 10mg   
  Paracetamol 500mg   
903-270318-AA-334 Simvastatin 40mg Amiodaron 200mg 6 7 
  Aspirin 100mg   
  Lorazepam 2mg   
  Isosorbide 10mg   
  Omeprazole 20mg   
903-270318-AA-335 Bisoprolol 5mg Amiodaron 200mg 8 11 
  Isosorbide 10mg   
  Paracetamol 500mg   
  Chlordiazepoxide 5mg   
  Aspirin 100mg   
  Lorazepam 2mg   
  Omeprazole 20mg   
903-270318-AA-336 Simvastatin 40mg Aspirin 100mg 6 6 
  Metformin 500mg   
  Clopidogrel 75mg   
  Lorazepam 2mg   
  Diclofenac 50mg   
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Appendix 10. Collection Protocol for DBS and VAMS Samples. 
1. Provide volunteer participant information leaflet, consent form and adherence questionnaire 
before sample collection. 
2. The researcher should prepare the lab for sample collection by covering lab bench with tissue 
roll paper. 
3. Wear safety spectacles, a laboratory coat, and disposable gloves. 
4. Welcome volunteer and introduce yourself and be ready to answer volunteer’s questions.  
5. Ask the patient if he/she has read the patient information leaflet. After reading this Participant 
Information Leaflet, volunteer will be asked to sign two copies of the consent form and to 
complete a short questionnaire prior to giving a blood spot sample. One copy of the signed consent 
form is given to volunteer before leaving the lab. 
6. Put the volunteer reference number on two copies of the consent form, the 'mini-questionnaire’ 
and the DBS sample collecting card and resealable bag using the following format: 903-date-
initials of the person taking sample-sample number starting 01 (903-ddmmyy-XX-01) where XX 
is the initials of the person taking the sample.  
7. Ask volunteer to warm their finger by gentle rubbing to increase the blood flow. 
8. Clean the site with an alcohol pad and allow the site to dry. 
9. The sampling should be carried out in a clean tray.  
  10. Lance the sample site and wipe away the first blood drop with sterile gauze.  
11. If the volunteer is not bleeding well, ask them to gently apply intermittent pressure near the 
puncture site to increase the blood flow. 
12. Allow blood to accumulate on the finger or thumb tip and drop onto the sampling card in the 
circled area. The blood drop(s) should fall freely to the sampling card. 
13. Apply the accumulated blood on the finger or the thumb tip to the circled area on the sampling 
card. 
14. Avoid touching the sampling site on the card and do not spread/smear/smudge blood to cover 
the circled area. The sample in such cases is considered as invalid. 
15. Allow multiple drops to fall on the same circled area until the area is fully covered and soaked. 
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16. After covering the circled area with a blood sample, start filling the next area. At least two 
circles must be filled for each volunteer. Overspotting and layering sample is invalid, and the 
sample should be excluded. 
17. After collecting sample, put the sampling card on the drying rack and leave to dry at room 
temperature for at least 2-3 hours. This should be done immediately to prevent 
contamination. Sample cards should be kept apart from each other and away from heat. 
 
18. If the volunteer bleeds well, label a Mitra sampler and package with the volunteer number in 
the following format: Mitra-ddmmyy-XX-01. Start numbering with 01 and then number 
consecutively. 
19. Remove the Mitra sampling device by opening the sealed pack and remove the clamshell 
package. Pull apart the clamshell and open the sides to form a handle. 
20. Apply sampler tip to drop of blood at an angle.  
21. Wait till the tip goes fully red then count 2 additional seconds. 
22. Remove the tip slowly.  
23. Complete sampling of at least two tips.  
24. Refold clamshell to cover tips and press close and label with volunteer reference number. 
25. Supply patient with a gauze and plaster.  
26. After drying, sampling cards and Mitra devices must be stored in individual plastic re-sealable 
bags.  
27. Label resealable bag with volunteer reference number and date. 
28. These are ready to be sent to the analytical laboratory with the completed consent form and 
short questionnaire. 
29. Record information in a record book and keep it in a secure place. This information includes 
volunteer reference number, date of collection, number of spots on each card and comments.  
30. Disposal of the lancet, gauze and alcohol pads should be via the clinical waste bin in the 
locally approved manner. 
31. Change gloves before taking sample from each new volunteer.  
32. If there is a spillage on the tray you should clean it with proper laboratory disinfectant.   
33. After completing sample collection, remove and dispose of gloves and take off lab coat and 
safety spectacles and wash your hands. 
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Appendix 11. The Standard Operation Procedure (SOP) for Preparation of 
Multicomponent Cardiovascular Medications in DBS 
1. Introduction 
The aim of this document is to prepare a protocol for the preparation of calibration and 
quality control standards for 9 selected cardiovascular medications and internal standard 
(Atenolol d7) in human whole blood. The target medications are Amlodipine Besylate 
salt, Atenolol, Atorvastatin Calcium salt, Bisoprolol Hemifumarate salt, Diltiazem 
Hydrochloride, Lisinopril, Losartan Potassium salt, Simvastatin, Valsartan and Atenolol-
d7 (internal standard). Concentration range of QC in whole blood for the selected 
cardiovascular drugs in the previously validated method are summarized in Table 1 
Table 1. Concentration range of the calibration and quality control standard in whole blood for the 
target medications  
Drug 
  
Calibration 
range ng/ml 
Calibration standards (ng/ml) 
    LOW     MED   HIGH 
Amlodipine 0.5-100  0.5 1 5 10 25 50 100 
Atenolol 10-1500 10 20 50 100 200 500 1000 1500 
Atorvastatin 0.5-100  0.5 1 5 10 25 50 100 
Bisoprolol 0.1-100 0.1 0.5 1 5 10 25 50 100 
Diltiazem   0.5-600 0.5 1 5 10 50 100 300 600 
Lisinopril 0.1-100 0.1 0.5 1 5 10 25 50 100 
Losartan 5-1000 5 10 25 50 100 250 500 1000 
Simvastatin 0.1-100 0.1 0.5 1 5 10 25 50 100 
Valsartan 50-4000 50 100 250 500 1000 2000 3000 4000 
 
2. Safety 
To prepare the QC standards, personal protective equipment must be worn as per the 
appropriate risk assessment and completed COSHH for each drug. Laboratory coat and 
disposable gloves must be worn. Hands should be washed and disinfected before and after 
handling blood samples. Care must be taken in case of any cut on the hands by covering 
the cut by waterproof dressing or plasters. Spillage should be cleaned by a suitable 
disinfectant and disposable paper towels. Lab benches should be wiped by a suitable 
disinfectant after each work session. 
 
 248 | P a g e 
 
3. Blood samples storage  
Blood samples in specimen tubes should be stored in number or code labelled re-sealable 
polythene bags in refrigerator in lab HB 00. 15. 
4. Disposal 
Discarded blood spots sampling paper and any contaminated materials used to clean 
spillages in the clinical waste bag (yellow plastic bag). Discarded specimens in micro-
centrifuge tubes, Specimen tubes and contaminated pipets tips and LC vial should be put 
into the clinical waste bags. Sharp contaminated materials such as needles should be 
disposed in the yellow rigid walled container.  
5. Equipment 
Analytical balance, volumetric pipets, Eppendorf tubes, volumetric flasks, 903 DBS cards 
and volumetric absorptive microsampling (VAMS) device. 
 
6. Materials 
Amlodipine besylate salt, atenolol, atorvastatin calcium salt, bisoprolol hemifumarate 
salt, diltiazem hydrochloride, lisinopril, losartan Potassium salt, simvastatin, valsartan, 
atenolol- D7 (Internal Standard), acetonitrile (LC-MS grade), methanol (LC-MS grade), 
and water (LC-MS grade). 
7. Preparation of diluent (70:30 MeOH: H2O v/v) 
To prepare 500 ml of diluent, transfer 350 ml of methanol in a 500 ml measuring cylinder 
and add LC-MS grade water to 500 ml. Transfer into 500 ml plain glass bottle and shake 
it well. Label the bottle with the date and dilution ratio.  
8. Preparation of standard stock solutions of the target medications  
Weigh 5 mg of amlodipine, atenolol, atorvastatin, bisoprolol, diltiazem, lisinopril, 
losartan, simvastatin and valsartan in 5 ml volumetric flask. Dissolve each drug in suitable 
volume of methanol to get 1 mg/ml for each medication see Table 2.  
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Table 2. Preparation of stock solution of the 9 target medications 
Drugs Weight in mg Volume of 100% MeOH (ml) Concentration mg/ml 
Amlodipine  5 5 1 
Atenolol 5 5 1 
Atorvastatin 5 5 1 
Bisoprolol 5 5 1 
Diltiazem 5 5 1 
Lisinopril 5 5 1 
Losartan 5 5 1 
Simvastatin 5 5 1 
Valsartan 5 5 1 
 
9. Preparation of intermediate stock solution with concentration 10000 ng /ml 
Intermediate stock solutions of the target medications amlodipine, bisoprolol, diltiazem, 
lisinopril, atorvastatin, and simvastatin were prepared by Pipetting 100 μl of the 1 mg/ml 
standard stock solution of drug into a 10 ml volumetric flask and dilute with 70:30 MeOH: 
H2O, v/v to the mark. Shake well and keep solution refrigerated. 
10. Preparation of Internal Standard stock solution (Atenolol- d7 10000 ng/ml)   
Weigh 0.4 mg of Atenolol d7 and dissolve it 400 µl methanol shake well to get 1 µg/µL 
primary stock of atenolol-D7. The stock solution was diluted to 10,000 ng/mL. Further 
dilution was with methanol/water (70:30, v/v) to produce internal standard (atenolol-D7) 
concentration of 20 ng/ml and keep solution refrigerated. 
11. Preparation of extraction solvent with 20ng/ml concentration of internal 
standard (Atenolol d7) 
Pipette 20 µl of the 10,000 ng/ml stock solution of (atenolol d7) into a 10 ml volumetric 
flask and make to the mark with 70:30 MeOH: H20, v/v. Shake well and keep solution 
refrigerated. 
12. Preparation of multicomponent solution for the target medications  
Tables 3-11 shows the final concentration of medications in solutions.  
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Table 3. Final concentration of amlodipine in solution 
 Amlodipine 
concentration 
(ng/ml) 
Volume of 10000 
ng/ml 
stock required(µl) 
Total volume 
(ml) 
Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 
Table 4. Final concentration of atenolol in solution 
 Atenolol 
concentration (ng/ml) 
Volume of 1 mg/ml 
stock required (µl) 
Total volume (ml) 
Solution 1 100 1 10 
Solution 2 200 2 10 
Solution 3 500 5 10 
Solution 4 1000 10 10 
Solution 5 2000 10 5 
Solution 6 5000 25 5 
Solution 7 10000 50 5 
Solution 8 15000 75 5 
 
Table 5.  Final concentration of atorvastatin in solution 
 Atorvastatin 
concentration 
(ng/ml) 
Volume of 10000 
ng/ml stock required 
(µl) 
Total volume 
(ml) 
Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 
 
 
 
 
 
 
 251 | P a g e 
 
Table 6. Final concentration of bisoprolol in solution  
 Bisoprolol 
concentration 
(ng/ml) 
Volume of 10000 
ng/ml stock 
required(µl) 
Total volume 
(ml) 
Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 
Table 7. Final concentration of diltiazem in solution  
 Diltiazem 
concentration 
(ng/ml) 
Volume of 10000 
ng/ml stock 
required(µl) 
Total volume 
(ml) 
Solution 1 5 5 10 
Solution 2 10 10 10 
Solution 3 50 50 10 
Solution 4 100 100 10 
Solution 5 500 250 5 
Solution 6 1000 500 5 
Solution 7 3000 1500 5 
Solution 8 6000 3000 5 
 
Table 8. Final concentration of lisinopril in solution 
 Lisinopril 
concentration 
(ng/ml) 
Volume of 10000 
ng/ml 
stock required(µl) 
Total volume (ml) 
Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
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Table 9. Final concentration of losartan in solution  
 Losartan 
concentration (ng/ml) 
Volume of 10000 
ng/ml stock 
required (µL) 
Total volume (ml) 
Solution 1 50 50 10 
Solution 2 100 100 10 
Solution 3 250 250 10 
Solution 4 500 500 10 
Solution 5 1000 500 5 
Solution 6 2500 1250 5 
Solution 7 5000 2500 5 
Solution 8 10000 5000 5 
 
Table 10. Final concentration of simvastatin in solution  
 Simvastatin  
Concentration 
(ng/ml) 
Volume of 10000 
ng/ml 
stock required (µl) 
Total volume (ml) 
Solution 1 1 1 10 
Solution 2 5 5 10 
Solution 3 10 10 10 
Solution 4 50 50 10 
Solution 5 100 50 5 
Solution 6 250 125 5 
Solution 7 500 250 5 
Solution 8 1000 500 5 
 
Table 11. Final concentration of valsartan in solution 
 Valsartan 
concentration 
(ng/ml) 
Volume of 1mg/ml 
stock required(µl) 
Total volume (ml) 
Solution 1 500 5 10 
Solution 2 1000 10 10 
Solution 3 2500 25 10 
Solution 4 5000 50 10 
Solution 5 10000 50 5 
Solution 6 20000 100 5 
Solution 7 30000 150 5 
Solution 8 40000 200 5 
From Tables 3-11 there will be 8 multicomponent solutions (1, 2, 3, 4, 5, 6, 7, and 8). 
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12. Preparation of multicomponent calibration standards and quality control 
standards (QC) for the target medications in whole blood 
For each multicomponent solution (3-11) solutions, pipet 100 µl to an Eppendorf tube 
and add 900 µl of fresh human blood. Vortex for 1 min to produce the final calibration 
concentration in Tables 13-21. For blank samples pipettes 100 µl of extraction solvent 
containing 10 ng/ml internal standard and add 900 µl of blood and mix well by vortexing 
for 1 min. Table 12 – 20 show the final calibration concentrations of each target drug in 
whole blood. 
Table 12. Final QC concentration of Amlodipine in whole blood  
 Concentration of 
amlodipine standard 
solution (ng/ml) 
Volume of standard to be 
added to whole blood 
(µl) 
Final concentration of 
amlodipine in whole 
blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table 13. Final concentration of atenolol in whole blood 
 Concentration of atenolol 
standard solution (ng/ml) 
Volume of standard to be 
added to whole blood 
(µl) 
Final concentration of 
atenolol in whole 
blood (ng/ml) 
Standard A 100 100 10 
Standard B 200 100 20 
Standard C 500 100 50 
Standard D 1000 100 100 
Standard E 2000 100 200 
Standard F 5000 100 500 
Standard G 10000 100 1000 
Standard H 15000 100 1500 
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Table 14. Final concentration of atorvastatin in whole blood 
 Concentration of 
atorvastatin standard 
solution (ng/ml) 
Volume of standard to be 
added to whole blood 
(µl) 
Final concentration of 
atorvastatin in whole 
blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table 15. Final concentration of Bisoprolol in whole blood 
 Concentration of 
bisoprolol standard 
solution (ng/ml) 
Volume of standard to be 
added to whole blood 
(µl) 
Final concentration of 
bisoprolol in whole 
blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table 16. Final concentration of diltiazem in whole blood 
 Concentration of diltiazem 
standard solution (ng/ml) 
Volume of standard to be 
added to whole blood 
(µl) 
Final concentration of 
diltiazem in whole 
blood (ng/ml) 
Standard A 5 100 0.5 
Standard B 10 100 1 
Standard C 50 100 5 
Standard D 100 100 10 
Standard E 500 100 50 
Standard F 1000 100 100 
Standard G 3000 100 300 
Standard H 6000 100 600 
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Table 17. Final concentration of lisinopril in whole blood 
 Concentration of lisinopril 
standard solution (ng/ml) 
Volume of standard to be 
added to whole blood 
(µl) 
Final concentration of 
lisinopril in whole 
blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
 
Table 18. Final concentration of losartan in whole blood 
 Concentration of losartan 
standard solution (ng/ml) 
Volume of standard to be 
added to whole blood 
(µl) 
Final concentration of 
losartan in whole 
blood (ng/ml) 
Standard A 50 100 5 
Standard B 100 100 10 
Standard C 250 100 25 
Standard D 500 100 50 
Standard E 1000 100 100 
Standard F 2500 100 250 
Standard G 5000 100 500 
Standard H 10000 100 1000 
 
Table 19. Final concentration of simvastatin in whole blood 
 Concentration of 
simvastatin   standard 
solution (ng/ml) 
Volume of standard to be 
added to whole blood 
(µl) 
Final concentration of 
simvastatin in whole 
blood (ng/ml) 
Standard A 1 100 0.1 
Standard B 5 100 0.5 
Standard C 10 100 1 
Standard D 50 100 5 
Standard E 100 100 10 
Standard F 250 100 25 
Standard G 500 100 50 
Standard H 1000 100 100 
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Table 20. Final concentration of valsartan in whole blood 
 Concentration of valsartan   
standard solution (ng/ml) 
Volume of standard to be 
added to whole blood 
(µl) 
Final concentration of 
valsartan in whole 
blood (ng/ml) 
Standard A 500 100 50 
Standard B 1000 100 100 
Standard C 2500 100 250 
Standard D 5000 100 500 
Standard E 10000 100 1000 
Standard F 20000 100 2000 
Standard G 30000 100 3000 
Standard H 40000 100 4000 
From Tables 12 – 20 there will be 8 calibration standards in whole blood (A, B, C, D, E, 
F, G, H and the blank). Standard C, F and H are chosen to represent low, medium and 
high  
13. Spotting of blood target on DBS cards and VAMS 
Pipette 30 µl of blood from low, medium and high standards on Whatman 903 cards and 
left at least 2 hrs to dry at ambient temperature and after drying keep each card in coded 
labelled re-sealable polythene bags in a secure cabinet at lab 00.15. For VAMS dip the 
blank VAMS tips at angle of about 45 degrees into each blood standard (A, B, C, 
including blank sample. Wait for 2 second till the tip becomes fully red and then count 
for more two (2) seconds. This confirms that the VAMS substrate precisely samples 10 
μL of blood. Remove slowly remove tip from the microcentrifuge tube and close the 
clamshell.  
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Appendix 12. Side by Side LC-HRMS Representative (EICs) of an Extracted Blank 
Blood Sample (red) and a Calibration Standard at the LOQ Spiked with the Nine 
Target Drugs (black) and Atenolol-d7 (The Internal Standard) on 903 Sampling 
Paper and VAMS.  
      903 sampling paper (DBS)     VAMS 
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Appendix 13. Qualitative Analysis of Blood Microsamples on 903 Card and VAMS 
for the Cardiovascular Drugs Studied in Iraqi Volunteers 
Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-280716-AA-01 M Control DBS 
VAMS 
- 
903-280716-AA-02 F Control DBS 
VAMS 
- 
903-280716-AA-03 M Control DBS 
VAMS 
- 
903-280716-AA-04 F Control DBS 
VAMS 
- 
903-280716-AA-05 M Control DBS 
VAMS 
- 
903-280716-AA-06 F Lisinopril DBS YES 
903-310716-AA-07 M Simvastatin DBS NO 
903-310716-AA-08 F Atenolol DBS NO 
903-310716-AA-09 F Control DBS - 
903-310716-AA-10 M Bisoprolol DBS NO 
903-310716-AA-11 F Valsartan DBS NO 
903-310716-AA-12 F Valsartan DBS YES 
903-310716-AA-13 M Control DBS 
VAMS 
- 
903-310716-AA-14 M Atenolol DBS 
VAMS 
YES 
YES 
903-310716-AA-15 F Bisoprolol DBS YES 
903-010816-AA-16 F Valsartan DBS 
VAMS 
YES 
YES 
903-010816-AA-17 M Valsartan DBS 
VAMS 
YES 
YES 
Atorvastatin DBS 
VAMS 
NO 
NO 
903-010816-AA-18 F Control DBS 
VAMS 
- 
903-030816-AA-19 F Bisoprolol DBS 
VAMS 
NO 
NO 
903-030816-AA-20 M Simvastatin DBS NO 
903-030816-AA-21 F Diltiazem DBS 
VAMS 
NO 
NO 
903-030816-AA-22 M Control DBS 
VAMS 
- 
903-030816-AA-23 M Atenolol DBS YES 
903-030816-AA-24 F Valsartan DBS 
VAMS 
YES 
YES 
903-030816-AA-25 F Losartan DBS 
VAMS 
YES 
YES 
903-030816-AA-26 F Control DBS 
VAMS 
- 
903-030816-AA-27 F Bisoprolol DBS 
VAMS 
YES 
YES 
Losartan DBS 
VAMS 
YES 
YES 
903-030816-AA-28 F Control DBS 
VAMS 
- 
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 Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-030816-AA-29 M Control DBS 
VAMS 
- 
903-040816-AA-30 M Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
YES 
YES 
903-040816-AA-31 M Valsartan DBS 
VAMS 
NO 
NO 
903-040816-AA-32 F Lisinopril DBS 
VAMS 
YES 
YES 
903-040816-AA-33 M Losartan DBS 
VAMS 
NO 
NO 
903-050816-AA-34 M Atenolol DBS YES 
903-050816-AA-35 M Control DBS 
VAMS 
- 
903-050816-AA-36 F Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
NO 
NO 
903-050816-AA-37 M Atenolol DBS 
VAMS 
YES 
YES 
903-050816-AA-38 M Bisoprolol DBS YES 
Losartan DBS NO 
903-050816-AA-39 F Control DBS 
VAMS 
- 
903-050816-AA-40 F Atenolol DBS 
VAMS 
YES 
YES 
903-050816-AA-41 F Losartan DBS NO 
903-050816-AA-42 M Atenolol DBS YES 
903-050816-AA-43 F Control DBS 
VAMS 
- 
903-050816-AA-44 M Control DBS 
VAMS 
- 
903-060816-AA-45 M Atenolol DBS YES 
903-060816-AA-46 F Control DBS 
VAMS 
- 
903-060816-AA-47 M Control DBS 
VAMS 
- 
903-060816-AA-48 M Bisoprolol DBS YES 
  Valsartan DBS NO 
903-060816-AA-49 M Control DBS - 
903-060816-AA-50 M Losartan DBS YES 
903-060816-AA-51 M Atenolol DBS YES 
903-060816-AA-52 M Atenolol DBS YES 
903-060816-AA-53 M Atenolol DBS YES 
903-060816-AA-54 F Control DBS - 
903-070816-AA-55 F Losartan DBS YES 
  Atorvastatin DBS NO 
903-070816-AA-56 F Atorvastatin DBS NO 
  Lisinopril DBS NO 
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 Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-070816-AA-57 F Bisoprolol DBS YES 
Lisinopril DBS YES 
903-070816-AA-58 M Atenolol DBS YES 
Atorvastatin DBS NO 
903-070816-AA-59   F Atorvastatin DBS NO 
  Bisoprolol DBS NO 
903-070816-AA-60  Diltiazem DBS NO 
903-070816-AA-61 M Diltiazem DBS 
VAMS 
YES 
YES 
Losartan 
 
DBS 
VAMS 
NO 
NO 
Valsartan DBS 
VAMS 
NO 
NO 
903-070816-AA-62 M Atorvastatin DBS NO 
903-070816-AA-63 F Control DBS - 
903-070816-AA-64 M Atorvastatin DBS NO 
903-070816-AA-65 M Diltiazem DBS YES 
903-080816-AA-66 F Lisinopril DBS 
VAMS 
YES 
YES 
903-080816-AA-67 M Atenolol DBS 
VAMS 
YES 
YES 
903-080816-AA-68 M Valsartan DBS 
VAMS 
YES 
YES 
903-080816-AA-69 M Losartan DBS 
VAMS 
YES 
YES 
903-080816-AA-70 M Atorvastatin DBS 
VAMS 
YES 
YES 
Bisoprolol 
 
DBS 
VAMS 
YES 
YES 
903-080816-AA-71 F Control DBS 
VAMS 
- 
903-090816-AA-72 F Atorvastatin DBS NO 
Diltiazem DBS YES 
Valsartan DBS NO 
903-090816-AA-73 F Valsartan 
 
DBS 
VAMS 
NO 
NO 
903-090816-AA-74 M Valsartan 
 
DBS 
VAMS 
NO 
NO 
903-090816-AA-75 F Atorvastatin DBS 
VAMS 
NO 
NO 
906-090816-AA-76 M Diltiazem DBS 
VAMS 
YES 
YES 
903-090816-AA-77 M Lisinopril DBS 
VAMS 
YES 
YES 
903-090816-AA-78 M Valsartan DBS 
VAMS 
YES 
YES 
903-090816-AA-79 F Control DBS 
VAMS 
- 
903-100816-AA-80 M Valsartan DBS NO 
  
 263 | P a g e 
 
 Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-100816-AA-81 F Control DBS 
VAMS 
- 
903-100816-AA-82 M Atorvastatin DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
NO 
NO 
903-100816-AA-83 M Control DBS - 
903-100816-AA-84 M Valsartan DBS 
VAMS 
YES 
YES 
903-100816-AA-85 F Control DBS - 
903-100816-AA-86 F Diltiazem DBS 
VAMS 
YES 
YES 
903-100816-AA-87 F Bisoprolol DBS YES 
903-100816-AA-88 M Atorvastatin DBS NO 
903-100816-AA-89 F Valsartan DBS 
VAMS 
YES 
YES 
903-110816-AA-90 M Bisoprolol DBS YES 
903-120816-AA-91 M Bisoprolol DBS 
VAMS 
YES 
YES 
Lisinopril DBS 
VAMS 
YES 
YES 
903-120816-AA-92 F Control DBS - 
903-120816-AA-93 M Lisinopril DBS YES 
903-120816-AA-94 M Control DBS - 
903-150816-AA-95 M Bisoprolol DBS NO 
903-150816-AA-96 M Bisoprolol DBS YES 
903-150816-AA-97 M Control DBS 
VAMS 
- 
903-150816-AA-98 F Control DBS 
VAMS 
- 
903-150816-AA-99 F Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
NO 
NO 
903-270717-AA-100 M Atenolol DBS YES 
Simvastatin DBS YES 
903-270717-AA-101 M Atenolol DBS YES 
Simvastatin DBS YES 
903-270717-AA-102 M Atenolol DBS YES 
Simvastatin DBS YES 
903-200717-AA-103 M Atenolol DBS YES 
Simvastatin DBS YES 
     
903-200717-AA-104 M Atenolol DBS YES 
  Lisinopril DBS YES 
903-200717-AA-105 M Atenolol DBS YES 
  Lisinopril DBS YES 
903-200717-AA-106 M Atenolol DBS YES 
  Lisinopril DBS YES 
903-200717-AA-107 M Atenolol DBS YES 
  Lisinopril DBS NO 
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Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-200717-AA-108 M Bisoprolol DBS YES 
Lisinopril DBS NO 
903-200717-AA-109 M Bisoprolol DBS YES 
Lisinopril DBS NO 
903-200717-AA-110 M Bisoprolol DBS YES 
Lisinopril DBS YES 
903-200717-AA-111 M Bisoprolol DBS YES 
Lisinopril DBS YES 
903-200717-AA-112 M Bisoprolol DBS YES 
Valsartan DBS NO 
903-200717-AA-113 M Bisoprolol DBS 
VAMS 
YES 
YES 
  Valsartan DBS 
VAMS 
YES 
YES 
903-200717-AA-114 M Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
YES 
YES 
903-200717-AA-115 F Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
YES 
YES 
903-200717-AA-116 F Bisoprolol DBS YES 
Valsartan DBS NO 
903-200717-AA-117 F Diltiazem DBS YES 
Lisinopril DBS YES 
903-200717-AA-118 M Diltiazem DBS YES 
Lisinopril DBS YES 
903-200717-AA-119 M Diltiazem DBS 
VAMS 
YES 
YES 
Lisinopril DBS 
VAMS 
YES 
YES 
903-200717-AA-120 M Diltiazem 
 
DBS 
VAMS 
YES 
YES 
Lisinopril 
 
DBS 
VAMS 
NO 
NO 
903-210717-AA-121 M Losartan DBS YES 
Simvastatin DBS NO 
903-210717-AA-122 F Losartan DBS YES 
Simvastatin DBS NO 
903-210717-AA-123 M Losartan DBS 
VAMS 
YES 
YES 
Simvastatin DBS 
VAMS 
YES 
YES 
903-210717-AA-124 F Losartan DBS 
VAMS 
NO 
NO 
Simvastatin DBS 
VAMS 
NO 
NO 
903-210717-AA-125 F Amlodipine DBS YES 
903-210717-AA-126 M Amlodipine DBS YES 
903-210717-AA-127 F Amlodipine DBS 
VAMS 
YES 
YES 
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 Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-210717-AA-128 M Amlodipine DBS 
VAMS 
YES 
YES 
903-210717-AA-129 F Losartan DBS 
VAMS 
YES 
YES 
903-210717-AA-130 M Losartan DBS 
VAMS 
YES 
YES 
903-220717-AA-131 M Losartan DBS 
VAMS 
YES 
YES 
903-220717-AA-132 M Simvastatin DBS 
VAMS 
YES 
YES 
903-220717-AA-133 M Simvastatin DBS 
VAMS 
NO 
NO 
903-220717-AA-134 M Valsartan DBS NO 
903-220717-AA-135 M Valsartan DBS 
VAMS 
NO 
NO 
903-220717-AA-136 M Valsartan DBS 
VAMS 
YES 
YES 
903-220717-AA-137 F Valsartan DBS 
VAMS 
YES 
YES 
903-220717-AA-138 F Atenolol DBS YES 
Simvastatin DBS YES 
     
903-220717-AA-139 M Atenolol DBS YES 
Simvastatin DBS YES 
903-220717-AA-140 F Atenolol DBS YES 
Simvastatin DBS YES 
903-230717-AA-141 M Atenolol DBS YES 
Simvastatin DBS YES 
903-230717-AA-142 F Atenolol DBS YES 
Lisinopril DBS YES 
903-230717-AA-143 M Atenolol DBS YES 
Lisinopril DBS YES 
903-230717-AA-144 M Atenolol DBS YES 
Lisinopril DBS YES 
903-230717-AA-145 M Bisoprolol DBS YES 
Lisinopril DBS NO 
903-230717-AA-146 M Bisoprolol DBS YES 
Lisinopril DBS NO 
903-230717-AA-147 F Bisoprolol DBS YES 
Lisinopril DBS YES 
903-230717-AA-148 M Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
YES 
YES 
903-230717-AA-149 F Bisoprolol DBS YES 
Valsartan DBS YES 
903-230717-AA-150 F Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
YES 
YES 
 903-230717-AA-151 F Control DBS 
VAMS 
- 
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 Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-240717-AA-152 M Diltiazem DBS YES 
Lisinopril DBS YES 
903-240717-AA-153 M Diltiazem DBS YES 
Lisinopril DBS YES 
903-240717-AA-154 F Diltiazem 
 
DBS 
VAMS 
YES 
YES 
Lisinopril 
 
DBS 
VAMS 
YES 
YES 
903-240717-AA-155 F Diltiazem 
 
DBS 
VAMS 
YES 
YES 
Lisinopril 
 
DBS 
VAMS 
YES 
YES 
903-240717-AA-156 M Losartan DBS 
VAMS 
YES 
YES 
Simvastatin DBS 
VAMS 
YES 
YES 
903-240717-AA-157 F Losartan DBS NO 
Simvastatin DBS NO 
903-240717-AA-158 F Losartan DBS NO 
Simvastatin DBS NO 
903-240717-AA-159 F Losartan DBS 
VAMS 
NO 
NO 
Simvastatin DBS 
VAMS 
NO 
NO 
903-240717-AA-160 M Amlodipine DBS YES 
903-240717-AA-161 F Amlodipine DBS YES 
903-250717-AA-162 F Amlodipine DBS 
VAMS 
YES 
YES 
903-250717-AA-163 M Amlodipine DBS 
VAMS 
YES 
YES 
903-250717-AA-164 M Losartan DBS 
VAMS 
YES 
YES 
903-250717-AA-165 M Losartan DBS 
VAMS 
YES 
YES 
903-250717-AA-166 F Losartan DBS 
VAMS 
YES 
YES 
903-250717-AA-167 M Simvastatin DBS 
VAMS 
YES 
YES 
903-250717-AA-168 M Simvastatin DBS 
VAMS 
NO 
NO 
903-250717-AA-169 F Atenolol DBS YES 
Simvastatin DBS YES 
903-250717-AA-170 M Atenolol DBS YES 
Simvastatin DBS YES 
903-270717-AA-171 F Atenolol DBS YES 
Simvastatin DBS YES 
903-270717-AA-172 M Atenolol DBS YES 
Simvastatin DBS YES 
903-270717-AA-173 F Atenolol DBS YES 
Lisinopril DBS YES 
903-270717-AA-174 F Atenolol DBS YES 
Lisinopril DBS YES 
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Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-270717-AA-175 F Atenolol DBS YES 
Lisinopril DBS YES 
903-270717-AA-176 M Atenolol DBS YES 
  Lisinopril DBS YES 
903-270717-AA-177 F Bisoprolol DBS YES 
Lisinopril DBS NO 
903-270717-AA-178 M Bisoprolol DBS YES 
Lisinopril DBS YES 
903-270717-AA-179 M Control DBS - 
903-270717-AA-180 F Bisoprolol DBS YES 
Lisinopril DBS NO 
903-280717-AA-181 M Bisoprolol DBS YES 
Lisinopril DBS NO 
903-280717-AA-182 F Bisoprolol DBS YES 
Lisinopril DBS YES 
903-280717-AA-183 F Bisoprolol DBS YES 
Valsartan DBS YES 
903-280717-AA-184 M Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
YES 
YES 
903-280717-AA-185 M Bisoprolol DBS YES 
Valsartan DBS YES 
903-280717-AA-186 F Diltiazem DBS YES 
Lisinopril DBS NO 
903-280717-AA-187 M Diltiazem DBS YES 
Lisinopril DBS YES 
903-280717-AA-188 M Diltiazem 
 
DBS 
VAMS 
YES 
YES 
Lisinopril DBS 
VAMS 
YES 
YES 
903-280717-AA-189 F Diltiazem 
 
DBS 
VAMS 
YES 
YES 
Lisinopril DBS 
VAMS 
NO 
NO 
903-280717-AA-190 F Losartan DBS NO 
Simvastatin DBS NO 
903-290717-AA-191 F Losartan DBS 
VAMS 
YES 
YES 
Simvastatin DBS 
VAMS 
YES 
YES 
903-290717-AA-192 F Losartan DBS 
VAMS 
YES 
YES 
Simvastatin DBS 
VAMS 
YES 
YES 
903-290717-AA-193 F Losartan DBS 
VAMS 
NO 
NO 
Simvastatin DBS 
VAMS 
NO 
NO 
903-290717-AA-194 M Losartan DBS 
VAMS 
YES 
YES 
Simvastatin DBS 
VAMS 
YES 
YES 
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Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-290717-AA-195 M Amlodipine DBS NO 
903-290717-AA-196 M Amlodipine DBS 
VAMS 
NO 
NO 
903-290717-AA-197 M Amlodipine DBS 
VAMS 
YES 
YES 
903-290717-AA-198 M Amlodipine DBS 
VAMS 
NO 
NO 
903-290717-AA-199 F Losartan DBS 
VAMS 
YES 
YES 
903-290717-AA-200 M Losartan DBS 
VAMS 
YES 
YES 
903-300717-AA-201 M Losartan DBS 
VAMS 
YES 
YES 
903-300717-AA-202 M Simvastatin DBS 
VAMS 
NO 
NO 
903-300717-AA-203 M Control DBS - 
903-300717-AA-204 M Valsartan DBS 
VAMS 
NO 
NO 
903-300717-AA-205 M Valsartan DBS 
VAMS 
YES 
YES 
903-300717-AA-206 F Atenolol DBS YES 
Simvastatin DBS YES 
903-300717-AA-207 M Atenolol DBS YES 
Simvastatin DBS YES 
903-300717-AA-208 F Atenolol DBS YES 
Simvastatin DBS YES 
903-300717-AA-209 F Atenolol DBS YES 
Lisinopril DBS YES 
903-300717-AA-210 F Atenolol DBS YES 
Lisinopril DBS YES 
903-300717-AA-211 F Atenolol DBS YES 
Lisinopril DBS NO 
903-300717-AA-212 F Bisoprolol DBS YES 
Lisinopril DBS NO 
903-300717-AA-213 M Diltiazem DBS YES 
Lisinopril DBS YES 
903-300717-AA-214 M Bisoprolol DBS YES 
Lisinopril DBS YES 
903-030717-AA-215 M Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
YES 
YES 
903-030717-AA-216 F Bisoprolol DBS YES 
Valsartan DBS YES 
903-030717-AA-217 M Bisoprolol DBS YES 
Valsartan DBS NO 
903-300717-AA-218 F Diltiazem DBS YES 
Lisinopril DBS NO 
903-300717-AA-219 F Diltiazem DBS YES 
Lisinopril DBS YES 
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 Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-300717-AA-220 F Diltiazem 
 
DBS 
VAMS 
NO 
NO 
Lisinopril DBS 
VAMS 
NO 
NO 
903-310717-AA-221 F Losartan DBS 
VAMS 
NO 
NO 
Simvastatin DBS 
VAMS 
NO 
NO 
903-310717-AA-222 M Amlodipine DBS YES 
903-310717-AA-223 F Losartan DBS 
VAMS 
YES 
YES 
903-310717-AA-224 F Valsartan DBS NO 
903-310717-AA-225 M Valsartan DBS 
VAMS 
YES 
903-310717-AA-226 F Atenolol DBS YES 
Simvastatin DBS YES 
903-310717-AA-227 F Atenolol DBS YES 
Simvastatin DBS YES 
903-310717-AA-228 F Atenolol DBS YES 
Lisinopril DBS YES 
903-310717-AA-229 F Atenolol DBS YES 
Lisinopril DBS YES 
903-310717-AA-230 M Bisoprolol DBS YES 
Lisinopril DBS NO 
903-010817-AA-231 M Bisoprolol DBS YES 
Lisinopril DBS NO 
903-010817-AA-232 M Bisoprolol DBS YES 
Lisinopril DBS YES 
903-010817-AA-233 F Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
YES 
YES 
903-010817-AA-234 F Bisoprolol DBS 
VAMS 
YES 
YES 
Valsartan DBS 
VAMS 
YES 
YES 
903-010817-AA-235 F Bisoprolol DBS YES 
Valsartan DBS NO 
903-010817-AA-236 F Diltiazem DBS NO 
Lisinopril DBS NO 
903-010817-AA-237 F Diltiazem DBS NO 
Lisinopril DBS NO 
903-010817-AA-238 F Diltiazem 
 
DBS 
VAMS 
NO 
NO 
Lisinopril DBS 
VAMS 
NO 
NO 
903-010817-AA-239 M Losartan DBS 
VAMS 
NO 
NO 
Simvastatin DBS 
VAMS 
NO 
NO 
903-010817-AA-240 M Amlodipine DBS 
VAMS 
NO 
NO 
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Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-020817-AA-241 M Valsartan DBS 
VAMS 
NO 
NO 
903-020817-AA-242 M Valsartan DBS 
VAMS 
NO 
NO 
903-020817-AA-243 M Valsartan DBS 
VAMS 
YES 
YES 
903-020817-AA-244 F Atenolol DBS YES 
Lisinopril DBS YES 
903-020817-AA-245 F Atenolol DBS YES 
Lisinopril DBS YES 
903-020817-AA-246 M Bisoprolol DBS YES 
Lisinopril DBS YES 
903-020817-AA-247 F Diltiazem 
 
DBS 
VAMS 
NO 
NO 
Lisinopril DBS 
VAMS 
NO 
NO 
903-020817-AA-248 F Diltiazem 
 
DBS 
VAMS 
NO 
NO 
Lisinopril DBS 
VAMS 
NO 
NO 
903-020817-AA-249 F Losartan DBS 
VAMS 
NO 
NO 
Simvastatin DBS 
VAMS 
NO 
NO 
903-020817-AA-250 F Losartan DBS 
VAMS 
NO 
NO 
Simvastatin DBS 
VAMS 
NO 
NO 
903-030817-AA-251 F Losartan DBS 
VAMS 
NO 
NO 
Simvastatin DBS 
VAMS 
NO 
NO 
903-030817-AA-252 
 
F Amlodipine DBS 
VAMS 
NO 
NO 
903-030817-AA-253 M Valsartan DBS 
VAMS 
NO 
NO 
 903-030817-AA-254 F Valsartan DBS 
VAMS 
YES 
YES 
903-030817-AA-255 F Valsartan DBS 
VAMS 
YES 
YES 
903-030817-AA-256 F Atenolol DBS YES 
Lisinopril DBS YES 
903-030817-AA-257 F Atenolol DBS YES 
Lisinopril DBS YES 
903-030817-AA-258 M Atenolol DBS YES 
Lisinopril DBS YES 
903-030817-AA-259 F Bisoprolol DBS YES 
Lisinopril DBS YES 
903-030817-AA-260 F Bisoprolol DBS YES 
Lisinopril DBS YES 
903-030817-AA-261 M Bisoprolol DBS YES 
Valsartan DBS NO 
903-040817-AA-262 M Bisoprolol DBS YES 
Valsartan DBS NO 
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 Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-040817-AA-263 M Valsartan DBS NO 
903-040817-AA-264 M Atenolol DBS NO 
903-040817-AA-265 M Losartan DBS NO 
903-040817-AA-266 M Valsartan DBS NO 
903-040817-AA-267 F Diltiazem DBS NO 
903-040817-AA-268 F Bisoprolol DBS NO 
903-040817-AA-269 F Diltiazem DBS NO 
903-040817-AA-270 F Atenolol DBS NO 
903-050817-AA-271 F Losartan DBS NO 
903-050817-AA-272 M Bisoprolol DBS NO 
903-050817-AA-273 F Valsartan DBS NO 
903-050817-AA-274 M Atenolol DBS NO 
903-050817-AA-275 F Losartan DBS NO 
903-050817-AA-276 F Valsartan DBS NO 
903-050817-AA-277 F Diltiazem DBS NO 
903-050817-AA-278 F Bisoprolol DBS NO 
903-050817-AA-279 F Losartan DBS NO 
903-050817-AA-280 F Valsartan DBS NO 
903-100817-AA-281 F Bisoprolol DBS NO 
903-100817-AA-282 F Diltiazem DBS NO 
903-100817-AA-283 M Atenolol DBS NO 
903-100817-AA-284 F Bisoprolol DBS NO 
903-100817-AA-285 F Diltiazem DBS NO 
903-100817-AA-286 F Valsartan DBS NO 
903-100817-AA-287 F Atenolol DBS NO 
903-100817-AA-288 F Losartan DBS NO 
903-100817-AA-289 F Diltiazem DBS NO 
903-100817-AA-290 F Bisoprolol DBS NO 
903-210318-AA-291 M Atorvastatin DBS YES 
903-210318-AA-292 M Valsartan DBS YES 
903-210318-AA-293 F Bisoprolol DBS YES 
903-210318-AA-294 M Lisinopril DBS NO 
903-210318-AA-295 F Losartan DBS NO 
903-210318-AA-296 M Atenolol DBS NO 
903-210318-AA-297 M Bisoprolol DBS YES 
903-210318-AA-298 F Bisoprolol DBS YES 
903-210318-AA-299 M Losartan DBS NO 
903-240318-AA-300 F Bisoprolol DBS NO 
903-240318-AA-301 F Atorvastatin DBS YES 
903-240318-AA-302 F Valsartan DBS YES 
903-240318-AA-303 F Bisoprolol DBS YES 
903-240318-AA-304 M Bisoprolol DBS NO 
903-240318-AA-305 F Losartan DBS NO 
903-240318-AA-306 M Bisoprolol DBS NO 
903-250318-AA-307 F Atenolol DBS NO 
903-250318-AA-308 F Losartan DBS NO 
903-250318-AA-309 M Valsartan DBS NO 
903-250318-AA-310 F Atenolol DBS NO 
903-250318-AA-311 F Atorvastatin DBS YES 
903-260318-AA-312 F Valsartan DBS YES 
903-260318-AA-313 F Lisinopril DBS NO 
903-260318-AA-314 M Simvastatin DBS NO 
903-260318-AA-315 F Bisoprolol DBS NO 
903-260318-AA-316 M Bisoprolol DBS NO 
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 Patients Ref. Sex CVD medication Sampling device (YES) Detected/ (NO) 
non-detected  
903-260318-AA-317 M Losartan DBS NO 
903-260318-AA-318 F Valsartan DBS NO 
903-260318-AA-319 F Bisoprolol DBS NO 
903-260318-AA-320 F Atorvastatin DBS YES 
903-260318-AA-321 M Valsartan DBS YES 
903-260318-AA-322 F Bisoprolol DBS NO 
903-260318-AA-323 F Simvastatin DBS NO 
903-260318-AA-324 M Simvastatin DBS NO 
903-260318-AA-325 F Simvastatin DBS NO 
903-260318-AA-326 F Simvastatin DBS NO 
903-260318-AA-327 M Bisoprolol DBS NO 
903-260318-AA-328 F Simvastatin DBS NO 
903-260318-AA-329 F Bisoprolol DBS YES 
903-260318-AA-330 F Atorvastatin DBS YES 
903-260318-AA-331 M Atorvastatin DBS YES 
903-260318-AA-332 F Lisinopril DBS NO 
903-270318-AA-333 M Bisoprolol DBS NO 
903-270318-AA-334 F Simvastatin DBS NO 
903-270318-AA-335 F Bisoprolol DBS NO 
903-270318-AA-336 M Simvastatin DBS NO 
Abbreviation: M: Male; F: Female. 
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Appendix 14. Drug Concentrations on 903 Cards and VAMS of the Cardiovascular Drugs Studied in Iraqi Samples from Patients Prescribed 
One or More of the CVD Drugs Under Consideration 
Patients Ref. Sex CVD 
medication 
Dose 
(mg) 
Sampling 
device 
Concentration 
(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
Cmax (ng/ml) tmax 
(h) 
Total 
number of 
medications 
Total 
number of 
tablets per 
day 
Adherence 
results  
903-280716-AA-01 M Control - DBS 
VAMS 
- - - - - - - 
903-280716-AA-02 F Control - DBS 
VAMS 
- - - - - - - 
903-280716-AA-03 M Control - DBS 
VAMS 
- - - - - - - 
903-280716-AA-04 F Control - DBS 
VAMS 
- - - - - - - 
903-280716-AA-05 M Control - DBS 
VAMS 
- - - - - - - 
903-280716-AA-06 F Lisinopril 10 mg DBS 32.87± 4.80 3 41.75-80.47 5.79-6.91 1 1 YES 
903-310716-AA-07 M Simvastatin 20 mg DBS ˂LLOQ 10 4.88-5.86 1.98-2.52 3 3 NO 
903-310716-AA-08 F Atenolol 50 mg DBS ˂LLOQ 36 159-377 1.5-6 8 13 NO 
903-310716-AA-09 F Control - DBS - - - - - -  
903-310716-AA-10 M Bisoprolol 10 mg DBS ˂LLOQ 48 37-87 1.5-4 8 11 NO 
903-310716-AA-11 F Valsartan 80 mg DBS ˂LLOQ 240 1010-2270 2 8 11 NO 
903-310716-AA-12 F Valsartan 160 mg DBS 2000.57± 10.33 5 1930-4000 1.5-3 1 1 YES 
903-310716-AA-13 M Control - DBS 
VAMS 
- - - - - - - 
903-310716-AA-14 M Atenolol 100 mg 
 
DBS 
VAMS 
204.87±2.09 
206.22±1.55 
5 240-1370 2-4 2 2 YES 
903-310716-AA-15 F Bisoprolol 5 mg DBS 11.28± 0.69 
12.87± 0.66 
10 16.64-26.9 1.2-3 2 2 YES 
903-010816-AA-16 F Valsartan 80 mg DBS 
VAMS 
147± 3.35 
160.21± 2.95 
12 1010-2270 1.5-3 1 1 YES 
903-010816-AA-17 M Valsartan 80 mg DBS 
VAMS 
655.34± 2.22 
655.52± 2.10 
12 1010-2270 2 8 6 YES 
Atorvastatin 40 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
48 5.53-28.57 0.38-1.37 NO 
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Patients Ref. Sex CVD 
medication 
Dose 
(mg) 
Sampling 
device 
Concentration 
(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
Cmax (ng/ml) tmax 
(h) 
Total 
number of 
medications 
Total 
number of 
tablets per 
day 
Adherence 
results  
903-010816-AA-18 F Control - DBS 
VAMS 
- - - - - - - 
903-030816-AA-19 F Bisoprolol 5 mg DBS 
VAMS 
˂LLOQ 27 16.64-26.9 1.2-3 8 11 NO 
903-030816-AA-20 M Simvastatin 20 mg DBS ˂LLOQ 12 4.88-5.86 1.98-2.52 5 6 NO 
903-030816-AA-21 F Diltiazem 90 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
72 105.65-150.87 10.05-12.25 7 11 NO 
903-030816-AA-22 M Control  DBS 
VAMS 
- - - - - - - 
903-030816-AA-23 M Atenolol 50 mg DBS 900.06±22.75 9 159-377 1.5-6 8 11 NO 
(˃CMAX) 
903-030816-AA-24 F Valsartan 80 mg DBS 
VAMS 
1231.40± 0.88 
1232.33± 0.55 
4 1010-2270 2 1 1 YES 
903-030816-AA-25 F Losartan 25 mg DBS 
VAMS 
19.04± 3.66 
19.27± 2.50 
10.5 43.6-125.4 0.5-1.1 2 3 YES 
903-030816-AA-26 F Control - DBS 
VAMS 
- - - - - - - 
903-030816-AA-27 F Bisoprolol 5 mg DBS 
VAMS 
15.96±3.12 
15.5±2.24 
13 16.64-26.9 1.2-3 2 2 YES 
Losartan 100 mg DBS 
VAMS 
120.30± 1.60 
120.31± 1.30 
13 
 
263.67-783.41 
 
0.54-1.88 
 
YES 
 
903-030816-AA-28 F Control - DBS 
VAMS 
- - - - - - - 
903-030816-AA-29 M Control - DBS 
VAMS 
- - - - - - - 
903-040816-AA-30 M Bisoprolol 5 mg DBS 
VAMS 
23.60± 4.82 
23.90± 3.75 
3 16.64-26.9 1.2-3 2 2 YES 
Valsartan 80 mg DBS 
VAMS 
277.13± 2.27 
277.12± 2.15 
3 1010-2270 2 YES 
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Patients Ref. Sex CVD 
medication 
Dose 
(mg) 
Sampling 
device 
Concentration 
(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
Cmax (ng/ml) tmax 
(h) 
Total 
number of 
medications 
Total 
number of 
tablets per 
day 
Adherence 
results  
903-040816-AA-31 M Valsartan 80 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
20 1010-2270 2 5 8 NO 
903-040816-AA-32 F Lisinopril 10 mg DBS 
VAMS 
55.65± 5.92 
55.68± 4.65 
8 41.75-80.47 5.79-6.91 2 2 YES 
903-040816-AA-33 M Losartan 25 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
48 43.6-125.4 0.5-1.1 8 9 NO 
903-050816-AA-34 M Atenolol 50 mg DBS 211.04±21.64 6 159-377 1.5-6 2 2 YES 
903-050816-AA-35 M Control - DBS 
VAMS 
- - - - - - - 
903-050816-AA-36 F Bisoprolol 5 mg DBS 
VAMS 
6.74± 0.702 
5.83± 0.66 
3 16.64-26.9 1.2-3 5 7 YES 
Valsartan 160 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
32 1930-4000 1.5-3  NO 
903-050816-AA-37 M Atenolol 50 mg DBS 
VAMS 
86.11±2.05 
85.9±2.02 
11 159-377 1.5-6 3 3 YES 
903-050816-AA-38 M Bisoprolol 5 mg   DBS 11.90± 0.67 15 16.64-26.9 1.2-3 5 7 YES 
Losartan 50 mg DBS ˂LLOQ 15 89.1-306.1 0.5-2.2 NO 
903-050816-AA-39 F Control  DBS 
VAMS 
- - - - - - - 
903-050816-AA-40 F Atenolol 50 mg DBS 
VAMS 
82.91±5.77 
82.7±5.67 
20 159-377 1.5-6 1 1 YES 
903-050816-AA-41 F Losartan 25 mg DBS ˂LLOQ 51 43.6-125.4 0.5-1.1 1 1 NO 
903-050816-AA-42 M Atenolol 50 mg DBS 159.25±18.26 3.5 159-377 1.5-6 2 2 YES 
903-050816-AA-43 F Control - DBS 
VAMS 
- - - - - - - 
903-050816-AA-44 M Control - DBS 
VAMS 
- - - - - - - 
903-060816-AA-45 M Atenolol 50 mg DBS 
VAMS 
639.18±17.9 
639.4±17.85 
10 159-377 1.5-6 4 6 NO 
(˃CMAX) 
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Patients Ref. Sex CVD 
medication 
Dose 
(mg) 
Sampling 
device 
Concentration 
(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
Cmax (ng/ml) tmax 
(h) 
Total 
number of 
medications 
Total 
number of 
tablets per 
day 
Adherence 
results  
903-060816-AA-46 F Control - DBS 
VAMS 
- - - - - - - 
903-060816-AA-47 M Control - DBS 
VAMS 
- - - - - - - 
903-060816-AA-48 M Bisoprolol 5 mg DBS 
VAMS 
5.13± 0.20 
5.29± 0.17 
21 16.64-26.9 1.2-3 8 12 YES 
 Valsartan 80 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
36 1010-2270 2  NO 
903-060816-AA-49 M Control  DBS - - - - - - - 
903-060816-AA-50 M Losartan 100 mg DBS 37.68± 1.10 12 263.67-783.41 0.54-1.88 2 2 YES 
903-060816-AA-51 M Atenolol 100 mg DBS 706.98± 20.46 10 240-1370 2-4 4 5 YES 
903-060816-AA-52 M Atenolol 50 mg DBS 
VAMS 
81.89± 0.69 
82.3± 0.62 
8 159-377 1.5-6 4 6 YES 
903-060816-AA-53 M Atenolol 100 mg DBS 
VAMS 
1524.11±10.53 
1525.3±10.44 
13 240-1370 2-4 5 8 NO 
(˃CMAX) 
903-060816-AA-54 F Control - DBS - - - - - - - 
903-070816-AA-55 F Losartan 100 mg DBS 297.80± 1.98 2 263.67-783.41 0.54-1.88 5 7 YES 
Atorvastatin 40 mg DBS ˂LLOQ 12 5.53-28.57 0.38-1.37 NO 
903-070816-AA-56 F Atorvastatin 40 mg DBS ˂LLOQ 12.5 5.53-28.57 0.38-1.37 3 4 NO 
Lisinopril 10 mg DBS ˂LLOQ 23.5 41.75-80.47 5.79-6.91 NO 
903-070816-AA-57 F Bisoprolol 5 mg DBS 14.86± 1.30 2.5 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 34.33± 6.55 2.5 41.75-80.47 5.79-6.91 YES 
903-070816-AA-58 M Atenolol 50 mg DBS 491.15± 33.77 15 159-377 1.5-6 8 12 NO 
(˃CMAX) 
Atorvastatin 40 mg DBS ˂LLOQ 15 5.53-28.57 0.38-1.37 NO 
903-070816-AA-59 F Atorvastatin 
  
40 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
76 5.53-28.57 0.38-1.37 7 9 NO 
Bisoprolol        
   
5 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
76 16.64-26.9 1.2-3 NO 
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Patients Ref. Sex CVD 
medication 
Dose 
(mg)  
Sampling 
device 
Concentration 
(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
Cmax (ng/ml) tmax 
(h) 
Total 
number of 
medications 
Total 
number of 
tablets per 
day 
Adherence 
results  
903-070816-AA-60 F Diltiazem 90 mg DBS ˂LLOQ 38 105.65-150.87 10.05-
12.25 
8 11 NO 
903-070816-AA-61 M Diltiazem 60 mg DBS 
VAMS 
25.17± 0.57 
25.66± 0.32 
1 74.72-82.38 2.23-2.49 8 10 YES 
Losartan 
       
50 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
13 89.1-306.1 0.5-2.2 NO 
Valsartan 160 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
72 1930-4000 1.5-3 NO 
903-070816-AA-62 M Atorvastatin 40 mg DBS ˂LLOQ 48 5.53-28.57 0.38-1.37 5 6 NO 
903-070816-AA-63 F Control - DBS - - - - - - - 
903-070816-AA-64 M Atorvastatin 40 mg DBS ˂LLOQ 25.5 5.53-28.57 0.38-1.37 8 12 NO 
903-070816-AA-65 M Diltiazem 60 mg DBS 38.22± 2.58 7.5 74.72-82.43 2.23-2.49 2 2 YES 
903-080816-AA-66 F Lisinopril 10 mg DBS 
VAMS 
38.61±6.30 
39.48±5.27 
13 41.75-80.47 5.79-6.91 1 1 YES 
903-080816-AA-67 M Atenolol 100 mg DBS 
VAMS 
1276.61±23.27 
1274.8±21.88 
10 240-1370 2-4 1 1 YES 
903-080816-AA-68 M Valsartan 80 mg DBS 
VAMS 
115.93±2.12 
114.43±2.11 
11 1010-2270 2 4 5 YES 
903-080816-AA-69 M Losartan 50 mg DBS 
VAMS 
37.66±1.40 
37.93±1.55 
8 89.1-306.1 0.5-2.2 2 3 YES 
903-080816-AA-70 M Atorvastatin 40 mg DBS 
VAMS 
14.04±4.13 
15.63±3.12 
12 5.53-28.57 0.38-1.37 1 1 YES 
Bisoprolol           
       
5 mg DBS 
VAMS 
24.72±3.15 
24.70±3.10 
2 16.64-26.9 1.2-3 YES 
903-080816-AA-71 F Control - DBS 
VAMS 
- - - - - - - 
903-090816-AA-72 F Atorvastatin       40 mg DBS ˂LLOQ 32 5.53-28.57 0.38-1.37 3 3 NO 
Diltiazem           60 mg DBS 51.56±2.20 8.5 74.72-82.43 2.23-2.49 YES 
Valsartan           160 mg DBS ˂LLOQ 22.5 1930-4000 1.5-3 NO 
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Patients Ref. Sex CVD 
medication 
Dose 
(mg) 
Sampling 
device 
Concentration 
(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
Cmax (ng/ml) tmax 
(h) 
Total 
number of 
medications 
Total 
number of 
tablets per 
day 
Adherence 
results  
903-090816-AA-73 F Valsartan           
      
80 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
7.5 1010-4501 1.55-2.2 3 4 NO 
903-090816-AA-74 M Valsartan           
       
80 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
11 1010-2270 2 7 12 NO 
903-090816-AA-75 F Atorvastatin        40 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
27.5 5.53-28.57 0.38-1.37 4 4 NO 
906-090816-AA-76 M Diltiazem 90 mg DBS 
VAMS 
87.26±3.43 
87.42±2.39 
11 105.65-150.87 10.05-12.25 1 1 YES 
903-090816-AA-77 M Lisinopril 10 mg DBS 
VAMS 
33.30±2.87 
32.71±2.75 
10 41.75-80.47 5.79-6.91 3 4 YES 
903-090816-AA-78 M Valsartan 160 mg DBS 
VAMS 
225.22±4.82 
226.80±4.77 
6 1930-4000 1.5-3 2 2 YES 
903-090816-AA-79 F Control - DBS 
VAMS 
- - - - - - - 
903-100816-AA-80 M Valsartan 80 mg DBS ˂LLOQ 26 1010-2270 2 7 9 NO 
903-100816-AA-81 F Control  DBS 
VAMS 
- - - - - - - 
903-100816-AA-82 M Atorvastatin 40 mg DBS 
VAMS 
8.78±1.31 
8.89±1.22 
13 5.53-28.57 0.38-1.37 4 5 YES 
Valsartan 80 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
20 1010-2270 2 NO 
903-100816-AA-83 M Control - DBS - -  - - - - 
903-100816-AA-84 M Valsartan 160 mg DBS 
VAMS 
3493.72 ± 8.78 
3493.76±4.30 
3.5 1930-4000 1.5-3 4 6 YES 
903-100816-AA-85 F Control - DBS - -  - - - - 
903-100816-AA-86 F Diltiazem 60 mg DBS 
VAMS 
8.86±0.34 
8.77±0.30 
18 74.72-82.43 2.23-2.49 2 2 YES 
903-100816-AA-87 F Bisoprolol 5 mg DBS 3.82±0.34 13 16.64-26.9 1.2-3 1 1 YES 
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Patients Ref. Sex CVD 
medication 
Dose 
(mg) 
Sampling 
device 
Concentration 
(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
Cmax (ng/ml) tmax 
(h) 
Total 
number of 
medications 
Total 
number of 
tablets per 
day 
Adherence 
results  
903-100816-AA-88 M Atorvastatin 40 mg DBS ˂LLOQ 26.5 5.53-28.57 0.38-1.37 3 4 NO 
903-100816-AA-89 F Valsartan 160 mg DBS 
VAMS 
419.41±2.89 
417.45±2.77 
15.5 1930-4000 1.5-3 4 6 YES 
903-110816-AA-90 M Bisoprolol 5 mg DBS 3.97±0.32 19 16.64-26.9 1.2-3 2 2 YES 
903-120816-AA-91 M Bisoprolol 5 mg DBS 
VAMS 
18.13±0.09 
17.88±0.07 
1 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 
VAMS 
24.97±2.05 
24.88±2.15 
1 41.75-80.47 5.79-6.91 YES 
903-120816-AA-92 F Control - DBS - - - - - - - 
903-120816-AA-93 M Lisinopril 10 mg DBS 45.86±2.87 10 41.75-80.47 5.79-6.91 2  YES 
903-120816-AA-94 M Control - DBS - - - - - - - 
903-150816-AA-95 M Bisoprolol 5 mg DBS ˂LLOQ 48 16.64-26.9 1.2-3 3 3 NO 
903-150816-AA-96 M Bisoprolol 5 mg DBS 3.38±0.13 18 16.64-26.9 1.2-3 2 2 YES 
903-150816-AA-97 M Control - DBS 
VAMS 
- - - - - - - 
903-150816-AA-98 F Control - DBS 
VAMS 
- - - - - - - 
903-150816-AA-99 F Bisoprolol 5 mg DBS 
VAMS 
11.39±0.36 
11.10±0.31 
4.5 16.64-26.9 1.2-3 3 2 YES 
Valsartan 160 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
15 1930-4000 1.5-3 NO 
903-270717-AA-100 M Atenolol 50 mg DBS 72.72±0.28 10 159-377 1.5-6 2 2 YES 
Simvastatin 40 mg DBS 2.73±0.33 12 5-40 2-3 YES 
903-270717-AA-101 M Atenolol 50 mg DBS 107.53±0.36 9 159-377 1.5-6 2 2 YES 
Simvastatin 40 mg DBS 2.23±0.18 12 5-40 2-3 YES 
903-270717-AA-102 M Atenolol 100 mg DBS 396.83±1.08 11 240-1370 2-4 2 2 YES 
Simvastatin 40 mg DBS 1.26±0.19 11 5-40 2-3 YES 
903-200717-AA-103 M Atenolol 50 mg DBS 198±1.73 11 159-377 1.5-6 3 3 YES 
Simvastatin 40 mg DBS 2.96±0.37 11 5-40 2-3 YES 
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Patients Ref. Sex CVD 
medication 
Dose 
(mg) 
Sampling 
device 
Concentration 
(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
Cmax (ng/ml) tmax (h) Total 
number of 
medications 
Total 
number of 
tablets per 
day 
Adherence 
results  
903-200717-AA-104 M Atenolol 50 mg DBS 131.72±1.14 11 159-377 1.5-6 2 2 YES 
Lisinopril 10 mg DBS 36.29±0.60 12 41.75-80.47 5.79-6.91 YES 
903-200717-AA-105 M Atenolol 50 mg DBS 246.27±1.43 16 159-377 1.5-6 2 2 YES 
Lisinopril 10 mg DBS 20.48±0.88 16 41.75-80.47 5.79-6.91 YES 
903-200717-AA-106 M Atenolol 100 mg DBS 508.05±3.06 12 240-1370 2-4 2 2 YES 
Lisinopril 10 mg DBS 20.62±1.06 12 41.75-80.47 5.79-6.91 YES 
903-200717-AA-107 M Atenolol 100 mg DBS 596.14±2.40 5.5 240-1370 2-4 3 3 YES 
Lisinopril 10 mg DBS ˂LLOQ 12.5 41.75-80.47 5.79-6.91 NO 
903-200717-AA-108 M Bisoprolol 5 mg DBS 4.32±0.13 15 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS ˂LLOQ 15 41.75-80.47 5.79-6.91 NO 
903-200717-AA-109 M Bisoprolol 5 mg DBS 12.17±0.25 10 16.64-26.9 1.2-3 3 3 YES 
Lisinopril 10 mg DBS ˂LLOQ 14 41.75-80.47 5.79-6.91 NO 
903-200717-AA-110 M Bisoprolol 5 mg DBS 21.68±0.49 2 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 22.99±0.82 12 41.75-80.47 5.79-6.91 YES 
903-200717-AA-111 M Bisoprolol 5 mg DBS 17.86±0.29 2.5 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 27.76±0.86 11 41.75-80.47 5.79-6.91 YES 
903-200717-AA-112 M Bisoprolol 5 mg DBS 13.70±0.14 7 16.64-26.9 1.2-3 3 4 YES 
Valsartan 80 mg DBS ˂LLOQ 12 1010-2270 2 NO 
903-200717-AA-113 M Bisoprolol 5 mg DBS 
VAMS 
24.51±0.11 
24.14±0.10 
2 16.64-26.9 1.2-3 2 2 YES 
  Valsartan 80 mg DBS 
VAMS 
2259.01±6.23 
2259.67±1.63 
2 1010-2270 2 YES 
903-200717-AA-114 M Bisoprolol 5 mg DBS 
VAMS 
22.83±0.13 
22.23±0.33 
3 16.64-26.9 1.2-3 2 2 YES 
Valsartan 80 mg DBS 
VAMS 
2268.49±3.14 
2268.65±1.80 
3 1010-2270 2 YES 
903-200717-AA-115 F Bisoprolol 5 mg DBS 
VAMS 
21.32±0.13 
21.15±0.18 
3 16.64-26.9 1.2-3 2 2 YES 
Valsartan 80 mg DBS 
VAMS 
2229.06±9.17 
2230.55±3.41 
3 1010-2270 2 YES 
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medication 
Dose 
(mg) 
Sampling 
device 
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(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
Cmax (ng/ml) tmax (h) Total 
number of 
medications 
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number of 
tablets per 
day 
Adherence 
results  
903-200717-AA-116 F Bisoprolol 5 mg DBS 26.09±0.16 2.5 16.64-26.9 1.2-3 2 2 YES 
Valsartan 80 mg DBS ˂LLOQ 12 1010-2270 2 NO 
903-200717-AA-117 F Diltiazem 60 mg DBS 10.62±0.64 11.5 74.72-82.43 2.23-2.49 2 2 YES 
Lisinopril 10 mg DBS 43.68±2.07 15 41.75-80.47 5.79-6.91 YES 
903-200717-AA-118 M Diltiazem 90 mg DBS 128.30±1.23 9 105.65-150.87 10.05-12.25 2 2 YES 
Lisinopril 10 mg DBS 23.61±1.26 9 41.75-80.47 5.79-6.91 YES 
903-200717-AA-119 M Diltiazem     90 mg DBS 
VAMS 
54.48±1.24 
54.39±1.22 
15 105.65-150.87 10.05-12.25 4 5 YES 
Lisinopril 10 mg DBS 
VAMS 
54.88±1.52 
54.51±0.27 
15 41.75-80.47 5.79-6.91 YES 
903-200717-AA-120 M Diltiazem         
                        
90 mg DBS 
VAMS 
128.30±1.23 
128.36±1.85 
9.5 105.65-150.87 10.05-
12.25 
4 4 YES 
Lisinopril        
                       
10 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
15 41.75-80.47 5.79-6.91 NO 
903-210717-AA-121 M Losartan 50 mg DBS 125.08±4.23 5 89.1-306.1 0.5-2.2 4 4 YES 
Simvastatin 40 mg DBS ˂LLOQ 15 5-40 2-3 NO 
903-210717-AA-122 F Losartan 50 mg DBS 132.20±4.67 2.5 89.1-306.1 0.5-2.2 4 5 YES 
Simvastatin 40 mg DBS ˂LLOQ 12 5-40 2-3 NO 
903-210717-AA-123 M Losartan 50 mg DBS 
VAMS 
45.33±1.20 
44.88±0.08 
3 89.1-306.1 0.5-2.2 2 2 YES 
Simvastatin 40 mg DBS 
VAMS 
5.33±0.04 
5.28±0.01 
11 5-40 2-3 YES 
903-210717-AA-124 F Losartan 50 mg DBS 
VAMS 
˂LLOQ 2.5 89.1-306.1 0.5-2.2 2 2 NO 
Simvastatin 40 mg DBS 
VAMS 
˂LLOQ 11 5-40 2-3 NO 
903-210717-AA-125 F Amlodipine 5 mg DBS 6.67±0.19 5.5 5-7.5 5-8 2 3 YES 
903-210717-AA-126 M Amlodipine 5 mg DBS 4.32±0.07 6 5-7.5 5-8 2 2 YES 
903-210717-AA-127 F Amlodipine 5 mg DBS 
VAMS 
5.26±0.23 
5.19±0.02 
6.5 5-7.5 5-8 2 2 YES 
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903-210717-AA-128 M Amlodipine 5 mg DBS 
VAMS 
5.18±0.23 
5.17±0.03 
8.5 5-7.5 5-8 2 2 YES 
903-210717-AA-129 F Losartan   50 mg DBS 
VAMS 
51.46±0.14 
51.68±0.77 
5 89.1-306.1 0.5-2.2 3 3 YES 
903-210717-AA-130 M Losartan   50 mg DBS 
VAMS 
49.53±1.99 
49.08±1.46 
5 89.1-306.1 0.5-2.2 2 3 YES 
903-220717-AA-131 M Losartan   50 mg DBS 
VAMS 
99.57±3.01 
99.69±2.92 
2.5 89.1-306.1 0.5-2.2 2 2 YES 
903-220717-AA-132 M Simvastatin  40 mg DBS 
VAMS 
5.86±0.35 
5.96±0.25 
11 5-40 2-3 2 3 YES 
903-220717-AA-133 M Simvastatin  40 mg DBS 
VAMS 
˂LLOQ 11.5 5-40 2-3 4 5 NO 
903-220717-AA-134 M Valsartan 80 mg DBS ˂LLOQ 10 1010-2270 2 2 2 NO 
903-220717-AA-135 M Valsartan 80 mg DBS 
VAMS 
˂LLOQ 8 1010-2270 2 2 2 NO 
903-220717-AA-136 M Valsartan 80 mg DBS 
VAMS 
1869.35±4.33 
1869.94±4.29 
5.5 1010-2270 2 2 3 YES 
903-220717-AA-137 F Valsartan 80 mg DBS 
VAMS 
1577.27±4.00 
1577.57±2.1 
6 1010-2270 2 1 1 YES 
903-220717-AA-138 F Atenolol 50 mg DBS 120.53±1.34 10.5 159-377 1.5-6 4 4 YES 
Simvastatin 40 mg DBS 2.87±0.05 13 5-40 2-3 YES 
903-220717-AA-139 M Atenolol 100 mg DBS 502.29±1.10 10 240-1370 2-4 2 2 YES 
Simvastatin 40 mg DBS 4.97±0.25 10 5-40 2-3 YES 
903-220717-AA-140 F Atenolol 50 mg DBS 218.80±0.9 6 159-377 1.5-6 2 2 YES 
Simvastatin 40 mg DBS 4.49±0.23 12 5-40 2-3 YES 
903-230717-AA-141 M Atenolol 100 mg DBS 517.23±1.45 6 240-1370 2-4 2 2 YES 
Simvastatin 40 mg DBS 4.73±0.38 10.5 5-40 2-3 YES 
903-230717-AA-142 F Atenolol 50 mg DBS 145.55±2.63 10.5 159-377 1.5-6 2 2 YES 
Lisinopril 10 mg DBS 26.64±1.00 10.5 41.75-80.47 5.79-6.91 YES 
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903-230717-AA-143 M Atenolol 100 mg DBS 504.20±2.77 12 240-1370 2-4 2 2 YES 
Lisinopril 10 mg DBS 24.44±1.02 12 41.75-80.47 5.79-6.91 YES 
903-230717-AA-144 M Atenolol 100 mg DBS 462±3.75 6 240-1370 2-4 3 3 YES 
Lisinopril 10 mg DBS 39.05±0.52 11.5 41.75-80.47 5.79-6.91 YES 
903-230717-AA-145 M Bisoprolol 5 mg DBS 6.60±0.20 16 16.64-26.9 1.2-3 4 5 YES 
Lisinopril 10 mg DBS ˂LLOQ 16 41.75-80.47 5.79-6.91 NO 
903-230717-AA-146 M Bisoprolol 5 mg DBS 9.82±0.27 10 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS ˂LLOQ 10 41.75-80.47 5.79-6.91 NO 
903-230717-AA-147 F Bisoprolol 5 mg DBS 22.11±0.67 3 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 24.74±0.82 12 41.75-80.47 5.79-6.91 YES 
903-230717-AA-148 M Bisoprolol           5 mg DBS 
VAMS 
25.96±0.16 
24.35±0.22 
3 16.64-26.9 1.2-3 2 2 YES 
Valsartan 80 mg DBS 
VAMS 
2224.41±4.90 
2223.42±1.55 
3 1010-2270 2 YES 
903-230717-AA-149 F Bisoprolol          5 mg DBS 11.44±0.31 7.5 16.64-26.9 1.2-3 2 2 YES 
Valsartan   80 mg DBS 546.67±9.29 14 1010-2270 2 YES 
903-230717-AA-150 F Bisoprolol 5 mg DBS 
VAMS 
25.50±0.18 
25.57±0.18 
2.5 16.64-26.9 1.2-3 2 2 YES 
Valsartan   80 mg DBS 
VAMS 
2030.86±2.77 
2030.82±1.14 
2.5 1010-2270 2 YES 
903-230717-AA-151 F Control - DBS 
VAMS 
- - - - - - - 
903-240717-AA-152 M Diltiazem 60 mg DBS 49.30±0.54 9.5 74.72-82.43 2.23-2.49 2 2 YES 
Lisinopril 10 mg DBS 23.82±0.69 9.5 41.75-80.47 5.79-6.91 YES 
903-240717-AA-153 M Diltiazem 60 mg DBS 18.14±0.82 9.5 74.72-82.43 2.23-2.49 5 7 YES 
Lisinopril  10 mg DBS 24.82±0.44  41.75-80.47 5.79-6.91 YES 
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903-240717-AA-154 F Diltiazem         
                        
60 mg DBS 
VAMS 
53.42±1.74 
53.52±0.67 
5.5 74.72-82.43 2.23-2.49 3 3 YES 
Lisinopril        
                       
10 mg DBS 
VAMS 
28.04±1.52 
27.88±0.10 
15.5 41.75-80.47 5.79-6.91 YES 
903-240717-AA-155 F Diltiazem         
                        
90 mg DBS 
VAMS 
135.50±1.78 
134.81±1.46 
9 105.65-150.87 10.05-
12.25 
2 2 YES 
Lisinopril        
                       
10 mg DBS 
VAMS 
25.04±1.33 
25.02±0.99 
15 41.75-80.47 5.79-6.91 YES 
903-240717-AA-156 M Losartan 100 mg DBS 
VAMS 
46.10±0.14 
45.65±0.09 
3.5 263.67-783.41 0.54-1.88 2 2 YES 
Simvastatin 40 mg DBS 
VAMS 
5.31±0.04 
5.33±0.01 
12 5-40 2-3 YES 
903-240717-AA-157 F Losartan 50 mg DBS ˂LLOQ 3 89.1-306.1 0.5-2.2 2 2 NO 
Simvastatin 40 mg DBS ˂LLOQ 12 5-40 2-3 NO 
903-240717-AA-158 F Losartan 50 mg DBS ˂LLOQ 5 89.1-306.1 0.5-2.2 2 2 NO 
Simvastatin 40 mg DBS ˂LLOQ 12.5 5-40 2-3 NO 
903-240717-AA-159 F Losartan 100 mg DBS 
VAMS 
˂LLOQ 4 263.67-783.41 0.54-1.88 2 2 NO 
Simvastatin 40 mg DBS 
VAMS 
˂LLOQ 12 5-40 2-3 NO 
903-240717-AA-160 M Amlodipine 5 mg DBS 6.23±0.10 5.5 5-7.5 5-8 3 4 YES 
903-240717-AA-161 F Amlodipine 5 mg DBS 6.39±0.22 5 5-7.5 5-8 2 2 YES 
903-250717-AA-162 F Amlodipine 5 mg DBS 
VAMS 
3.41±0.27 
3.40±0.02 
6 5-7.5 5-8 2 2 YES 
903-250717-AA-163 M Amlodipine 5 mg DBS 
VAMS 
5.28±0.20 
5.23±0.02 
8.5 5-7.5 5-8 5 7 YES 
903-250717-AA-164 M Losartan   50 mg DBS 
VAMS 
204.72±1.13 
204.63±1.33 
3 89.1-306.1 0.5-2.2 7 11 YES 
903-250717-AA-165 M Losartan   50 mg DBS 
VAMS 
250.10±0.58 
250.50±0.54 
2.5 89.1-306.1 0.5-2.2 2 2 YES 
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903-250717-AA-166 F Losartan   50 mg DBS 
VAMS 
175.19±0.74 
175.14±1.25 
4.5 89.1-306.1 0.5-2.2 2 2 YES 
903-250717-AA-167 M Simvastatin  40 mg DBS 
VAMS 
6.14±0.28 
6.25±0.20 
11.5 5-40 2-3 7 11 YES 
903-250717-AA-168 M Simvastatin  40 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
11.5 5-40 2-3 2 2 NO 
903-250717-AA-169 F Atenolol 50 mg DBS 148.55±2.19 11 159-377 1.5-6 2 2 YES 
Simvastatin 40 mg DBS 2.48±0.29 12.5 5-40 2-3 YES 
903-250717-AA-170 M Atenolol 100 mg DBS 555.30±2.28 10.5 240-1370 2-4 2 2 YES 
Simvastatin 40 mg  DBS 2.70±0.14 10.5 5-40 2-3 YES 
903-270717-AA-171 F Atenolol 50 mg DBS 218.63±1.17 5 159-377 1.5-6 2 2 YES 
Simvastatin 40 mg DBS 3.43±0.15 12 5-40 2-3 YES 
903-270717-AA-172 M Atenolol 100 mg DBS 524.55±1.82 6.5 240-1370 2-4 4 4 YES 
Simvastatin 40 mg DBS 2.48±0.28 12.5 5-40 2-3 YES 
903-270717-AA-173 F Atenolol 50 mg DBS 112.38±1.24 10.5 159-377 1.5-6 4 5 YES 
Lisinopril 10 mg DBS 24.37±0.59 10.5 41.75-80.47 5.79-6.91 YES 
903-270717-AA-174 F Atenolol 50 mg DBS 200.61±2.94 16 159-377 1.5-6 4 4 YES 
Lisinopril 10 mg DBS 19.02±0.33 16 41.75-80.47 5.79-6.91 YES 
903-270717-AA-175 F Atenolol 100 mg DBS 494.09±2.21 12 240-1370 2-4 2 2 YES 
Lisinopril 10 mg DBS 22.69±1.33 12 41.75-80.47 5.79-6.91 YES 
903-270717-AA-176 M Atenolol 100 mg DBS 503.30±1.91 6.5 240-1370 2-4 6 8 YES 
Lisinopril 10 mg DBS 21.76±0.48 10 41.75-80.47 5.79-6.91 YES 
903-270717-AA-177 F Bisoprolol 5 mg DBS 4.63±0.18 15.5 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS ˂LLOQ 15.5 41.75-80.47 5.79-6.91 NO 
903-270717-AA-178 M Bisoprolol 5 mg DBS 22.99±0.42 3 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 23.44±0.85 11.5 41.75-80.47 5.79-6.91 YES 
903-270717-AA-179 M Control - DBS - - - - - - - 
903-270717-AA-180 F Bisoprolol 5 mg DBS 5.47±0.18 15 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS ˂LLOQ 15 41.75-80.47 5.79-6.91 NO 
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903-280717-AA-181 M Bisoprolol 5 mg DBS 8.36±0.20 8 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS ˂LLOQ 12 41.75-80.47 5.79-6.91 NO 
903-280717-AA-182 F Bisoprolol 5 mg DBS 25.30±0.17 1.5 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 27.54±0.84 12.5 41.75-80.47 5.79-6.91 YES 
903-280717-AA-183 F Bisoprolol 5 mg DBS 18.59±0.28 10 16.64-26.9 1.2-3 6 6 YES 
Valsartan   80 mg DBS 538.56±9.28 15 1010-2270 2 YES 
903-280717-AA-184 M Bisoprolol 5 mg DBS 
VAMS 
24.56±0.46 
24.30±0.29 
2.5 16.64-26.9 1.2-3 3 3 YES 
Valsartan   80 mg DBS 
VAMS 
1988.35±2.12 
1988.51±1.58 
2.5 1010-2270 2 YES 
903-280717-AA-185 M Bisoprolol 5 mg DBS 24.77±0.72 3 16.64-26.9 1.2-3 4 4 YES 
Valsartan   80 mg DBS 531.77±5.12 15 1010-2270 2 YES 
903-280717-AA-186 F Diltiazem 60 mg DBS 20.41±0.96 10.5 74.72-82.43 2.23-2.49 5 7 YES 
Lisinopril  10 mg DBS ˂LLOQ 15 41.75-80.47 5.79-6.91 NO 
903-280717-AA-187 M Diltiazem 90 mg DBS 134.03±1.24 9 105.65-150.87 10.05-12.25 2 2 YES 
Lisinopril  10 mg DBS 27.55±1.97 9 41.75-80.47 5.79-6.91 YES 
903-280717-AA-188 M Diltiazem         
                        
90 mg DBS 
VAMS 
57.88±0.90 
57.59±0.86 
15 105.65-150.87 10.05-12.25 5 6 YES 
Lisinopril        10 mg DBS 
VAMS 
28.55±1.88 
27.88±1.22 
15 41.75-80.47 5.79-6.91 YES 
903-280717-AA-189 F Diltiazem         
                        
90 mg DBS 
VAMS 
83.33±0.65 
83.08±0.93 
9 105.65-150.87 10.05-
12.25 
2 2 YES 
Lisinopril        10 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
12 41.75-80.47 5.79-6.91 NO 
903-280717-AA-190 F Losartan  50 mg DBS ˂LLOQ 5 89.1-306.1 0.5-2.2 5 5 NO 
Simvastatin 40 mg DBS ˂LLOQ 12 5-40 2-3 NO 
903-290717-AA-191 F Losartan 100 mg DBS 
VAMS 
259.02±3.44 
260.51±1.56 
3 263.67-783.41 0.54-1.88 2 2 YES 
Simvastatin 40 mg DBS 
VAMS 
3.68±0.35 
3.80±0.10 
11.5 5-40 2-3 YES 
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903-290717-AA-192 F Losartan 100 mg DBS 
VAMS 
312.79±2.52 
311.94±2.46 
3 263.67-783.41 0.54-1.88 6 8 YES 
Simvastatin 40 mg DBS 
VAMS 
5.61±0.29 
5.47±0.02 
12.5 5-40 2-3 YES 
903-290717-AA-193 F Losartan 100 mg DBS 
VAMS 
˂LLOQ 4.5 263.67-
783.41 
0.54-1.88 5 6 NO 
Simvastatin 40 mg DBS 
VAMS 
˂LLOQ 15 5-40 2-3 NO 
903-290717-AA-194 M Losartan 100 ng DBS 
VAMS 
244.74±2.64 
245.95±2.05 
3.5 263.67-783.41 0.54-1.88 2 2 YES 
Simvastatin 40 mg DBS 
VAMS 
6.35±0.25 
6.27±0.09 
12 5-40 2-3 YES 
903-290717-AA-195 M Amlodipine 5 mg DBS ˂LLOQ 5.5 5-7.5 5-8 2 2 NO 
903-290717-AA-196 M Amlodipine 5 mg DBS 
VAMS 
˂LLOQ 5 5-7.5 5-8 2 2 NO 
903-290717-AA-197 M Amlodipine 5 mg DBS 
VAMS 
6.22±0.17 
5.99±0.19 
8 5-7.5 5-8 2 3 YES 
903-290717-AA-198 M Amlodipine 5 mg DBS 
VAMS 
˂LLOQ 
˂LLOQ 
8 5-7.5 5-8 6 10 NO 
903-290717-AA-199 F Losartan   50 mg DBS 
VAMS 
155.70±1.72 
156.89±1.11 
5 89.1-306.1 0.5-2.2 2 3 
YES 
903-290717-AA-200 M Losartan   50 mg DBS 
VAMS 
137.29±2.04 
137.82±2.25 
3 89.1-306.1 0.5-2.2 2 2 YES 
903-300717-AA-201 M Losartan   50 mg DBS 
VAMS 
167.60±1.73 
167.16±1.67 
3.5 89.1-306.1 0.5-2.2 5 7 YES 
903-300717-AA-202 M Simvastatin  40 mg DBS 
VAMS 
˂LLOQ 11 5-40 2-3 5 8 NO 
903-300717-AA-203 M Control - DBS - - - - - - - 
903-300717-AA-204 M Valsartan 80 mg DBS 
VAMS 
˂LLOQ 8.5 1010-2270 2 7 10 NO 
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903-300717-AA-205 M Valsartan 80 mg DBS 
VAMS 
978.56±3.49 
975.96±1.95 
6.5 1010-2270 2 2 2 YES 
903-300717-AA-206 F Atenolol 50 mg DBS 147.32±1.15 8 159-377 1.5-6 4 5 YES 
Simvastatin 40 mg DBS 2.62±0.19 14 5-40 2-3 YES 
903-300717-AA-207 M Atenolol 100 mg DBS 507.74±1.94 11 240-1370 2-4 5 8 YES 
Simvastatin 40 mg DBS 4.35±0.46 11 5-40 2-3 YES 
903-300717-AA-208 F Atenolol 50 mg DBS 202.57±1.80 5.5 159-377 1.5-6 7 8 YES 
Simvastatin 40 mg DBS 2.44±0.23 11.5 5-40 2-3 YES 
903-300717-AA-209 F Atenolol 100 mg DBS 195.07±2.23 16.5 240-1370 2-4 5 6 YES 
Lisinopril 10 mg DBS 18.33±0.87 16.5 41.75-80.47 5.79-6.91 YES 
903-300717-AA-210 F Atenolol 100 mg DBS 522.22±1.74 10 240-1370 2-4 2 2 YES 
Lisinopril 10 mg DBS 19.30±0.70 10 41.75-80.47 5.79-6.91 YES 
903-300717-AA-211 F Atenolol 100 mg DBS 517.49±1.73 5.5 240-1370 2-4 6 9 YES 
Lisinopril 10 mg DBS ˂LLOQ 12 41.75-80.47 5.79-6.91 NO 
903-300717-AA-212 F Bisoprolol 5 mg DBS 5.41±0.21 16 16.64-26.9 1.2-3 6 10 YES 
Lisinopril 10 mg DBS ˂LLOQ 16 41.75-80.47 5.79-6.91 NO 
903-300717-AA-213 M Diltiazem 90 mg DBS 137.58±1.14 9 105.65-150.87 10.05-12.25 2 2 YES 
Lisinopril  10 mg DBS 25.13±1.42 9 41.75-80.47 5.79-6.91 YES 
903-300717-AA-214 M Bisoprolol 5 mg DBS 21.66±0.37 2.5 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 22.36±0.67 12.5 41.75-80.47 5.79-6.91 YES 
903-030717-AA-215 M Bisoprolol 5 mg DBS 
VAMS 
25.68±0.29 
25.39±0.22 
3 16.64-26.9 1.2-3 2 2 YES 
Valsartan   80 mg DBS 
VAMS 
2249.4±5.1 
2250.77±2.67 
3 1010-2270 2 YES 
903-030717-AA-216 F Bisoprolol          5 mg DBS 26.28±0.25 1.5 16.64-26.9 1.2-3 2 2 YES 
Valsartan   80 mg DBS 2261.12±5.37 1.5 1010-2270 2 YES 
903-030717-AA-217 M Bisoprolol          5 mg DBS 20.36±0.26 2 16.64-26.9 1.2-3 2 2 YES 
Valsartan   80 mg DBS ˂LLOQ 12 1010-2270 2 NO 
903-300717-AA-218 F Diltiazem 60 mg DBS 11.94±0.65 10.5 74.72-82.43 2.23-2.49 6 8 YES 
Lisinopril  10 mg DBS ˂LLOQ 10.5 41.75-80.47 5.79-6.91 NO 
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903-300717-AA-219 F Diltiazem 90 mg DBS 102.93±2.17 9 105.65-150.87 10.05-12.25 2 2 YES 
Lisinopril  10 mg DBS 26.68±2.16 9 41.75-80.47 5.79-6.91 YES 
903-300717-AA-220 F Diltiazem         
                        
90 mg DBS 
VAMS 
˂LLOQ 9.5 105.65-150.87 10.05-12.25 7 8 NO 
Lisinopril        10 mg DBS 
VAMS 
˂LLOQ 13 41.75-80.47 5.79-6.91 NO 
903-310717-AA-221 F Losartan 100 mg DBS 
VAMS 
˂LLOQ 3.5 263.67-783.41 0.54-1.88 4 5 NO 
Simvastatin 40 mg DBS 
VAMS 
˂LLOQ 12 5-40 2-3 NO 
903-310717-AA-222 M Amlodipine 5 mg DBS 5.28±0.07 5.5 5-7.5 5-8 2 2 YES 
903-310717-AA-223 F Losartan   50 mg DBS 
VAMS 
49.53±1.99 
49.08±1.46 
5 89.1-306.1 0.5-2.2 2 2 YES 
903-310717-AA-224  Valsartan 80 mg DBS ˂LLOQ 16 1010-2270 2 2 2 NO 
903-310717-AA-225 M Valsartan 80 mg DBS 
VAMS 
1861.79±3.59 
1861.77±2.44 
7.5 1010-2270 2 3 4 YES 
903-310717-AA-226 F Atenolol 100 mg DBS 506.76±1.22 11 240-1370 2-4 2 2 YES 
Simvastatin 40 mg DBS 1.56±0.27 11 5-40 2-3 YES 
903-310717-AA-227 F Atenolol 50 mg DBS 142.59±1.39 4.5 159-377 1.5-6 5 7 YES 
Simvastatin 40 mg DBS 2.64±0.19 11 5-40 2-3 YES 
903-310717-AA-228 F Atenolol 100 mg DBS 465.20±1.45 11 240-1370 2-4 2 2 YES 
Lisinopril 10 mg DBS 21.37±1.24 11 41.75-80.47 5.79-6.91 YES 
903-310717-AA-229 F Atenolol 100 mg DBS 426.05±3.53 7 240-1370 2-4 4 6 YES 
Lisinopril 10 mg DBS 20.52±0.47 12.5 41.75-80.47 5.79-6.91 YES 
903-310717-AA-230 M Bisoprolol 5 mg DBS 5.30±0.12 15.5 16.64-26.9 1.2-3 5 6 YES 
Lisinopril 10 mg DBS ˂LLOQ 15.5 41.75-80.47 5.79-6.91 NO 
903-010817-AA-231 M Bisoprolol 5 mg DBS 12.65±0.21 9 16.64-26.9 1.2-3 5 5 YES 
Lisinopril 10 mg DBS ˂LLOQ 12 41.75-80.47 5.79-6.91 NO 
903-010817-AA-232 M Bisoprolol 5 mg DBS 23.61±0.27 3 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 20.38±0.98 11 41.75-80.47 5.79-6.91 YES 
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Patients Ref. Sex CVD 
medication 
Dose 
(mg) 
Sampling 
device 
Concentration 
(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
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number of 
medications 
Total 
number of 
tablets per 
day 
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results  
903-010817-AA-233 F Bisoprolol 5 mg DBS 
VAMS 
23.82±0.39 
23.51±0.22 
2.5 16.64-26.9 1.2-3 2 2 YES 
Valsartan   80 mg DBS 
VAMS 
2261.36±3.18 
2259.69±3.03 
2.5 1010-2270 2 YES 
903-010817-AA-234 F Bisoprolol 5 mg DBS 
VAMS 
24.45±0.49 
22.71±0.26 
1.5 16.64-26.9 1.2-3 2 2 YES 
Valsartan   80 mg DBS 
VAMS 
2245.79±5.46 
2245.03±3.10 
1.5 1010-2270 2 YES 
903-010817-AA-235 F Bisoprolol          5 mg DBS 24.66±0.16 2.5 16.64-26.9 1.2-3 5 6 YES 
Valsartan   80 mg DBS ˂LLOQ 14 1010-2270 2 NO 
903-010817-AA-236 F Diltiazem 60 mg DBS ˂LLOQ 11.5 74.72-82.43 2.23-2.49 5 6 NO 
Lisinopril  10 mg DBS ˂LLOQ 15 41.75-80.47 5.79-6.91 NO 
903-010817-AA-237 F Diltiazem 90 mg DBS ˂LLOQ 9.5 105.65-150.87 10.05-12.25 2 2 NO 
Lisinopril  10 mg DBS ˂LLOQ 9.5 41.75-80.47 5.79-6.91 NO 
903-010817-AA-238 F Diltiazem         
                        
90 mg DBS 
VAMS 
˂LLOQ 9.5 105.65-150.87 10.05-12.25 3 3 NO 
Lisinopril        10 mg DBS 
VAMS 
˂LLOQ 12 41.75-80.47 5.79-6.91 NO 
903-010817-AA-239 M Losartan 100 mg DBS 
VAMS 
˂LLOQ 3.5 263.67-783.41 0.54-1.88 4 4 NO 
Simvastatin 40 mg DBS 
VAMS 
˂LLOQ 15 5-40 2-3 NO 
903-010817-AA-240 M Amlodipine 5 mg DBS 
VAMS 
˂LLOQ 8 5-7.5 5-8 5 7 NO 
903-020817-AA-241 M Valsartan 80 mg DBS 
VAMS 
˂LLOQ 
 
16.5 1010-2270 2 7 8 NO 
903-020817-AA-242 M Valsartan 80 mg DBS 
VAMS 
˂LLOQ 
 
7.5 1010-2270 2 2 2 NO 
903-020817-AA-243 M Valsartan 80 mg DBS 
VAMS 
1734.91±2.93 
1734.98±1.25 
7 1010-2270 2 2 2 YES 
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903-020817-AA-244 F Atenolol  100 mg DBS 415.62±1.29 8 240-1370 2-4 4 4 YES 
Lisinopril 10 mg DBS 22.32±0.67 12.5 41.75-80.47 5.79-6.91 YES 
903-020817-AA-245 F Atenolol 100 mg DBS 392.32±0.77 8 240-1370 2-4 3 4 YES 
Lisinopril 10 mg DBS 21.32±0.57 11.5 41.75-80.47 5.79-6.91 YES 
903-020817-AA-246 M Bisoprolol 5 mg DBS 20.80±0.20 3 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 15.43±0.74 11.5 41.75-80.47 5.79-6.91 YES 
903-020817-AA-247 F Diltiazem         
                        
90 mg DBS 
VAMS 
˂LLOQ 9.5 105.65-150.87 10.05-12.25 4 5 NO 
Lisinopril        10 mg DBS 
VAMS 
˂LLOQ 12.5 41.75-80.47 5.79-6.91 NO 
903-020817-AA-248 F Diltiazem         
                        
90 mg DBS 
VAMS 
˂LLOQ 9 105.65-150.87 10.05-12.25 3 4 NO 
Lisinopril        10 mg DBS 
VAMS 
˂LLOQ 14 41.75-80.47 5.79-6.91 NO 
903-020817-AA-249 F Losartan 100 mg DBS 
VAMS 
˂LLOQ 4 263.67-783.41 0.54-1.88 5 5 NO 
Simvastatin 40 mg DBS 
VAMS 
˂LLOQ 12 5-40 2-3 NO 
903-020817-AA-250 F Losartan 100 mg DBS 
VAMS 
˂LLOQ 4 263.67-783.41 0.54-1.88 7 10 NO 
Simvastatin 40 mg DBS 
VAMS 
˂LLOQ 12 5-40 2-3 NO 
903-030817-AA-251 F Losartan 100 mg DBS 
VAMS 
˂LLOQ 4 263.67-783.41 0.54-1.88 3 3 NO 
Simvastatin 40 mg DBS 
VAMS 
˂LLOQ 15 5-40 2-3 NO 
903-030817-AA-252 
 
 
F Amlodipine 5 mg DBS 
VAMS 
˂LLOQ 6.5 5-7.5 5-8 5 8 NO 
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number of 
medications 
Total 
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day 
Adherence 
results  
903-030817-AA-253 M Valsartan 80 mg DBS 
VAMS 
˂LLOQ 7 1010-2270 2 5 7 NO 
903-030817-AA-254 F Valsartan 80 mg DBS 
VAMS 
1756.12±3.84 
1754.24±3.68 
8 1010-2270 2 2 3 YES 
903-030817-AA-255 F Valsartan 80 mg DBS 
VAMS 
1799.53±3.89 
1799±1.33 
8.5 1010-2270 2 3 3 YES 
903-030817-AA-256 F Atenolol 100 mg DBS 445.50±1.75 5.5 240-1370 2-4 4 5 YES 
Lisinopril 10 mg DBS 22.32±0.55 11.5 41.75-80.47 5.79-6.91 YES 
903-030817-AA-257 F Atenolol 100 mg DBS 446.17±1.54 6 240-1370 2-4 4 5 YES 
Lisinopril 10 mg DBS 21.12±0.55 13 41.75-80.47 5.79-6.91 YES 
903-030817-AA-258 M Atenolol 100 mg DBS 486.90±2.02 11.5 240-1370 2-4 2 2 YES 
Lisinopril 10 mg DBS 19.46±1.26 11.5 41.75-80.47 5.79-6.91 YES 
903-030817-AA-259 F Bisoprolol 5 mg DBS 21.56±0.23 3 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 15.53±0.56 11.5 41.75-80.47 5.79-6.91 YES 
903-030817-AA-260 F Bisoprolol 5 mg DBS 21.52±0.29 2.5 16.64-26.9 1.2-3 2 2 YES 
Lisinopril 10 mg DBS 22.44±0.80 11 41.75-80.47 5.79-6.91 YES 
903-030817-AA-261 M Bisoprolol          5 mg DBS 21.75±0.20 3 16.64-26.9 1.2-3 3 3 YES 
Valsartan   80 mg DBS ˂LLOQ 15 1010-2270 2 NO 
903-040817-AA-262 M Bisoprolol          5 mg DBS 23.03±0.19 2 16.64-26.9 1.2-3 3 3 YES 
Valsartan   80 mg DBS ˂LLOQ 12 1010-2270 2 NO 
903-040817-AA-263 M Valsartan     80 mg DBS ˂LLOQ 8.5 1010-2270 2 5 7 NO 
903-040817-AA-264 M Atenolol 100 mg DBS ˂LLOQ 30 240-1370 2-4 7 11 NO 
903-040817-AA-265 M Losartan   100 mg DBS ˂LLOQ 28 263.67-783.41 0.54-1.88 6 7 NO 
903-040817-AA-266 M Valsartan     80 mg DBS ˂LLOQ 36 1010-2270 2 8 13 NO 
903-040817-AA-267 F Diltiazem         90 mg DBS ˂LLOQ 25 105.65-150.87 10.05-12.25 8 11 NO 
903-040817-AA-268 F Bisoprolol 5 mg DBS ˂LLOQ 33 16.64-26.9 1.2-3 7 11 NO 
903-040817-AA-269 F Diltiazem    90 mg DBS ˂LLOQ 36 105.65-150.87 10.05-12.25 6 8 NO 
903-040817-AA-270 F Atenolol 100 mg DBS ˂LLOQ 30 240-1370 2-4 8 8 NO 
903-050817-AA-271 F Losartan   50 mg DBS ˂LLOQ 12 89.1-306.1 0.5-2.2 6 6 NO 
903-050817-AA-272 M Bisoprolol 5 mg DBS ˂LLOQ 15 16.64-26.9 1.2-3 6 9 NO 
903-050817-AA-273 F Valsartan     80 mg DBS ˂LLOQ 12 1010-2270 2 6 7 NO 
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903-050817-AA-274 M Atenolol 100 mg DBS ˂LLOQ 36 240-1370 2-4 7 8 NO 
903-050817-AA-275 F Losartan   50 mg DBS ˂LLOQ 14 89.1-306.1 0.5-2.2 6 7 NO 
903-050817-AA-276 F Valsartan     80 mg DBS ˂LLOQ 33 1010-2270 2 6 10 NO 
903-050817-AA-277 F Diltiazem  90 mg DBS ˂LLOQ 16 105.65-150.87 10.05-12.25 8 10 NO 
903-050817-AA-278 F Bisoprolol 5 mg DBS ˂LLOQ 13 16.64-26.9 1.2-3 5 7 NO 
903-050817-AA-279 F Losartan   50 mg DBS ˂LLOQ 12 89.1-306.1 0.5-2.2 8 12 NO 
903-050817-AA-280 F Valsartan     80 mg DBS ˂LLOQ 12 1010-2270 2 6 7 NO 
903-100817-AA-281 F Bisoprolol 5 mg DBS ˂LLOQ 30 16.64-26.9 1.2-3 5 6 NO 
903-100817-AA-282 F Diltiazem 90 mg DBS ˂LLOQ 20 105.65-150.87 10.05-12.25 7 9 NO 
903-100817-AA-283 M Atenolol 100 mg DBS ˂LLOQ 11 240-1370 2-4 7 10 NO 
903-100817-AA-284 F Bisoprolol 5 mg DBS ˂LLOQ 36 16.64-26.9 1.2-3 4 4 NO 
903-100817-AA-285 F Diltiazem 90 mg DBS ˂LLOQ 12 105.65-150.87 10.05-12.25 8 10 NO 
903-100817-AA-286 F Valsartan     80 mg DBS ˂LLOQ 12 1010-2270 2 6 10 NO 
903-100817-AA-287 F Atenolol 100 mg DBS ˂LLOQ 15 240-1370 2-4 5 7 NO 
903-100817-AA-288 F Losartan   50 mg DBS ˂LLOQ 14 89.1-306.1 0.5-2.2 5 5 NO 
903-100817-AA-289 F Diltiazem 60 mg DBS ˂LLOQ 20 74.72-82.43 2.23-2.49 5 5 NO 
903-100817-AA-290 F Bisoprolol 5 mg DBS ˂LLOQ 15 16.64-26.9 1.2-3 6 9 NO 
903-210318-AA-291 M Atorvastatin 40 mg  DBS 20.5±1.89 12 5.53-28.57 0.38-1.37 3 4 YES 
903-210318-AA-292 M Valsartan 80 mg  DBS 2726.80±17 11.5 1010-2270 2 2 2 YES 
903-210318-AA-293 F Bisoprolol 5 mg  DBS 23.27±0.47 11.5 16.64-26.9 1.2-3 3 3 YES 
903-210318-AA-294 M Lisinopril 10 mg DBS ˂LLOQ 31 41.75-80.47 5.79-6.91 7 11 NO 
903-210318-AA-295 F Losartan 50 mg DBS ˂LLOQ 12.5 89.1-306.1 0.5-2.2 6 8 NO 
903-210318-AA-296 M Atenolol 100 mg DBS ˂LLOQ 15 240-1370 2-4 8 11 NO 
903-210318-AA-297 M Bisoprolol 5 mg DBS 22.13±0.41 11.5 16.64-26.9 1.2-3 6 10 YES 
903-210318-AA-298 F Bisoprolol 5 mg DBS 22.45±0.33 11.5 16.64-26.9 1.2-3 8 13 YES 
903-210318-AA-299 M Losartan 50 mg DBS ˂LLOQ 15 89.1-306.1 0.5-2.2 6 12 NO 
903-240318-AA-300 F Bisoprolol 5 mg DBS ˂LLOQ 12.5 16.64-26.9 1.2-3 7 12 NO 
903-240318-AA-301 F Atorvastatin 40 mg DBS 19.37±1.89 11.5 5.53-28.57 0.38-1.37 2 2 YES 
903-240318-AA-302 F Valsartan 80 mg DBS 941.67±3.55 12 1010-2270 2 3 4 YES 
903-240318-AA-303 F Bisoprolol 5 mg DBS 25.86±3.32 12 16.64-26.9 1.2-3 3 5 YES 
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903-240318-AA-304 M Bisoprolol 5 mg DBS ˂LLOQ 30 16.64-26.9 1.2-3 6 8 NO 
903-240318-AA-305 F Losartan 50 mg DBS ˂LLOQ 12 89.1-306.1 0.5-2.2 6 8 NO 
903-240318-AA-306 M Bisoprolol 5 mg DBS ˂LLOQ 11 16.64-26.9 1.2-3 6 8 NO 
903-250318-AA-307 F Atenolol 100 mg DBS ˂LLOQ 15 240-1370 2-4 6 9 NO 
903-250318-AA-308 F Losartan 50 mg DBS ˂LLOQ 11 89.1-306.1 0.5-2.2 8 12 NO 
903-250318-AA-309 M Valsartan 80 mg DBS ˂LLOQ 12 1010-2270 2 8 12 NO 
903-250318-AA-310 F Atenolol 100 mg DBS ˂LLOQ 12.5 240-1370 2-4 7 9 NO 
903-250318-AA-311 F Atorvastatin 40 mg DBS 22.18±0.35 12.5 5.53-28.57 0.38-1.37 2 2 YES 
903-260318-AA-312 F Valsartan 80 mg DBS 2013±7.05 11.5 1010-2270 2 3 3 YES 
903-260318-AA-313 F Lisinopril 10 mg DBS ˂LLOQ 40 41.75-80.47 5.79-6.91 6 8 NO 
903-260318-AA-314 M Simvastatin 40 mg DBS ˂LLOQ 11.5 5-40 2-3 7 9 NO 
903-260318-AA-315 F Bisoprolol 5 mg DBS ˂LLOQ 13 16.64-26.9 1.2-3 7 10 NO 
903-260318-AA-316 M Bisoprolol 5 mg DBS ˂LLOQ 12 16.64-26.9 1.2-3 8 10 NO 
903-260318-AA-317 M Losartan 50 mg DBS ˂LLOQ 16 89.1-306.1 0.5-2.2 5 5 NO 
903-260318-AA-318 F Valsartan 80 mg DBS ˂LLOQ 15 1010-2270 2 8 11 NO 
903-260318-AA-319 F Bisoprolol 5 mg DBS ˂LLOQ 12.5 16.64-26.9 1.2-3 7 12 NO 
903-260318-AA-320 F Atorvastatin 40 mg DBS 27.45±1.99 11.5 5.53-28.57 0.38-1.37 2 3 YES 
903-260318-AA-321 M Valsartan 80 mg DBS 2108±3.32 12 1010-2270 2 3 4 YES 
903-260318-AA-322 F Bisoprolol 5 mg DBS ˂LLOQ 35 16.64-26.9 1.2-3 6 9 NO 
903-260318-AA-323 F Simvastatin 40 mg DBS ˂LLOQ 12.5 16.64-26.9 1.2-3 6 9 NO 
903-260318-AA-324 M Simvastatin 40 mg DBS ˂LLOQ 13 5-40 2-3 7 8 NO 
903-260318-AA-325 F Simvastatin 40 mg DBS ˂LLOQ 13 5-40 2-3 8 12 NO 
903-260318-AA-326 F Simvastatin 40 mg DBS ˂LLOQ 13 5-40 2-3 7 12 NO 
903-260318-AA-327 M Bisoprolol 5 mg DBS ˂LLOQ 12.5 16.64-26.9 1.2-3 8 12 NO 
903-260318-AA-328 F Simvastatin 40 mg DBS ˂LLOQ 12 5-40 2-3 7 10 NO 
903-260318-AA-329 F Bisoprolol 5 mg DBS 18.67±0.74 12.5 16.64-26.9 1.2-3 2 2 YES 
903-260318-AA-330 F Atorvastatin 40 mg DBS 23.62±2.47 11.5 5.53-28.57 0.38-1.37 3 3 YES 
903-260318-AA-331 M Atorvastatin 40 mg DBS 20.15±0.12 12.5 5.53-28.57 0.38-1.37 2 2 YES 
903-260318-AA-332 F Lisinopril 10 mg DBS ˂LLOQ 33 41.75-80.47 5.79-6.91 8 11 NO 
903-270318-AA-333 M Bisoprolol 5 mg DBS ˂LLOQ 12.5 16.64-26.9 1.2-3 7 9 NO 
 
 
 295 | P a g e 
 
Patients Ref. Sex CVD 
medication 
Dose 
(mg) 
Sampling 
device 
Concentration 
(ng/ml) ± (sd) 
Time 
since last 
dose (h) 
Cmax (ng/ml) tmax (h) Total 
number of 
medications 
Total 
number of 
tablets per 
day 
Adherence 
results  
903-270318-AA-334 F Simvastatin 40 mg DBS ˂LLOQ 12 5-40 2-3 6 7 NO 
903-270318-AA-335 F Bisoprolol 5 mg DBS ˂LLOQ 12 16.64-26.9 1.2-3 8 11 NO 
903-270318-AA-336 M Simvastatin 40 mg DBS ˂LLOQ 12.5 5-40 2-3 6 6 NO 
    Abbreviation: M: Male; F: Female. 
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Appendix 15. MMAS-8 License Contract and Copyright Agreement 
 
MMAS-8 License Contract and Copyright Agreement 
 
Required citations and copyright acknowledgement for the MMAS-8 item scale are 
available on the final license contract and copyright agreement  
 
In consideration for the right to use certain Morisky proprietary psychometric tools and 
intellectual property, the undersigned researcher (hereunder "Licensee" or "you") agrees 
to the following: 
 
A.  Ownership and Fees: All psychometric products as well as their translations, 
adaptations, computer programs, and scoring algorithms, trade secrets, and any other 
related documents and information (including those in electronic form) which embody or 
are related to the MMAS tools (including without limitation the Morisky Medication 
Adherence Scale 4- and 8-item versions, 4-item Morisky Adherence Questionnaire, and 
any documentation thereof) are intellectual property of Donald E. Morisky, ScD, ScM, 
MSPH. ("Owner") Professor of Community Health Sciences, UCLA Fielding School of 
Public Health, Los Angeles, CA 90095-1772 (the address for all payments and 
communications related to this agreement).  
 
B.  Translations: Permission will only be granted to translate the MMAS tools subject 
to the following requirements: all new translations must be made by contracting with the 
MAPI Institute and final translations must be approved by the Owner.  The MAPI Institute 
employs the most rigorous standards in the translation process using two native linguistic 
experts to independently conduct forward and backwards translation; the Owner is 
actively involved in validating each item in the scale and grants use of the translated scale 
through a separate license agreement that is linked to the License Agreement 
Contract/Copyright Agreement.  Languages that have already been translated and 
validated by the MAPI Institute can be requested through the Owner/Developer, Dr. 
Donald E. Morisky. 
 
 297 | P a g e 
 
C. Use:  Licensee understands and agrees that 
 1) Changes to the wording or phrasing of any Morisky scale, tool or document 
require written permission. If any changes made to the wording or phrasing of any MMAS 
item or other Morisky document without permission, the result cannot be considered the 
MMAS, and subsequent analyses and/or comparisons to other MMAS data may violate 
Owner's rights. 
 
 2) Coding and scoring criteria of the MMAS-8 are trade secrets of the Owner and 
as such cannot be divulged in any publication or report without the Owner's prior written 
permission; 
 
 3) Permission to use the trademarks "Morisky," "MORISKY SCALE" or 
"MMAS" is not and will not be granted for any unauthorized use or translations of the 
MMAS or other MORISKY intellectual property, in whole or in part. No analyses, 
research results or publications based on unauthorized changes or translated versions, or 
results thereof, will use MORISKY, MMAS or confusingly similar attributions. 
 
 4) The MORISKY SCALE intellectual property legend on the documents 
provided to you must be included on the first page of a MORISKY SCALE questionnaire 
in study documents, and in any reproductions for manuscript or other publication 
purposes. The footnote must be noted at the end of the first Table or Figure that displays 
the MMAS-8 items. 
 
 5) In case of scientific, administrative or intellectual property misconduct in using 
the MORISKY SCALE system of questionnaires or the Morisky name or MMAS names, 
Owner reserves the right to withdraw permission for use and to pursue all legal remedies.  
Licensee agrees to the jurisdiction in and venue of the State and Federal Courts in Los 
Angeles County. 
 
 6) Further specific requirements, e.g., citations required in publications, may be 
obtained from the Owner via <dmorisky@ucla.edu>. If you publish your work, you must 
acknowledge the use of the MMAS-8 in the acknowledgement section of your manuscript 
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by indicating: I have obtained written permission from copyright owners for any excerpts 
from copyrighted works that are included and have credited the sources in the Article or 
the Supplemental Materials. The credit footnote is located in the copyright agreement. 
             
Please print, sign, and scan (PDF) and email this agreement to dmorisky@ucla.edu  
 
Please sign and return this contractual agreement in a PDF format, to Professor Morisky 
and he will provide you (upon receipt of the payment invoice) with pages listing the 
MMAS-8 items, scoring and re-coding criteria and signature authorizing full use of this 
copyrighted scale.  I agree to use only the English version of the MMAS-8 unless I 
purchase a validated translation of the MMAS-8 through Professor Morisky. I understand 
that it is a violation of international copyright laws to either use your own translation and 
call it the “MMAS-8” or use an existing MMAS-8 scale that has been translated and used 
for another study.  The validated translation is non-transferrable and is linked to a specific 
license agreement and cannot be reproduced, copied, distributed, placed on the internet, 
published, or used by another individual. If the licensee violates any copyright laws 
contained in this licensing agreement, they will be solely responsible for a $5000.00 
penalty and any associated legal costs. 
 
Name and Contact Information of Licensee: AHMED DAYER ALWAN ALALAQI 
 
Title of Study:  ADHERENCE TO CARDIOVASCULAR MEDIATIONS IN IRAQ.  
 
Total number of administrations: 426, one time only. 
 Signature of developer/owner of the MMAS-8:  
Donald E. Morisky, ScD, Developer/Owner of the MMAS-8 
Date Signed:  
 
Signature of Licensee:                                   /AHMED DAYER ALWAN ALALAQI 
 
Date Signed:  
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LICENSURE AGREEMENT 
The following shall constitute a contract for use of the © MORISKY MEDICATION 
ADHERENCE SCALE (MMAS-8) made on February 17, 2016, between AHMED 
DAYER ALWAN ALALAQI, Licensee, and Donald E. Morisky, ScD. ScM, MSPH, 
herein referred to developer/owner of the MMAS- 8. 
SECTION 1. USE OF THE MORISKY MEDICATION ADHERENCE SCALE 
Client hereby uses the Morisky Medication Adherence Scale on the terms set forth in 
this contract. 
SECTION 2. FEES AND TERMS OF USAGE 
In consideration of the owner’s intellectual property, client agrees to pay owner a fee of 
$426($1.00 x 426 participants administered the MMAS-8 for one time).  The license fee 
is in effect for a one-year period or the duration of the study, whichever is shorter. 
SECTION 3. DUTIES OF OWNER 
Owner shall provide the client with a listing of the © 8-item Morisky English scale along 
with a description of how each item is to be coded and summed to give a total score, 
ranging from 0 to 8.  Psychometric properties of the scale (reliability and validity) will 
also be provided upon request. 
SECTION 4. DUTIES OF THE CLIENT 
Client agrees not to publish, distribute, copy or divulge the contents of the © Morisky 
Scale or its coding methodology to any individual. Transfer of this intellectual property 
is prohibited under copyright law. 
          SECTION 5. TERMS and TERMINATION 
The license contract is in effect for a one-year or the duration of the study, whichever is 
shorter. This contract shall automatically terminate without further notice at the end of 
the term of usage as specified in SECTION 2. 
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This contract shall automatically terminate without further notice at the end of the term 
of usage as specified above. 
If the Licensee terminated contract the owner will be entitled to the full amount of the 
contract terms. 
SECTION 6. PAYMENT OF FEES 
Client shall pay owner the amount of fees calculated based on the terms stated under 
SECTION 2 at the time of contract signature.  Payment shall be made out to: Dr. 
Donald E. Morisky, Professor, UCLA School of Public Health, 650 Charles E. Young 
Drive South, Los Angeles, CA 90095-1772. Payment must be made at least 45 days 
after to the signing of this contract. A 10% late payment will be assessed on all late 
payments. Written notification must be sent to the Owner prior to the payment deadline 
date if Licensee needs additional time processing the invoice, otherwise a late fee will 
be assessed. 
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Appendix 16. Ethical Approval for Application of 8-item Morisky Questionnaire 
from De Montfort University’s Faculty of Health and Life Science Research Ethics 
Committee  
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Appendix 17. Participant Information Leaflet for the Application of MMAS-8 
(English Vesion). 
Version 1  
DATE   /       / 
 
Faculty of Health and Life Sciences 
Assessment of adherence to cardiovascular medications in Iraq by Morisky -8 items 
questionnaire 
What is the study? 
Cardiovascular disease (CVD) covers disorders of the heart and blood vessels, namely 
hypertension, angina, heart attack, stroke and heart failure. It is one of the biggest killers 
worldwide and in 2012 accounted for one in three of all deaths. According to the 2006 Iraqi 
national survey for chronic disease risk factors, 40.4% of the Iraqi adult population have elevated 
blood pressure. Ischemic heart diseases and stroke take positions one and two, respectively, in the 
top 10 causes of death in Iraq. The current medical care of CVD patients uses a combination of 
cardiovascular therapy drugs including beta-blockers and ace inhibitors to treat hypertension, and 
statins to lower cholesterol. There is evidence that, worldwide, as many as 50% of prescribed 
CVD drugs are not taken by patients as recommended. This non-adherence to medications results 
in morbidity, mortality, medicine wastage and higher costs of care. 
 What will happen? 
The programme for this study will involve testing the adherence to cardiovascular medication in 
volunteers who are able to read and write in Arabic with no visual or cognitive impairment by 
using a standardized and validated Arabic version of the Morisky eight-item questionnaire 
(MMAS-8 questionnaire) which consists of eight standardized questions. Patient adherence 
profile will be determined according to the adherence drug index. Response choices for questions 
1 to 7 are “Yes” or “No”. Question No. 8 is a Likert-type question. In addition to the MMAS-8, 
a checklist to gather demographic data as well as variables about other diseases or medications 
the patients were taking will also be used. 
Do have to take part? 
It is up to you to decide whether or not to take part, and if you decide to take part you are still free 
to withdraw at any time and without giving any reason. 
What if I agree to take part and then change my mind? 
You can withdraw from the study at any time without giving any reason. 
How will you be involved? 
After reading this Participant Information Leaflet, recruited volunteers will be asked to complete 
the questionnaire which consists of eight standardised questions. 
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How is the questionnaire analysed? 
Patient adherence profiles will be determined according to the adherence drug index. Response 
choices for questions 1 to 7 are “Yes” or “No”. Question No. 8 is a Likert-type question. The total 
score ranges from 0 to 8. Scores of less than 6 indicate low adherence, scores of 6 to < 8 indicate 
moderate adherence, and a score of 8 indicates high adherence. 
What if something goes wrong/who can I complain to? 
If you have a complaint regarding anything to do with this study, you can initially approach the 
lead investigator and, if a satisfactory outcome is not achieved, then you can contact the ethical 
committee in Misan Health Directorate, Misan, Amara or the Administrator for the Faculty 
Research Ethics Committee, Research & Commercial Office, Faculty of Health & Life Science, 
1.25 Edith Murphy House, De Montfort University, The Gateway, Leicester, LE1 9BH or 
hlsfro@dmu.ac.uk  
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept on a 
password-protected database and is strictly confidential. A reference code will be used instead of 
your name and any identifiable information you may give will be removed and anonymized. 
What will happen to the results of the research study? 
The results will form an essential part of a PhD thesis in clinical pharmacy practice at De Montfort 
University, Leicester. 
Who is organizing and funding the research? 
The research is for a PhD studentship at De Montfort University Leicester and is funded by the 
Iraqi Ministry of Health, Misan Health Directorate. 
Who has reviewed the study? 
This study has been reviewed and approved by De Montfort University, Faculty of Health and 
Life Sciences Research Ethics Committee and the ethical committee of the Misan Health 
Directorate. 
Who should I contact if I have further questions? 
Dr Sangeeta Tanna                                                               
Leicester School of Pharmacy 
De Montfort University 
The Gateway                                                                          
Leicester LE1 9BH 
T: 0116 2078274                                                                    
E: stanna@dmu.ac.uk                                                             
Dr Graham Lawson
Leicester School of Pharmacy 
De Montfort University   
The Gateway 
Leicester LE1 9BH   
T: 0116 2577129   
E: glawson@dmu.ac.uk                                                                                                               
Ahmed Alalaqi 
Leicester School of Pharmacy 
De Montfort University 
The Gateway 
Leicester LE1 9BH 
T:07714714552 
E: 14018429@my365.dmu.ac.uk 
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Appendix 18. English Version of Patient Consent Form for the Eight-Item Morisky 
Medication Adherence Scale MMAS-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morisky Medication Adherence Scale MMAS-8 to assess adherence to cardiovascular 
medications 
Participant Reference Number: 
(To be completed by research team) 
Name of Researchers: Dr Sangeeta Tanna, Dr Graham Lawson & Ahmed Alalaqi 
                                                                                                                 Please initial 
box 
 
 
I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my legal 
rights being affected. 
I confirm that I have read and understand the information sheet for 
the above study. I have had the opportunity to consider the 
information and ask questions and have had these answered 
satisfactorily. 
 
 
I understand that the data collected during the study, may be looked 
at by responsible individuals from the research team or from 
individuals from regulatory authorities. 
I agree to take part in this study. 
 
__________________            _________________           _______ 
Name of Participant                  Signature                              Date 
____________________            ____________________            ________ 
Name of person                                Signature                                   Date 
taking consent    
                                         
1 copy to participant; 1 copy for research file 
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 .)noisreV
 
 
 
 
 
 
 ما هي الدراسة؟
أمراض القلب والأوعية الدموية ويشمل اضطرابات في القلب والأوعية الدموية، وهي ارتفاع ضغط الدم والذبحة 
الصدرية والنوبات القلبية والسكتة الدماغية وقصور القلب. وهو واحد من أكبر أسباب الوفاة في جميع أنحاء العالم 
ب هذا المرض. ووفقا للمسح الوطني العراقي عام مثل واحد من كل ثلاثة  اشخاص يموتون بسب 2102وفي عام 
 ٪ من السكان البالغين في العراق يعانون من ارتفاع ضغط الدم. 4.04لعوامل خطر الإصابة بأمراض مزمنة،  6002
اسباب للوفاة في العراق.  01أمراض القلب  والسكتة الدماغية اخذت المرتبه الاولى والثانيه على التوالي  في أعلى 
اية الطبية لمرضى الأمراض القلبية الوعائية تستخدم توليفة من الأدوية في علاج القلب والأوعية الدموية بما الرع
في ذلك حاصرات بيتا ومثبطات ايس لعلاج ارتفاع ضغط الدم، والستاتين لخفض الكولسترول. هناك أدلة على أن 
لا تؤخذ من قبل المرضى على النحو الموصى به.  ٪ من الأدوية القلبية الوعائية المنصوص عليها05ما يصل إلى 
 هذا عدم الالتزام النتائج الأدوية في المراضة والوفيات، والأدوية الهدر وارتفاع تكاليف الرعاية.
 ماذا يحدث في البحث
القراءة والكتابة البرنامج لهذه الدراسة تشمل اختبار الالتزام في دواء القلب والأوعية الدموية في المتطوعين القادرين على 
 8-SAMMبنود الاستبيان ( 8 yksiroMباللغة العربية مع عدم وجود ضعف  في البصر وباستخدام  النسخة العربية من 
الاستبيان) والذي يتألف من ثمانية أسئلة موحدة. وسيتم تحديد ا التزام المريض وفقا لمؤشر الالتزام.. اختيارات الإجابة عن 
 أو "لا". والسوال الثامن  هو ليكرت  هي "نعم" 7-1الأسئلة 
 يجب أن يشارك؟ 
 الأمر متروك لك لتقرر ما إذا كانت أو عدم المشاركة وإذا قررت المشاركة لا تزال تتردد في الانسحاب في أي وقت ودون
 إبداء أي سبب
 كيف تشارك في البحث؟
المتطوعين اكمال الاستبيان الذي يتكون من ثمانية أسئلة بعد قراءة المعلومات عن البحث في ورقه مشاركه المريض سيطلب 
 .موحدة
 كيفيه تحليل الاستبيان؟
 استماره معلومات للمشارك في البحث 
  1نموذج 
 التاريخ :
 TELFAEL NOITAMROFNI TNAPICITRAP
 ذو الثمان نقاط يبادويه القلب والاوعيه الدمويه بواسطه استبيان مورسكتقييم الالتزام 
 
 
  e g a P | 703
 
 8هي "نعم" أو "لا". والسؤال رقم  7-1وسيتم تحديد التزام المريض وفقا لمؤشر الالتزام. اختيارات الإجابة عن الأسئلة 
تشير إلى  8إلى < 6تشير إلى التزام منخفضة، و من  6. أقل من 8إلى  0هو من نوع ليكرت . وتتراوح الدرجة الكلية من 
 يدل على التزام عالي 8التزام المعتدل، والنتيجة = 
 ماذا لو حدث خطأ ما؟ / يمكنني تقديم شكوى ؟
إذا كان لديك أي شكوى يمكنك الاتصال مع اللجنة الأخلاقية في ميسان مديرية الصحة أو اللجنة الأخلاقية في كلية الصحة 
 ku.ca.umd@orfslhإديث ميرفي دي مونتفورت  52.1لحياة وعلوم ا
 هل ستبقى مشاركتي في البحث سريه؟
وستبقى جميع المعلومات التي يتم جمعها عنك أثناء البحث في قاعدة بيانات محمية بكلمة مرور وسرية تامة. سيتم إزالة رمز 
 دامها بدلا من اسمك وأية معلومات تعريفية قد تعطي.إشارة التي سيتم استخ
 ماذا سيحدث لنتائج الدراسة؟
 .وسوف تكون نتائج الدراسه جزءا أساسيا من رسالة الدكتوراه في الصيدلة السريرية في جامعة دي مونتفورت، ليستر
 من يمول هذا البحث 
 .يستر وتموله وزارة الصحة العراقية، دائره صحة ميسانهذا البحث هو لدراسه لدرجة الدكتوراة في جامعة دي مونتفورت 
 من يتابع ويشرف على الدراسه؟
وقد استعرضت هذه الدراسة والموافقة عليها من قبل جامعة دي مونتفورت، كلية الصحة وعلوم الحياة ولجنة أخلاقيات 
 البحث في  دائره  صحة ميسان
 
 المعلومات؟بمن يمكن الاتصال لمعرفه مزيد من 
  
                                                                                                                
 
 
 الدكتور جراهام لونسون
 مدرسه ليستر للصيدله
 جامعه دي مونت فورت
 HB9 1EL retsecieL
 9217752 6110 :T
 ku.ca.umd@noswalg
 الدكتور سانكيتا تانا
 مدرسه ليستر للصيدله
 جامعه دي مونت فورت
 HB9 1EL retsecieL
 4728702 6110 :T
 ku.ca.umd@annats
 
  العلاق أحمد
  الصيدلة ليستر مدرسة
  مونت فورت دي جامعة
 HB9 1EL ليستر
 25541741770 :T                   
 Ku.ca.umd.liameym@92481041
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 استماره الموافقه
 mrof tnesnoC
 
  والاوعيه الدمويه في العراق بواسطه استبيان مورسكي ذو الثمان نقاطتقييم الالتزام بادويه القلب 
 الرقم المرجعي للمشارك:
 يملىء من قبل فريق البحث 
 اسماء الباحثين    احمد العلاق            د.سانكيتا تانا    د.كراهام لاوسن            
 
  للدراسة المذكورة أعلاه. وقد أتيحت لي الفرصة للنظرأؤكد أنني قد قرأت وفهمت ورقة المعلومات 
  في المعلومات، وطرح الأسئلة، وكان هذه الإجابة مرضية. 
 
 وأنا أفهم أن مشاركتي طوعية وأنا حر في الانسحاب في أي وقت دون إبداء أي سبب، دون  تاثر
  حقوقي القانونية             
 
  التي تم جمعها خلال هذه الدراسة، يمكن النظر فيها من قبل الأفراد المسؤولينوأنا أفهم أن البيانات 
  عن فريق البحث أو من الأفراد من السلطات التنظيمية. 
 
   أنا أوافق على المشاركة في هذه الدراسة                                                                                        
 
 
    التوقيع                                             التاريخ                                                           اسم المشارك
   التوقيع                                              التاريخ                                    اسم الشخص الذي اخذ الموافقه
 
 
 نسخه الى المشارك ونسخه الى الملف 
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 3102-01-5 noitalsnarT cibarA  مقياس مورسكي للالتزام بالعلاج
توجد اجابه صحيحه او الاشخاص لديهم سلوك مختلف تجاه اخذهم للأدويه ونحن مهتمون بتجُربَتك الشخصيه. لا 
  . الرجاء ان تجيب على هذه الاسئله بناء على تجربتك الشخصيه في تناول العلاج. خاطئه
 
  
  ؟ الرجاء وضع دائرع حول ما يناسبك: (من غير قصد): إلى أي مدى تجدت صعوبه في تذكر اخذ جميع أدويتك. 8
 4......……………………………….  مطلقا/ابدا •
 3…………………………………..  من حين لاخر •
  2……………………………………………احيانا •
 1….…………………………………………عادة •
 0……………………………………….كل الاوقات •
 
 
 
 السؤال  )0نعم (  )1لا(
الاحيان ان تتناول علاجك الخاص ؟(من .هل تنسى في بعض 1  
 غير قصد)
الناس أحيانا ًلا يأخذون أدويتهم لسبب آخر غير النسيان ,  .2  
فهل كان هناك ايام لم تأخذ فيها أدويتك خلال الاسبوعين 
  ؟(عن قصد)الماضيين 
هل سبق لك ان توقفت أو أنقصت جرعه علاجك  بدون إخبار . 3  
  ؟(عن قصد) الطبيب لانك شعرت بسوء أو تعب عند اخذك للدواء
البيت او تسافر, هل تنسى في بعض لاحيان ان  . عندما تغادر4  
 تحضر علاجك الخاص معك؟ (من غير قصد)
  .هل تناولت علاجك في الامس؟ (من غير قصد)5  
. عندما تشعر بان وضعك الصحي تحت السيطره او هل تتوقف 6  
 في بعض الاحيان عن تناول علاجك ؟ (عن قصد)
بالنسبة هوأمر مزعج تناول العلاج بشكل يومي هو  ان.7  
؟  هل شعرت يوما بالانزعاج من الإلتزام بخطه علاجكللبعض. 
  (عن قصد)
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Appendix 22. The Response of Iraqi Patients to Their Clinician in Iraq After 
Reporting the Results to Their Clinician 
Introduction  
The obtained data about the non-adherence level for 303 Iraqi volunteers by the research 
conducted by Ahmed Alalaqi is specific for each patient and provide specific information 
about each medication in the regimen and this helps physician to track the problem of 
non-adherence for each patient in order to improve clinical outcomes, prevent the 
deterioration of the diseases and saving cost. Saving of cost come from decreasing waste 
of medications and prevent unnecessary rehospitalisation.   
I started blame free discussion and encouraged patient to explain they were non-adherent 
to medications to find out the reason and this will help me to apply the required 
intervention. I asked non-adherent patients open-ended questions (why you not adhere to 
……medication?), to reveal more reasons associated with non-adherence and to increase 
patients’ involvement in the treatment plan. I explained to patients the purpose of asking 
these questions. The following are samples of patients’ response and the required 
intervention. This approach is considered as novel and this is the first research in Iraq that 
is helpful for physician to track poor adherence in cardiovascular diseases.   
1. Medication side effect and complex regimen and 
Most of non-adherent patients reported that they feel worse when taking cardiovascular 
medications. For examples, non-adherent patients to statins reported that side effect and 
complicated regimen were the main cause of non-adherent  
[… muscle pain…] [ patient reference number…17, 323,334] 
[ feel tired…weakness in muscle….] [ patient reference number…59] 
[……Feel worse………… and complicated regimen….] [ patient reference number…88] 
[………………I sometimes do not take medication because I feel not good…….] [ 
patient reference number…314] 
Some patients taking losartan reported they feel bad after taking losartan  
[…Losartan makes me ill…………] [ patient reference number…190] 
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[…Feeling bad taking losartan …dizziness…] [ patient reference number…305] 
I explained to them the possible and significant side-effect of statins on muscle and side 
effect of losartan such as vertigo. However, I explained the benefits of using medications.  
I also discuss with the possibility of switching to another medicine with less risk of side 
effects and this may improve patients’ adherence. I also discussed with patients their 
concerns about medicines, and whether they believe they need them.  I told my patients 
that he can report this, and I will be happy to listen to him and looking for solutions.  
Significant number of non-adherent patients reported that taking many tables a day is 
distracting and disturb daily routine and sometimes they stop taking some medicines. 
 [It is inconvenient to me to take many medications...] [ patient reference number…8] 
... [Taking many medications disturb my life……work….] [ patient reference 
number…10] 
…... [Daily life disturbed by taking many medications….] [ patient reference 
number…11] 
I started simplifying the medical regimen or prescribing of a fixed-dose combination 
(FDC) of pills if possible.  
2. Cost of medications  
Some non-adherent patients to atorvastatin, simvastatin and valsartan stated that 
medications are expensive and are not always available in the public sector, and we can’t 
afford the price. 
Some patients stated that they intentionally stopped taking some medications because 
they don’t have job and tried to reduce out pocket expenditure. 
… [I cannot find these medications in the hospital……] [ patient reference number…17, 
55, 62, 134, 204] 
… [Medications are expensive…I am jobless...] [ patient reference number…64] 
… [I cannot afford the price…….] [ patient reference number…75] 
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…. [I did not take medicines …. I could not find medicines in the hospital...] [ patient 
reference number…121, 124,133,159] 
I discussed with the patients the possibility of prescribing less expensive medications and 
for some patient I changed the medical regimen to include medicines available in the 
public sector to reduce the cost. 
3. Patient knowledge  
Most of non-adherent patients stated that they do not know that they need to take 
medications even if they feel better and they do not believe taking all medications is 
necessary.  
… [I think some medications are used as needed….] [ patient reference number…157] 
… [I feel OK…. I did not take medications….] [ patient reference number…168] 
[……feel that this condition is under control and no need for medications ….] [ patient 
reference number…220] 
I tried to improve patients’ knowledge about cardiovascular diseases as chronic diseases 
and explained the rational use of each medication using everyday language avoiding 
jargon language to make information accessible and understandable 
4. Forgetfulness 
Some patients who took amlodipine stated that the main cause of non-adherence to 
medication is forgetfulness  
… [We are old ……. forgetfulness is common with our age group …….] [ patient 
reference number…198] 
… [Busy life…. forget medications….] [ patient reference number…240] 
The same response was obtained from patients took atenolol, patient with reference 
number  
… [ …Missed medications….] [ patient reference number…274] 
… […Forget medications….] [ patient reference number…283] 
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… [ …Doing works made me forgot medications….] [ patient reference number…310] 
I encouraged patients to ask about their treatment to find out their preferences. I prepared 
cards for my patients including: 
• what the medicine is 
• how the medicine is likely to affect their condition (that is, its benefits), likely or 
significant adverse effects and what to do if they think they are experiencing them 
• how to use the medicine 
• what to do if they miss a dose 
Also, I advise them to use their mobile phone to alert for the next dose.  
Some patients stated that they are busy and working for long time and sometime forget 
taking medications when travelled or leaving home. I started friendly discussion about 
balance of life and being healthy will be important for career and family 
 ….. [Forget my medications when I travelled ….] [ patient reference number…224] 
[Forget taking medicine when travelling….] [ patient reference number…238] 
5. Patients attitude and beliefs 
Some non-adherent patients stated that continuing taking medications will harm them and 
some expressed that they do not believe in medicines.  
 [……we think if we continue using medications we you cannot stop it; your body will 
get used to it]. [ patient reference number…242] 
[…. will addict on these medications…….] [ patient reference number…252] 
Some patients stated [……, in my opinion, these tablets cannot improve my diseases, so 
I decided to stop it….] [ patient reference number…263] 
Regarding patients 23, 45, 53, 58 showed high concentration of atenolol in their blood for 
the reported dose of atenolol (50 mg or 100 mg).  
Patient 23, 45, 53 thinks if they would take higher dose this will be better for them.  
[This dose may not enough …….] [ patient reference number…23] 
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[Taking high dose is better….] [ patient reference number…45] 
[Taking two tables will not harm…. better….] [ patient reference number…53] 
For patients 58 when I checked the medicines I found that patient by mistake inserted the 
strip of atenolol in the package of atorvastatin and in this case, patient took double dose 
from atenolol and miss the atorvastatin dose.  
I discussed this issue with them by explaining the reason of prescribing medicines and 
possibility of getting adverse drug reaction and toxicity if patient has taken high dose.  
One patient stated that he did not want his family worry about that 
 […. I did not tell his family that I have cardiac problem because I do not want them to 
worry so I did not take medication at home and kept them at office ...] [ patient reference 
number…283] 
I stared blame free discussion with this patient and told him that patients need support 
from the family to use medications effectively also his health is important for his family 
and if you are ill the family will be unhappy. I explain to him the possible complication 
of cardiovascular diseases.  
Patients should be supported to use medications effectively 
6. Patient–provider relationship 
  
Some patients stated that they were unable to understand how they receive the medicine, 
but they were shy to say that.  
[…. I was shy to aske….] [ patient reference number…285,296] 
[…. I did not understand …. I was shy…] [ patient reference number…300] 
7. Outcomes  
There was significant improvement the health outcomes after starting blame free 
environment to address all issues raised by non-adherent patients and this may indicate 
improvement in level of adherence in patients. A Comparative study is recommended to 
compare the level of non-adherence before and after interventions for future.  
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The results of current study provide an evidence that the health system in Iraq should be 
improved and apply a guideline for management and supporting of patients’ adherence to 
cardiovascular disease in Iraq. 
Professor Yaseen Obaid Yaseen 
Dean of college of medicine 
University of Misan 
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Appendix 23. Letter from Misan Health Directorate Showed the Desire to Transfer 
This Technology for Application in Its Laboratories. 
 
